

Series MB1 no. 36

# Cancer statistics

## registrations

[Click here to go to Contents Page](#)

Registrations of cancer diagnosed in 2005, England

© Crown copyright 2008

Published with the permission of the Controller of Her Majesty's Stationery Office (HMSO)

ISBN 978-1-85774-671-6

ISSN 0143-4829

You may re-use this publication (excluding logos) free of charge in any format for research, private study or internal circulation within an organisation. You must re-use it accurately and not use it in a misleading context. The material must be acknowledged as crown copyright and you must give the title of the source publication. Where we have identified any third party copyright material you will need to obtain permission from the copyright holders concerned.

This publication is also available at the National Statistics website: [www.statistics.gov.uk](http://www.statistics.gov.uk)

For any other use of this material please apply for a Click-Use Licence for core material at [www.opsi.gov.uk/click-use/system/online/pLogin.asp](http://www.opsi.gov.uk/click-use/system/online/pLogin.asp) or by writing to:

Office of Public Sector Information

Information Policy Team

St Clements House

2-16 Colegate

Norwich NR3 1BQ

Fax: 01603 723000

E-mail: [hmsolicensing@cabinet-office.x.gsi.gov.uk](mailto:hmsolicensing@cabinet-office.x.gsi.gov.uk)

### **Contact points**

For enquiries about this publication, contact

Vital Statistics Outputs Branch

Tel: 01329 813758

E-mail: [vsob@ons.gsi.gov.uk](mailto:vsob@ons.gsi.gov.uk)

For general enquiries, contact the National Statistics

Customer Contact Centre on: 0845 601 3034

(minicom: 01633 812399)

E-mail: [info@statistics.gsi.gov.uk](mailto:info@statistics.gsi.gov.uk)

Fax: 01633 652747

Post: Room 1015, Government Buildings,

Cardiff Road, Newport NP10 8XG

You can also find National Statistics on the Internet at:

**[www.statistics.gov.uk](http://www.statistics.gov.uk)**

### **About the Office for National Statistics**

The Office for National Statistics (ONS) is the government agency responsible for compiling, analysing and disseminating many of the United Kingdom's economic, social and demographic statistics, including the retail prices index, trade figures and labour market data, as well as the periodic census of the population and health statistics. It is also the agency that administers the statutory registration of births, marriages, civil partnerships and deaths in England and Wales. The Director of ONS is also the National Statistician and the Registrar General for England and Wales.

### **A National Statistics publication**

National Statistics are produced to high professional standards set out in the National Statistics Code of Practice. They undergo regular quality assurance reviews to ensure that they meet customer needs. They are produced free from any political influence.

# Contents

Select the HAND tool. Position it over the Contents list below and when an ARROW appears on the hand click the mouse button once to enlarge the text. Continue clicking the arrowed hand tool to advance down the page. When the HAND tool changes to a POINTED FINGER click the mouse button once to link to the listed item

|  | <b>Page</b> |
|--|-------------|
| <b>List of tables</b>  | <b>v</b>    |
| <b>1. Introduction</b>   | <b>1</b>    |
| 1.1 Background   | 1           |
| 1.2 Cancer registration system                                     | 2           |
| 1.3 Acknowledgements   | 2           |
| 1.4 Outline of contents  | 2           |
| <b>2. Cancer registration in England and Wales</b>                 | <b>3</b>    |
| 2.1 Background and early history                                   | 3           |
| 2.2 The 1960s  | 3           |
| 2.3 Advisory Committee Report 1970                                 | 3           |
| 2.4 Revised scheme   | 4           |
| 2.5 Advisory Committee Report 1980                                 | 4           |
| 2.6 Medical Advisory Committee review 1990                         | 5           |
| 2.7 The role of ONS in cancer registration                         | 5           |
| 2.8 Redevelopment of the ONS cancer registration computer system   | 6           |
| 2.9 Proposed extension to the cancer registration minimum data set | 7           |
| 2.10 Advisory Committee on Cancer Registration review 1999/2000    | 7           |
| 2.11 Cancer Reform Strategy 2007                                   | 8           |
| <b>3. The United Kingdom Association of Cancer Registries</b>      | <b>9</b>    |
| <b>4. Cancer registrations, 2005</b>                               | <b>11</b>   |
| 4.1 Interpretation   | 11          |
| 4.2 Non-melanoma skin cancer                                       | 11          |
| 4.3 Cancer registrations in England, 2005                          | 11          |
| 4.4 Major cancer sites   | 12          |
| <b>5. Guidance notes and definitions</b>                           | <b>14</b>   |
| 5.1 Quality of cancer registration data                            | 14          |
| 5.2 Mortality data   | 18          |
| 5.3 Quality of mortality data                                      | 19          |
| 5.4 Advantages and disadvantages of incidence and mortality data   | 19          |
| 5.5 Populations  | 20          |
| 5.6 Government Office Regions (GORs)                               | 20          |
| 5.7 Methods  | 20          |
| <i>Age-standardised rates</i>                                      | 20          |
| <i>Cumulative lifetime risk</i>                                    | 21          |
| <i>Survival</i>  | 21          |
| 5.8 Symbols and conventions used                                   | 21          |

|   | <b>Page</b> |
|---|-------------|
| <b>6. Maps and contact addresses</b>  | <b>22</b>   |
| <b>References</b>   | <b>25</b>   |
| <b>Figures and Tables in the text</b>   |             |
| Figure A The cancer registration system of England and Wales  | 4           |
| Figure B All malignant neoplasms (excluding nmsc): incidence rates by age group, 2005   | 12          |
| Figure C All malignant neoplasms (excluding nmsc): frequency distribution by age group, 2005  | 12          |
| Table A The three most common cancers, 2005   | 12          |
| Figure D All malignant neoplasms (excluding nmsc): standardised registration ratios by GOR, 2005                                      | 13          |
| Figure E Registrations – major sites, 2005  | 13          |
| Table B Number of newly diagnosed cases of cancer by quality status, as at December 2007, England, 1971-2005                          | 15          |
| Figure F Number of registrations (thousands) published in ARVs and currently (December 2007) on the NCIC database, England, 1971–2005 | 16          |
| Figure G Advantages and disadvantages of incidence and mortality data   | 19          |
| Table C Distribution of the European Standard Population  | 20          |
| Figure H Areas covered by the regional cancer registries, England, 2007   | 22          |
| Figure I Areas covered by the Government Office Regions, England, 2005  | 23          |

# List of tables

|                 |  |                                       | <b>Page</b> |
|-----------------|--|---------------------------------------|-------------|
| <b>Table 1</b>  | Registrations of newly diagnosed cases of cancer (3 <sup>rd</sup> digit): site, sex and age, 2005  | England                               | <b>28</b>   |
| <b>Table 2</b>  | Estimated resident population: sex and age, as at 30 June 2005   | England and Government Office Regions | <b>40</b>   |
| <b>Table 3</b>  | Rates per 100,000 population of newly diagnosed cases of cancer (3 <sup>rd</sup> digit): site, sex and age, 2005                                   | England                               | <b>42</b>   |
| <b>Table 4</b>  | Registrations of newly diagnosed cases of cancer (3 <sup>rd</sup> digit): site, sex and Government Office Region of residence, 2005                | England and Government Office Regions | <b>54</b>   |
| <b>Table 5</b>  | Rates per 100,000 population of newly diagnosed cases of cancer (3 <sup>rd</sup> digit): site, sex and Government Office Region of residence, 2005 | England and Government Office Regions | <b>60</b>   |
| <b>Table 6</b>  | Standardised registration ratios: site, sex and Government Office Region of residence, 2005 (England = 100)  | Government Office Regions             | <b>66</b>   |
| <b>Table 7</b>  | Registrations of newly diagnosed cases of cancer (4 <sup>th</sup> digit): site, sex and age, 2005  | England                               | <b>*</b>    |
| <b>Table 8</b>  | Rates per 100,000 population of newly diagnosed cases of cancer (4 <sup>th</sup> digit): site, sex and age, 2005                                   | England                               | <b>*</b>    |
| <b>Table 9</b>  | Cancer mortality to incidence ratios: site, sex and Government Office Region of residence, 2005  | England and Government Office Regions | <b>72</b>   |
| <b>Table 10</b> | Directly age-standardised registration rates per 100,000 population: site and sex, 1996 to 2005  | England                               | <b>77</b>   |

\* These large tables are available on the National Statistics website: [www.statistics.gov.uk/downloads/theme\\_health/MB1\\_36/MB1\\_36.pdf](http://www.statistics.gov.uk/downloads/theme_health/MB1_36/MB1_36.pdf)



# 1. Introduction

*Cancer statistics - registrations 2005* presents data for England on those patients who were diagnosed with cancer during 2005 and whose registrations were received at the Office for National Statistics (ONS) by the end of October 2007.

For the purposes of the national cancer registration scheme the term 'cancer' includes all malignant neoplasms and the reticuloses, that is conditions listed under site code numbers C00 to C97 of the Tenth Revision of the *International Statistical Classification of Diseases and Related Health Problems*.<sup>1</sup> In addition, all in situ neoplasms (D00-D09), benign neoplasms (D10-D36) and neoplasms of uncertain or unknown behaviour (D37-D48) are registered, together with hydatidiform mole (O01).

In April 1996, the Office of Population Censuses and Surveys (OPCS) merged with the Central Statistical Office (CSO) to form ONS. ONS is responsible for the full range of functions previously carried out by CSO and OPCS, including labour market statistics and registration of births, marriages, civil partnerships and deaths.

While ONS is responsible for assembling and disseminating UK statistics, no functions held by Scottish or Northern Irish Statistics Agencies have been transferred to ONS. Previous volumes in this series up to no.27 (1994)<sup>2</sup> have presented data for England and Wales. This volume, as did nos. 28 to 35,<sup>3-10</sup> covers only England, because all matters relating to health in Wales have been devolved to the National Assembly for Wales (NAW). Cancer registration in Wales is carried out by the Welsh Cancer Intelligence and Surveillance Unit (WCISU) under a service level agreement with NAW, the terms of which are closely similar to those in the national standards for cancer registration in England. The WCISU is a member of the United Kingdom Association of Cancer Registries (UKACR - see section 3) and voluntarily adheres to all the UKACR's agreed standards and guidelines.

Comparable statistics for England and Wales for 1971 to 1994 have been published in the *Cancer statistics - registrations* (Series MB1) reports. ACD-ROM<sup>11</sup> is also available from ONS containing anonymised records of new cases diagnosed from 1971 to 1992 and deaths from cancer from 1971 to 1997 in England and Wales (see section 5.1); work is currently being carried out to produce an update to this for data from 1991 onwards. For years prior to 1971, statistics have been published in the *Registrar General's Statistical Review of England and Wales, Supplements on Cancer*.

In 2001, ONS published the book *Cancer Trends in England and Wales 1950-1999*.<sup>12</sup> This brought together for the first time the long-term trends in cancer incidence, mortality, prevalence and survival for all the major cancers (which together make up almost 90 per cent of the total cases in both males and

females) accompanied by brief notes on aetiology (causes) and risk factors. New analyses, based on data for the whole population, highlight the wide variations in cancer incidence and mortality with socio-economic deprivation. The book paints the broad picture of the cancer burden and illustrates the baselines against which progress in cancer control will be measured.

## 1.1 Background

Marked changes in the incidence of, and mortality from, cancer have occurred since the beginning of the last century. Currently, about one person in three in England develops a cancer sometime in their life, and cancer now causes about one in four deaths. In 2005, around 359,000 new cases of cancer were registered, and there were 142,000 deaths from cancer. Both these figures relate to all malignant and non-malignant neoplasms, coded to ICD-10 C00-D48, and hydatidiform mole, coded to O01.

It has been estimated that the treatment of cancer accounts for 5 per cent of all NHS expenditure.<sup>13</sup> £3.4 billion was spent on cancer services in 2003/04, £3.8 billion in 2004/05 and £4.3 billion was spent in 2005/06, demonstrating an increase of 12 per cent per year.<sup>13</sup> In total, approximately £4.35 billion was spent on cancer services in 2006/07.<sup>13</sup> Estimates indicate that cancer services received an additional £639 million of funding between 2000/01 and 2003/04.<sup>14</sup>

The National Cancer Research Institute (NCRI), launched in 2001, brings together the major funders of research including the government, voluntary sector and industry to ensure a national strategic approach to identifying and supporting cancer research. The total direct cancer research spend by NCRI Partners on projects live on 1 April 2006 was £393 million.<sup>15</sup> This excludes NHS service support for cancer research on which NHS organisations reported spending £137 million in 2005-06.<sup>16</sup>

Key people involved in cancer prevention and control include scientists investigating the mechanisms that cause cells to become malignant; those carrying out clinical trials to evaluate new treatments; clinicians treating individual patients; public health physicians implementing screening programmes and educating the public; and epidemiologists attempting to characterise high and low-risk populations, identify causal factors and provide clues to carcinogenic mechanisms.

Evaluation of this work in any coherent way requires a population-based cancer surveillance system that can monitor variations in incidence and survival over time, between places and between different groups in the population. The NHS Cancer Reform Strategy<sup>14</sup> published in 2007 set out the next steps for delivering cancer services in England. It recognised

that the collection and use of improved information on different aspects of cancer services was essential to ensuring delivery of this strategy.

## 1.2 Cancer registration system

Cancer registration was, until April 2006, conducted by nine independent regional registries in England. However, the Merseyside and Cheshire Cancer Registry and the North Western Cancer Registry have recently combined to form North West Cancer Intelligence Service across two sites. The eight regional registries collect, on a voluntary basis, data on cancers registered to residents of their areas, and submit a standard data set on these registrations to ONS. In England, each of the regional health authority (RHA) areas that existed in 1994 was covered by its own cancer registry - except that all four Thames RHAs were covered by one registry. As a result of subsequent changes to administrative boundaries in the NHS, together with mergers of some regional cancer registries, by 2001 when the health regions were abolished, the only registry whose area was fully coterminous with a health region boundary was the West Midlands Cancer Intelligence Unit based in Birmingham. A map showing the areas covered by the eight cancer registries is given in section 6. As noted above, NAW is now responsible for cancer registration in Wales.

Under similar arrangements there is a system of cancer registration in Scotland, co-ordinated by the Information and Statistics Division (ISD) of the NHS in Scotland Common Services Agency in Edinburgh. The Scottish Cancer Registry is a full member of the UKACR. ONS and the regional registries in England maintain close contacts with the Welsh Cancer Intelligence and Surveillance Unit, the Scottish Cancer Registry and the Northern Ireland Cancer Registry, and co-operate in several areas, including answering Parliamentary Questions relating to Great Britain or the UK; supplying information for projects such as the preparation of a cancer atlas,<sup>17</sup> and for the examination of clusters of disease by the Small Area Health Statistics Unit at the Imperial College School of Medicine at St Mary's; and assisting the charity Cancer Research UK with information for its UK-based 'CancerStats'. The book *Cancer Trends in England and Wales 1950-1999*<sup>12</sup> also contains some key cancer statistics on the major sites for the UK, and each of the 20 site specific chapters contains a summary table with information for all the regions of England and for Wales, Scotland and Northern Ireland.

## 1.3 Acknowledgements

ONS is very grateful for the work of the regional cancer registries over the years that the national scheme has been in operation, and their close co-operation with the national registry. The current directors of the registries in England are:

|                      |  |
|----------------------|--|
| Northern & Yorkshire | Professor D Forman (Director)<br>Dr C Pollock (Medical Director) |
| Trent                | Mr D Meechan   |

|               |   |
|---------------|---|
| Eastern       | Dr J Rashbass (General Director)<br>Dr C H Brown (Medical Director) |
| Thames        | Professor H Møller  |
| Oxford        | Dr M Roche  |
| South West    | Dr J Verne  |
| West Midlands | Dr G Lawrence   |
| North West    | Dr A Moran  |

The full addresses, telephone and fax numbers of the registries in England, and the registries in Wales, Scotland and Northern Ireland, are given in section 6.

## 1.4 Outline of contents

The commentary begins with a brief history of the cancer registration scheme, covering the four reviews of the system published in 1970, 1980, 1990 and 2001; the role of ONS; and the setting up of the National Steering Committee on Cancer Registration (subsequently the Advisory Committee). The following section gives an overview of the United Kingdom Association of Cancer Registries. The next sections give the overall results for all cancer sites in 2005. Lastly, there are guidance notes and definitions and a discussion of some factors relevant to the interpretation of cancer registration data, a description of methods used, and information on the cancer registries.

The section of text on cancer incidence in the UK, and the accompanying table containing incidence figures for the 20 or so most common cancers, have been omitted from this volume. This information can be found on the National Statistics website at [www.statistics.gov.uk/statbase/Product.asp?vlnk=14209](http://www.statistics.gov.uk/statbase/Product.asp?vlnk=14209), along with data on cancer mortality in the UK.

Following the text are the detailed data tables. The cancer site codes and descriptions reflect the adoption by the NHS in 1995 of the Tenth Revision of the *International Statistical Classification of Diseases and Related Health Problems* (ICD-10).<sup>1</sup> **Table 1** contains the numbers of newly diagnosed cases of cancer by site to the 3rd digit of the ICD-10 code, sex and five-year age group. **Table 2** presents population estimates by sex and five-year age group for 2005, based on the 2001 Census (see section 5.5). **Table 3** gives the rates of cancer incidence per 100,000 population by sex and five-year age group corresponding to the numbers of cases in Table 1. **Table 4** gives the numbers of cancer registrations and **Table 5** the rates per 100,000 population by sex and Government Office Region (GOR). **Table 6** gives the standardised registration ratios by GOR by site and sex (using England as the base). **Tables 7 and 8** present the numbers and rates per 100,000 population respectively, of newly diagnosed cases of cancer, by site to the 4th digit of the ICD-10 code, sex and age group. These very large tables are not included in this volume, but are available on the National Statistics website: [www.statistics.gov.uk/statbase/product.asp?vlnk=8843](http://www.statistics.gov.uk/statbase/product.asp?vlnk=8843). **Table 9** contains cancer mortality to incidence ratios by site, sex and GOR. **Table 10** gives the directly age-standardised rates per 100,000 population, using the European Standard Population, of new cancer cases for England for the 10 year period 1996-2005 by site and sex. Data for all years have been updated using the live database of cancer registrations.

## 2. Cancer registration in England and Wales

This chapter presents a brief history of the cancer registration system in England and Wales and an outline of the role of the Office for National Statistics (ONS).

### 2.1 Background and early history

Cancer registration is the process of maintaining a systematic collection of data on the occurrence and characteristics of malignant neoplasms and certain non-malignant tumours. The procedure is widely established throughout the world and generally follows guidelines established by bodies such as the International Union Against Cancer (UICC), the International Agency for Research on Cancer (IARC), the International Association of Cancer Registries (IACR),<sup>18,19</sup> and the World Health Organisation (WHO).

The great and increasing suffering due to cancer was of concern to the Ministry of Health in the early 1920s and with the introduction of radium treatment, a system was initiated in parts of England and Wales to follow the outcome of treated patients. Both the Radium Commission of 1929 and the Cancer Act of 1939 (never implemented because of the war) incorporated the principle that statistical information about cancer patients was essential for planning and operating cancer care services. In 1945, the Radium Commission was designated as the Statistical Bureau to which the data should be sent for final analysis. This work was taken over by the General Register Office in 1947, and the Cancer Act was repealed in 1948 when the National Health Service Act came into force. From that time the General Register Office, its successors OPCS and, more recently, ONS, have collected and processed data forwarded under voluntary arrangements. Since January 1993, it has been mandatory for the NHS, including trusts, to provide the core items listed in the cancer registration minimum data set to the regional cancer registries, and for the registries to send these data to ONS (see section 2.7).

### 2.2 The 1960s

Complete geographic national coverage of cancer registration was first achieved in 1962. In February 1963, a conference was held at the Ministry of Health to pave the way for 100 per cent registration of cancer patients and to seek ways of improving the cancer registration scheme. A Working Party agreed on the regional and national objectives of the cancer registration scheme. At the **regional** level, the objectives were to improve the service to the cancer patient through good record keeping and efficient follow-up, and to provide information for local research into the value of treatment and for epidemiological studies, for the planning and assessment

of the cancer service, and for the production of national statistics. At the **national** level, the objectives were to produce national statistical analyses likely to assist in the management of the disease and the understanding of it; to cooperate with other government departments and outside bodies in any survey aimed at furthering knowledge of the disease; and to participate, by supplying statistical data as required, in the work of international cancer organisations established to carry out research into the cause and course of cancer.

The Working Party spent a considerable amount of time determining what information should be obtained for analysis at the national level, but it was agreed that the information requested should be kept to a minimum - with the intention of obtaining a more complete record and a greater degree of accuracy. The Working Party's report also discussed and agreed recommendations on desirable national and regional tabulations; the elimination of duplicate activity (in data processing); duplicate registrations; dissemination of information; and the unique difficulties of the (then) Metropolitan Regional Hospital Board areas, which are now covered by the Thames registry and the office of South West Cancer Intelligence Service in Winchester (formerly the Wessex registry).

### 2.3 Advisory Committee Report 1970

Following discussions in 1969 between the Department of Health and Social Security (DHSS) and the Registrar General, an Advisory Committee on Cancer Registration was set up. It was requested simply 'to consider and advise on matters of policy and method relating to the national cancer registration scheme'. Its members included several eminent epidemiologists in addition to representatives from the DHSS, the registries and (the then) OPCS.

The Committee reviewed the existing scheme, in which each case of cancer was registered first of all on a registration form and the data subsequently transferred onto an abstract card. These were to be updated and resubmitted to OPCS after five, ten and fifteen years. Each registry received, through the co-operation of Registration Division at ONS, details of any death in its area where cancer was mentioned on the death certificate (this is known as the 'green card' system after the colour of the paper onto which the death certificate information was copied). Much difficulty had been caused at OPCS by the late submission of abstract cards, and, even worse, of follow-up cards. The quality of data varied considerably among the regions and even the best fell 'rather short' of 100 per cent accuracy in all particulars. The Committee felt that some of the data collected (for example, on treatment) were of doubtful value and placed an unnecessary workload on the registries.

There was, however, unanimous agreement that some form of national cancer registration scheme was necessary in order not only to establish national incidence rates and monitor them for purposes of logistic planning and general epidemiological research, but also to permit prospective studies of cancer in selected groups of the population. In addition, information at the international level for comparison with experience in other countries made a valuable contribution to the understanding of the disease.

### 2.4 Revised scheme


A revised scheme was proposed,<sup>20</sup> covering the definition of cases to be registered; the documentation (a revised and shortened abstract card); a nominal index for use by research workers; national tabulations (to be produced by OPCS); and death notifications (green cards). Probably the most important change suggested was that the system of five, ten and fifteen year follow-up abstract cards should be stopped. Instead, cancer registrations would be ‘flagged’ in the records maintained by the National Health Service Central Register (NHSCR), another part of OPCS in Southport, in the same way that deaths were. As non-cancer deaths of persons flagged as cancer-registered could be notified routinely to the registries, this, together with the green cards, would relieve them of the expensive and laborious task of tracing patients clerically (for example, by using hospital records or writing to GPs). This revised scheme was introduced in 1971, backdated to cover all registrations whose anniversary date fell on or after 1 January 1971. The essential features of the system (illustrated in Figure A) have now remained unchanged for over 30 years.

### 2.5 Advisory Committee Report 1980

The revised scheme was reviewed some ten years later when the Advisory Committee was reconvened. Its report<sup>21</sup> presented many national statistics on cancer incidence, survival, prevalence and mortality. It also highlighted the growing demands for information for clinical research; planning, organising and evaluating services for the prevention and treatment of cancer; epidemiological research; and education of the public.

Many of the Committee’s comments on areas where problems were being experienced are still relevant today. The Committee re-emphasised the great value of recording the NHS number, and stressed that personal identification data were essential for the elimination of duplicate notifications; to enable follow-up and calculation of survival rates; and to enable registrations data to be linked (with suitable safeguards) to other data about the same person. They found a substantial degree of variation among the regions in the excess of registrations over deaths; although difficult to interpret, this suggested an equivalent variation in the degree of ascertainment. The report discussed the three main methods of collection: peripatetic staff, hospital staff and the Hospital Activity Analysis (HAA) system. HAA data were often considered to be insufficiently reliable, but the Committee noted that the three registries that used HAA as their primary source were not those that had low numbers of registrations compared with deaths. The use of information from pathology departments, to increase not only the accuracy but also the completeness of ascertainment, was encouraged.

**Figure A The cancer registration system of England and Wales**



As well as being complete, the data needed to be up-to-date and here the Committee found grave shortcomings since the inception of the revised scheme.

While the average cost of registering one patient with cancer was only a very small fraction of the total cost of the management of the patient's illness, it was noted that (in England) the regional registries were funded by the regional health authorities, with no direct financial input from the DHSS or OPCS. It was possible that registration might not be given the necessary resources at regional level where priorities were decided autonomously.

The Committee concluded that cancer registration covering the whole of England and Wales should continue and be improved in several areas for the following reasons: preventative action was usually based on information from epidemiological studies (using the national register linked to the NHSCR); changes in incidence needed to be monitored because of public, political and medical concern, and improvements in treatment were making mortality data increasingly unreliable as an index of trends; changes in survival needed to be monitored; and reliable and up-to-date data on incidence were essential for the planning and operating of services for cancer detection and treatment.

## 2.6 Medical Advisory Committee review 1990

A Working Group of the Registrar General's Medical Advisory Committee (MAC) was set up in 1989 to review the operation of the cancer registration system, particularly the regional and national data collection methods; the quality and timeliness of the statistics produced; the uses made of the regional and national registers; and the growing tendency to treat cancers in out-patient departments or privately. It was also asked to consider the implications of changes in demand for information and developments in information technology, and the priorities and level of resources required to maintain adequate registers. The potential implications of the recommendations of the White Paper *Working for Patients*<sup>22</sup> were also considered.

The Working Group<sup>23</sup> noted that in addition to the traditional uses of cancer registration (monitoring of time trends and geographical variation in incidence), the system had become vital in several other areas. These included the management of the substantial resources required for the preventative, curative and laboratory services for cancer; the planning and evaluation of services, particularly the screening programmes for breast and cervical cancer; the planning and evaluation of clinical management and treatment based on accurate and unbiased survival data and clinical trials; research into causes of cancer, involving case-control studies and the flagging of cohorts at the NHSCR; and information for health education and health promotion for both professionals and the public. Future uses of cancer registration (especially if linked with other databases) were identified, including evaluating programmes of care, quality assurance, and relating costs to clinical outcome.

The seventeen recommendations made by the Working Group

for improvements to the system fell into several categories, relating to the organisation of the system; the collection, processing, quality, timeliness and completeness of the data; and the safeguarding of the necessary data release in view of the impending NHS changes and the growing use of the private sector.

One of the six recommendations in the 'organisational' area was that a Steering Committee should be established to oversee national cancer registration, with representation from the registries, OPCS, regional and district health authorities, the United Kingdom Co-ordinating Committee of Cancer Research, the Health and Safety Executive and the private health sector. This Steering Committee, which was chaired by Dr J Metters, the Deputy Chief Medical Officer at the Department of Health, held its first meeting in June 1991 and met subsequently at approximately six monthly intervals. This committee was re-formed as the Advisory Committee on Cancer Registration; it was chaired by Dr S Atkinson of the NHS Executive.

Three recommendations involved both the registries and OPCS: an expanded national core data set; co-operation with the private health sector; and the establishment of guidelines for the handling and release of data. These have been discussed at several consultative meetings with the registries. Work on three other recommendations, relating to the provision of timely estimates of incidence at the national and regional level; quality control checks; and the provision of up-to-date anonymous and summary data, was carried forward at ONS, which in 1995 completed the redevelopment of its longstanding computer system to a new database environment (see section 2.8).

## 2.7 The role of ONS in cancer registration

The Office for National Statistics (ONS) was formed by the merger of OPCS and the Central Statistical Office (CSO) in 1996. The Director of ONS, Karen Dunnell, is also the Registrar General for England and Wales. The National Cancer Intelligence Centre (NCIC) at ONS includes part of the Social and Health Analysis and Reporting Division in London, which co-ordinates all the work on cancer registration and carries out a wide range of secondary analysis and research; part of the Social Data Collection and Administrative Sources Division in Titchfield, which conducts the primary data processing of registry data; and a section at the NHSCR in Southport, which flags the cancer registrations on the central register. Much of the secondary analysis and research, which is carried out by a statistician and researchers, supported by a medical epidemiologist and a Professor of Epidemiology and Vital Statistics at the London School of Hygiene and Tropical Medicine (LSHTM), is done in collaboration with academic and external researchers, for example at the LSHTM, the Cancer Screening Evaluation Unit at the Institute for Cancer Research, and the Small Area Health Statistics Unit at Imperial College.

The Vital Statistics Output Branch (VSOB) in ONS Titchfield have taken over production of the annual reference volume in recent years. This includes quality checks of the figures and tables.

Most registries collect a large amount of information about the patient, the tumour and the treatment. The registries carefully collate all the data for any one patient to avoid duplication of records. This is not a quick process, as information is often not made available to the registry until the main course of treatment is finished. A subset of the data, as defined in the cancer registration minimum data set,<sup>24</sup> is sent to the national registry at the ONS office in Titchfield, near Southampton. The data items are:

| Core  | Optional                              |
|---|---------------------------------------|
| Record type (new registration, amendment, deletion) | Country of birth                      |
| Identity number (unique)                            | Ethnic origin*                        |
| Patient's name                                      | Patient's occupation                  |
| Patient's previous surname                          | Patient's employment status           |
| Patient's address                                   | Patient's industry                    |
| Postcode  | Head of household's occupation        |
| Employment  | Head of household's employment status |
| Sex   | Head of household's industry          |
| NHS number  | Diagnosis from screening*             |
| Marital status                                      |                                       |
| Date of birth                                       |                                       |
| Date of death (if dead)                             |                                       |
| Incidence date                                      |                                       |
| Site of primary growth                              |                                       |
| Type of growth                                      |                                       |
| Behaviour of growth                                 |                                       |
| Multiple tumour indicator                           |                                       |
| Previous registration details                       |                                       |
| Basis of diagnosis*                                 |                                       |
| Death certificate only indicator*                   |                                       |
| Side (laterality)*                                  |                                       |
| Treatment(s) (indicators)*                          |                                       |
| Stage†  |                                       |
| Grade†  |                                       |

\* From incidence year 1993

† From incidence year 1993; phased introduction - initially only for breast and cervix.

These data are loaded onto the new person-based database (see section 2.8) and validated. The extensive checks include the compatibility of the cancer site and the associated histology; these checks are closely based on those promulgated by IARC.<sup>18</sup> Once all the expected records for any one incidence year have been received and validated at ONS, detailed tables are published on the numbers and rates of all types of cancer by age and sex, and by region of residence, as presented in this volume.

All the work on processing in Titchfield and flagging at the NHSCR in Southport has, since 1993, been paid for by the Department of Health (DH). A service level agreement (SLA) has been negotiated between DH and ONS. Work on the key targets and outputs established in the relevant ONS divisional business plans and the SLA is monitored continuously. ONS makes formal six-monthly progress reports to DH.

## 2.8 Redevelopment of the ONS cancer registration computer system

Beginning in 1990, over 20 of the major computer processing systems at OPCS, including births, deaths, cancer registrations, the Longitudinal Study (1 per cent linked sample from the censuses), marriages and divorces, were redeveloped onto a modern database environment. The two main objectives of the redevelopment of the cancer registration computer system were to have an effective and efficient processing system and a person-based database (rather than annual files of tumours). To meet the timetable for introducing the new system, it was necessary to convert the 21 annual tumour files (1971 to 1991 inclusive) to a person-based database before the new system began operation. From among the 4.5 million records, those which were either duplicates or were true multiple primary records for the same person were linked together by a probability matching process<sup>25</sup> based on those successfully operated by the Oxford Record Linkage Study, Statistics Canada, and the Information and Statistics Division (ISD) of the Scottish Health Service.<sup>26,27,28</sup> Information on linked registrations was sent to the cancer registries for the deletion or amendment of records as appropriate. The essential structure of the cancer registration system in England and Wales, shown in Figure A, has remained unchanged. However, the identification and the sending to the regional cancer registries of the death certificates mentioning cancer and the non-cancer deaths to flagged cases is now done by the new system in Titchfield. In addition, all validation errors are now returned to the appropriate registry for resolution.

In parallel with the work on the redevelopment of the system at ONS, much data enhancement work was completed. This included 13,000 new registrations, amendments and cancellations; amendments to about 40,000 records from the probability matching exercise; 15,000 updates of date of death; 25,000 date of birth and date of death discrepancies; 7,000 no trace indicators added to the database; and smaller numbers of trace and event rejects, multiple primary cancer queries from registries, mis-traced Welsh records, "dead" now known to be alive, sex discrepancies, partial or invalid postcodes, and embarks. In addition, 36,000 queries from NHSCR about possible multiple primary cancers were dealt with.

The backlog of over 600,000 records that had built up in the registries during the time that the person-based database was being constructed was successfully processed by the NCIC in Titchfield. Priority for the processing of amendments resulting from validation errors was given to data for incidence years 1990 and 1991. At the same time, the NCIC worked steadily through the remaining problems - some left over from the old computer system, and some new ones. These included amendments to the way the system handled the notifications to the registries of death certificates containing a mention of cancer; corrections to records with duplicate identity numbers; re-numbering of some records for one regional registry; and improvements to postcodes. In addition, revalidation to the

higher standards embedded in the new system of all data previously processed on the old computer system has been carried out, queries sent to the regional registries and records amended. The new NHS numbers for flagged cases, together with any dates of death, were sent from the NHSCR to Titchfield and passed to the cancer registries. This information has enabled both ONS and the registries to amend records for the “immortals” - cases registered alive, but whose death was not previously linked to the cancer registration.

Once the testing of the new NHSCR computer system that deals with the flagging of cancer cases had been completed, the backlog of records that had been processed in Titchfield was sent to the NHSCR in Southport. It was known that about 65,000 of these were for people who had died before 1991 when the computerised index was assembled and so they would not be on the database at NHSCR. These records were therefore stripped off the Titchfield database and sent separately to Southport on paper. Of the remaining records, which were sent on electronic media, it was expected that about 300,000 would match automatically on the system. It was planned to do the batch runs in order, i.e. the earliest registrations first, to facilitate the determination of true multiple cancers and duplicates. The flagging of the stockpiled registrations for incidence years 1971 to 1990 was completed in January 1997; and the resulting trace and event (death, embark, re-entry) data were sent to Titchfield and added to the database. All flagging for records up to incidence year 2005 that have been received at ONS and have passed the validation checks has been completed and work is in progress on cases diagnosed in 2006 and 2007. At the same time, ONS is attempting to keep earlier incidence years up-to-date by processing and flagging any “late” registrations received from the cancer registries.

## **2.9 Proposed extension to the cancer registration minimum data set**

A conflict exists between the number of data items collected and data quality. This has been recognised by the three reviews of the national system described above.<sup>20,21,23</sup> The minimum data set has been revised in the context of the wider National Cancer Data Set and includes the stage of disease for all cancers, and details of treatment. This will require the information on stage to be made explicit by clinicians. Although the private sector is not covered by the minimum data set, members of the Independent Healthcare Association have generally been very co-operative; however, the growth of private pathology laboratories is a concern.

## **2.10 Advisory Committee on Cancer Registration review 1999/2000**

In recent years, and particularly since the publication in 1995 of the Calman-Hine report on cancer services,<sup>29</sup> the role of cancer registries has been extended. Cancer registries have contributed to studies on the variations in the outcomes for cancer patients across the UK and in the investigations into the

underlying causes of these variations. Cancer registries were also increasingly being asked to provide data to support the planning and monitoring of cancer service delivery, including the national breast and cervical screening programmes. For these purposes, more extensive data sets are needed and the timeliness of information is of great importance. For the purposes of clinical governance, data on the patterns of care and outcomes for specified sub-groups of patients, for example, defined by extent of disease or “stage”, are needed.

This expansion of the traditional role of cancer registries led to renewed interest in them, but drew attention to the variable quality of the service that individual registries provided. Concerns were expressed about their capacity to provide up-to-date, complete and accurate data.

Despite the changes implemented following the three national reviews described above, these concerns had persisted, and in April 1999 the Advisory Committee on Cancer Registration, on behalf of the Department of Health, commissioned Professor Charles Gillis, then Director of the West of Scotland Cancer Surveillance Unit, to undertake a further review of cancer registration in England.

The review<sup>30</sup> found that due to the history of the cancer registries, which had grown up more or less autonomously since before the second world war, there were considerable variations among them in terms of organisational structures; type of host institution (hospital, health authority, academic); title; data collection process (predominantly manual or electronic); range of tumours registered; data items collected; IT systems; research activity; and significant variations in completeness, accuracy and timeliness of data submission to ONS. The budgets per head of population served and the cost per case registered appeared to vary considerably, although those for the majority of registries clustered closely around the average.

The timeliness of data acquisition by some of the registries had been poor, with the knock on effect that they were, in turn, slow in submitting data to ONS for national collation. For example, it was only in August 1997 that provisional figures were published for cancers diagnosed in 1992 (so at first sight national cancer registration data looked five years out of date) and confirmed registrations for 1991 were only published in December 1997. However, the timeliness of several registries improved dramatically during the late 1990s following redevelopment of their computer systems, and the provisional results up to incidence year 1996 were only two years out of date (and two years behind the available mortality data).

The issue of timeliness was addressed through the allocation by the Department of Health of £500,000 from the Public Health Development Fund, with the aim of ensuring a measurable improvement in the timeliness and quality of national cancer

incidence and survival data. The target was that through this investment, all cancer registries would submit complete data up to and including 1997, to the quality standard in the national core contract, to ONS by the end of September 2000.

The review noted that data quality varied between registries. The editors of *Cancer Incidence in Five Continents Volume VII*<sup>31</sup> assessed the quality of data submitted by individual cancer registries. It was a matter of concern that not all cancer registries in England provided data acceptable to the editors of this standard work.

Most cancer registries collect far more data than required for the national minimum data set. The review found tensions regarding the priority given to local and national need for data. In some cases, national priorities were unduly neglected. Some cancer registries had not complied with the requirement to submit data to ONS within the timescales specified in the national core contract. Data on variables relating to stage of disease and treatment were variably collected. Registries generally only collected information on treatment given within six months of diagnosis, as specified in the core contract, and so surgical, radiotherapy and chemotherapy treatments given later in the course of a patient's illness would have been excluded.

The review concluded that the credibility of the data for comparisons of the risks of cancer over time, and of outcomes within some cancer registry areas, was well established. But the reliability of inter-regional comparisons was doubtful and the requirement for data of a uniform high standard in all parts of England for the purposes of public health and clinical governance was certainly not being met.

The review made a number of key recommendations for how cancer registries should be strengthened, so that they would be able to contribute fully to the cancer modernisation agenda by providing robust data to support the planning and monitoring of cancer service delivery and identify the scope for NHS intervention in relation to deprivation and cancer. The Department of Health published an action plan<sup>32</sup> to improve the organisation and effectiveness of the cancer registries in England. An additional £2 million of funding was allocated to cancer registration in each of the three financial years 2001/2 to 2003/4, a National Co-ordinator for Cancer Registration was appointed, and a National Cancer Registry Advisory Group was established.

## **2.11 Cancer Reform Strategy 2007**

The Department of Health published the Cancer Reform Strategy (CRS) in December 2007, which builds on the progress made since the Cancer Plan in 2000. The strategy recognises that there are major challenges ahead and sets out a package of measures to be taken forward over the next five years on prevention, early diagnosis, better treatment, improving the

patients' experience and reducing inequalities. Collecting and using improved information on cancer was identified as central to delivering this strategy.

A new National Cancer Intelligence Network (NCIN) is being established to bring together relevant stakeholders in cancer information including cancer registries; and is tasked to ensure optimum use is made of all sources of cancer data currently collected. The NCIN will be responsible for the development, building, maintenance and quality assurance of a new national repository of cancer data. The NCIN will oversee the provision of information needed to improve cancer services and increase patient choice. It will also provide a valuable new resource for epidemiological and health services research. National Cancer Research Institute (NCRI) partners will help fund research on the data collected by the NCIN, facilitating a more informed analysis of cancer services. A Steering Group has been established to oversee the NCIN development and this replaces the National Cancer Registry Advisory Group.

The NCIN, initially led in its formation stages by the National Co-ordinator for Cancer Registration, will introduce a new funding allocation for cancer registries in England based on the population for their area; this is to be phased in over the financial years 2008/9 and 2009/10. A Cancer Registry Core Contract is currently being developed between the cancer registries in England and the NCIN. NCIN is establishing a lead registry role for specific cancers with the cancer registries in England.

### 3. The United Kingdom Association of Cancer Registries

In the early 1990s, the cancer registration system in the UK was subject to rapid change. With the development of information technology, the pace of change in registration practice quickened, and increasing demands for accurate and timely information were made on the cancer registration system. Changes in the organisation of the health service and in the methods of health care delivery contributed to an increased interest from various authorities and scientists. There were new uses that could and should be made of registration data, such as medical audit and quality assurance of health care, as well as the routine uses that have been made of these data in the past, such as estimation of incidence and evaluation of survival and mortality.

There was widespread awareness, both of the need to improve the quality and completeness of cancer registration data and of the opportunities to do so through the use of information technology. Together with the increased interest from external bodies in using the data, this led to the creation of several groups bringing together cancer registry staff and personnel from OPCS (as it then was) to discuss and resolve matters of common interest.

The longest standing of these was the *Cancer Registries' Consultative Group* (CRCG), which concerned itself essentially with issues of data collection, including coding and data quality. It had representation from all cancer registries in the UK and Ireland, and its members were for the most part registry managers and others closely involved in the day-to-day business of data collection. The *Cancer Surveillance Group* (CSG) was set up in 1989 to meet a perceived need for a forum bringing together those with an interest in the use of cancer data. It had a loose, open and informal membership and structure. Its members included epidemiologists and statisticians, as well as other registry staff. The *Cancer Registries' Information Technology Group* (CRITG) brought together technical experts from the various registries. Education and training was another area of activity thought to be of such importance that it could justify the establishment of another group. There was however, no forum that brought together registry directors on a regular basis. There was a danger, therefore, with so many different perspectives and forums in which different points of view could be expressed, that the cancer registries might fail to speak with a united voice when, for example, making representations or giving advice to government. With no coherent framework of organisation, there would be a strong possibility of duplication of effort and inadequate communication between the various groups.

It was therefore proposed that a United Kingdom Association of Cancer Registries (UKACR) be established. Following preliminary meetings at which almost all of the UK registries were represented, the Association was brought into being on 2nd April 1992 in Cardiff.

The Association has a federal structure. All affiliated population-based cancer registries in the UK, ONS, the Information and Statistics Division of the NHS in Scotland and the Northern Ireland Cancer Registry are full members with their representative, usually the director, having a vote on the Executive Committee. Associate (non-voting) members, as of October 2007, comprise the National Registry of Ireland, the CRC Paediatric and Familial Cancer Research Group in Manchester, the Northern Region Children and Young Persons Malignant Disease Registry in Newcastle, the West Midlands Regional Children's Tumour Registry in Birmingham, the Yorkshire Specialist Register of Cancer in Children and Young People in Leeds, UK Childrens Cancer Study Group in Leicester, Bristol Children's Cancer Research Registry, and the charities Cancer Research UK and Marie Curie Cancer Care. Since the formation of the UKACR, a Quality Assurance Group was set up to standardise the methodology for, and report on, various registry performance indicators included in the national core contract<sup>33,34</sup> such as timeliness and the percentage of registrations made solely from a death certificate. A Training Group and a Coding and Classification Group were established to oversee and co-ordinate the implementation of developments in those particular aspects of cancer registries' work. A Clinical Effectiveness Group took forward issues relating to the registries' expanding role in clinical audit and performance monitoring on cancer. The Chairs of the various sub-groups were invited, as appropriate, to attend Executive Committee meetings as observers.

In 2003, the structure of the UKACR's sub-groups was re-organised. Three new sub-groups were established, chaired by a registry director, and with new terms of reference and some decision-making powers delegated from the Executive Committee. The Registration Sub-group has the former Coding and Classification Group and the Quality Assurance Group reporting to it. The other groups are the Information, Communications and Technology Sub-group, and the Analysis Sub-group.

The current officers as from October 2007 are:  
Co-Chairs - Dr M Roche, Director of the Oxford Cancer Intelligence Unit, and Dr A Gavin, Director of the Northern

Ireland Cancer Registry; and Treasurer – Mrs S Reynolds, of the Welsh Cancer Intelligence and Surveillance Unit. The central coordinating team of the National Cancer Intelligence Network provides the Secretariat support.

The UKACR provides:

- a focus for national initiatives in cancer registration
- a coherent voice for representation of cancer registries in the UK
- a channel for liaison between registries and for agreeing policy on matters connected with cancer registration
- a framework to facilitate the operation of special interest groups and regional registries, and
- a means of stimulating the development of cancer registration, of information procedures and practices, and of research based on cancer registry data

The UKACR represents the views of its members to government and other bodies operating at national level on issues concerned with data quality, the definition of information requirements, and the development of health information systems where these have implications for cancer registration, in particular where matters of overall policy are concerned. The Association was represented on the re-formed National Advisory Committee on Cancer Registration and on the National Cancer Registration Advisory Group (NCRAG). Plans for similar representation within NCIN groups are being drawn up. The establishment of such close links is very important given the intimate ties many regional registries have with NHS information systems, and the potential importance of cancer registration to NHS functions such as medical audit and contracting.

The UKACR has, through consensus, examined and improved coding and classification issues; agreed the complex interface document for transmission of data to and from ONS; developed performance indicators; produced a training manual and cancer-specific training packs for registry staff; developed guidelines for the release of data, including for the rapidly expanding field of genetic counselling; developed guidelines for standardisation of reported results; and established a forum for sharing the latest epidemiological research. This consensus is valuable as it allows agreed procedures to be followed.

## 4. Cancer registrations, 2005

### 4.1 Interpretation

Care is required in the interpretation of cancer registration statistics, particularly when addressing either trends over time or differences between regions.

Registration of cases of cancer is a dynamic process in the sense that the data files both in the cancer registries and at ONS are always open. Cancer records may be amended - for example, the site code may be modified should later and more accurate information become available. The date of death is added for cases registered when the person was alive. Records may be cancelled, although this is relatively unusual. Also, complete new 'late' registrations may be made after either the cancer registry, or ONS, or both, have published what were thought at the time to be virtually complete results for a particular year.

Consequently, the figures for registrations published by a cancer registry in its reference volume may be different from those in the corresponding annual reference volume (ARV) published by ONS in the series MB1, which will generally have been produced at a different (usually later) time. In addition, both sets of published figures will differ again from the numbers of registrations currently on the databases. Further differences between cancer registry and ONS figures may arise if records that have been rejected by the validation process at ONS have not been corrected by the registry concerned before the corresponding ARV tables are produced.

In the section on 'validity' in section 5.1, it is noted that the cancer registries probably differ in their levels of completeness of registration. It may be difficult to interpret any apparent trends in cancer registrations because the registries are continually striving to increase their levels of ascertainment of cases. Any particularly large increases from year to year in the numbers of registrations for an individual registry are most likely to have arisen because of this.

Other aspects of the cancer registration system that are relevant to the interpretation of the data are discussed in detail in section 5.1.

### 4.2 Non-melanoma skin cancer

ONS has been advised both by expert epidemiologists and by members of the former Steering Committee on Cancer Registration, that non-melanoma skin cancer (ICD-10 C44) is greatly under-registered. Registration varies widely depending

on a registry's degree of access to out-patient records and general practitioners. This under-registration of non-melanoma skin cancer is not just a problem for the cancer registries in England. *Cancer Incidence in Five Continents Volume VI*<sup>5</sup> reported that cancer registries in the United States, Australia, and parts of Europe, also collected very limited information on these skin cancers. In the commentary that follows, the figures for 'all malignancies' (ICD-10 C00-C97) **exclude non-melanoma skin cancer** (nmisc).

### 4.3 Cancer registrations in England, 2005

In 2005 there were totals of around 171,000 registrations of cases of cancer (malignant and non-malignant) for males and 188,000 for females. In the Tenth revision of the *International Statistical Classification of Diseases and Related Health Problems* (ICD-10), malignant neoplasms are coded C00-C97, and benign, in situ, uncertain and unknown neoplasms are coded D00-D48. In 2005, of the total registrations about 17,100 for males and 40,100 for females were non-malignant. Over half of the non-malignant neoplasms for females were carcinoma in situ of the cervix (ICD-10 D06).

Cancer is predominantly a disease of the elderly. The overall crude rates of cancer registrations (excluding nmisc), 483 per 100,000 population for males and 464 per 100,000 population for females, conceal wide differences between the sexes and across the age groups, as illustrated in Figure B. The numbers on which this figure is based are given in **Table 3**. Following the small decrease in rates after early childhood, rates increased continuously across the age range for both males and females.

Rates of cancer rose more quickly with age in females than in males; this is reflected in the age distribution described below. In the 40–44 age group, the rate in females was more than double that for males. Subsequently, the overall rates rose more rapidly for males and were broadly similar to those for females in the 55–59 age group. After this, the rates rose much more rapidly for males: they were just under 38 per cent higher than those for females in the 65–69 age group and over 68 per cent higher in those aged 80–84.

The age distribution of malignant neoplasms is shown in Figure C. The numbers on which this figure is based are given in **Table 1**. Of the total of 238,977 malignancies, only 1,177 (0.5 per cent) occurred in children aged under 15; of these, 368 (31 per cent) were leukaemias (ICD-10 C91-C95). The percentages of cancers in the five-year age groups tended to rise earlier in

females than in males, owing largely to the influence of the incidence of cancers of the breast (ICD-10 C50) and of the cervix (ICD-10 C53). Cancers in those aged under 45 amounted to just over 5.5 per cent of the total for males and 9.2 per cent for females. The peaks in the age distributions occurred in the 75–79 age group for females and 70–74 for males.


The standardised registration ratios (SRRs) by GOR are illustrated in Figure D. The numbers on which this figure is based are given in **Table 6**. These SRRs should be interpreted with caution because it is difficult to separate the effect of variation in levels of ascertainment from genuine differences in incidence.

#### 4.4 Major cancer sites


In the ICD Tenth Revision, there are 88 3-digit site codes relating to malignant neoplasms; of these, four relate to males only and eight to females only. For both males and females just **three** of the sites (different ones for each sex) constituted just over half of the total registrations in 2005, as shown in Table A.

The numbers of registrations for the major sites are illustrated in Figure E (and given in **Table 1**). The numbers of registrations for these 21 major sites represent 90 per cent of the total for all malignant neoplasms (excluding nmssc) for males and 89 per cent for females in 2005.

**Figure B All malignant neoplasms (excluding nmssc): incidence rates by sex and age-group, 2005**



**Figure C All malignant neoplasms (excluding nmssc): frequency distribution by age group, 2005**




**Table A The three most common cancers\*, 2005**


|                    | ICD-10 | Site description  | Number of registrations | % of total malignancies |
|--------------------|--------|-------------------|-------------------------|-------------------------|
| <b>(a) Males</b>   |        |                   |                         |                         |
| 1                  | C61    | Prostate          | 28,886                  | 24.1                    |
| 2                  | C34    | Lung              | 18,020                  | 15.1                    |
| 3                  | C18-20 | Colorectal        | 16,282                  | 13.6                    |
|                    |        | Total             | 63,188                  | 52.8                    |
|                    |        | All malignancies* | 119,625                 | 100                     |
| <b>(b) Females</b> |        |                   |                         |                         |
| 1                  | C50    | Breast            | 38,212                  | 32.0                    |
| 2                  | C18-20 | Colorectal        | 13,283                  | 11.1                    |
| 3                  | C34    | Lung              | 12,977                  | 10.9                    |
|                    |        | Total             | 64,472                  | 54.0                    |
|                    |        | All malignancies* | 119,352                 | 100                     |

\* Excluding non-melanoma skin cancer (ICD-10 C44) - see section 4.2

**Figure D All malignant neoplasms (excluding nmesc): standardised registration ratios by GOR, 2005**



**Figure E Registrations - major sites, 2005**



## 5. Guidance notes and definitions

### 5.1 Quality of cancer registration data

A brief history of cancer registration in England and Wales is given in section 2. The essential features of the current system have remained unchanged for over 30 years. The main flows of information to and from the regional registries and ONS, including the National Health Service Central Register (NHSCR), are illustrated in Figure A. Some aspects of the system that are relevant to the interpretation of the data have been discussed in considerable detail by Swerdlow.<sup>36</sup> These and others including geographic coverage; methods of data collection; ascertainment (or completeness of registration); completeness of recording of data items; validity; accuracy; timeliness; late registrations, deletions and amendments; duplicate and multiple registrations; registrations from information on death certificates; clinical and pathological definitions and diagnoses; changes in coding systems; completeness of flagging at NHSCR; changes in definition of resident population; and error, are discussed below.

Over the years, changes have occurred to the number of registries and to their **geographic coverage**. In 1950, there were 74 centres registering cancer in England and Wales, but the system was progressively simplified and by 1958 ten regions were covered by regional cancer registries; full coverage of England and Wales (but not 100 per cent ascertainment of cases - see below) was achieved in 1962. Some registries covered more than one RHA: the Thames Registry was formed in 1985 with the merger of the North West, North East and South Thames registries (the last of these covered both the South West and South East Thames RHAs). Wessex was separated from the South Thames registry in 1973; this coincided with a change in the method of data collection and a substantial increase in numbers of registrations for some parts of the Wessex region. Following reorganisations at the regional level in the NHS in 1996, the former South Western and Wessex RHAs are now covered by the South West Cancer Intelligence Service based in Bristol and Winchester. The former Yorkshire RHA and part of the former Northern RHA are now covered by the Northern and Yorkshire Cancer Registry and Information Service based in Leeds (the remainder of the former Northern RHA, South Cumbria, is now covered by the North Western Registry). Further reorganisations at the regional level in the NHS occurred in 1999 and 2001, but no corresponding major changes have been made to the areas covered by the cancer registries. Some registries received reports from several centres in their areas - at various times five regional centres existed in Trent, two in South Western, and three in East Anglian.

The independent cancer registries differ considerably in their **methods of data collection**; some employ peripatetic clerks,

others use hospital record staff to extract data for the registry, and several rely heavily on other organisations' computer systems including those in hospitals and pathology laboratories. The registries probably also differ in the level of **ascertainment** of their data (that is the degree to which reportable incident cases of cancer in the population are actually recorded in the registry) but the best are known to have very high levels. Direct measures are only available from occasional special studies.<sup>37,38</sup> That by Hawkins and Swerdlow<sup>37</sup> estimated that the under-ascertainment of registration of childhood cancers by the regional registries was just under 5 per cent; under-ascertainment may be greater for adults, for whom registration and record linkage (in the registries and at NHSCR) may be more difficult, than for children. General indications of ascertainment levels can be obtained from comparisons of the numbers of registrations and deaths in a period. The figures for deaths are those coded to a particular type of cancer as the underlying cause of death in residents of the same geographical area. Such mortality to incidence ratios by sex and site for 2005 are presented in **Table 9**. These ratios have several limitations, but there are variations between regions (and over time) that would be difficult to explain unless there were similar variations in ascertainment.

It should be noted that some cancer registries are not always able to collect complete information about benign, uncertain and unknown neoplasms and therefore these registration rates are almost certainly underestimates of the true incidence. In particular, this should be noted when interpreting regional differences.

It may be difficult to interpret any apparent trends in cancer registrations because the registries are continually striving to increase their levels of ascertainment of cases. Any particularly large increases from year to year in the numbers of registrations for an individual registry are most likely to have arisen because of this. For example, the recorded incidence for residents in some parts of the Thames Regional Health Authorities was unusually high in 1992, and unusually low in 1993, as a result of a one-off exercise by the Thames Cancer Registry in 1993 to find further information for people with cancer mentioned on their death certificate.<sup>39</sup>

**Completeness** is the extent to which all appropriate data items have been recorded in the registry database. Some data items are essential; if high proportions of such items are missing, this is an indicator of poor quality. For example, for cases that have been registered solely from the information on a death certificate (DCO) the incidence date is unknown and has to be taken as the date of death and the case may well be recorded against the wrong calendar year. A high DCO rate also implies

under-ascertainment<sup>18</sup> because patients are being missed by the registry while they are alive and not all cancer patients die of their disease (in which case, cancer is not mentioned on the death certificate). Other quality indicators are the proportion of cases where the primary site is unknown, and the proportions where important information such as the age of the patient or their postcode, is missing. Tables giving the proportions of registrations by region that have zero survival (which include both DCO cases and patients who were known to have died on the day of diagnosis - true zero survival) are given in Appendix E1 of the *Cancer Trends* volume;<sup>12</sup> tables giving the proportions of registrations by region with site unspecified are given in its Appendix E2.

The agreed procedures to be followed by the cancer registries and ONS when submitting and processing data are set out in the 'Registry/ONS Interface Document'.<sup>40</sup> When a registry's submission is loaded onto the database at ONS, a large number

of **validity** checks are carried out. There are over 40 checks on individual data items. These include that dates are valid, or that an 'indicator' is either 0 or 1 (or '&' if not known). There are around 20 cross checks between data items. These include the consistency of dates, for example that the incidence date is not after the date of death, and that the cancer site and histology are compatible. These latter cross checks are based closely on those promulgated by the International Agency for Research on Cancer (IARC)<sup>18</sup> and used by them when verifying data for inclusion in *Cancer Incidence in Five Continents*.<sup>41</sup> Combinations of site and histology are checked against three lists:

- (i) histology codes that will be accepted in combination with any site code
- (ii) histology codes that will only be accepted if the site code is in the appropriate group (of which there are over 50), and

**Table B** Number of newly diagnosed cases of cancer\* by quality status†, as at December 2007, England, 1971-2005

| Year | Total   | Status 1 | Status 2 | Status 3 | Status 3 as % of total |
|------|---------|----------|----------|----------|------------------------|
| 1971 | 143,880 | 141,263  | 2,063    | 554      | 0.4                    |
| 1972 | 146,410 | 143,885  | 1,668    | 857      | 0.6                    |
| 1973 | 152,028 | 148,750  | 1,456    | 1,822    | 1.2                    |
| 1974 | 156,809 | 154,692  | 376      | 1,741    | 1.1                    |
| 1975 | 157,311 | 155,194  | 187      | 1,930    | 1.2                    |
| 1976 | 158,278 | 155,090  | 170      | 3,018    | 1.9                    |
| 1977 | 161,184 | 158,576  | 162      | 2,446    | 1.5                    |
| 1978 | 161,169 | 159,212  | 155      | 1,802    | 1.1                    |
| 1979 | 164,467 | 163,507  | 253      | 707      | 0.4                    |
| 1980 | 169,929 | 168,623  | 293      | 1,013    | 0.6                    |
| 1981 | 174,748 | 172,459  | 1,374    | 915      | 0.5                    |
| 1982 | 175,794 | 173,027  | 1,435    | 1,332    | 0.8                    |
| 1983 | 180,007 | 176,493  | 1,871    | 1,643    | 0.9                    |
| 1984 | 179,797 | 175,531  | 2,671    | 1,595    | 0.9                    |
| 1985 | 190,417 | 188,242  | 1,169    | 1,006    | 0.5                    |
| 1986 | 187,455 | 184,838  | 1,433    | 1,184    | 0.6                    |
| 1987 | 192,118 | 188,891  | 1,891    | 1,336    | 0.7                    |
| 1988 | 197,701 | 194,280  | 2,204    | 1,217    | 0.6                    |
| 1989 | 197,992 | 194,126  | 2,587    | 1,279    | 0.6                    |
| 1990 | 199,655 | 180,693  | 18,367   | 595      | 0.3                    |
| 1991 | 203,324 | 199,201  | 3,396    | 727      | 0.4                    |
| 1992 | 211,671 | 206,909  | 3,645    | 1,117    | 0.5                    |
| 1993 | 208,109 | 203,539  | 4,033    | 537      | 0.3                    |
| 1994 | 213,441 | 212,281  | 328      | 832      | 0.4                    |
| 1995 | 215,272 | 214,565  | 29       | 678      | 0.3                    |
| 1996 | 216,015 | 215,370  | 26       | 619      | 0.3                    |
| 1997 | 222,927 | 222,507  | 23       | 397      | 0.2                    |
| 1998 | 223,069 | 222,487  | 30       | 552      | 0.2                    |
| 1999 | 230,062 | 229,070  | 370      | 622      | 0.3                    |
| 2000 | 229,585 | 229,406  | 15       | 164      | 0.1                    |
| 2001 | 232,771 | 232,602  | 6        | 163      | 0.1                    |
| 2002 | 230,323 | 230,061  | 6        | 256      | 0.1                    |
| 2003 | 234,431 | 234,229  | 5        | 197      | 0.1                    |
| 2004 | 238,697 | 238,514  | 34       | 149      | 0.1                    |
| 2005 | 240,283 | 240,086  | 64       | 133      | 0.1                    |

\*All malignant neoplasms excluding non-melanoma skin cancer (ICD-10 C44) - see section 4.2.

† See section on 'validity' in section 5.1.

- (iii) histology codes that will not be accepted in combination with any of the sites in a group (of which there are two)

If a record passes all the checks and cross checks, it is given a quality status of 1. If a record fails any one of a small number of vital checks and cross checks, for example if the date of birth is invalid, thus making it impossible either to include the data in an output table in the ONS annual reference volume<sup>10</sup> or to flag the person concerned at the NHSCR, it is given a quality status of 3. If a record passes all the vital checks and cross checks but fails one or more other checks, it is given a quality status of 2, and along with records that have a quality status of 1, can be used in outputs and sent to the NHSCR for flagging. Information about all records that fail any of the validation checks is sent to the registries for them to investigate and submit corrections.


The national standards for cancer registries<sup>33,34,42</sup> require that when a registry's data for a particular year are complete, no more than 0.5 per cent of records should have a quality status of 3. When OPCS redeveloped its cancer registration computer processing system in the early 1990s, all the previously submitted records were re-validated using the more stringent checks<sup>40</sup> incorporated in the new system. The quality status of all the records on the database at the National Cancer Intelligence Centre (NCIC) from 1971 up to 2005 is shown in Table B. Over the past five years, the proportion of records with serious errors has consistently been 0.1 per cent.

As with completeness, the **accuracy** of the data (that is the proportion of cases recorded with a given characteristic that truly have the attribute) is only occasionally known directly from special studies. Various indirect measures, however, suggest that there is considerable variation between regions. A report of a project to audit the quality and comparability of cancer registration data in the UK, carried out under the aegis of the United Kingdom Association of Cancer Registries (see section 3) was published in 1995.<sup>43</sup> Variations among the registries were found in data quality for diagnostic factors, incidence date, stage of disease, treatment information, and use of death information. A study at the Merseyside and Cheshire Registry<sup>44</sup> also found that data quality within a registry varied by the age of the patient, the cancer site, and area of residence. However, a substantial audit of Scottish cancer registry data,<sup>45</sup> in which information was re-abstracted from the available records, found that severe discrepancies had occurred in under 3 per cent of cases. The review<sup>42</sup> concluded that although comparisons between the various published studies was difficult, cancer registry records were largely complete, accurate and reliable. The review found that the quality of cancer registry data depended heavily on the competence and experience of staff in the registry; on maintaining good relationships with clinicians, staff in health authorities, and scientists; and on the registry's active involvement in research.

The **timeliness** of national data based on the full set of individual records depends on the speed of the slowest registry in completing its submissions to ONS. In the past, there has often been (at least) one registry that, for a variety of excellent reasons at the time, has lagged considerably behind the others. Also, cancer registration is not statutory, and ONS has no organisational, managerial or financial control over the regional registries. In 1994, the registries passed from regional control to lead purchasers. Local needs for up-to-date information have in some areas resulted in considerable improvements in timeliness. On the other hand, although safeguards and quality and timeliness standards for national data were included in the national core contract,<sup>33,34</sup> the requirements of lead purchasers who hold the registries' budgets sometimes took priority over the supply of data to ONS. Several registries have recently redeveloped their computer systems and their timeliness has improved dramatically.

The point in time at which ONS, in consultation with the cancer registries, decides to produce the tables for the annual reference volume is necessarily a compromise between two principal considerations: the need to minimise the delay between the relevant data year and the publication of the detailed results, and the requirement to obtain a very high level of completeness of the data and hence minimise the number of **late registrations**. The gap between the data year and production of tables has varied considerably; as a result there are currently varying proportions of additional cancer registrations held on the computer files at ONS compared with the numbers published in the corresponding annual reference volume, as shown in Figure F. Over the thirty-three year period the differences have averaged around 3 per cent although for 1985, 1986 and 1987 there are now around 10 per cent more cases on the national register than when the annual reference volumes were published. This was the result of problems with the transmission of data between the Thames Registry and ONS.<sup>46</sup> The overall figures contain within them some substantial variations among

**Figure F** Number of registrations (thousands) published in ARVs and currently (December 2007) on the NCIC database, England, 1971–2005



the regions. For example, a problem at OPCS (as it was then) with the processing of one data tape for 1985 from the North Western registry resulted in a shortfall in the published figures of around two thousand registrations. Although this made a difference of less than 1 per cent to the total for England and Wales, it represented a shortfall of around 10 per cent for the North Western region.

The cancer registration database is “dynamic” in the sense that records may be modified or deleted if new information is obtained. The information from “trace back” of a death certificate may result in a case being registered many years after the true incidence date. **Late deletions and amendments** to data are in general a much smaller problem than late new registrations.

A CD-ROM containing anonymised records of new cases of cancer, including all the ‘late’ registrations, for incidence years 1971 to 1992 has been produced by ONS;<sup>11</sup> the data are geographically coded to regional health authority level. Also included are anonymised records of deaths from cancer for 1971-1997, and the relevant mid-year population estimates to enable the calculation of incidence and mortality rates. The NCIC plans to update this CD-ROM with data from 1991 onwards. The CD-ROM can be purchased from ONS.

Special tabulations involving data not on the CD-ROM are available to order (subject to confidentiality thresholds) and on repayment. Such requests or enquiries should be made to:

✉ Cancer@ons.gsi.gov.uk

While late registrations result in the figures published in the annual reference volume being too low, **duplicate registrations** can artificially inflate them. Such duplication may arise if a patient is resident in one area but treated in another; this is particularly so for those resident in North Wales and treated in Liverpool, and for those resident around London who are treated in central London. Duplications are prevented firstly by the cancer registries that hold alphabetic indexes of names and carry out computer searches; and secondly by the flagging at NHSCR, where if on flagging, a previous registration is found for the individual, the registrations are examined to see if they are duplicates or **true multiple primary** cancers. The rules for decisions on duplicates/multiples have changed over time, particularly for 1978 registrations, which led to a 13 per cent decrease in registrations for Welsh residents. Currently, with the agreement of the cancer registries, all such cases are referred back to them by ONS, and decisions taken according to an agreed set of rules.<sup>40</sup>

Since the early 1960s, copies of **information from all death certificates** mentioning cancer have been sent by ONS to the registry covering the area in which the death occurred. Any cancers registered solely from the information on the death certificates were not included in the published information

prior to 1974, at which point an abrupt increase occurred. Registries use the death certificate information in different ways. For example, some check the data by reference to clinical notes or other local data sources, but others simply enter the death as a registration (with the year of death as the incidence year).

Inaccuracies and incompleteness may arise from **diagnostic practice**, and changes in it, although such errors and changes come from outside the cancer registration system and are not under its control. Misclassification of cancers is more likely to occur when there is no opportunity to obtain histological confirmation of disease, or if the tumour has a pre-malignant stage that can be confused with invasive carcinoma. Misclassification may also result from mistakes in the collection, abstraction or coding of information both before and after it reaches the registry. Also, **clinical and pathological (and registry) definitions of cancer** may change over time and between places, particularly for borderline malignant conditions.

Changes in **coding systems** may cause discontinuities in published data. For the national data held by ONS for incidence years 1971 to 1978, site is coded to ICD-8 and histology by the *Manual of Tumor Nomenclature and Coding* (MOTNAC) 1968 edition;<sup>47</sup> for incidence years 1979 to 1994, site is coded to ICD-9 and histology to ICD-O;<sup>17</sup> and from incidence year 1995 onwards, site is coded to ICD-10 and histology to ICD-O2<sup>1</sup>. Details of the effect of the changes between the ICD revisions on mortality statistics have been published;<sup>48</sup> these give an indication of their likely effect on cancer registrations. In addition, there have been some minor changes in ONS coding and classification rules.<sup>37</sup> Over time the submission of data from the registries to ONS on abstract cards was superseded by computer media (punched cards, magnetic tape and diskettes). Abstract cards were coded at ONS whereas magnetic tapes and diskettes were coded by the registry before being sent to ONS. Thus a change to magnetic tape (the last registry to do so was Oxford in 1985) may have been accompanied by changes in interpretation of coding.

In addition, the **completeness of flagging** of registrations by NHSCR is important for cohort studies. The proportion of cancer registrations received by ONS that were successfully linked to an NHSCR record was on average about 96 per cent from 1971 up to 1989. With the computerisation at NHSCR and improvements in data quality by the regional cancer registries, this has risen to over 99 per cent for data for 1993 and subsequent years. The importance for any particular study of the records not traced will depend upon any biases by area, cancer site or other main factors of interest.<sup>49</sup>

Rates of cancer incidence are dependent not only on the accuracy of the cancer registration data but also on that of the **population denominator data**. Recent censuses are believed to have been very accurate overall: in 1991 the non-responsive rate was estimated to be 3.8 per cent and in 2001

was estimated to be 6.1 per cent, but this varied by age and by geographic area. In 2001 these results were fully adjusted to take account of the estimated non-response. Annual mid-year estimates of population, based on census data together with information on births, deaths and migration (see section 5.5) also appear to be very accurate on a national basis, although errors of several per cent have been found for some counties, districts and London boroughs. There may also be differences between the definitions of 'place of residence' used for cancer registrations and for population estimates. For the former, the address used is 'the usual place of residence as given by the patient, whereas the census definition is not so straightforward, particularly when a person lives at more than one address throughout the year.<sup>50</sup> This may lead to biases in analyses of data for small areas that include large numbers of students, armed forces or people living in institutions.

Although the census population figures for 2001 were overall some 1 million lower than the previously published population estimates, the differences were concentrated largely in the younger age groups, particularly for males. Cancer is a disease predominantly of older people, and checks on data for England and Wales have shown that in general the effects on overall cancer incidence rates of using populations for the 1990s that have been revised in the light of the results of the 2001 Census, and subsequently, are very small.

Finally, in published data on the scale of the national cancer registration system it is almost inevitable that straightforward **errors** will occur, for example in the transcription and printing of tables. Corrections to known errors have been published.

## 5.2 Mortality data

Most deaths are certified by a medical practitioner. The death certificate is then usually taken to a registrar of births and deaths by a person known as an informant - usually a near relative of the deceased. In certain cases, deaths are referred to, and sometimes then investigated by, a coroner who sends information to the registrar of deaths, which is used instead of that from the medical practitioner. In some cases, additional information from the coroner's certificate is forwarded to ONS by the registrar. Thus the information used in ONS mortality statistics may have come from one of four sources: the doctor, the informant, a coroner, or derived from one or other of the above (for example, the age of the dead person is derived from date of birth and date of death).

A full set of notes and definitions for mortality data has been published by ONS.<sup>51</sup> This includes: base populations; occurrences and registrations; areal coverage; death rates and standardisation; certification of cause of death; coding the underlying cause of death; analysis of conditions mentioned on the death certificate; amended cause of death; accelerated registrations; legislation on registration of deaths and the processing, reporting and analysis of mortality data; and

historical changes in mortality data including the introduction of the Ninth Revision of the International Classification of Diseases in 1979, industrial action taken by registration officers in 1981-82, the amendment by OPCS in 1984 of WHO Rule 3 (one of the rules used to select the underlying cause of death), and the introduction of the Tenth Revision of the *International Classification of Diseases and Related Health Problems*.

In the early 1990s, OPCS redeveloped its deaths registrations computer processing system. The main changes affecting the data included the progressive computerisation of local offices of registrars of births and deaths, and the automation of cause of death coding. Further information is available<sup>51</sup> on the redevelopment of the deaths computer processing system, and the use of WHO Rule 3. There is also advice on using cause of death from 1993 onwards.

The main change in introducing automated cause of death coding was in the interpretation of WHO Rule 3. The death certificate is set out in two parts; part I gives the condition or sequence of conditions leading to death, while part II gives details of any associated conditions. Rule 3 states that 'if the condition selected by the General rules or Rules 1 and 2 can be considered a direct sequel of another reported condition, whether in part I or part II, select this primary condition'. The interpretation of Rule 3 was broadened by OPCS in 1984 so that certain conditions that were often terminal, such as bronchopneumonia or pulmonary embolism, could be considered a direct sequel of any more specific condition reported. The more specific condition would then be regarded as the underlying cause. This change in interpretation meant that the numbers of deaths from certain conditions such as pneumonia fell suddenly in 1984, while deaths from conditions often mentioned in part II of the certificate rose.<sup>52</sup> The change in 1993 was a move back to the internationally accepted interpretation of Rule 3 operating in England and Wales before 1984.

Information on the effects of moving back to this earlier interpretation of Rule 3 have been published.<sup>53,54</sup> The expected effects were based on the assumption that any allowance for them was the same in 1993 as it was in 1984 (which is unlikely to be exactly true). The effects of the change, however, appear to be generally in the opposite direction to those of 1984 and of a similar magnitude.<sup>51</sup>

Since January 2001, cause of death has been coded to ICD-10.<sup>1</sup> Under ICD-10, the interpretation of WHO Rule 3 is different from that in ICD-9, but similar to that adopted by OPCS for deaths in 1984-1992 (see above). In order to quantify the effects of this and other differences between ICD-9 and ICD-10, ONS carried out a bridge coding study: all deaths registered in 1999 were independently coded to both ICD-9 and ICD-10, and the causes compared using internationally agreed groups of equivalent codes. The full results can be found in the Report 'Results of the ICD bridge coding study,

England and Wales, 1999' in *Health Statistics Quarterly* 14.<sup>55</sup> The numbers of deaths coded to "malignant neoplasms" in ICD-10 were higher than in ICD-9 by around 3 per cent for males and 2 per cent for females.

### 5.3 Quality of mortality data

As explained above, mortality statistics in England and Wales are derived from the registration of deaths certified by a doctor or coroner. The data pass through a number of processes before becoming usable for analysis. These processes are complex, and involve a wide range of people, organisations and computer systems. The scope for error is correspondingly wide. ONS aims to produce mortality statistics with the highest achievable quality given the available resources.

There are quality checks and validations carried out at the various stages in the creation of mortality statistics<sup>51</sup>. These include: writing the medical certificate of death; registration of the death; entry of data in the computer system used by registrars of births and deaths; other checks made by the registration service; receipt of death registration data at ONS; validation processes; routine checks by ONS; the automated cause coding system; checks before and after extraction of data for analysis; checks on routine outputs; and analysis of ill-defined causes of death.

### 5.4 Advantages and disadvantages of incidence and mortality data

In 1981, Doll and Peto<sup>56</sup> compared the quality and utility of incidence and mortality data in the USA. The incidence data came from two 'one off' national cancer surveys in 1947/48 and 1969-71, and from continuous collection up to 1977 by the Surveillance, Epidemiology and End Results (SEER) cancer registries (which operated in various cities and states and in total covered about 10 per cent of the US population). They showed that mortality data were largely reliable and stable over time. However, examples for a few major sites

such as breast (in females) and prostate indicated that there were discrepancies with incidence that were too large to be explained without there being serious upward biases in the trends in cancer registration data, and that mortality data were generally more trustworthy.

These conclusions do not apply to cancer registration data in the UK. As noted above, a review of the quality of UK cancer registry data<sup>43</sup> concluded that results were largely complete, accurate and reliable. The data on cancer registration 'quality indicators' (mortality to incidence ratios, zero survival cases, and unspecified site) demonstrate that although there is some variability within England and Wales, the overall ascertainment and reliability is good. Also, the trends in incidence and mortality illustrated for the major cancer sites in Chapter 2 of the *Cancer Trends* volume<sup>12</sup> clearly confirm that, although there may have been some under registration, particularly for lung and stomach cancer, in the early 1970s, from the late 1970s onwards the trends in incidence are consistent with those for mortality and the recorded improvements in survival.<sup>57,58</sup>

Mortality data are generally more timely than incidence data (the current gap is now one year - the latest mortality data are for 2006,<sup>59</sup> while incidence data are available up to 2005). This is largely because there is a statutory requirement to register a death within five days, and for the large majority of deaths there is only one source document. As explained above, cancer registration is not statutory and collating information from the necessary wide variety of sources is time consuming, and ONS cannot produce final results for England until data have been received from all registries. But trends in mortality give only a delayed indication of trends in new cases, because for cancers with moderate or good survival, those dying in any one year may have been diagnosed and treated many years earlier. Even in the 1970s, five year survival from many of the major cancers, for example breast (in females), cervix, larynx, melanoma of skin, testis and uterus, was in the range 50-70 per cent and since then there have been notable improvements in survival for almost all except the highly fatal cancers (lung,

**Figure G Advantages and disadvantages of incidence and mortality data**

| Incidence   | Mortality   |
|---|---|
| <p><b>Advantages</b></p> <ul style="list-style-type: none"> <li>• high quality coding</li> <li>• both cancer site and histology</li> <li>• very low proportion site unspecified</li> <li>• incidence date known (except for small proportion registered solely from a death certificate)</li> </ul> | <p><b>Disadvantages</b></p> <ul style="list-style-type: none"> <li>• diagnostic accuracy less certain than for incidence</li> <li>• site only, no histology</li> <li>• around 10 per cent site unspecified</li> <li>• deaths in any one year result from cases diagnosed over a long previous period</li> </ul> |
| <p><b>Disadvantages</b></p> <ul style="list-style-type: none"> <li>• may not be complete</li> <li>• may not be sufficiently timely</li> <li>• national coverage not achieved until 1962; evidence of under-ascertainment in the early 1970s</li> </ul>  | <p><b>Advantages</b></p> <ul style="list-style-type: none"> <li>• virtually 100 per cent complete</li> <li>• timely (within months of the end of a data year)</li> <li>• very long time series (if not affected by ICD or other coding changes<sup>48</sup>)</li> </ul>   |

oesophagus, pancreas).<sup>57,58</sup> This has made incidence data increasingly more important for early monitoring of trends, and for assessment of major public health interventions such as breast and cervical screening.<sup>60-63</sup>

Death is not always correctly certified, or the underlying cause correctly coded, even for cancer. Many studies have shown wide variability in certification and coding, particularly between countries.<sup>64-75</sup> Although the mortality data are virtually 100 per cent complete, while cancer registration data may not be, around 10 per cent of deaths in England and Wales are coded to 'site unspecified',<sup>51</sup> whereas the corresponding proportion for incidence data is only 3 per cent. These and other advantages and disadvantages of incidence and mortality data are summarised in Figure G.

Cancer mortality trends are therefore an imperfect and fuzzy indicator of trends in the efficacy of treatment: they reflect earlier trends in both incidence and survival and cannot be interpreted sensibly without them. Incidence and survival trends from the national cancer registry, based on data from the regional cancer registries, provide additional insight into the complex problems of cancer control. None of these indicators is perfect, and none is adequate on its own.<sup>76</sup>

## 5.5 Populations

The population figures in **Table 2** used to calculate incidence rates for 2005 are mid-2005 estimates of the resident population of England and Wales based on the 2001 Census of Population. These estimates include members of HM and non-UK armed forces stationed in England and Wales, but exclude those stationed outside. ONS mid-year population estimates are based on updates from the most recent census, allowing for births, deaths, net migration and ageing of the population.

Whenever results become available from a census, ONS creates a new base for the population estimates. Thus, following the 2001 Census, ONS revised the mid-year population estimates from 1982 to 2000. Further revisions were made to the estimates from 1992 because further information from research following the Census became available. The research was carried out to understand the reasons for differences between the 2001 Census-based estimates and the mid-year estimates rolled forward from earlier censuses.

Population estimates for mid-2005 were published on 24 August 2006 and revised along with estimates for 2002 to 2004 on 22 August 2007. Revised estimates for mid-2001 were published on 9 September 2004 and revised estimates for 1992 to 2000 were published on 7 October 2004. All these estimates incorporate the findings of the local authority population studies, the results of which were published in July 2004. Further information on population estimates, and their methodology, can be found on the National Statistics website: [www.statistics.gov.uk/popest](http://www.statistics.gov.uk/popest).

## 5.6 Government Office Regions (GORs)

Regional incidence data in this annual reference volume are presented by the patient's Government Office Region of usual residence.

Some cancer registry publications present statistics based on the number of patients treated in the cancer registry area. Statistics in some cancer registry reports may therefore differ from the analyses by region of residence given in this volume.

## 5.7 Methods

### *Age-standardised rates*

The incidence of cancer varies greatly with age. Differences in the age structure of populations between geographical areas or over time therefore need to be controlled to give unbiased comparisons of incidence. This can be achieved through either direct or indirect standardisation.<sup>77</sup>

- (i) Direct standardisation: age- and sex-specific rates in each group in the populations to be compared are multiplied by the corresponding number of people in a 'standard' population, usually the World or (here) European Standard Population (Table C), and then summed to give an overall rate per 100,000 population.

Thus the directly standardised incidence rate using the European Standard Population is given by:

$$I(\text{ASR/E}) = \left\{ \sum_k i_k P_k \right\} / \sum_k P_k$$

where  $i_k$  = observed incidence rate in age group  $k$   
 $k$  = 1, ..., 19 and the 19 age groups are 0, 1-4, 5-9, ..., 80-84, and 85 and over  
 $P_k$  = standard population in age group  $k$

Such directly standardised rates are presented in **Table 10**,

**Table C Distribution of the European Standard Population**

| Age   | Population | Age          | Population     |
|-------|------------|--------------|----------------|
| 0     | 1,600      | 45-49        | 7,000          |
| 1-4   | 6,400      | 50-54        | 7,000          |
| 5-9   | 7,000      | 55-59        | 6,000          |
| 10-14 | 7,000      | 60-64        | 5,000          |
| 15-19 | 7,000      | 65-69        | 4,000          |
| 20-24 | 7,000      | 70-74        | 3,000          |
| 25-29 | 7,000      | 75-79        | 2,000          |
| 30-34 | 7,000      | 80-84        | 1,000          |
| 35-39 | 7,000      | 85 +         | 1,000          |
| 40-44 | 7,000      |              |                |
|       |            | <b>Total</b> | <b>100,000</b> |

Source: L Sharp et al, *Cancer registration statistics Scotland, 1981-1990*, (Edinburgh, Information and Statistics Division of NHS Scotland, 1993).

which gives time series for 1996 to 2005.

(ii) Indirect standardisation: one set of age- and sex-specific rates (here those for England as a whole) is taken as the standard. These rates are then applied to each of several index populations of known age structure to show how many registrations would have been expected in these index populations had they, at each age, experienced the cancer incidence of the standard population. The ‘expected’ incidence so found is then compared with the observed, their ratio being multiplied by 100 to give an index, called the standardised registration ratio (SRR), in which 100 is the value for the standard population. Calculations are based on nineteen age groups (those used in **Table 1**).

The use of the SRR enables data for a particular site and sex to be presented as a single index figure relative to a defined standard or baseline. If the incidence patterns in the various age groups are different in the two populations or time periods, however, SRRs are an unreliable guide to comparison, and age-specific rates should be examined.

**Table 6** shows the SRRs in GORs of residence for 2005. For each cancer, the registration rates in England are taken as standards (with the sexes considered separately). For example, the SRR for cancer of the stomach in the East Midlands GOR was calculated as:

$$\text{SRR} = \frac{100 \times \text{No. of registrations of cancer of the stomach in East Midlands GOR}}{\sum_{\text{Age group}} \left[ \begin{array}{l} \text{Population in each age group, East} \\ \text{Midlands GOR} \times \text{registration rate for} \\ \text{cancer of the stomach for that age, England} \end{array} \right]}$$

### Cumulative lifetime risk

The risk of a person developing cancer during their lifetime is obtained by applying sex- and age-specific incidence rates to the person years at risk derived from the numbers of survivors from a hypothetical cohort based on an England life table. It gives the percentage of the cohort that would develop cancer should the current age- and sex-specific rates be experienced throughout the lifetime of the cohort.<sup>35</sup> It can also be expressed as the odds of developing the disease during a person’s lifetime.

### Survival

ONS registrations since 1971 have been linked at the NHSCR to the death records (as already described); national survival tables have been published in *Cancer Survival Trends in England and Wales, 1971-1995: deprivation and NHS region*,<sup>57</sup> and extended in *Cancer Survival in England and Wales, 1991-98*,<sup>58</sup> *Cancer Survival 1992-1999*,<sup>78</sup> *Cancer Survival, England, 1993-2000*,<sup>79</sup> *Cancer Survival, England and Wales 1991-2001*,<sup>80</sup> *Trends and socio-economic inequalities in cancer*

*survival in England and Wales up to 2001*,<sup>81</sup> *Cancer Survival, England, 1998-2003*,<sup>82</sup> *Cancer Survival, England, 1998-2004*,<sup>83</sup> and *Cancer Survival, England, 1999-2004*.<sup>84</sup>

The results of the first EURO CARE cancer survival study, which covered 30 cancer registries in 12 European countries, including England and Scotland, were published<sup>85</sup> in 1995. Six cancer registries in England participated; these were geographically spread around the country and covered almost half the population. Cancer registration data up to 1985 were included.

Results from the second EURO CARE study, which covered 45 cancer registries in 17 countries, also including England and Scotland, have also been published.<sup>86,87</sup> Seven cancer registries in England participated. Cancer registration data up to 1989 were included.

Some results from the third EURO CARE study, which covered 56 cancer registries in 22 countries, including eight English registries and the registries in Wales and Scotland, were released at the European Cancer Conference (ECCO 12) in September 2003; full results were published in the journal *Annals of Oncology*.<sup>88</sup> Cancer registration data up to 1994 were included in the study.

Some of the results from the fourth EURO CARE study, which covered 83 cancer registries in 23 countries, including nine English registries and the registries in Wales, Scotland and Northern Ireland, were published<sup>89</sup> in 2007. Cancer registration data up to 1999 were included in the study. In addition, period analyses to estimate cancer survival by the use of recent data was undertaken. These results covered 47 registries in 21 countries, including the registries in England, Wales, Scotland & Northern Ireland, and were published<sup>90</sup> in 2007. Cancer registration data up to 2002 were included in the study. Full results from the fourth EURO CARE study will be published in 2008.

### 5.8 Symbols and conventions used

- 0.0 less than 0.05
- nil
- .. not available
- : not appropriate
- nos not otherwise specified
- nec not elsewhere classified

## 6. Maps and contact addresses

**Figure H** Areas covered by the regional cancer registries, England, 2007



### Cancer registries in the United Kingdom: current directors, addresses, telephone and fax numbers

United Kingdom Association of Cancer Registries website: [www.ukacr.org](http://www.ukacr.org)

#### (a) England

|  |  |  |   |
|--|--|--|---|
| Northern & Yorkshire   | Professor D Forman, Director<br>Tel: 0113 206 8334<br>Fax: 0113 206 8766<br>david.forman@nycris.leedsth.nhs.uk | Trent  | Mr D Meechan<br><br>Trent Cancer Registry<br>5 Old Fulwood Road<br>SHEFFIELD, S10 3TG<br><br>Tel: 0114 226 3564<br>Fax: 0114 226 3561 |
| Dr C Pollock, Medical Director<br><br>Tel: 0113 206 8350<br>Fax: 0113 206 8766<br>colin.pollock@nycris.leedsth.nhs.uk<br><br>Northern and Yorkshire Cancer Registry<br>and Information Service<br>Level 6, Bexley Wing<br>St James's University Hospital<br>Beckett Street<br>Leeds<br>LS9 7TF | Eastern  | Dr J Rashbass, Director<br>Dr C Brown, Medical Director<br><br>Eastern Cancer Registration and<br>Information Centre<br>Unit C,<br>Magog Court<br>Shelford Bottom<br>CAMBRIDGE, CB22 3AD<br><br>Tel: 01223 213499<br>Fax: 01223 213571<br>jem@cbcu.cam.ac.uk |   |
| Tel: 0113 206 8830<br>Fax: 0113 206 8766   |  |  |   |

**Figure I Areas covered by the Government Office Regions, England, 2005**



Thames Professor H Møller, Director  
& Professor of Epidemiology

Thames Cancer Registry  
1st Floor  
Capital House  
42 Weston Street  
LONDON, SE1 3QD

Tel: 020 7378 7688  
Fax: 020 7378 9510  
henrik.moller@kcl.ac.uk

Oxford Dr M Roche, Medical Director

Oxford Cancer Intelligence Unit  
4150 Chancellor Court  
Oxford Business Park South  
OXFORD OX4 2GX

Tel: 01865 334770  
Fax: 01865 334794  
monica.roche@ociu.nhs.uk

South West Dr J Verne, Director

South West Public Health Observatory  
Grosvenor House  
149 Whiteladies Road  
BRISTOL, BS8 2RA

Tel: 0117 970 6474  
Fax: 0117 970 6481  
julia.verne@swpho.nhs.uk

Mr T Malik, Deputy Director

South West Cancer Intelligence Service  
South West Public Health Observatory  
The Meadows, Dean Hill Park  
Wiltshire  
SP5 1EZ

Tel: 01794 344690  
Fax: 01794 344699  
tariq.malik@swpho.nhs.uk

West Midlands Dr G Lawrence, Director  
West Midlands Cancer Intelligence Unit  
Public Health Building  
The University of Birmingham  
Edgbaston  
BIRMINGHAM, B15 2TT  
Tel: 0121 414 7711  
Fax: 0121 414 7712  
gill.lawrence@wmciu.nhs.uk

North West Dr A Moran, Director  
North West Cancer Intelligence Service  
2nd Floor  
Muspratt Building  
The University of Liverpool  
LIVERPOOL, L69 3GB  
Tel: 0151 794 5691  
Fax: 0151 794 5700  
info@mccr.nhs.uk  
North West Cancer Intelligence Service  
Centre for Cancer Epidemiology  
Christie Hospital NHS Foundation Trust  
Kinnaird Road  
Whthington  
MANCHESTER, M20 4QL  
Tel: 0161 446 3579  
Fax: 0161 446 3590  
tony.moran@nwcis.nhs.uk  
info@nwcr.nhs.uk

**(b) Wales**

Dr J Steward, Director  
Welsh Cancer Intelligence  
& Surveillance Unit  
Floor 13  
Brunel House  
2 Fitzalan Road  
CARDIFF, CF24 0HA  
Tel: 029 20 373500  
Fax: 029 20 502121  
john.steward@velindre-tr.wales.nhs.uk

**(c) Scotland**

Dr D Brewster, Director of Cancer  
Registration in Scotland  
Scottish Cancer Registry  
Epidemiology and Statistics Group  
Information Services  
1st Floor, Gyle Square  
1 South Gyle Crescent  
EDINBURGH EH12 9EB  
Tel: 0131 275 6092  
Fax: 0131 275 7511  
david.brewster@isd.csa.scot.nhs.uk

**(d) N Ireland**

Dr A Gavin, Director  
Northern Ireland Cancer Registry  
Centre for Clinical and population Sciences  
Queen's University of Belfast  
Mulhouse Building  
Grosvenor Road  
BELFAST, BT12 6BJ  
Tel: 028 9063 2573  
Fax: 028 9024 8017  
nicr@qub.ac.uk

## References

1. World Health Organisation. *International Statistical Classification of Diseases and Related Health Problems, volumes 1, 2 and 3 (Tenth Revision)*. Geneva: WHO, 1992–1994.
2. Office for National Statistics. *Cancer statistics - registrations, England and Wales, 1994*. Series MB1 no.27. London: The Stationery Office, 2000.
3. Office for National Statistics. *Cancer statistics - registrations, England, 1995-1997*. Series MB1 no.28. London: The Stationery Office, 2001.
4. Office for National Statistics. *Cancer statistics - registrations, England, 1998*. Series MB1 no. 29. London: Office for National Statistics, 2001.
5. Office for National Statistics. *Cancer statistics - registrations, England, 1999*. Series MB1 no. 30. London: Office for National Statistics, 2002.
6. Office for National Statistics. *Cancer statistics - registrations, England, 2000*. Series MB1 no. 31. London: Office for National Statistics, 2003.
7. Office for National Statistics. *Cancer statistics - registrations, England, 2001*. Series MB1 no.32. London: Office for National Statistics, 2004.
8. Office for National Statistics. *Cancer statistics - registrations, England, 2002*. Series MB1 no.33. London: Office for National Statistics, 2005.
9. Office for National Statistics. *Cancer statistics - registrations, England, 2003*. Series MB1 no. 34. London: Office for National Statistics, 2005.
10. Office for National Statistics. *Cancer statistics - registrations, England, 2004*. Series MB1 no. 35. London: Office for National Statistics, 2006.
11. Quinn MJ, Babb PJ, Jones J, Baker A, Ault C. *Cancer 1971-1997*. Registrations of cancer cases and deaths in England and Wales by sex, age, year, health region and type of cancer (CD-ROM). London: Office for National Statistics, 1999.
12. Quinn MJ, Babb P, Brock A, Kirby L, Jones J. *Cancer Trends in England and Wales 1950-1999*. Studies on Medical and Population Subjects No.66. London: The Stationery Office, 2001.
13. Data Source: Department of Health programme budgeting data at <http://www.dh.gov.uk>
14. Department of Health. *The Cancer Reform Strategy* London: Department of Health, 2007.
15. Unpublished information from the National Cancer Research Institute
16. Unpublished information from the Department of Health
17. Quinn MJ, Wood H, Cooper N, Rowan S. *Cancer Atlas of the United Kingdom and Ireland 1991-2000*. Studies on Medical and Population Subjects No 68. London: HMSO, 2005.
18. Parkin DM, Chen VW, Ferlay J, Galceran J, Storm HH, Whelan SL. *Comparability and Quality Control in Cancer Registration*. IARC Technical Report No. 19. Lyons: International Agency for Research on Cancer, 1994.
19. Jensen OM, Parkin DM, Maclellan R, Muir CS, Skeet RG. *Cancer Registration: Principles and Methods*. IARC Scientific Publications No.95. Lyons: International Agency for Research on Cancer, 1991.
20. Office of Population Censuses and Surveys. *Report of the Advisory Committee on Cancer Registration*. London: OPCS, 1970.
21. Office of Population Censuses and Surveys. *Report of the Advisory Committee on Cancer Registration, 1980: Cancer registration in the 1980s*. Series MB1 no.6. London: HMSO, 1981.
22. Department of Health. *Working for Patients. The Health Service. Caring for the 1990s*. CM 555. London: HMSO, 1989.
23. Office of Population Censuses and Surveys. *A Review of the National Cancer Registration System in England and Wales*. Series MB1 no.17. London: HMSO, 1990.
24. NHS Management Executive. *Minimum data set for the National Cancer Registration System*. EL(92)95. London: Department of Health, 1992.
25. Quinn MJ, Charlton JRH. Person-based follow-up of cancer cases: linkage using fuzzy matching. Proc Int Conf IASS/IAOS Satellite Meeting on Longitudinal Studies, Jerusalem, 1997.
26. Gill LE, Simmons HM. *An algorithm for fixed-length proper name compression: Oxford Name Compression Algorithm (ONCA)*. University of Oxford, Unit of Clinical Epidemiology, 1992.
27. Newcombe HB. *Handbook of Record Linkage – Methods for Health and Statistical Studies, Administration and Business*. Oxford: Oxford Medical Publications, Oxford University Press, 1988.
28. Kendrick S, Clarke J. The Scottish Record Linkage System. *Health Bulletin (Edinburgh)* 51 No.2, March 1993.
29. Department of Health and Welsh Office. *A policy framework for commissioning cancer services. A report by the Expert Advisory Group on Cancer to the Chief Medical Officers of England and Wales*. London: Department of Health, 1995. (Calman-Hine report.)
30. Cancer Registration in England: A way forward. [The “Gillis” Report.] Department of Health 2001: <http://www.doh.gov.uk/cancer>
31. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J. *Cancer Incidence in Five Continents, Volume VII*. IARC Scientific Publications No.143. Lyons: International Agency for Research on Cancer, 1997.
32. Department of Health. Action Programme for Cancer Registration. Department of Health, 2001: <http://www.doh.gov.uk/cancer>
33. NHS Executive. *Core contract for purchasing Cancer Registration*. EL(96)7. London: NHS Executive, 1996.

34. Winyard G. EL(96)7: *Core contract for purchasing cancer registration* (letter). Leeds: NHS Executive, 1998.
35. Parkin DM, Muir CS, Whelan SL, Gao Y-T, Ferlay J, Powell J. *Cancer Incidence in Five Continents, Volume VI*. IARC Scientific Publications No. 120. Lyons: International Agency for Research on Cancer, 1993.
36. Swerdlow AJ. Cancer registration in England and Wales: Some aspects relevant to interpretation of the data. *Journal of the Royal Statistical Society Series A* 1986; **149**: 146-160.
37. Hawkins MM, Swerdlow AJ. Completeness of cancer and death follow-up obtained through the National Health Service Central Register for England and Wales. *British Journal of Cancer* 1992; **66**: 408-413.
38. Villard-Mackintosh L, Coleman MP, Vessey MP. The completeness of cancer registration in England: an assessment from Oxford FPA study. *British Journal of Cancer* 1988; **58**: 507-511.
39. Office for National Statistics. *Cancer statistics registrations, England and Wales, 1993*. Series MB1 no.26. London: The Stationery Office, 1999.
40. Office of Population Censuses and Surveys. *Registry/ONS Interface Document. National Cancer Registration System, England and Wales*. London: OPCS, 1994 (subsequently revised).
41. Parkin DM, Whelan SL, Ferlay J, Teppo L and Thomas DB, (eds). *Cancer Incidence in Five Continents, Vol. VIII*. IARC Scientific Publications No.155. Lyons: International Agency for Research on Cancer, 2003.
42. Department of Health. *Cancer Registry Standards for England, v2.1*. London: DH, 2001.
43. Huggett C. *Review of the Quality and Comparability of Data held by Regional Cancer Registries*. Bristol: Bristol Cancer Epidemiology Unit incorporating the South West Cancer Registry, 1995.
44. Seddon DJ, Williams EMI. Data quality in population based cancer registration: an assessment of the Merseyside and Cheshire Cancer Registry. *British Journal of Cancer* 1997; **76**: 667-674.
45. Brewster D, Crichton J, Muir C. How accurate are Scottish cancer registration data? *British Journal of Cancer* 1994; **70**: 954-959.
46. Office of Population Censuses and Surveys. *Cancer statistics – registrations, England and Wales, 1988*. Series MB1 no.21. London: HMSO, 1994.
47. American Cancer Society. *Manual of tumor nomenclature and coding (MOTNAC)*. Washington DC: American Cancer Society, 1951.
48. Office of Population Censuses and Surveys. *Mortality statistics - comparison of 8th and 9th Revision of the International Classification of Diseases*. Series DH1 no.10. London: HMSO, 1983.
49. Quinn MJ. Progress on flagging cancers at NHSCR. *The Researcher* 2000; **14**: 4-5.
50. Office for National Statistics, General Register Office (Scotland) and Northern Ireland Statistics Research Agency. *2001 Census: Definitions, Great Britain*. London: HMSO, 2004.
51. Office for National Statistics. *Mortality statistics 2005: cause, England and Wales*. Series DH2 no.32. London: The Stationery Office, 2006.
52. Office of Population Censuses and Surveys. *Mortality statistics 1984: cause, England and Wales*. Series DH2 no.11. London: HMSO, 1985.
53. Office for National Statistics. *Mortality statistics 1993 (revised) and 1994: cause, England and Wales*. Series DH2 no.21. London: The Stationery Office, 1996.
54. Rooney C, Devis T. Mortality trends by cause of death in England and Wales 1980-94: the impact of introducing automated cause coding and related changes in 1993. *Population Trends* 1996; **86**: 29-35.
55. Office for National Statistics. Report: Results of the ICD-10 bridge coding study, England and Wales, 1999. *Health Statistics Quarterly* 2002; **14**: 75-83.
56. Doll R, Peto R. *The Causes of Cancer*. Oxford: Oxford University Press, 1981.
57. Coleman MP, Babb P, Damiecki P, Grosclaude P, Honjo S, Jones J, Knerer G, Pitard A, Quinn MJ, Sloggett A, De Stavola B. *Cancer Survival Trends in England and Wales, 1971-1995: deprivation and NHS Region*. Studies in Medical and Population Subjects No. 61. London: The Stationery Office, 1999.
58. Coleman MP, Babb PJ, Harris S, Quinn MJ, Sloggett A, De Stavola BL. Report: Cancer survival in England and Wales, 1991-98. *Health Statistics Quarterly* 2000; **6**: 71-80.
59. Office for National Statistics. Report: *Death registrations in England and Wales, 2006: causes*. Web supplement to Health Statistics Quarterly 34; [www.statistics.gov.uk/downloads/theme\\_health/Death\\_registration\\_2006.pdf](http://www.statistics.gov.uk/downloads/theme_health/Death_registration_2006.pdf)
60. Quinn MJ, Allen EJ, on behalf of the United Kingdom Association of Cancer Registries. Changes in incidence of and mortality from breast cancer in England and Wales since introduction of screening. *British Medical Journal* 1995; **311**: 1391-1395.
61. Blanks RG, Moss SM, McGahan CE, Quinn MJ, Babb PJ. Effect of NHS breast screening programme on mortality from breast cancer in England and Wales, 1990-8: comparison of observed with predicted mortality. *British Medical Journal* 2000; **321**: 665-669.
62. Quinn MJ, Babb PJ, Jones J, Allen E, on behalf of the United Kingdom Association of Cancer Registries. The effect of screening on the incidence of and mortality from cancer of the cervix in England: evaluation based on routinely collected statistics. *British Medical Journal* 1999; **318**: 904-908.
63. Sasieni P, Adams J. Effect of screening on cervical cancer mortality in England and Wales: analysis of trends with an age-cohort model. *British Medical Journal* 1999; **318**: 1244-1245.
64. Heasman MA, Lipworth L. *Accuracy of certification of cause of death*. Studies in Medical and Population Subjects no.20. London: HMSO, 1966.

65. Alderson MR, Meade TW. Accuracy of diagnosis on death certificates compared with that in hospital records. *British Journal of Preventive and Social Medicine* 1967; **21**: 22-29.
66. Grulich AE, Swerdlow AJ, dos Santos Silva I, Beral V. Is the apparent rise in cancer mortality in the elderly real? Analysis of changes in certification and coding of cause of death in England and Wales, 1970-1990. *International Journal of Cancer* 1995; **63**: 164-168.
67. Percy CL, Muir CS. The international comparability of cancer mortality data: results of an international death certificate study. *American Journal of Epidemiology* 1989; **129**: 934-946.
68. Ashworth TG. Inadequacy of death certification: proposal for change. *Journal of Clinical Pathology* 1991; **44**: 265-268.
69. Percy CL, Dolman AB. Comparison of the coding of death certificates related to cancer in seven countries. *Public Health Reports* 1978; **93**: 335-350.
70. Percy CL, Stanek E, Gloeckler Ries LA. Accuracy of cancer death certificates and its effect on cancer mortality statistics. *American Journal of Public Health* 1981; **71**: 242-250.
71. Percy CL, Miller BA, Gloeckler Ries LA. Effect of changes in cancer classification and the accuracy of cancer death certificates on trends in cancer mortality. *Annals of the New York Academy of Sciences* 1990; **609**: 87-97.
72. Hoel DG, Ron E, Carter R, Mabuchi K. Influence of death certificate errors on cancer mortality trends. *Journal of the National Cancer Institute* 1993; **85**: 1063-1068.
73. Lindahl BI, Johansson LA. Multiple cause-of-death data as a tool for detecting artificial trends in the underlying cause statistics: a methodological study. *Scandinavian Journal of Social Medicine* 1994; **22**: 145-158.
74. Garne JP, Aspegren K, Balldin G. Breast cancer as cause of death – a study over the validity of the officially registered cause of death in 2631 breast cancer patients dying in Malmö, Sweden 1964-1992. *Acta Oncologica* 1996; **35**: 671-675.
75. Jablon S, Thompson D, McConney M, Mabuchi K. Accuracy of cause-of-death certification in Hiroshima and Nagasaki, Japan. *Annals of the New York Academy of Sciences* 1990; **609**: 100-109.
76. Coleman MP, Babb PJ, Stockton D, Forman D, Møller H. Trends in breast cancer incidence, survival and mortality in England and Wales. *Lancet* 2000; **356**: 590-591 (letter).
77. dos Santos Silva I. *Cancer Epidemiology: Principles and Methods*. Lyons: International Agency for Research on Cancer, 1999.
78. Office for National Statistics. *Cancer Survival 1992-1999*. London: ONS, 2001.
79. Office for National Statistics. *Cancer survival, England, 1993-2000*. London: ONS, 2002.
80. Office for National Statistics. *Cancer survival, England and Wales, 1991-2001*. London: ONS, 2003.
81. Coleman MP, Rachet B, Woods L, Mitry E, Riga M, Cooper N, Quinn MJ, Brenner H and Estève J. Trends and socioeconomic inequalities in cancer survival in England and Wales up to 2001. *British Journal of Cancer* 2004; **90**: 1367-1313.
82. Office for National Statistics. *Cancer survival, England, 1998-2003*. London: ONS, 2005.
83. Office for National Statistics; Shah A, Rachet B, Cooper N, Westlake S, Rowan S, Quaresma M & Coleman M. *Cancer survival in England, 1998-2004*. London: ONS, 2007.  
<http://www.statistics.gov.uk/statbase/Product.asp?vlnk=14007>
84. Office for National Statistics; Shah A, Rachet B, Cooper N, Westlake S, Rowan S, Quaresma M & Coleman M. *Cancer survival in England, 1999-2004*. London: ONS, 2007.  
<http://www.statistics.gov.uk/statbase/Product.asp?vlnk=14007>
85. Berrino F, Sant M, Verdecchia A, Capocaccia R, Hakulinen T, Estève J (eds). *Survival of cancer patients in Europe. The EUROCORE Study*. Lyons: International Agency for Research on Cancer, IARC Scientific Publication No.132, 1995.
86. Coebergh JWW, Sant M, Berrino F, Verdecchia A (eds). *Survival of Adult Cancer Patients diagnosed from 1978-1989: The EUROCORE II Study*. European Journal of Cancer 1998, **34**, 2137-2278.
87. Berrino F, Sant M, Verdecchia A, Capocaccia R, Hakulinen T, Estève J (eds). *Survival of cancer patients in Europe during 1985-1989. EUROCORE II*. Lyons: International Agency for Research on Cancer, IARC Scientific Publication No. 151, 1999.
88. Micheli A, Baili P, Quinn MJ, Mugno E, Capocaccia R, Groscloude P and the EUROCORE working group. Life expectancy and cancer survival in EUROCORE-3 cancer registry areas. *Annals of Oncology* 2003; **14** (Supp 15): v28-v40.
89. Berrino F, De Angelis R, Sant M, Rosso S, Lasota M B, Coebergh J W and Santaquilani M. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCORE-4 study. *Lancet Oncology* 2007; **8**: 773-783.
90. Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, Kunkler I. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCORE-4 data. *Lancet Oncology* 2007; **8**: 784-796.

Table 1 Series MBI no. 36

To link to Excel version of the table - click on the red box surrounding the table title

**Table 1 Registrations of newly diagnosed cases of cancer: site, sex and age, 2005**

| ICD-10 code                  | Site description  | All ages | Age group      |           |            |            |            |            |              |              |              |              |
|------------------------------|---|----------|----------------|-----------|------------|------------|------------|------------|--------------|--------------|--------------|--------------|
|                              |   |          | Under 1        | 1-4       | 5-9        | 10-14      | 15-19      | 20-24      | 25-29        | 30-34        | 35-39        |              |
| <b>C00-C97, D00-D48, O01</b> | <b>All registrations</b>  | <b>M</b> | <b>171,255</b> | <b>73</b> | <b>243</b> | <b>209</b> | <b>223</b> | <b>418</b> | <b>613</b>   | <b>864</b>   | <b>1,359</b> | <b>2,161</b> |
|                              |   | <b>F</b> | <b>187,931</b> | <b>68</b> | <b>215</b> | <b>163</b> | <b>203</b> | <b>473</b> | <b>3,885</b> | <b>6,832</b> | <b>6,746</b> | <b>6,874</b> |
| <b>C00-C97</b>               | <b>All cancers</b>  | <b>M</b> | <b>154,191</b> | <b>61</b> | <b>227</b> | <b>182</b> | <b>176</b> | <b>355</b> | <b>520</b>   | <b>755</b>   | <b>1,180</b> | <b>1,860</b> |
|                              |   | <b>F</b> | <b>147,854</b> | <b>60</b> | <b>197</b> | <b>137</b> | <b>155</b> | <b>287</b> | <b>524</b>   | <b>989</b>   | <b>1,818</b> | <b>3,203</b> |
| <b>C00-C97 excl.C44</b>      | <b>All cancers excluding nmse<sup>1</sup></b>   | <b>M</b> | <b>119,625</b> | <b>61</b> | <b>225</b> | <b>182</b> | <b>169</b> | <b>341</b> | <b>491</b>   | <b>692</b>   | <b>983</b>   | <b>1,470</b> |
|                              |   | <b>F</b> | <b>119,352</b> | <b>60</b> | <b>197</b> | <b>135</b> | <b>148</b> | <b>273</b> | <b>483</b>   | <b>896</b>   | <b>1,598</b> | <b>2,738</b> |
| C00-C14                      | Malignant neoplasm of lip, mouth and pharynx  | M        | 2,934          | -         | -          | 3          | 3          | 11         | 8            | 16           | 28           | 52           |
|                              |   | F        | 1,625          | -         | 3          | 3          | 6          | 6          | 14           | 10           | 17           | 40           |
| C00                          | Malignant neoplasm of lip   | M        | 150            | -         | -          | -          | -          | -          | -            | 2            | 4            | -            |
|                              |   | F        | 82             | -         | 1          | -          | -          | -          | -            | -            | -            | -            |
| C01                          | Malignant neoplasm of base of tongue  | M        | 241            | -         | -          | -          | -          | -          | -            | -            | 1            | 2            |
|                              |   | F        | 81             | -         | -          | -          | -          | -          | -            | -            | 1            | 1            |
| C02                          | Malignant neoplasm of other and unspecified parts of tongue                           | M        | 481            | -         | -          | -          | -          | 2          | 1            | 2            | 8            | 14           |
|                              |   | F        | 342            | -         | -          | -          | 1          | -          | 3            | 3            | 5            | 6            |
| C03                          | Malignant neoplasm of gum   | M        | 130            | -         | -          | -          | -          | -          | -            | -            | 3            | 3            |
|                              |   | F        | 112            | -         | -          | 1          | -          | -          | 2            | -            | 1            | 2            |
| C04                          | Malignant neoplasm of floor of mouth  | M        | 239            | -         | -          | -          | -          | -          | -            | -            | -            | 5            |
|                              |   | F        | 105            | -         | -          | -          | -          | -          | -            | -            | -            | 3            |
| C05                          | Malignant neoplasm of palate  | M        | 135            | -         | -          | -          | -          | 1          | 1            | -            | -            | 3            |
|                              |   | F        | 122            | -         | 1          | -          | -          | -          | -            | 3            | 2            | 4            |
| C06                          | Malignant neoplasm of other and unspecified parts of mouth                            | M        | 182            | -         | -          | -          | -          | 1          | -            | 1            | 3            | 2            |
|                              |   | F        | 161            | -         | 1          | -          | -          | -          | -            | 1            | 1            | 4            |
| C07                          | Malignant neoplasm of parotid gland   | M        | 194            | -         | -          | 1          | 2          | 2          | 3            | 6            | 2            | 5            |
|                              |   | F        | 145            | -         | -          | -          | 4          | 4          | 5            | 2            | 5            | 8            |
| C08                          | Malignant neoplasm of other and unspecified major salivary glands                     | M        | 56             | -         | -          | -          | -          | 1          | -            | -            | 1            | 2            |
|                              |   | F        | 60             | -         | -          | -          | 1          | -          | 1            | -            | -            | 2            |
| C09                          | Malignant neoplasm of tonsil  | M        | 468            | -         | -          | -          | -          | -          | -            | 4            | 1            | 5            |
|                              |   | F        | 158            | -         | -          | -          | -          | 1          | -            | -            | 2            | 5            |
| C10                          | Malignant neoplasm of oropharynx  | M        | 121            | -         | -          | -          | -          | -          | -            | -            | -            | 3            |
|                              |   | F        | 36             | -         | -          | -          | -          | -          | -            | -            | -            | 2            |
| C11                          | Malignant neoplasm of nasopharynx   | M        | 152            | -         | -          | 1          | 1          | 4          | 3            | -            | 2            | 6            |
|                              |   | F        | 62             | -         | -          | 2          | -          | 1          | 3            | 1            | -            | 3            |
| C12                          | Malignant neoplasm of pyriform sinus  | M        | 164            | -         | -          | -          | -          | -          | -            | -            | 2            | -            |
|                              |   | F        | 37             | -         | -          | -          | -          | -          | -            | -            | -            | -            |
| C13                          | Malignant neoplasm of hypopharynx   | M        | 81             | -         | -          | -          | -          | -          | -            | -            | -            | -            |
|                              |   | F        | 48             | -         | -          | -          | -          | -          | -            | -            | -            | -            |
| C14                          | Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynx | M        | 140            | -         | -          | 1          | -          | -          | -            | 1            | 1            | 2            |
|                              |   | F        | 74             | -         | -          | -          | -          | -          | -            | -            | -            | -            |
| C15                          | Malignant neoplasm of oesophagus  | M        | 4,147          | -         | -          | -          | -          | -          | 2            | 1            | 3            | 14           |
|                              |   | F        | 2,290          | -         | -          | -          | -          | -          | -            | 1            | -            | 6            |
| C16                          | Malignant neoplasm of stomach   | M        | 4,247          | 1         | -          | -          | -          | 1          | 2            | 3            | 13           | 29           |
|                              |   | F        | 2,241          | -         | -          | -          | -          | -          | 1            | 5            | 15           | 19           |
| C17                          | Malignant neoplasm of small intestine   | M        | 379            | -         | -          | -          | -          | -          | -            | 2            | 5            | 5            |
|                              |   | F        | 323            | -         | -          | 1          | -          | -          | 1            | 3            | -            | 9            |
| C18-C20                      | Malignant neoplasm of colon and rectum  | M        | 16,282         | -         | -          | -          | -          | 6          | 19           | 32           | 45           | 107          |
|                              |   | F        | 13,283         | -         | -          | -          | -          | -          | 20           | 27           | 43           | 89           |

1. These figures exclude non-melanoma skin cancer (ICD-10 C44) - see section 4.2.

England  
Registered by October 2007

|       |       |        |        |        |        |        |        |        |             | Site description | ICD-10 code  |                             |
|-------|-------|--------|--------|--------|--------|--------|--------|--------|-------------|------------------|--|-----------------------------|
| 40-44 | 45-49 | 50-54  | 55-59  | 60-64  | 65-69  | 70-74  | 75-79  | 80-84  | 85 and over |                  |  |                             |
| 3,059 | 4,461 | 7,322  | 14,242 | 18,386 | 24,393 | 27,461 | 28,027 | 22,319 | 15,422      | M                | All registrations  | C00-C97,<br>D00-D48,<br>O01 |
| 7,736 | 8,701 | 11,418 | 15,424 | 16,731 | 18,893 | 19,646 | 21,768 | 20,903 | 21,252      | F                |  |                             |
| 2,650 | 3,962 | 6,525  | 12,825 | 16,687 | 22,141 | 24,814 | 25,289 | 20,063 | 13,919      | M                | All cancers  | C00-C97                     |
| 5,281 | 6,951 | 9,535  | 13,374 | 14,649 | 16,649 | 17,464 | 19,313 | 18,471 | 18,797      | F                |  |                             |
| 2,005 | 3,025 | 5,077  | 10,201 | 13,313 | 17,604 | 19,537 | 19,415 | 14,879 | 9,955       | M                | All cancers excluding nm5c <sup>1</sup>  | C00-C97<br>excl.C44         |
| 4,503 | 5,920 | 8,177  | 11,318 | 12,135 | 13,751 | 13,968 | 15,196 | 14,168 | 13,688      | F                |  |                             |
| 143   | 228   | 375    | 453    | 425    | 388    | 281    | 232    | 172    | 116         | M                | Malignant neoplasm of lip,<br>mouth and pharynx  | C00-C14                     |
| 56    | 100   | 141    | 170    | 190    | 177    | 185    | 158    | 175    | 174         | F                |  |                             |
| 6     | 3     | 9      | 12     | 14     | 28     | 13     | 26     | 14     | 19          | M                | Malignant neoplasm of lip  | C00                         |
| -     | -     | 4      | 4      | 4      | 14     | 9      | 10     | 14     | 22          | F                |  |                             |
| 14    | 23    | 45     | 37     | 45     | 32     | 20     | 11     | 10     | 1           | M                | Malignant neoplasm of<br>base of tongue  | C01                         |
| 1     | 6     | 11     | 13     | 6      | 10     | 12     | 8      | 7      | 5           | F                |  |                             |
| 21    | 41    | 52     | 83     | 71     | 61     | 51     | 31     | 28     | 15          | M                | Malignant neoplasm of<br>other and unspecified<br>parts of tongue                              | C02                         |
| 12    | 19    | 32     | 35     | 44     | 44     | 31     | 29     | 35     | 43          | F                |  |                             |
| 2     | 6     | 9      | 9      | 18     | 19     | 13     | 24     | 14     | 10          | M                | Malignant neoplasm of gum  | C03                         |
| -     | 1     | 7      | 8      | 10     | 17     | 17     | 14     | 19     | 13          | F                |  |                             |
| 14    | 18    | 35     | 47     | 40     | 30     | 29     | 11     | 7      | 3           | M                | Malignant neoplasm of<br>floor of mouth  | C04                         |
| 7     | 9     | 8      | 14     | 18     | 11     | 13     | 9      | 7      | 6           | F                |  |                             |
| 6     | 9     | 22     | 20     | 24     | 19     | 14     | 9      | 5      | 2           | M                | Malignant neoplasm of<br>palate  | C05                         |
| 6     | 9     | 10     | 14     | 15     | 15     | 13     | 8      | 12     | 10          | F                |  |                             |
| 11    | 11    | 27     | 17     | 24     | 20     | 25     | 14     | 12     | 14          | M                | Malignant neoplasm of<br>other and unspecified<br>parts of mouth                               | C06                         |
| 3     | 8     | 12     | 16     | 22     | 14     | 19     | 19     | 18     | 23          | F                |  |                             |
| 5     | 12    | 10     | 17     | 19     | 21     | 16     | 21     | 26     | 26          | M                | Malignant neoplasm of<br>parotid gland   | C07                         |
| 7     | 7     | 7      | 17     | 10     | 8      | 18     | 13     | 12     | 18          | F                |  |                             |
| 3     | 6     | 3      | 8      | 5      | 7      | 6      | 6      | 3      | 5           | M                | Malignant neoplasm of<br>other and unspecified<br>major salivary glands                        | C08                         |
| 5     | 4     | 2      | 2      | 7      | 5      | 6      | 7      | 12     | 6           | F                |  |                             |
| 35    | 59    | 91     | 102    | 61     | 55     | 23     | 14     | 14     | 4           | M                | Malignant neoplasm of<br>tonsil  | C09                         |
| 7     | 19    | 25     | 27     | 19     | 15     | 12     | 14     | 10     | 2           | F                |  |                             |
| 4     | 7     | 18     | 20     | 22     | 13     | 16     | 13     | 3      | 2           | M                | Malignant neoplasm of<br>oropharynx  | C10                         |
| 2     | 2     | 3      | 5      | 7      | 2      | 4      | 1      | 4      | 4           | F                |  |                             |
| 14    | 12    | 17     | 21     | 16     | 26     | 13     | 7      | 7      | 2           | M                | Malignant neoplasm of<br>nasopharynx   | C11                         |
| 4     | 6     | 5      | 5      | 6      | 6      | 8      | 2      | 3      | 7           | F                |  |                             |
| 3     | 13    | 19     | 28     | 26     | 21     | 14     | 19     | 16     | 3           | M                | Malignant neoplasm of<br>pyriform sinus  | C12                         |
| 1     | 4     | 4      | 3      | 6      | 2      | 7      | 5      | 3      | 2           | F                |  |                             |
| 2     | 5     | 9      | 6      | 13     | 11     | 13     | 11     | 8      | 3           | M                | Malignant neoplasm of<br>hypopharynx   | C13                         |
| 1     | -     | 4      | 4      | 7      | 7      | 6      | 9      | 5      | 5           | F                |  |                             |
| 3     | 3     | 9      | 26     | 27     | 25     | 15     | 15     | 5      | 7           | M                | Malignant neoplasm of<br>other and ill-defined<br>sites in the lip, oral<br>cavity and pharynx | C14                         |
| -     | 6     | 7      | 3      | 9      | 7      | 10     | 10     | 14     | 8           | F                |  |                             |
| 42    | 116   | 216    | 464    | 509    | 592    | 649    | 674    | 523    | 342         | M                | Malignant neoplasm of<br>oesophagus  | C15                         |
| 18    | 38    | 89     | 149    | 178    | 220    | 277    | 406    | 426    | 482         | F                |  |                             |
| 59    | 71    | 142    | 271    | 389    | 568    | 750    | 852    | 630    | 466         | M                | Malignant neoplasm of<br>stomach   | C16                         |
| 34    | 44    | 57     | 99     | 125    | 215    | 266    | 402    | 417    | 542         | F                |  |                             |
| 8     | 10    | 22     | 44     | 37     | 48     | 55     | 60     | 57     | 26          | M                | Malignant neoplasm of<br>small intestine   | C17                         |
| 12    | 17    | 14     | 34     | 20     | 33     | 52     | 36     | 56     | 35          | F                |  |                             |
| 196   | 404   | 681    | 1,387  | 1,715  | 2,285  | 2,802  | 2,936  | 2,241  | 1,426       | M                | Malignant neoplasm of colon<br>and rectum  | C18-C20                     |
| 181   | 330   | 512    | 899    | 1,094  | 1,491  | 1,908  | 2,269  | 2,254  | 2,166       | F                |  |                             |

**Table 1 Series MBI no. 36**

To link to Excel version of the table - click on the red box surrounding the table title

**Table 1 Registrations - continued**

| ICD-10 code | Site description   |   | All ages | Age group |     |     |       |       |       |       |       |       |  |
|-------------|--|---|----------|-----------|-----|-----|-------|-------|-------|-------|-------|-------|--|
|             |  |   |          | Under 1   | 1-4 | 5-9 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 |  |
| C18         | Malignant neoplasm of colon  | M | 9,640    | -         | -   | -   | -     | 5     | 13    | 23    | 32    | 63    |  |
|             |  | F | 9,022    | -         | -   | -   | -     | -     | 12    | 19    | 25    | 63    |  |
| C19         | Malignant neoplasm of rectosigmoid junction  | M | 1,455    | -         | -   | -   | -     | -     | -     | 1     | 4     | 7     |  |
|             |  | F | 1,021    | -         | -   | -   | -     | -     | 2     | 1     | 5     | 5     |  |
| C20         | Malignant neoplasm of rectum   | M | 5,187    | -         | -   | -   | -     | 1     | 6     | 8     | 9     | 37    |  |
|             |  | F | 3,240    | -         | -   | -   | -     | -     | 6     | 7     | 13    | 21    |  |
| C21         | Malignant neoplasm of anus and anal canal  | M | 265      | -         | -   | -   | -     | -     | 1     | 1     | 4     | 7     |  |
|             |  | F | 438      | -         | -   | -   | -     | -     | -     | 1     | 4     | 13    |  |
| C22         | Malignant neoplasm of liver and intrahepatic bile ducts  | M | 1,599    | 2         | 5   | 1   | 2     | 2     | 4     | 4     | 4     | 10    |  |
|             |  | F | 985      | 2         | 4   | -   | -     | 4     | 3     | 1     | 3     | 4     |  |
| C23         | Malignant neoplasm of gallbladder  | M | 136      | -         | -   | -   | -     | -     | -     | -     | -     | -     |  |
|             |  | F | 350      | -         | -   | -   | -     | -     | -     | 1     | -     | 2     |  |
| C24         | Malignant neoplasm of other and unspecified parts of biliary tract                                   | M | 324      | -         | -   | -   | -     | -     | -     | 1     | -     | 4     |  |
|             |  | F | 301      | -         | -   | -   | -     | -     | -     | 1     | 3     | -     |  |
| C25         | Malignant neoplasm of pancreas   | M | 3,133    | -         | -   | -   | -     | 1     | 1     | 3     | 5     | 24    |  |
|             |  | F | 3,289    | -         | -   | -   | -     | -     | 2     | 3     | 7     | 10    |  |
| C26         | Malignant neoplasm of other and ill-defined digestive organs   | M | 265      | -         | -   | -   | -     | -     | -     | 1     | 2     | 5     |  |
|             |  | F | 314      | -         | -   | -   | -     | -     | -     | -     | 2     | 4     |  |
| C30         | Malignant neoplasm of nasal cavity and middle ear  | M | 100      | -         | 1   | 1   | -     | -     | 1     | 1     | 1     | 3     |  |
|             |  | F | 85       | -         | -   | -   | -     | -     | -     | -     | 1     | 3     |  |
| C31         | Malignant neoplasm of accessory sinuses  | M | 65       | -         | -   | -   | -     | -     | 1     | -     | 2     | 2     |  |
|             |  | F | 43       | -         | -   | -   | 1     | 1     | 2     | -     | -     | -     |  |
| C32         | Malignant neoplasm of larynx   | M | 1,432    | -         | -   | -   | 1     | -     | -     | -     | 2     | 7     |  |
|             |  | F | 297      | -         | -   | -   | -     | -     | -     | -     | 1     | 5     |  |
| C33-C34     | Malignant neoplasm of trachea, bronchus and lung   | M | 18,037   | -         | -   | -   | -     | 2     | -     | 11    | 22    | 47    |  |
|             |  | F | 13,000   | -         | -   | -   | -     | 1     | 4     | 7     | 14    | 42    |  |
| C33         | Malignant neoplasm of trachea  | M | 17       | -         | -   | -   | -     | -     | -     | -     | 1     | 1     |  |
|             |  | F | 23       | -         | -   | -   | -     | -     | 1     | -     | 1     | -     |  |
| C34         | Malignant neoplasm of bronchus and lung  | M | 18,020   | -         | -   | -   | -     | 2     | -     | 11    | 21    | 46    |  |
|             |  | F | 12,977   | -         | -   | -   | -     | 1     | 3     | 7     | 13    | 42    |  |
| C37         | Malignant neoplasm of thymus   | M | 50       | -         | -   | -   | -     | -     | -     | -     | -     | 3     |  |
|             |  | F | 42       | -         | -   | -   | -     | 1     | -     | -     | 3     | 1     |  |
| C38         | Malignant neoplasm of heart,mediastinum and pleura   | M | 120      | 2         | -   | -   | -     | 1     | 3     | 1     | 3     | 3     |  |
|             |  | F | 86       | 1         | 1   | 1   | -     | -     | -     | -     | 1     | 2     |  |
| C39         | Malignant neoplasm of other and ill-defined sites in the respiratory system and intrathoracic organs | M | 4        | -         | -   | -   | -     | -     | -     | -     | -     | -     |  |
|             |  | F | 2        | -         | -   | -   | -     | -     | -     | -     | -     | -     |  |
| C40         | Malignant neoplasm of bone and articular cartilage of limbs  | M | 99       | -         | -   | 4   | 11    | 14    | 10    | 6     | 3     | 5     |  |
|             |  | F | 87       | -         | -   | 5   | 14    | 7     | 5     | 4     | 4     | 6     |  |
| C41         | Malignant neoplasm of bone and articular cartilage of other and unspecified sites                    | M | 145      | -         | 3   | 4   | 4     | 13    | 6     | 6     | 5     | 8     |  |
|             |  | F | 83       | -         | 2   | 1   | 2     | 5     | 10    | 1     | 2     | 3     |  |
| C43         | Malignant melanoma of skin   | M | 3,663    | -         | -   | -   | 2     | 25    | 48    | 70    | 119   | 196   |  |
|             |  | F | 4,362    | -         | 2   | 2   | 3     | 38    | 104   | 178   | 242   | 295   |  |
| C44         | Other malignant neoplasms of skin  | M | 34,566   | -         | 2   | -   | 7     | 14    | 29    | 63    | 197   | 390   |  |
|             |  | F | 28,502   | -         | -   | 2   | 7     | 14    | 41    | 93    | 220   | 465   |  |
| C45         | Mesothelioma   | M | 1,569    | -         | -   | -   | -     | -     | -     | -     | -     | 2     |  |
|             |  | F | 289      | -         | -   | -   | 1     | -     | -     | 1     | -     | 2     |  |

|       |       |       |       |       |       |       |       |       |             | Site description | ICD-10 code  |         |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------------|------------------|--|---------|
| 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85 and over |                  |  |         |
| 120   | 218   | 349   | 726   | 900   | 1,297 | 1,632 | 1,886 | 1,435 | 941         | M                | Malignant neoplasm of  | C18     |
| 108   | 208   | 294   | 553   | 695   | 989   | 1,298 | 1,600 | 1,615 | 1,543       | F                | colon  |         |
| 15    | 33    | 66    | 126   | 178   | 228   | 280   | 228   | 188   | 101         | M                | Malignant neoplasm of  | C19     |
| 17    | 28    | 54    | 93    | 106   | 122   | 149   | 158   | 147   | 134         | F                | rectosigmoid junction  |         |
| 61    | 153   | 266   | 535   | 637   | 760   | 890   | 822   | 618   | 384         | M                | Malignant neoplasm of  | C20     |
| 56    | 94    | 164   | 253   | 293   | 380   | 461   | 511   | 492   | 489         | F                | rectum   |         |
| 17    | 11    | 27    | 31    | 30    | 37    | 36    | 23    | 22    | 18          | M                | Malignant neoplasm of  | C21     |
| 17    | 31    | 30    | 45    | 60    | 38    | 39    | 44    | 52    | 64          | F                | anus and anal canal  |         |
| 23    | 51    | 96    | 159   | 179   | 225   | 260   | 244   | 203   | 125         | M                | Malignant neoplasm of liver  | C22     |
| 8     | 23    | 34    | 55    | 67    | 117   | 127   | 169   | 179   | 185         | F                | and intrahepatic bile ducts  |         |
| 1     | 4     | 7     | 9     | 14    | 23    | 22    | 24    | 18    | 14          | M                | Malignant neoplasm of  | C23     |
| 6     | 5     | 7     | 28    | 35    | 48    | 49    | 62    | 62    | 45          | F                | gallbladder  |         |
| 2     | 10    | 17    | 24    | 37    | 56    | 44    | 60    | 45    | 24          | M                | Malignant neoplasm of  | C24     |
| 5     | 5     | 15    | 19    | 23    | 35    | 38    | 46    | 53    | 58          | F                | other and unspecified parts of biliary tract                             |         |
| 29    | 75    | 142   | 323   | 343   | 451   | 508   | 505   | 434   | 289         | M                | Malignant neoplasm of  | C25     |
| 21    | 52    | 97    | 214   | 298   | 360   | 484   | 541   | 576   | 624         | F                | pancreas   |         |
| 3     | 5     | 10    | 16    | 23    | 29    | 29    | 35    | 48    | 59          | M                | Malignant neoplasm of  | C26     |
| 2     | 4     | 5     | 5     | 16    | 18    | 27    | 50    | 58    | 123         | F                | other and ill-defined digestive organs                                   |         |
| 7     | 4     | 8     | 9     | 8     | 12    | 13    | 14    | 12    | 5           | M                | Malignant neoplasm of  | C30     |
| 1     | 5     | 5     | 8     | 12    | 16    | 12    | 10    | 6     | 6           | F                | nasal cavity and middle ear  |         |
| 2     | 3     | 2     | 12    | 7     | 13    | 11    | 5     | 3     | 2           | M                | Malignant neoplasm of  | C31     |
| 2     | 4     | 4     | 5     | 3     | 3     | 2     | 3     | 5     | 8           | F                | accessory sinuses  |         |
| 20    | 52    | 108   | 212   | 237   | 218   | 197   | 170   | 132   | 76          | M                | Malignant neoplasm of  | C32     |
| 5     | 16    | 24    | 35    | 43    | 37    | 32    | 49    | 31    | 19          | F                | larynx   |         |
| 116   | 304   | 656   | 1,348 | 2,078 | 2,694 | 3,155 | 3,366 | 2,622 | 1,616       | M                | Malignant neoplasm of  | C33-C34 |
| 127   | 263   | 563   | 1,024 | 1,356 | 1,745 | 2,070 | 2,450 | 1,987 | 1,347       | F                | trachea, bronchus and lung   |         |
| -     | -     | 1     | 3     | 3     | 3     | 3     | 1     | 1     | -           | M                | Malignant neoplasm of  | C33     |
| -     | 2     | -     | 4     | 2     | 1     | 4     | 6     | 2     | -           | F                | trachea  |         |
| 116   | 304   | 655   | 1,345 | 2,075 | 2,691 | 3,152 | 3,365 | 2,621 | 1,616       | M                | Malignant neoplasm of  | C34     |
| 127   | 261   | 563   | 1,020 | 1,354 | 1,744 | 2,066 | 2,444 | 1,985 | 1,347       | F                | bronchus and lung  |         |
| 3     | 2     | 4     | 11    | 8     | 8     | 6     | 4     | 1     | -           | M                | Malignant neoplasm of  | C37     |
| 1     | 3     | 1     | 5     | 4     | 9     | 5     | 4     | 4     | 1           | F                | thymus   |         |
| 3     | 7     | 1     | 7     | 11    | 22    | 13    | 20    | 16    | 7           | M                | Malignant neoplasm of  | C38     |
| 1     | 3     | 1     | 5     | 6     | 6     | 7     | 19    | 14    | 18          | F                | heart, mediastinum and pleura  |         |
| -     | -     | -     | -     | -     | -     | -     | 2     | 1     | 1           | M                | Malignant neoplasm of other  | C39     |
| -     | -     | -     | 1     | -     | -     | -     | -     | -     | 1           | F                | and ill-defined sites in the respiratory system and intrathoracic organs |         |
| 5     | 7     | 6     | 5     | 5     | 4     | 3     | 9     | 2     | -           | M                | Malignant neoplasm of  | C40     |
| 3     | 8     | 1     | 5     | 2     | 5     | 4     | 3     | 3     | 8           | F                | bone and articular cartilage of limbs                                    |         |
| 10    | 6     | 6     | 10    | 16    | 18    | 9     | 9     | 5     | 7           | M                | Malignant neoplasm of bone   | C41     |
| 3     | 3     | 5     | 8     | 3     | 8     | 3     | 7     | 13    | 4           | F                | and articular cartilage of other and unspecified sites                   |         |
| 251   | 236   | 281   | 444   | 378   | 432   | 412   | 337   | 268   | 164         | M                | Malignant melanoma of skin   | C43     |
| 339   | 333   | 351   | 421   | 374   | 379   | 349   | 360   | 306   | 286         | F                |  |         |
| 645   | 937   | 1,448 | 2,624 | 3,374 | 4,537 | 5,277 | 5,874 | 5,184 | 3,964       | M                | Other malignant neoplasms  | C44     |
| 778   | 1,031 | 1,358 | 2,056 | 2,514 | 2,898 | 3,496 | 4,117 | 4,303 | 5,109       | F                | of skin  |         |
| 3     | 17    | 52    | 137   | 224   | 264   | 299   | 279   | 175   | 117         | M                | Mesothelioma   | C45     |
| -     | 3     | 11    | 18    | 30    | 50    | 34    | 56    | 47    | 36          | F                |  |         |

**Table 1 Series MBI no. 36**

To link to Excel version of the table - click on the red box surrounding the table title

**Table 1 Registrations - continued**

| ICD-10 code | Site description  |   | All ages      | Age group |     |     |       |       |       |       |       |       |       |
|-------------|---|---|---------------|-----------|-----|-----|-------|-------|-------|-------|-------|-------|-------|
|             |   |   |               | Under 1   | 1-4 | 5-9 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 |       |
| C46         | Kaposi's sarcoma  | M | <b>98</b>     | -         | -   | -   | -     | -     | -     | 1     | 9     | 16    | 17    |
|             |   | F | <b>17</b>     | -         | -   | -   | -     | -     | -     | 1     | 3     | 2     | 2     |
| C47         | Malignant neoplasm of peripheral nerves and autonomic nervous system    | M | <b>42</b>     | 2         | 7   | -   | 3     | 1     | 2     | 2     | 2     | 3     | 3     |
|             |   | F | <b>29</b>     | -         | 4   | 2   | 2     | -     | 1     | 1     | 2     | 3     | 3     |
| C48         | Malignant neoplasm of retroperitoneum and peritoneum                    | M | <b>111</b>    | 1         | -   | 2   | -     | -     | -     | 2     | 1     | 3     | 3     |
|             |   | F | <b>348</b>    | 1         | -   | -   | -     | -     | 1     | -     | 5     | 3     | 3     |
| C49         | Malignant neoplasm of other connective and soft tissue                  | M | <b>615</b>    | 3         | 8   | 7   | 6     | 9     | 15    | 16    | 21    | 31    | 31    |
|             |   | F | <b>506</b>    | 3         | 3   | 1   | 3     | 13    | 11    | 14    | 18    | 24    | 24    |
| C50         | Malignant neoplasm of breast  | M | <b>250</b>    | -         | -   | -   | -     | -     | -     | 1     | -     | 3     | 3     |
|             |   | F | <b>38,212</b> | -         | -   | -   | -     | 4     | 21    | 121   | 483   | 1,220 | 1,220 |
| C51         | Malignant neoplasm of vulva   | F | <b>842</b>    | -         | -   | -   | -     | 1     | 1     | 2     | 13    | 19    | 19    |
| C52         | Malignant neoplasm of vagina  | F | <b>216</b>    | 1         | -   | -   | -     | -     | -     | -     | 4     | 10    | 10    |
| C53         | Malignant neoplasm of cervix uteri                                      | F | <b>2,253</b>  | -         | -   | -   | -     | 4     | 39    | 193   | 296   | 281   | 281   |
| C54         | Malignant neoplasm of corpus uteri                                      | F | <b>5,438</b>  | -         | -   | -   | -     | 1     | 2     | 6     | 15    | 56    | 56    |
| C55         | Malignant neoplasm of uterus,part unspecified                           | F | <b>281</b>    | -         | -   | -   | -     | -     | -     | 2     | 2     | 6     | 6     |
| C56-C57     | Malignant neoplasm of ovary and other unspecified female genital organs | F | <b>5,589</b>  | 1         | 2   | 1   | 5     | 24    | 35    | 58    | 79    | 145   | 145   |
| C56         | Malignant neoplasm of ovary   | F | <b>5,456</b>  | 1         | 2   | 1   | 5     | 24    | 35    | 58    | 79    | 142   | 142   |
| C57         | Malignant neoplasm of other and unspecified female genital organs       | F | <b>133</b>    | -         | -   | -   | -     | -     | -     | -     | -     | 3     | 3     |
| C58         | Malignant neoplasm of placenta  | F | <b>9</b>      | -         | -   | -   | -     | -     | 2     | 4     | -     | 2     | 2     |
| C60         | Malignant neoplasm of penis   | M | <b>389</b>    | -         | -   | -   | -     | -     | 1     | 1     | 6     | 14    | 14    |
| C61         | Malignant neoplasm of prostate  | M | <b>28,886</b> | -         | 1   | -   | -     | 1     | -     | 1     | -     | 8     | 8     |
| C62         | Malignant neoplasm of testis  | M | <b>1,715</b>  | 5         | 2   | -   | 2     | 62    | 177   | 269   | 286   | 305   | 305   |
| C63         | Malignant neoplasm of other and unspecified male genital organs         | M | <b>61</b>     | -         | 1   | 2   | 1     | 2     | -     | -     | 3     | -     | -     |
| C64         | Malignant neoplasm of kidney,except renal pelvis                        | M | <b>3,243</b>  | 7         | 25  | 5   | 2     | 1     | 4     | 6     | 25    | 47    | 47    |
|             |   | F | <b>1,934</b>  | 4         | 21  | 13  | 2     | 2     | 5     | 8     | 14    | 29    | 29    |
| C65         | Malignant neoplasm of renal pelvis                                      | M | <b>251</b>    | -         | 1   | -   | -     | -     | -     | -     | 1     | 1     | 1     |
|             |   | F | <b>148</b>    | -         | -   | -   | -     | -     | -     | -     | -     | -     | -     |
| C66         | Malignant neoplasm of ureter  | M | <b>207</b>    | -         | -   | -   | -     | -     | -     | -     | -     | -     | -     |
|             |   | F | <b>116</b>    | -         | -   | -   | -     | -     | -     | -     | 1     | -     | -     |
| C67         | Malignant neoplasm of bladder   | M | <b>6,091</b>  | -         | 1   | -   | -     | 1     | -     | 1     | 9     | 16    | 16    |
|             |   | F | <b>2,403</b>  | -         | 1   | -   | -     | 1     | 1     | 1     | 6     | 13    | 13    |
| C68         | Malignant neoplasm of other and unspecified urinary organs              | M | <b>121</b>    | -         | -   | -   | -     | 1     | -     | -     | -     | -     | -     |
|             |   | F | <b>46</b>     | -         | -   | -   | -     | -     | -     | 1     | -     | -     | -     |
| C69         | Malignant neoplasm of eye and adnexa                                    | M | <b>188</b>    | 5         | 7   | 1   | 1     | -     | 2     | 2     | 3     | 4     | 4     |
|             |   | F | <b>155</b>    | 14        | 13  | 3   | -     | -     | -     | 1     | 8     | 6     | 6     |

|       |       |       |       |       |       |       |       |       |             | Site description | ICD-10 code   |         |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------------|------------------|---|---------|
| 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85 and over |                  |   |         |
| 20    | 12    | 4     | 2     | 6     | 2     | 3     | 2     | 3     | 1           | M                | Kaposi's sarcoma  | C46     |
| 2     | 1     | 1     | -     | 1     | 1     | 1     | -     | 2     | -           | F                |   |         |
| 3     | 3     | -     | 1     | 1     | 2     | 3     | 3     | 2     | 1           | M                | Malignant neoplasm of peripheral nerves and autonomic nervous system    | C47     |
| 2     | 2     | -     | -     | -     | 1     | 2     | 3     | 3     | 1           | F                |   |         |
| 5     | 9     | 9     | 9     | 13    | 12    | 18    | 8     | 13    | 6           | M                | Malignant neoplasm of retroperitoneum and peritoneum                    | C48     |
| 9     | 17    | 14    | 46    | 44    | 61    | 49    | 49    | 26    | 23          | F                |   |         |
| 21    | 32    | 30    | 61    | 53    | 57    | 56    | 66    | 62    | 61          | M                | Malignant neoplasm of other connective and soft tissue                  | C49     |
| 25    | 32    | 37    | 52    | 44    | 39    | 49    | 45    | 50    | 43          | F                |   |         |
| 9     | 8     | 15    | 29    | 28    | 28    | 47    | 29    | 20    | 33          | M                | Malignant neoplasm of breast  | C50     |
| 2,413 | 3,141 | 4,088 | 4,727 | 4,657 | 4,611 | 3,498 | 3,319 | 2,934 | 2,975       | F                |   |         |
| 31    | 44    | 56    | 61    | 50    | 79    | 101   | 103   | 105   | 176         | F                | Malignant neoplasm of vulva   | C51     |
| 4     | 9     | 18    | 20    | 19    | 17    | 23    | 23    | 28    | 40          | F                | Malignant neoplasm of vagina  | C52     |
| 266   | 191   | 166   | 143   | 137   | 147   | 109   | 86    | 93    | 102         | F                | Malignant neoplasm of cervix uteri                                      | C53     |
| 92    | 183   | 422   | 850   | 807   | 867   | 760   | 609   | 434   | 334         | F                | Malignant neoplasm of corpus uteri                                      | C54     |
| 10    | 20    | 28    | 26    | 16    | 30    | 35    | 31    | 35    | 40          | F                | Malignant neoplasm of uterus,part unspecified                           | C55     |
| 203   | 298   | 414   | 596   | 672   | 654   | 714   | 678   | 540   | 470         | F                | Malignant neoplasm of ovary and other unspecified female genital organs | C56-C57 |
| 201   | 288   | 402   | 571   | 660   | 641   | 702   | 664   | 528   | 452         | F                | Malignant neoplasm of ovary   | C56     |
| 2     | 10    | 12    | 25    | 12    | 13    | 12    | 14    | 12    | 18          | F                | Malignant neoplasm of other and unspecified female genital organs       | C57     |
| -     | -     | 1     | -     | -     | -     | -     | -     | -     | -           | F                | Malignant neoplasm of placenta  | C58     |
| 18    | 26    | 28    | 45    | 53    | 47    | 57    | 34    | 28    | 31          | M                | Malignant neoplasm of penis   | C60     |
| 31    | 181   | 649   | 2,320 | 3,680 | 5,447 | 5,605 | 5,073 | 3,548 | 2,341       | M                | Malignant neoplasm of prostate  | C61     |
| 241   | 152   | 73    | 44    | 32    | 21    | 22    | 9     | 7     | 6           | M                | Malignant neoplasm of testis  | C62     |
| -     | 2     | 3     | 4     | 4     | 7     | 5     | 14    | 10    | 3           | M                | Malignant neoplasm of other and unspecified male genital organs         | C63     |
| 81    | 136   | 237   | 378   | 380   | 457   | 503   | 445   | 320   | 184         | M                | Malignant neoplasm of kidney,except renal pelvis                        | C64     |
| 58    | 87    | 116   | 188   | 182   | 252   | 274   | 263   | 225   | 191         | F                |   |         |
| 4     | 6     | 9     | 21    | 31    | 26    | 52    | 50    | 34    | 15          | M                | Malignant neoplasm of renal pelvis                                      | C65     |
| 3     | 2     | 4     | 13    | 10    | 29    | 23    | 23    | 26    | 15          | F                |   |         |
| 1     | 5     | 10    | 12    | 28    | 32    | 35    | 47    | 29    | 8           | M                | Malignant neoplasm of ureter  | C66     |
| 2     | -     | 4     | 6     | 7     | 18    | 23    | 31    | 16    | 8           | F                |   |         |
| 39    | 86    | 155   | 350   | 560   | 801   | 1,060 | 1,200 | 1,001 | 811         | M                | Malignant neoplasm of bladder   | C67     |
| 25    | 38    | 53    | 100   | 181   | 246   | 341   | 421   | 476   | 499         | F                |   |         |
| 4     | 3     | 2     | 9     | 6     | 11    | 19    | 40    | 18    | 8           | M                | Malignant neoplasm of other and unspecified urinary organs              | C68     |
| 1     | -     | 4     | 2     | 4     | 4     | 3     | 9     | 9     | 9           | F                |   |         |
| 8     | 13    | 14    | 23    | 19    | 23    | 26    | 24    | 8     | 5           | M                | Malignant neoplasm of eye and adnexa                                    | C69     |
| 8     | 10    | 6     | 13    | 12    | 14    | 14    | 12    | 13    | 8           | F                |   |         |

**Table 1 Series MBI no. 36**

To link to Excel version of the table - click on the red box surrounding the table title

**Table 1 Registrations - continued**

| ICD-10 code | Site description   |   | All ages | Age group |     |     |       |       |       |       |       |       |   |
|-------------|--|---|----------|-----------|-----|-----|-------|-------|-------|-------|-------|-------|---|
|             |  |   |          | Under 1   | 1-4 | 5-9 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 |   |
| C70         | Malignant neoplasm of meninges   | M | 16       | -         | -   | -   | -     | -     | -     | -     | -     | 1     | 1 |
|             |  | F | 22       | -         | -   | -   | -     | 1     | -     | -     | -     | 1     | 2 |
| C71         | Malignant neoplasm of brain  | M | 2,192    | 8         | 43  | 48  | 34    | 37    | 32    | 41    | 79    | 91    |   |
|             |  | F | 1,501    | 9         | 27  | 34  | 25    | 16    | 30    | 30    | 42    | 46    |   |
| C72         | Malignant neoplasm of spinal cord,cranial nerves and other parts of central nervous system | M | 56       | -         | 5   | 7   | 2     | 1     | -     | 1     | 3     | 2     |   |
|             |  | F | 50       | 1         | 9   | 1   | 1     | 1     | 4     | 3     | 3     | 1     |   |
| C73         | Malignant neoplasm of thyroid gland  | M | 376      | -         | 1   | 2   | 1     | 3     | 6     | 18    | 24    | 40    |   |
|             |  | F | 1,099    | -         | 1   | -   | 6     | 26    | 51    | 62    | 91    | 95    |   |
| C74         | Malignant neoplasm of adrenal gland  | M | 78       | 7         | 15  | 2   | -     | 2     | -     | -     | 3     | 4     |   |
|             |  | F | 81       | 5         | 15  | 5   | 1     | 2     | -     | 2     | 2     | 2     |   |
| C75         | Malignant neoplasm of other endocrine glands and related structures                        | M | 68       | -         | 3   | -   | 5     | 9     | 3     | 3     | 5     | 3     |   |
|             |  | F | 34       | -         | 1   | 3   | -     | -     | 1     | -     | 3     | -     |   |
| C76         | Malignant neoplasm of other and ill-defined sites  | M | 205      | 1         | 3   | 2   | -     | 2     | 3     | 1     | 2     | 11    |   |
|             |  | F | 268      | 5         | 3   | 1   | 2     | -     | 1     | 2     | 5     | 6     |   |
| C77         | Secondary and unspecified malignant neoplasm of lymph nodes                                | M | 321      | -         | -   | -   | -     | -     | 2     | 2     | 1     | 6     |   |
|             |  | F | 288      | -         | -   | -   | -     | -     | -     | 2     | 3     | 5     |   |
| C78         | Secondary malignant neoplasm of respiratory and digestive organs                           | M | 1,648    | -         | -   | -   | -     | -     | -     | 5     | 8     | 11    |   |
|             |  | F | 1,912    | -         | -   | -   | -     | -     | -     | 6     | 3     | 14    |   |
| C79         | Secondary malignant neoplasm of other sites  | M | 692      | -         | -   | -   | -     | 1     | 1     | 1     | 2     | 5     |   |
|             |  | F | 678      | -         | -   | -   | -     | -     | -     | 2     | 2     | 7     |   |
| C80         | Malignant neoplasm without specification of site   | M | 2,012    | 1         | 1   | 1   | 1     | 3     | 6     | 4     | 12    | 13    |   |
|             |  | F | 2,449    | -         | -   | -   | 1     | 1     | 1     | 2     | 7     | 11    |   |
| C81         | Hodgkin's disease  | M | 749      | -         | 5   | 8   | 27    | 44    | 53    | 62    | 70    | 72    |   |
|             |  | F | 563      | -         | 1   | 2   | 23    | 57    | 56    | 62    | 44    | 43    |   |
| C82-C85     | Non-Hodgkin's lymphoma   | M | 4,622    | -         | 9   | 18  | 28    | 34    | 36    | 45    | 88    | 133   |   |
|             |  | F | 3,907    | 3         | 1   | 6   | 11    | 19    | 23    | 28    | 50    | 79    |   |
| C82         | Follicular (nodular) non-Hodgkin's lymphoma  | M | 637      | -         | -   | 2   | -     | 2     | 2     | 2     | 18    | 16    |   |
|             |  | F | 733      | -         | -   | -   | -     | 1     | 2     | 2     | 7     | 24    |   |
| C83         | Diffuse non-Hodgkin's lymphoma   | M | 2,262    | -         | 8   | 10  | 18    | 20    | 20    | 25    | 37    | 66    |   |
|             |  | F | 1,751    | 1         | 1   | 4   | 8     | 10    | 11    | 16    | 26    | 28    |   |
| C84         | Peripheral and cutaneous T-cell lymphomas  | M | 280      | -         | -   | 2   | 1     | 4     | 2     | 3     | 2     | 8     |   |
|             |  | F | 215      | 1         | -   | -   | 1     | 2     | 4     | 1     | 2     | 4     |   |
| C85         | Other and unspecified types of non-Hodgkin's lymphoma                                      | M | 1,443    | -         | 1   | 4   | 9     | 8     | 12    | 15    | 31    | 43    |   |
|             |  | F | 1,208    | 1         | -   | 2   | 2     | 6     | 6     | 9     | 15    | 23    |   |
| C88         | Malignant immunoproliferative diseases   | M | 110      | -         | -   | -   | -     | -     | -     | -     | -     | -     |   |
|             |  | F | 65       | -         | -   | -   | -     | -     | -     | -     | -     | 1     |   |
| C90         | Multiple myeloma and malignant plasma cell neoplasms                                       | M | 1,739    | -         | -   | -   | -     | -     | -     | 1     | 2     | 20    |   |
|             |  | F | 1,504    | -         | 1   | -   | -     | -     | -     | -     | 1     | 4     |   |
| C91-C95     | All leukaemias   | M | 3,459    | 15        | 76  | 64  | 32    | 51    | 41    | 39    | 42    | 73    |   |
|             |  | F | 2,565    | 10        | 82  | 50  | 39    | 37    | 29    | 35    | 31    | 48    |   |
| C91         | Lymphoid leukaemia   | M | 1,753    | 7         | 68  | 57  | 21    | 33    | 20    | 11    | 11    | 27    |   |
|             |  | F | 1,142    | 5         | 65  | 39  | 29    | 22    | 5     | 7     | 7     | 10    |   |
| C92         | Myeloid leukaemia  | M | 1,532    | 6         | 8   | 6   | 9     | 14    | 17    | 25    | 30    | 43    |   |
|             |  | F | 1,273    | 5         | 13  | 11  | 10    | 14    | 20    | 25    | 22    | 36    |   |
| C93         | Monocytic leukaemia  | M | 27       | 1         | -   | -   | -     | 1     | 1     | -     | -     | -     |   |
|             |  | F | 29       | -         | -   | -   | -     | -     | 2     | -     | 1     | -     |   |

|       |       |       |       |       |       |       |       |       |             | Site description | ICD-10 code  |         |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------------|------------------|--|---------|
| 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85 and over |                  |  |         |
| -     | 4     | 2     | 1     | 1     | 1     | 1     | 1     | 2     | 1           | M                | Malignant neoplasm of meninges   | C70     |
| 1     | 2     | -     | 2     | 1     | -     | 4     | 2     | 4     | 2           | F                |  |         |
| 107   | 118   | 171   | 213   | 237   | 274   | 272   | 202   | 126   | 59          | M                | Malignant neoplasm of brain  | C71     |
| 74    | 73    | 86    | 148   | 140   | 172   | 158   | 185   | 137   | 69          | F                |  |         |
| 1     | 2     | 3     | 4     | 8     | 1     | 8     | 3     | 3     | 2           | M                | Malignant neoplasm of spinal cord,cranial nerves and other parts of central nervous system | C72     |
| 2     | -     | 3     | 7     | 5     | 1     | 1     | 3     | 2     | 2           | F                |  |         |
| 30    | 28    | 28    | 36    | 32    | 34    | 29    | 33    | 18    | 13          | M                | Malignant neoplasm of thyroid gland  | C73     |
| 117   | 101   | 84    | 100   | 63    | 77    | 59    | 70    | 48    | 48          | F                |  |         |
| 4     | 3     | 3     | 4     | 5     | 5     | 11    | 6     | 3     | 1           | M                | Malignant neoplasm of adrenal gland  | C74     |
| 5     | 4     | 3     | 7     | 5     | 5     | 6     | 6     | 2     | 4           | F                |  |         |
| 1     | 2     | 5     | 4     | 3     | 5     | 9     | 3     | 4     | 1           | M                | Malignant neoplasm of other endocrine glands and related structures                        | C75     |
| -     | 1     | 5     | 4     | 3     | 2     | 3     | 3     | 2     | 3           | F                |  |         |
| 10    | 9     | 8     | 12    | 13    | 20    | 22    | 33    | 28    | 25          | M                | Malignant neoplasm of other and ill-defined sites  | C76     |
| 8     | 8     | 10    | 15    | 11    | 13    | 20    | 28    | 46    | 84          | F                |  |         |
| 18    | 16    | 33    | 51    | 35    | 37    | 39    | 30    | 25    | 26          | M                | Secondary and unspecified malignant neoplasm of lymph nodes                                | C77     |
| 10    | 13    | 21    | 28    | 35    | 40    | 34    | 34    | 30    | 33          | F                |  |         |
| 15    | 37    | 68    | 108   | 137   | 191   | 231   | 290   | 302   | 245         | M                | Secondary malignant neoplasm of respiratory and digestive organs                           | C78     |
| 24    | 39    | 60    | 117   | 148   | 168   | 233   | 348   | 347   | 405         | F                |  |         |
| 11    | 13    | 24    | 42    | 68    | 93    | 109   | 137   | 106   | 79          | M                | Secondary malignant neoplasm of other sites  | C79     |
| 14    | 14    | 26    | 36    | 57    | 72    | 80    | 124   | 136   | 108         | F                |  |         |
| 25    | 29    | 62    | 106   | 154   | 250   | 296   | 352   | 363   | 333         | M                | Malignant neoplasm without specification of site   | C80     |
| 24    | 35    | 58    | 112   | 145   | 181   | 261   | 409   | 521   | 680         | F                |  |         |
| 59    | 57    | 53    | 55    | 41    | 30    | 34    | 40    | 24    | 15          | M                | Hodgkin's disease  | C81     |
| 29    | 22    | 23    | 31    | 26    | 47    | 34    | 24    | 23    | 16          | F                |  |         |
| 174   | 245   | 273   | 449   | 505   | 593   | 618   | 627   | 465   | 282         | M                | Non-Hodgkin's lymphoma   | C82-C85 |
| 110   | 143   | 228   | 348   | 410   | 494   | 556   | 498   | 492   | 408         | F                |  |         |
| 37    | 43    | 48    | 91    | 89    | 92    | 68    | 72    | 37    | 18          | M                | Follicular (nodular) non-Hodgkins's lymphoma   | C82     |
| 31    | 39    | 70    | 98    | 108   | 109   | 83    | 62    | 63    | 34          | F                |  |         |
| 79    | 117   | 128   | 215   | 250   | 299   | 321   | 296   | 230   | 123         | M                | Diffuse non-Hodgkin's lymphoma   | C83     |
| 35    | 50    | 87    | 153   | 175   | 237   | 265   | 242   | 220   | 182         | F                |  |         |
| 11    | 11    | 23    | 34    | 43    | 36    | 38    | 37    | 15    | 10          | M                | Peripheral and cutaneous T-cell lymphomas  | C84     |
| 6     | 14    | 10    | 19    | 32    | 22    | 40    | 24    | 21    | 12          | F                |  |         |
| 47    | 74    | 74    | 109   | 123   | 166   | 191   | 222   | 183   | 131         | M                | Other and unspecified types of non-Hodgkin's lymphoma                                      | C85     |
| 38    | 40    | 61    | 78    | 95    | 126   | 168   | 170   | 188   | 180         | F                |  |         |
| -     | 3     | 5     | 3     | 6     | 11    | 17    | 33    | 21    | 11          | M                | Malignant immunoproliferative diseases   | C88     |
| 1     | 1     | 1     | 3     | 7     | 3     | 9     | 13    | 14    | 12          | F                |  |         |
| 31    | 58    | 90    | 136   | 194   | 259   | 287   | 266   | 247   | 148         | M                | Multiple myeloma and malignant plasma cell neoplasms                                       | C90     |
| 13    | 36    | 66    | 110   | 150   | 191   | 215   | 240   | 256   | 221         | F                |  |         |
| 89    | 103   | 150   | 292   | 307   | 438   | 487   | 453   | 408   | 299         | M                | All leukaemias   | C91-C95 |
| 75    | 63    | 103   | 152   | 146   | 205   | 305   | 360   | 368   | 427         | F                |  |         |
| 35    | 50    | 89    | 168   | 158   | 217   | 236   | 229   | 174   | 142         | M                | Lymphoid leukaemia   | C91     |
| 21    | 26    | 37    | 75    | 68    | 94    | 140   | 155   | 180   | 157         | F                |  |         |
| 48    | 48    | 57    | 115   | 136   | 202   | 226   | 201   | 211   | 130         | M                | Myeloid leukaemia  | C92     |
| 48    | 35    | 64    | 69    | 71    | 107   | 145   | 186   | 164   | 228         | F                |  |         |
| 1     | -     | 2     | 3     | 2     | 5     | 3     | 2     | 4     | 2           | M                | Monocytic leukaemia  | C93     |
| 2     | 1     | 1     | 2     | 1     | 2     | 7     | 3     | 5     | 2           | F                |  |         |

**Table 1 Series MBI no. 36**

To link to Excel version of the table - click on the red box surrounding the table title

**Table 1 Registrations - continued**

| ICD-10 code | Site description  |   | All ages | Age group |     |     |       |       |       |       |       |       |
|-------------|---|---|----------|-----------|-----|-----|-------|-------|-------|-------|-------|-------|
|             |   |   |          | Under 1   | 1-4 | 5-9 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 |
| C94         | Other leukaemias of specified cell type   | M | 22       | 1         | -   | -   | 1     | -     | -     | 1     | 1     | 1     |
|             |   | F | 16       | -         | 3   | -   | -     | -     | -     | -     | -     | -     |
| C95         | Leukaemia of unspecified cell type  | M | 125      | -         | -   | 1   | 1     | 3     | 3     | 2     | -     | 2     |
|             |   | F | 105      | -         | 1   | -   | -     | 1     | 2     | 3     | 1     | 2     |
| C96         | Other and unspecified malignant neoplasms of lymphoid,haematopoietic and related tissue           | M | 18       | 1         | 2   | -   | 1     | -     | -     | -     | 1     | -     |
|             |   | F | 9        | -         | -   | -   | -     | -     | 1     | 1     | -     | -     |
| C97         | Malignant neoplasms of independent(primary) multiple sites  | M | 1        | -         | -   | -   | -     | -     | -     | -     | -     | -     |
|             |   | F | -        | -         | -   | -   | -     | -     | -     | -     | -     | -     |
| D00         | Carcinoma in situ of oral cavity,oesophagus and stomach   | M | 186      | -         | -   | -   | -     | -     | -     | -     | -     | 1     |
|             |   | F | 102      | -         | -   | -   | -     | -     | -     | -     | -     | 2     |
| D01         | Carcinoma in situ of other and unspecified digestive organs                                       | M | 556      | -         | -   | -   | -     | 1     | 1     | 1     | 2     | 12    |
|             |   | F | 419      | -         | -   | -   | -     | -     | -     | 3     | 6     | 4     |
| D02         | Carcinoma in situ of middle ear and respiratory system  | M | 190      | -         | -   | -   | -     | -     | -     | -     | -     | 1     |
|             |   | F | 59       | -         | -   | -   | -     | -     | -     | -     | -     | 1     |
| D03         | Melanoma in situ  | M | 1,198    | -         | -   | -   | 1     | 6     | 6     | 21    | 23    | 48    |
|             |   | F | 1,489    | -         | 1   | -   | 2     | 14    | 24    | 35    | 72    | 100   |
| D04         | Carcinoma in situ of skin   | M | 3,269    | -         | -   | -   | -     | 1     | 1     | 2     | 7     | 13    |
|             |   | F | 5,496    | -         | -   | -   | -     | 1     | 1     | 4     | 8     | 19    |
| D05         | Carcinoma in situ of breast   | M | 22       | -         | -   | -   | -     | -     | -     | 2     | -     | -     |
|             |   | F | 4,197    | -         | -   | -   | 1     | -     | 1     | 6     | 19    | 94    |
| D06         | Carcinoma in situ of cervix uteri   | F | 19,984   | -         | -   | -   | -     | 63    | 3,191 | 5,608 | 4,578 | 3,091 |
| D07         | Carcinoma in situ of other and unspecified genital organs   | M | 859      | -         | -   | -   | -     | 2     | 1     | 2     | 5     | 6     |
|             |   | F | 551      | -         | -   | -   | -     | 2     | 7     | 20    | 33    | 70    |
| D09         | Carcinoma in situ of other and unspecified sites  | M | 2,592    | -         | -   | -   | 1     | -     | 3     | 6     | 9     | 19    |
|             |   | F | 753      | -         | -   | -   | -     | -     | 1     | 1     | 4     | 6     |
| D33         | Benign neoplasm of brain and other parts of central nervous system                                | M | 269      | 3         | 2   | 8   | 4     | 6     | 12    | 5     | 16    | 25    |
|             |   | F | 273      | -         | 1   | 2   | 5     | 3     | 8     | 7     | 15    | 21    |
| D35.2       | Benign neoplasm of pituitary gland  | M | 339      | -         | -   | -   | -     | 3     | 4     | 9     | 14    | 21    |
|             |   | F | 269      | -         | -   | 1   | 4     | 4     | 7     | 5     | 22    | 25    |
| D35.3       | Benign neoplasm of craniopharyngeal duct  | M | -        | -         | -   | -   | -     | -     | -     | -     | -     | -     |
|             |   | F | -        | -         | -   | -   | -     | -     | -     | -     | -     | -     |
| D35.4       | Benign neoplasm of pineal gland   | M | -        | -         | -   | -   | -     | -     | -     | -     | -     | -     |
|             |   | F | -        | -         | -   | -   | -     | -     | -     | -     | -     | -     |
| D37         | Neoplasm of uncertain or unknown behaviour of oral cavity and digestive organs                    | M | 829      | 1         | -   | 1   | 9     | 11    | 13    | 4     | 11    | 12    |
|             |   | F | 848      | -         | 1   | 3   | 14    | 19    | 19    | 21    | 15    | 20    |
| D38         | Neoplasm of uncertain or unknown behaviour of middle ear and respiratory and intrathoracic organs | M | 78       | -         | -   | -   | -     | -     | -     | 2     | -     | 2     |
|             |   | F | 51       | -         | -   | -   | 1     | -     | -     | -     | 2     | 1     |
| D39         | Neoplasm of uncertain or unknown behaviour of female genital organs                               | F | 289      | -         | -   | -   | -     | 9     | 14    | 15    | 19    | 28    |
| D40         | Neoplasm of uncertain or unknown behaviour of male genital organs                                 | M | 52       | 1         | 2   | -   | 2     | 1     | 3     | 6     | 3     | 11    |

|       |       |       |       |       |       |       |       |       |             | Site description | ICD-10 code   |       |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------------|------------------|---|-------|
| 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85 and over |                  |   |       |
| 2     | 3     | -     | -     | 3     | 2     | 2     | 1     | 3     | 1           | M                | Other leukaemias of specified cell type   | C94   |
| 1     | -     | -     | -     | 1     | -     | 2     | 4     | 4     | 1           | F                |   |       |
| 3     | 2     | 2     | 6     | 8     | 12    | 20    | 20    | 16    | 24          | M                | Leukaemia of unspecified cell type  | C95   |
| 3     | 1     | 1     | 6     | 5     | 2     | 11    | 12    | 15    | 39          | F                |   |       |
| 2     | 1     | 2     | 1     | -     | 2     | 2     | 2     | 1     | -           | M                | Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue          | C96   |
| -     | -     | 1     | 3     | 1     | -     | 1     | -     | 1     | -           | F                |   |       |
| -     | -     | -     | -     | -     | -     | -     | -     | -     | 1           | M                | Malignant neoplasms of independent(primary) multiple sites  | C97   |
| -     | -     | -     | -     | -     | -     | -     | -     | -     | -           | F                |   |       |
| 4     | 9     | 20    | 20    | 24    | 31    | 26    | 24    | 19    | 8           | M                | Carcinoma in situ of oral cavity, oesophagus and stomach  | D00   |
| 3     | 5     | 4     | 6     | 9     | 7     | 14    | 19    | 22    | 11          | F                |   |       |
| 9     | 15    | 34    | 56    | 70    | 67    | 97    | 99    | 60    | 32          | M                | Carcinoma in situ of other and unspecified digestive organs                                       | D01   |
| 14    | 17    | 31    | 39    | 32    | 50    | 56    | 63    | 56    | 48          | F                |   |       |
| 4     | 3     | 13    | 21    | 28    | 33    | 33    | 30    | 15    | 9           | M                | Carcinoma in situ of middle ear and respiratory system  | D02   |
| -     | 4     | 3     | 6     | 8     | 8     | 9     | 13    | 3     | 4           | F                |   |       |
| 48    | 44    | 61    | 126   | 123   | 150   | 174   | 160   | 132   | 75          | M                | Melanoma in situ  | D03   |
| 87    | 108   | 93    | 162   | 133   | 156   | 132   | 139   | 124   | 107         | F                |   |       |
| 23    | 53    | 94    | 201   | 273   | 444   | 522   | 613   | 566   | 456         | M                | Carcinoma in situ of skin   | D04   |
| 36    | 77    | 99    | 214   | 340   | 534   | 816   | 1,066 | 1,079 | 1,202       | F                |   |       |
| 1     | 3     | 1     | 3     | 4     | 4     | 1     | 1     | 2     | -           | M                | Carcinoma in situ of breast   | D05   |
| 179   | 335   | 825   | 704   | 717   | 668   | 299   | 174   | 122   | 53          | F                |   |       |
| 1,708 | 785   | 353   | 294   | 192   | 68    | 28    | 13    | 8     | 4           | F                | Carcinoma in situ of cervix uteri   | D06   |
| 12    | 17    | 42    | 132   | 135   | 183   | 144   | 109   | 52    | 17          | M                | Carcinoma in situ of other and unspecified genital organs   | D07   |
| 97    | 75    | 55    | 57    | 34    | 30    | 26    | 14    | 20    | 11          | F                |   |       |
| 45    | 53    | 109   | 209   | 292   | 405   | 469   | 483   | 322   | 167         | M                | Carcinoma in situ of other and unspecified sites  | D09   |
| 7     | 13    | 30    | 65    | 67    | 102   | 107   | 142   | 117   | 91          | F                |   |       |
| 28    | 17    | 29    | 31    | 27    | 23    | 16    | 11    | 5     | 1           | M                | Benign neoplasm of brain and other parts of central nervous system                                | D33   |
| 23    | 26    | 35    | 33    | 26    | 24    | 15    | 15    | 9     | 5           | F                |   |       |
| 16    | 31    | 27    | 40    | 31    | 40    | 46    | 30    | 20    | 7           | M                | Benign neoplasm of pituitary gland  | D35.2 |
| 25    | 21    | 29    | 28    | 23    | 26    | 20    | 12    | 10    | 7           | F                |   |       |
| -     | -     | -     | -     | -     | -     | -     | -     | -     | -           | M                | Benign neoplasm of craniopharyngeal duct  | D35.3 |
| -     | -     | -     | -     | -     | -     | -     | -     | -     | -           | F                |   |       |
| -     | -     | -     | -     | -     | -     | -     | -     | -     | -           | M                | Benign neoplasm of pineal gland   | D35.4 |
| -     | -     | -     | -     | -     | -     | -     | -     | -     | -           | F                |   |       |
| 12    | 20    | 54    | 73    | 97    | 111   | 116   | 124   | 96    | 64          | M                | Neoplasm of uncertain or unknown behaviour of oral cavity and digestive organs                    | D37   |
| 26    | 34    | 44    | 58    | 73    | 86    | 93    | 106   | 130   | 86          | F                |   |       |
| 3     | 4     | 4     | 8     | 7     | 7     | 10    | 15    | 10    | 6           | M                | Neoplasm of uncertain or unknown behaviour of middle ear and respiratory and intrathoracic organs | D38   |
| 1     | -     | 5     | 3     | 4     | 3     | 9     | 6     | 11    | 5           | F                |   |       |
| 27    | 18    | 27    | 32    | 27    | 15    | 21    | 14    | 11    | 12          | F                | Neoplasm of uncertain or unknown behaviour of female genital organs                               | D39   |
| 5     | 3     | 2     | 3     | 3     | 1     | 2     | -     | 2     | 2           | M                | Neoplasm of uncertain or unknown behaviour of male genital organs                                 | D40   |

**Table 1 Series MBI no. 36**

To link to Excel version of the table - click on the red box surrounding the table title

**Table 1 Registrations - continued**

| ICD-10 code | Site description  |   | All ages     | Age group |     |     |       |       |       |       |       |       |
|-------------|---|---|--------------|-----------|-----|-----|-------|-------|-------|-------|-------|-------|
|             |   |   |              | Under 1   | 1-4 | 5-9 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 |
| D41         | Neoplasm of uncertain or unknown behaviour of urinary organs                                    | M | <b>2,690</b> | -         | -   | 1   | -     | 1     | 6     | 4     | 9     | 28    |
|             |   | F | <b>885</b>   | -         | -   | -   | -     | -     | -     | 2     | 3     | 10    |
| D42         | Neoplasm of uncertain or unknown behaviour of meninges  | M | <b>24</b>    | -         | 1   | -   | -     | -     | 1     | 1     | 1     | 1     |
|             |   | F | <b>30</b>    | -         | -   | -   | -     | 1     | -     | 1     | 1     | -     |
| D43         | Neoplasm of uncertain or unknown behaviour of brain and central nervous system                  | M | <b>273</b>   | 2         | 6   | 3   | 10    | 5     | 2     | 8     | 5     | 16    |
|             |   | F | <b>270</b>   | 3         | 5   | 6   | 8     | 7     | 5     | 8     | 8     | 7     |
| D44         | Neoplasm of uncertain or unknown behaviour of endocrine glands                                  | M | <b>87</b>    | -         | -   | 2   | 4     | 4     | 5     | 3     | 5     | 2     |
|             |   | F | <b>112</b>   | -         | 1   | 4   | -     | 2     | 3     | 9     | 6     | 8     |
| D45         | Polycythaemia vera  | M | <b>588</b>   | -         | -   | -   | -     | 2     | 7     | 11    | 17    | 25    |
|             |   | F | <b>323</b>   | -         | -   | -   | 1     | -     | 1     | 4     | 1     | 7     |
| D46         | Myelodysplastic syndromes   | M | <b>1,150</b> | -         | 1   | 2   | 1     | -     | 1     | 2     | 3     | 6     |
|             |   | F | <b>951</b>   | -         | 2   | 1   | 1     | 3     | 4     | 2     | -     | 5     |
| D47         | Other neoplasms of uncertain or unknown behaviour of lymphoid,haematopoietic and related tissue | M | <b>1,019</b> | 1         | 1   | -   | 2     | 7     | 2     | 4     | 16    | 12    |
|             |   | F | <b>1,041</b> | -         | 1   | 3   | 2     | 4     | 2     | 6     | 9     | 19    |
| D48         | Neoplasm of uncertain or unknown behaviour of other and unspecified sites                       | M | <b>375</b>   | 4         | 2   | 8   | 11    | 7     | 21    | 10    | 22    | 25    |
|             |   | F | <b>441</b>   | 5         | 6   | 3   | 7     | 10    | 16    | 12    | 19    | 43    |
| O01         | Hydatidiform mole   | F | <b>264</b>   | -         | -   | -   | 1     | 33    | 45    | 58    | 57    | 37    |

|          |          |           |           |           |            |            |            |            |             | Site description | ICD-10 code  |     |
|----------|----------|-----------|-----------|-----------|------------|------------|------------|------------|-------------|------------------|--|-----|
| 40-44    | 45-49    | 50-54     | 55-59     | 60-64     | 65-69      | 70-74      | 75-79      | 80-84      | 85 and over |                  |  |     |
| 48<br>17 | 77<br>25 | 118<br>39 | 231<br>77 | 283<br>91 | 354<br>116 | 458<br>118 | 486<br>137 | 385<br>132 | 201<br>118  | M<br>F           | Neoplasm of uncertain or unknown behaviour of urinary organs                                     | D41 |
| -<br>2   | 2<br>2   | 2<br>2    | 2<br>2    | 3<br>6    | 3<br>3     | 2<br>7     | 3<br>-     | 2<br>-     | -<br>3      | M<br>F           | Neoplasm of uncertain or unknown behaviour of meninges   | D42 |
| 14<br>8  | 16<br>11 | 17<br>10  | 14<br>16  | 20<br>15  | 24<br>20   | 25<br>24   | 25<br>26   | 42<br>38   | 19<br>45    | M<br>F           | Neoplasm of uncertain or unknown behaviour of brain and central nervous system                   | D43 |
| 10<br>9  | 6<br>10  | 6<br>4    | 6<br>6    | 8<br>11   | 4<br>8     | 8<br>9     | 6<br>7     | 5<br>10    | 3<br>5      | M<br>F           | Neoplasm of uncertain or unknown behaviour of endocrine glands                                   | D44 |
| 39<br>9  | 41<br>19 | 64<br>28  | 63<br>26  | 72<br>31  | 60<br>31   | 73<br>46   | 60<br>50   | 40<br>34   | 14<br>35    | M<br>F           | Polycythaemia vera   | D45 |
| 6<br>5   | 9<br>6   | 14<br>13  | 45<br>20  | 51<br>35  | 109<br>55  | 164<br>97  | 226<br>168 | 263<br>195 | 247<br>339  | M<br>F           | Myelodysplastic syndromes  | D46 |
| 29<br>23 | 31<br>33 | 42<br>55  | 65<br>60  | 95<br>77  | 120<br>114 | 168<br>130 | 161<br>160 | 153<br>186 | 110<br>157  | M<br>F           | Other neoplasms of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue | D47 |
| 23<br>41 | 21<br>46 | 11<br>29  | 27<br>40  | 24<br>39  | 30<br>33   | 36<br>26   | 32<br>23   | 31<br>20   | 30<br>23    | M<br>F           | Neoplasm of uncertain or unknown behaviour of other and unspecified sites                        | D48 |
| 28       | 4        | 1         | -         | -         | -          | -          | -          | -          | -           | F                | Hydatidiform mole  | O01 |

**Table 2 Series MBI no. 36**

To link to Excel version of the table - click on the red box surrounding the table title

**Table 2 Estimated resident population: sex and age as at 30 June 2005<sup>1</sup>**

*(Figures in thousands)*

| Area                            |          | All ages        | Under 1      | 1-4            | 5-9            | 10-14          | 15-19          | 20-24          | 25-29          | 30-34          | 35-39          |
|---------------------------------|----------|-----------------|--------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| <b>England</b>                  | <b>M</b> | <b>24,757.8</b> | <b>310.4</b> | <b>1,171.8</b> | <b>1,522.2</b> | <b>1,637.7</b> | <b>1,690.8</b> | <b>1,674.2</b> | <b>1,595.5</b> | <b>1,769.1</b> | <b>1,955.3</b> |
|                                 | <b>F</b> | <b>25,707.8</b> | <b>296.1</b> | <b>1,116.9</b> | <b>1,453.6</b> | <b>1,547.2</b> | <b>1,606.3</b> | <b>1,612.1</b> | <b>1,600.8</b> | <b>1,777.1</b> | <b>1,962.0</b> |
| <b>Government Office Region</b> |          |                 |              |                |                |                |                |                |                |                |                |
| North East                      | M        | 1,240.5         | 14.2         | 54.7           | 73.9           | 83.2           | 88.6           | 89.5           | 70.5           | 76.5           | 89.4           |
|                                 | F        | 1,309.1         | 13.7         | 51.9           | 70.5           | 78.9           | 84.7           | 87.1           | 72.3           | 81.0           | 94.7           |
| North West                      | M        | 3,341.5         | 41.5         | 156.4          | 207.9          | 231.8          | 239.6          | 230.5          | 196.2          | 221.6          | 252.7          |
|                                 | F        | 3,498.3         | 39.6         | 148.8          | 197.1          | 218.7          | 230.8          | 227.0          | 197.3          | 227.0          | 259.4          |
| Yorkshire and The Humber        | M        | 2,503.2         | 30.7         | 116.4          | 153.4          | 169.2          | 180.5          | 190.6          | 151.9          | 163.7          | 187.4          |
|                                 | F        | 2,604.3         | 29.5         | 110.9          | 147.7          | 160.5          | 171.4          | 179.8          | 149.6          | 170.2          | 192.3          |
| East Midlands                   | M        | 2,135.7         | 24.9         | 96.7           | 129.3          | 143.6          | 148.9          | 147.6          | 121.8          | 140.6          | 164.5          |
|                                 | F        | 2,191.9         | 23.6         | 91.0           | 122.4          | 134.4          | 140.8          | 139.0          | 120.6          | 143.9          | 167.3          |
| West Midlands                   | M        | 2,630.6         | 33.6         | 126.7          | 167.5          | 179.6          | 186.6          | 178.6          | 154.2          | 175.5          | 202.3          |
|                                 | F        | 2,720.1         | 32.1         | 121.3          | 159.4          | 171.5          | 177.2          | 170.2          | 155.8          | 176.4          | 202.3          |
| East                            | M        | 2,728.9         | 33.2         | 129.8          | 171.2          | 181.2          | 178.8          | 164.7          | 163.0          | 185.3          | 213.6          |
|                                 | F        | 2,834.1         | 31.7         | 123.8          | 163.9          | 172.7          | 171.0          | 157.0          | 162.9          | 190.8          | 215.0          |
| London                          | M        | 3,685.2         | 57.2         | 196.0          | 221.6          | 216.9          | 225.9          | 260.3          | 361.9          | 383.4          | 353.4          |
|                                 | F        | 3,770.9         | 54.5         | 188.1          | 214.7          | 205.5          | 215.5          | 270.1          | 370.2          | 351.7          | 325.3          |
| South East                      | M        | 4,005.7         | 48.1         | 188.7          | 250.9          | 271.1          | 271.2          | 251.9          | 238.6          | 269.0          | 310.4          |
|                                 | F        | 4,178.8         | 45.6         | 179.9          | 238.0          | 252.7          | 256.0          | 240.1          | 240.0          | 278.5          | 319.2          |
| South West                      | M        | 2,486.6         | 27.1         | 106.4          | 146.5          | 161.2          | 170.6          | 160.6          | 137.3          | 153.5          | 181.6          |
|                                 | F        | 2,600.2         | 25.9         | 101.2          | 140.0          | 152.4          | 158.8          | 141.9          | 132.1          | 157.6          | 186.6          |

1. See section 5.5.

**England,  
Government Office Regions**

| 40-44          | 45-49          | 50-54          | 55-59          | 60-64          | 65-69          | 70-74          | 75-79        | 80-84        | 85 and over  |          | Area                            |
|----------------|----------------|----------------|----------------|----------------|----------------|----------------|--------------|--------------|--------------|----------|---------------------------------|
| <b>1,912.2</b> | <b>1,670.2</b> | <b>1,509.0</b> | <b>1,611.6</b> | <b>1,266.6</b> | <b>1,083.4</b> | <b>900.1</b>   | <b>702.9</b> | <b>476.2</b> | <b>298.5</b> | <b>M</b> | <b>England</b>                  |
| <b>1,942.7</b> | <b>1,691.6</b> | <b>1,540.2</b> | <b>1,652.7</b> | <b>1,319.3</b> | <b>1,167.1</b> | <b>1,038.8</b> | <b>921.5</b> | <b>764.6</b> | <b>697.1</b> | <b>F</b> |                                 |
|                |                |                |                |                |                |                |              |              |              |          | <b>Government Office Region</b> |
| 95.7           | 88.5           | 82.1           | 85.5           | 64.9           | 59.0           | 50.0           | 37.4         | 23.7         | 13.4         | M        | North East                      |
| 99.6           | 91.5           | 82.3           | 86.8           | 67.5           | 65.2           | 58.6           | 50.4         | 39.7         | 32.7         | F        |                                 |
| 257.0          | 227.0          | 209.4          | 225.3          | 175.5          | 153.2          | 124.3          | 94.2         | 61.6         | 36.0         | M        | North West                      |
| 263.8          | 232.4          | 211.7          | 227.6          | 182.5          | 166.0          | 146.1          | 128.3        | 103.4        | 91.1         | F        |                                 |
| 189.1          | 170.1          | 154.6          | 165.8          | 129.4          | 112.3          | 91.9           | 70.5         | 47.3         | 28.5         | M        | Yorkshire and The Humber        |
| 192.6          | 171.5          | 155.6          | 168.7          | 132.8          | 122.0          | 107.9          | 94.8         | 76.9         | 69.6         | F        |                                 |
| 165.7          | 144.9          | 134.8          | 147.1          | 117.5          | 96.8           | 79.9           | 62.8         | 42.8         | 25.5         | M        | East Midlands                   |
| 166.0          | 145.9          | 134.9          | 147.9          | 119.6          | 101.9          | 89.8           | 79.8         | 65.4         | 57.6         | F        |                                 |
| 196.9          | 173.9          | 162.8          | 173.2          | 143.0          | 120.7          | 98.1           | 76.8         | 50.4         | 30.4         | M        | West Midlands                   |
| 200.0          | 175.1          | 163.6          | 174.0          | 147.3          | 128.2          | 113.0          | 99.5         | 81.3         | 72.0         | F        |                                 |
| 212.2          | 186.4          | 170.0          | 187.3          | 146.5          | 124.3          | 105.6          | 83.5         | 56.7         | 35.6         | M        | East                            |
| 214.6          | 186.3          | 174.1          | 193.3          | 152.5          | 132.7          | 118.8          | 105.2        | 87.6         | 80.4         | F        |                                 |
| 293.4          | 233.6          | 187.8          | 180.2          | 133.7          | 118.4          | 98.4           | 75.9         | 51.9         | 35.2         | M        | London                          |
| 292.2          | 237.2          | 199.3          | 192.2          | 146.8          | 131.2          | 114.4          | 101.3        | 83.6         | 77.1         | F        |                                 |
| 317.1          | 279.8          | 250.8          | 270.7          | 210.0          | 175.7          | 148.1          | 117.1        | 81.7         | 55.0         | M        | South East                      |
| 322.6          | 280.2          | 255.1          | 278.7          | 219.0          | 189.6          | 171.4          | 153.2        | 131.6        | 127.5        | F        |                                 |
| 185.2          | 166.1          | 156.8          | 176.7          | 146.1          | 123.0          | 104.0          | 84.8         | 60.1         | 39.0         | M        | South West                      |
| 191.2          | 171.6          | 163.8          | 183.4          | 151.4          | 130.3          | 118.8          | 109.1        | 95.1         | 89.0         | F        |                                 |

Table 3 Series MB1 no. 36

To link to Excel version of the table - click on the red box surrounding the table title

**Table 3 Rates per 100,000 population of newly diagnosed cases of cancer: site, sex and age, 2005**

| ICD-10 code                  | Site description  | All ages | Age group    |             |             |             |             |             |              |              |              |              |
|------------------------------|---|----------|--------------|-------------|-------------|-------------|-------------|-------------|--------------|--------------|--------------|--------------|
|                              |   |          | Under 1      | 1-4         | 5-9         | 10-14       | 15-19       | 20-24       | 25-29        | 30-34        | 35-39        |              |
| <b>C00-C97, D00-D48, O01</b> | <b>All registrations</b>  | <b>M</b> | <b>691.7</b> | <b>23.5</b> | <b>20.7</b> | <b>13.7</b> | <b>13.6</b> | <b>24.7</b> | <b>36.6</b>  | <b>54.2</b>  | <b>76.8</b>  | <b>110.5</b> |
|                              |   | <b>F</b> | <b>731.0</b> | <b>23.0</b> | <b>19.3</b> | <b>11.2</b> | <b>13.1</b> | <b>29.4</b> | <b>241.0</b> | <b>426.8</b> | <b>379.6</b> | <b>350.3</b> |
| <b>C00-C97</b>               | <b>All cancers</b>  | <b>M</b> | <b>622.8</b> | <b>19.7</b> | <b>19.4</b> | <b>12.0</b> | <b>10.7</b> | <b>21.0</b> | <b>31.1</b>  | <b>47.3</b>  | <b>66.7</b>  | <b>95.1</b>  |
|                              |   | <b>F</b> | <b>575.1</b> | <b>20.3</b> | <b>17.6</b> | <b>9.4</b>  | <b>10.0</b> | <b>17.9</b> | <b>32.5</b>  | <b>61.8</b>  | <b>102.3</b> | <b>163.2</b> |
| <b>C00-C97 excl.C44</b>      | <b>All cancers excluding nmssc<sup>1</sup></b>  | <b>M</b> | <b>483.2</b> | <b>19.7</b> | <b>19.2</b> | <b>12.0</b> | <b>10.3</b> | <b>20.2</b> | <b>29.3</b>  | <b>43.4</b>  | <b>55.6</b>  | <b>75.2</b>  |
|                              |   | <b>F</b> | <b>464.3</b> | <b>20.3</b> | <b>17.6</b> | <b>9.3</b>  | <b>9.6</b>  | <b>17.0</b> | <b>30.0</b>  | <b>56.0</b>  | <b>89.9</b>  | <b>139.5</b> |
| C00-C14                      | Malignant neoplasm of lip, mouth and pharynx  | M        | 11.9         | -           | -           | 0.2         | 0.2         | 0.7         | 0.5          | 1.0          | 1.6          | 2.7          |
|                              |   | F        | 6.3          | -           | 0.3         | 0.2         | 0.4         | 0.4         | 0.9          | 0.6          | 1.0          | 2.0          |
| C00                          | Malignant neoplasm of lip   | M        | 0.6          | -           | -           | -           | -           | -           | -            | 0.1          | 0.2          | -            |
|                              |   | F        | 0.3          | -           | 0.1         | -           | -           | -           | -            | -            | -            | -            |
| C01                          | Malignant neoplasm of base of tongue  | M        | 1.0          | -           | -           | -           | -           | -           | -            | -            | 0.1          | 0.1          |
|                              |   | F        | 0.3          | -           | -           | -           | -           | -           | -            | -            | 0.1          | 0.1          |
| C02                          | Malignant neoplasm of other and unspecified parts of tongue                           | M        | 1.9          | -           | -           | -           | -           | 0.1         | 0.1          | 0.1          | 0.5          | 0.7          |
|                              |   | F        | 1.3          | -           | -           | -           | 0.1         | -           | 0.2          | 0.2          | 0.3          | 0.3          |
| C03                          | Malignant neoplasm of gum   | M        | 0.5          | -           | -           | -           | -           | -           | -            | -            | 0.2          | 0.2          |
|                              |   | F        | 0.4          | -           | -           | 0.1         | -           | -           | 0.1          | -            | 0.1          | 0.1          |
| C04                          | Malignant neoplasm of floor of mouth  | M        | 1.0          | -           | -           | -           | -           | -           | -            | -            | -            | 0.3          |
|                              |   | F        | 0.4          | -           | -           | -           | -           | -           | -            | -            | -            | 0.2          |
| C05                          | Malignant neoplasm of palate  | M        | 0.5          | -           | -           | -           | -           | 0.1         | 0.1          | -            | -            | 0.2          |
|                              |   | F        | 0.5          | -           | 0.1         | -           | -           | -           | -            | 0.2          | 0.1          | 0.2          |
| C06                          | Malignant neoplasm of other and unspecified parts of mouth                            | M        | 0.7          | -           | -           | -           | -           | 0.1         | -            | 0.1          | 0.2          | 0.1          |
|                              |   | F        | 0.6          | -           | 0.1         | -           | -           | -           | -            | 0.1          | 0.1          | 0.2          |
| C07                          | Malignant neoplasm of parotid gland   | M        | 0.8          | -           | -           | 0.1         | 0.1         | 0.1         | 0.2          | 0.4          | 0.1          | 0.3          |
|                              |   | F        | 0.6          | -           | -           | -           | 0.3         | 0.2         | 0.3          | 0.1          | 0.3          | 0.4          |
| C08                          | Malignant neoplasm of other and unspecified major salivary glands                     | M        | 0.2          | -           | -           | -           | -           | 0.1         | -            | -            | 0.1          | 0.1          |
|                              |   | F        | 0.2          | -           | -           | -           | 0.1         | -           | 0.1          | -            | -            | 0.1          |
| C09                          | Malignant neoplasm of tonsil  | M        | 1.9          | -           | -           | -           | -           | -           | -            | 0.3          | 0.1          | 0.3          |
|                              |   | F        | 0.6          | -           | -           | -           | -           | 0.1         | -            | -            | 0.1          | 0.3          |
| C10                          | Malignant neoplasm of oropharynx  | M        | 0.5          | -           | -           | -           | -           | -           | -            | -            | -            | 0.2          |
|                              |   | F        | 0.1          | -           | -           | -           | -           | -           | -            | -            | -            | 0.1          |
| C11                          | Malignant neoplasm of nasopharynx   | M        | 0.6          | -           | -           | 0.1         | 0.1         | 0.2         | 0.2          | -            | 0.1          | 0.3          |
|                              |   | F        | 0.2          | -           | -           | 0.1         | -           | 0.1         | 0.2          | 0.1          | -            | 0.2          |
| C12                          | Malignant neoplasm of pyriform sinus  | M        | 0.7          | -           | -           | -           | -           | -           | -            | -            | 0.1          | -            |
|                              |   | F        | 0.1          | -           | -           | -           | -           | -           | -            | -            | -            | -            |
| C13                          | Malignant neoplasm of hypopharynx   | M        | 0.3          | -           | -           | -           | -           | -           | -            | -            | -            | -            |
|                              |   | F        | 0.2          | -           | -           | -           | -           | -           | -            | -            | -            | -            |
| C14                          | Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynx | M        | 0.6          | -           | -           | 0.1         | -           | -           | -            | 0.1          | 0.1          | 0.1          |
|                              |   | F        | 0.3          | -           | -           | -           | -           | -           | -            | -            | -            | -            |
| C15                          | Malignant neoplasm of oesophagus  | M        | 16.8         | -           | -           | -           | -           | -           | 0.1          | 0.1          | 0.2          | 0.7          |
|                              |   | F        | 8.9          | -           | -           | -           | -           | -           | -            | 0.1          | -            | 0.3          |
| C16                          | Malignant neoplasm of stomach   | M        | 17.2         | 0.3         | -           | -           | -           | 0.1         | 0.1          | 0.2          | 0.7          | 1.5          |
|                              |   | F        | 8.7          | -           | -           | -           | -           | -           | 0.1          | 0.3          | 0.8          | 1.0          |
| C17                          | Malignant neoplasm of small intestine   | M        | 1.5          | -           | -           | -           | -           | -           | -            | 0.1          | 0.3          | 0.3          |
|                              |   | F        | 1.3          | -           | -           | 0.1         | -           | -           | 0.1          | 0.2          | -            | 0.5          |
| C18-C20                      | Malignant neoplasm of colon and rectum  | M        | 65.8         | -           | -           | -           | -           | 0.4         | 1.1          | 2.0          | 2.5          | 5.5          |
|                              |   | F        | 51.7         | -           | -           | -           | -           | -           | 1.2          | 1.7          | 2.4          | 4.5          |

1. These figures exclude non-melanoma skin cancer (ICD-10 C44) - see section 4.2.

England  
Registered by October 2007

|       |       |       |       |        |        |        |        |        |             | Site description |  | ICD-10 code |
|-------|-------|-------|-------|--------|--------|--------|--------|--------|-------------|------------------|--|-------------|
| 40-44 | 45-49 | 50-54 | 55-59 | 60-64  | 65-69  | 70-74  | 75-79  | 80-84  | 85 and over |                  |  |             |
| 160.0 | 267.1 | 485.2 | 883.7 | 1451.6 | 2251.5 | 3050.8 | 3987.2 | 4686.9 | 5167.3      | M                | All registrations                        | C00-C97,    |
| 398.2 | 514.4 | 741.3 | 933.3 | 1268.1 | 1618.8 | 1891.2 | 2362.1 | 2733.8 | 3048.8      | F                |  | D00-D48,    |
|       |       |       |       |        |        |        |        |        |             |                  |  | O01         |
| 138.6 | 237.2 | 432.4 | 795.8 | 1317.4 | 2043.6 | 2756.8 | 3597.7 | 4213.2 | 4663.7      | M                | All cancers                              | C00-C97     |
| 271.8 | 410.9 | 619.1 | 809.2 | 1110.3 | 1426.5 | 1681.1 | 2095.7 | 2415.8 | 2696.6      | F                |  |             |
| 104.9 | 181.1 | 336.4 | 633.0 | 1051.1 | 1624.9 | 2170.5 | 2762.0 | 3124.6 | 3335.5      | M                | All cancers excluding nmssc <sup>1</sup> | C00-C97     |
| 231.8 | 350.0 | 530.9 | 684.8 | 919.8  | 1178.2 | 1344.6 | 1649.0 | 1853.0 | 1963.7      | F                |  | excl.C44    |
| 7.5   | 13.7  | 24.9  | 28.1  | 33.6   | 35.8   | 31.2   | 33.0   | 36.1   | 38.9        | M                | Malignant neoplasm of lip,               | C00-C14     |
| 2.9   | 5.9   | 9.2   | 10.3  | 14.4   | 15.2   | 17.8   | 17.1   | 22.9   | 25.0        | F                | mouth and pharynx                        |             |
| 0.3   | 0.2   | 0.6   | 0.7   | 1.1    | 2.6    | 1.4    | 3.7    | 2.9    | 6.4         | M                | Malignant neoplasm of lip                | C00         |
| -     | -     | 0.3   | 0.2   | 0.3    | 1.2    | 0.9    | 1.1    | 1.8    | 3.2         | F                |  |             |
| 0.7   | 1.4   | 3.0   | 2.3   | 3.6    | 3.0    | 2.2    | 1.6    | 2.1    | 0.3         | M                | Malignant neoplasm of                    | C01         |
| 0.1   | 0.4   | 0.7   | 0.8   | 0.5    | 0.9    | 1.2    | 0.9    | 0.9    | 0.7         | F                | base of tongue                           |             |
| 1.1   | 2.5   | 3.4   | 5.2   | 5.6    | 5.6    | 5.7    | 4.4    | 5.9    | 5.0         | M                | Malignant neoplasm of                    | C02         |
| 0.6   | 1.1   | 2.1   | 2.1   | 3.3    | 3.8    | 3.0    | 3.1    | 4.6    | 6.2         | F                | other and unspecified                    |             |
|       |       |       |       |        |        |        |        |        |             |                  | parts of tongue                          |             |
| 0.1   | 0.4   | 0.6   | 0.6   | 1.4    | 1.8    | 1.4    | 3.4    | 2.9    | 3.4         | M                | Malignant neoplasm of gum                | C03         |
| -     | 0.1   | 0.5   | 0.5   | 0.8    | 1.5    | 1.6    | 1.5    | 2.5    | 1.9         | F                |  |             |
| 0.7   | 1.1   | 2.3   | 2.9   | 3.2    | 2.8    | 3.2    | 1.6    | 1.5    | 1.0         | M                | Malignant neoplasm of                    | C04         |
| 0.4   | 0.5   | 0.5   | 0.8   | 1.4    | 0.9    | 1.3    | 1.0    | 0.9    | 0.9         | F                | floor of mouth                           |             |
| 0.3   | 0.5   | 1.5   | 1.2   | 1.9    | 1.8    | 1.6    | 1.3    | 1.0    | 0.7         | M                | Malignant neoplasm of                    | C05         |
| 0.3   | 0.5   | 0.6   | 0.8   | 1.1    | 1.3    | 1.3    | 0.9    | 1.6    | 1.4         | F                | palate                                   |             |
| 0.6   | 0.7   | 1.8   | 1.1   | 1.9    | 1.8    | 2.8    | 2.0    | 2.5    | 4.7         | M                | Malignant neoplasm of                    | C06         |
| 0.2   | 0.5   | 0.8   | 1.0   | 1.7    | 1.2    | 1.8    | 2.1    | 2.4    | 3.3         | F                | other and unspecified                    |             |
|       |       |       |       |        |        |        |        |        |             |                  | parts of mouth                           |             |
| 0.3   | 0.7   | 0.7   | 1.1   | 1.5    | 1.9    | 1.8    | 3.0    | 5.5    | 8.7         | M                | Malignant neoplasm of                    | C07         |
| 0.4   | 0.4   | 0.5   | 1.0   | 0.8    | 0.7    | 1.7    | 1.4    | 1.6    | 2.6         | F                | parotid gland                            |             |
| 0.2   | 0.4   | 0.2   | 0.5   | 0.4    | 0.6    | 0.7    | 0.9    | 0.6    | 1.7         | M                | Malignant neoplasm of                    | C08         |
| 0.3   | 0.2   | 0.1   | 0.1   | 0.5    | 0.4    | 0.6    | 0.8    | 1.6    | 0.9         | F                | other and unspecified                    |             |
|       |       |       |       |        |        |        |        |        |             |                  | major salivary glands                    |             |
| 1.8   | 3.5   | 6.0   | 6.3   | 4.8    | 5.1    | 2.6    | 2.0    | 2.9    | 1.3         | M                | Malignant neoplasm of                    | C09         |
| 0.4   | 1.1   | 1.6   | 1.6   | 1.4    | 1.3    | 1.2    | 1.5    | 1.3    | 0.3         | F                | tonsil                                   |             |
| 0.2   | 0.4   | 1.2   | 1.2   | 1.7    | 1.2    | 1.8    | 1.8    | 0.6    | 0.7         | M                | Malignant neoplasm of                    | C10         |
| 0.1   | 0.1   | 0.2   | 0.3   | 0.5    | 0.2    | 0.4    | 0.1    | 0.5    | 0.6         | F                | oropharynx                               |             |
| 0.7   | 0.7   | 1.1   | 1.3   | 1.3    | 2.4    | 1.4    | 1.0    | 1.5    | 0.7         | M                | Malignant neoplasm of                    | C11         |
| 0.2   | 0.4   | 0.3   | 0.3   | 0.5    | 0.5    | 0.8    | 0.2    | 0.4    | 1.0         | F                | nasopharynx                              |             |
| 0.2   | 0.8   | 1.3   | 1.7   | 2.1    | 1.9    | 1.6    | 2.7    | 3.4    | 1.0         | M                | Malignant neoplasm of                    | C12         |
| 0.1   | 0.2   | 0.3   | 0.2   | 0.5    | 0.2    | 0.7    | 0.5    | 0.4    | 0.3         | F                | pyriform sinus                           |             |
| 0.1   | 0.3   | 0.6   | 0.4   | 1.0    | 1.0    | 1.4    | 1.6    | 1.7    | 1.0         | M                | Malignant neoplasm of                    | C13         |
| 0.1   | -     | 0.3   | 0.2   | 0.5    | 0.6    | 0.6    | 1.0    | 0.7    | 0.7         | F                | hypopharynx                              |             |
| 0.2   | 0.2   | 0.6   | 1.6   | 2.1    | 2.3    | 1.7    | 2.1    | 1.0    | 2.3         | M                | Malignant neoplasm of                    | C14         |
| -     | 0.4   | 0.5   | 0.2   | 0.7    | 0.6    | 1.0    | 1.1    | 1.8    | 1.1         | F                | other and ill-defined                    |             |
|       |       |       |       |        |        |        |        |        |             |                  | sites in the lip, oral                   |             |
|       |       |       |       |        |        |        |        |        |             |                  | cavity and pharynx                       |             |
| 2.2   | 6.9   | 14.3  | 28.8  | 40.2   | 54.6   | 72.1   | 95.9   | 109.8  | 114.6       | M                | Malignant neoplasm of                    | C15         |
| 0.9   | 2.2   | 5.8   | 9.0   | 13.5   | 18.9   | 26.7   | 44.1   | 55.7   | 69.1        | F                | oesophagus                               |             |
| 3.1   | 4.3   | 9.4   | 16.8  | 30.7   | 52.4   | 83.3   | 121.2  | 132.3  | 156.1       | M                | Malignant neoplasm of                    | C16         |
| 1.8   | 2.6   | 3.7   | 6.0   | 9.5    | 18.4   | 25.6   | 43.6   | 54.5   | 77.8        | F                | stomach                                  |             |
| 0.4   | 0.6   | 1.5   | 2.7   | 2.9    | 4.4    | 6.1    | 8.5    | 12.0   | 8.7         | M                | Malignant neoplasm of                    | C17         |
| 0.6   | 1.0   | 0.9   | 2.1   | 1.5    | 2.8    | 5.0    | 3.9    | 7.3    | 5.0         | F                | small intestine                          |             |
| 10.2  | 24.2  | 45.1  | 86.1  | 135.4  | 210.9  | 311.3  | 417.7  | 470.6  | 477.8       | M                | Malignant neoplasm of colon              | C18-C20     |
| 9.3   | 19.5  | 33.2  | 54.4  | 82.9   | 127.8  | 183.7  | 246.2  | 294.8  | 310.7       | F                | and rectum                               |             |

Table 3 Series MB1 no. 36

To link to Excel version of the table - click on the red box surrounding the table title

Table 3 Rates per 100,000 population - continued

| ICD-10 code | Site description   |   | All ages     | Age group |     |     |       |       |       |       |       |       |  |
|-------------|--|---|--------------|-----------|-----|-----|-------|-------|-------|-------|-------|-------|--|
|             |  |   |              | Under 1   | 1-4 | 5-9 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 |  |
| C18         | Malignant neoplasm of colon  | M | <b>38.9</b>  | -         | -   | -   | -     | 0.3   | 0.8   | 1.4   | 1.8   | 3.2   |  |
|             |  | F | <b>35.1</b>  | -         | -   | -   | -     | -     | 0.7   | 1.2   | 1.4   | 3.2   |  |
| C19         | Malignant neoplasm of rectosigmoid junction  | M | <b>5.9</b>   | -         | -   | -   | -     | -     | -     | 0.1   | 0.2   | 0.4   |  |
|             |  | F | <b>4.0</b>   | -         | -   | -   | -     | -     | 0.1   | 0.1   | 0.3   | 0.3   |  |
| C20         | Malignant neoplasm of rectum   | M | <b>21.0</b>  | -         | -   | -   | -     | 0.1   | 0.4   | 0.5   | 0.5   | 1.9   |  |
|             |  | F | <b>12.6</b>  | -         | -   | -   | -     | -     | 0.4   | 0.4   | 0.7   | 1.1   |  |
| C21         | Malignant neoplasm of anus and anal canal  | M | <b>1.1</b>   | -         | -   | -   | -     | -     | 0.1   | 0.1   | 0.2   | 0.4   |  |
|             |  | F | <b>1.7</b>   | -         | -   | -   | -     | -     | -     | 0.1   | 0.2   | 0.7   |  |
| C22         | Malignant neoplasm of liver and intrahepatic bile ducts  | M | <b>6.5</b>   | 0.6       | 0.4 | 0.1 | 0.1   | 0.1   | 0.2   | 0.3   | 0.2   | 0.5   |  |
|             |  | F | <b>3.8</b>   | 0.7       | 0.4 | -   | -     | 0.2   | 0.2   | 0.1   | 0.2   | 0.2   |  |
| C23         | Malignant neoplasm of gallbladder  | M | <b>0.5</b>   | -         | -   | -   | -     | -     | -     | -     | -     | -     |  |
|             |  | F | <b>1.4</b>   | -         | -   | -   | -     | -     | -     | 0.1   | -     | 0.1   |  |
| C24         | Malignant neoplasm of other and unspecified parts of biliary tract                                   | M | <b>1.3</b>   | -         | -   | -   | -     | -     | -     | 0.1   | -     | 0.2   |  |
|             |  | F | <b>1.2</b>   | -         | -   | -   | -     | -     | -     | 0.1   | 0.2   | -     |  |
| C25         | Malignant neoplasm of pancreas   | M | <b>12.7</b>  | -         | -   | -   | -     | 0.1   | 0.1   | 0.2   | 0.3   | 1.2   |  |
|             |  | F | <b>12.8</b>  | -         | -   | -   | -     | -     | 0.1   | 0.2   | 0.4   | 0.5   |  |
| C26         | Malignant neoplasm of other and ill-defined digestive organs   | M | <b>1.1</b>   | -         | -   | -   | -     | -     | -     | 0.1   | 0.1   | 0.3   |  |
|             |  | F | <b>1.2</b>   | -         | -   | -   | -     | -     | -     | -     | 0.1   | 0.2   |  |
| C30         | Malignant neoplasm of nasal cavity and middle ear  | M | <b>0.4</b>   | -         | 0.1 | 0.1 | -     | -     | 0.1   | 0.1   | 0.1   | 0.2   |  |
|             |  | F | <b>0.3</b>   | -         | -   | -   | -     | -     | -     | -     | 0.1   | 0.2   |  |
| C31         | Malignant neoplasm of accessory sinuses  | M | <b>0.3</b>   | -         | -   | -   | -     | -     | 0.1   | -     | 0.1   | 0.1   |  |
|             |  | F | <b>0.2</b>   | -         | -   | -   | 0.1   | 0.1   | 0.1   | -     | -     | -     |  |
| C32         | Malignant neoplasm of larynx   | M | <b>5.8</b>   | -         | -   | -   | 0.1   | -     | -     | -     | 0.1   | 0.4   |  |
|             |  | F | <b>1.2</b>   | -         | -   | -   | -     | -     | -     | -     | 0.1   | 0.3   |  |
| C33-C34     | Malignant neoplasm of trachea, bronchus and lung   | M | <b>72.9</b>  | -         | -   | -   | -     | 0.1   | -     | 0.7   | 1.2   | 2.4   |  |
|             |  | F | <b>50.6</b>  | -         | -   | -   | -     | 0.1   | 0.2   | 0.4   | 0.8   | 2.1   |  |
| C33         | Malignant neoplasm of trachea  | M | <b>0.1</b>   | -         | -   | -   | -     | -     | -     | -     | 0.1   | 0.1   |  |
|             |  | F | <b>0.1</b>   | -         | -   | -   | -     | -     | 0.1   | -     | 0.1   | -     |  |
| C34         | Malignant neoplasm of bronchus and lung  | M | <b>72.8</b>  | -         | -   | -   | -     | 0.1   | -     | 0.7   | 1.2   | 2.4   |  |
|             |  | F | <b>50.5</b>  | -         | -   | -   | -     | 0.1   | 0.2   | 0.4   | 0.7   | 2.1   |  |
| C37         | Malignant neoplasm of thymus   | M | <b>0.2</b>   | -         | -   | -   | -     | -     | -     | -     | -     | 0.2   |  |
|             |  | F | <b>0.2</b>   | -         | -   | -   | -     | 0.1   | -     | -     | 0.2   | 0.1   |  |
| C38         | Malignant neoplasm of heart, mediastinum and pleura  | M | <b>0.5</b>   | 0.6       | -   | -   | -     | 0.1   | 0.2   | 0.1   | 0.2   | 0.2   |  |
|             |  | F | <b>0.3</b>   | 0.3       | 0.1 | 0.1 | -     | -     | -     | -     | 0.1   | 0.1   |  |
| C39         | Malignant neoplasm of other and ill-defined sites in the respiratory system and intrathoracic organs | M | <b>0.0</b>   | -         | -   | -   | -     | -     | -     | -     | -     | -     |  |
|             |  | F | <b>0.0</b>   | -         | -   | -   | -     | -     | -     | -     | -     | -     |  |
| C40         | Malignant neoplasm of bone and articular cartilage of limbs  | M | <b>0.4</b>   | -         | -   | 0.3 | 0.7   | 0.8   | 0.6   | 0.4   | 0.2   | 0.3   |  |
|             |  | F | <b>0.3</b>   | -         | -   | 0.3 | 0.9   | 0.4   | 0.3   | 0.2   | 0.2   | 0.3   |  |
| C41         | Malignant neoplasm of bone and articular cartilage of other and unspecified sites                    | M | <b>0.6</b>   | -         | 0.3 | 0.3 | 0.2   | 0.8   | 0.4   | 0.4   | 0.3   | 0.4   |  |
|             |  | F | <b>0.3</b>   | -         | 0.2 | 0.1 | 0.1   | 0.3   | 0.6   | 0.1   | 0.1   | 0.2   |  |
| C43         | Malignant melanoma of skin   | M | <b>14.8</b>  | -         | -   | -   | 0.1   | 1.5   | 2.9   | 4.4   | 6.7   | 10.0  |  |
|             |  | F | <b>17.0</b>  | -         | 0.2 | 0.1 | 0.2   | 2.4   | 6.5   | 11.1  | 13.6  | 15.0  |  |
| C44         | Other malignant neoplasms of skin  | M | <b>139.6</b> | -         | 0.2 | -   | 0.4   | 0.8   | 1.7   | 3.9   | 11.1  | 19.9  |  |
|             |  | F | <b>110.9</b> | -         | -   | 0.1 | 0.5   | 0.9   | 2.5   | 5.8   | 12.4  | 23.7  |  |
| C45         | Mesothelioma   | M | <b>6.3</b>   | -         | -   | -   | -     | -     | -     | -     | -     | 0.1   |  |
|             |  | F | <b>1.1</b>   | -         | -   | -   | 0.1   | -     | -     | 0.1   | -     | 0.1   |  |

|       |       |       |       |       |       |       |       |        |             | Site description |  | ICD-10 code |
|-------|-------|-------|-------|-------|-------|-------|-------|--------|-------------|------------------|--|-------------|
| 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84  | 85 and over |                  |  |             |
| 6.3   | 13.1  | 23.1  | 45.0  | 71.1  | 119.7 | 181.3 | 268.3 | 301.3  | 315.3       | M                | Malignant neoplasm of colon  | C18         |
| 5.6   | 12.3  | 19.1  | 33.5  | 52.7  | 84.7  | 124.9 | 173.6 | 211.2  | 221.4       | F                |  |             |
| 0.8   | 2.0   | 4.4   | 7.8   | 14.1  | 21.0  | 31.1  | 32.4  | 39.5   | 33.8        | M                | Malignant neoplasm of rectosigmoid junction  | C19         |
| 0.9   | 1.7   | 3.5   | 5.6   | 8.0   | 10.5  | 14.3  | 17.1  | 19.2   | 19.2        | F                |  |             |
| 3.2   | 9.2   | 17.6  | 33.2  | 50.3  | 70.1  | 98.9  | 116.9 | 129.8  | 128.7       | M                | Malignant neoplasm of rectum   | C20         |
| 2.9   | 5.6   | 10.6  | 15.3  | 22.2  | 32.6  | 44.4  | 55.5  | 64.3   | 70.2        | F                |  |             |
| 0.9   | 0.7   | 1.8   | 1.9   | 2.4   | 3.4   | 4.0   | 3.3   | 4.6    | 6.0         | M                | Malignant neoplasm of anus and anal canal  | C21         |
| 0.9   | 1.8   | 1.9   | 2.7   | 4.5   | 3.3   | 3.8   | 4.8   | 6.8    | 9.2         | F                |  |             |
| 1.2   | 3.1   | 6.4   | 9.9   | 14.1  | 20.8  | 28.9  | 34.7  | 42.6   | 41.9        | M                | Malignant neoplasm of liver and intrahepatic bile ducts  | C22         |
| 0.4   | 1.4   | 2.2   | 3.3   | 5.1   | 10.0  | 12.2  | 18.3  | 23.4   | 26.5        | F                |  |             |
| 0.1   | 0.2   | 0.5   | 0.6   | 1.1   | 2.1   | 2.4   | 3.4   | 3.8    | 4.7         | M                | Malignant neoplasm of gallbladder  | C23         |
| 0.3   | 0.3   | 0.5   | 1.7   | 2.7   | 4.1   | 4.7   | 6.7   | 8.1    | 6.5         | F                |  |             |
| 0.1   | 0.6   | 1.1   | 1.5   | 2.9   | 5.2   | 4.9   | 8.5   | 9.4    | 8.0         | M                | Malignant neoplasm of other and unspecified parts of biliary tract                                   | C24         |
| 0.3   | 0.3   | 1.0   | 1.1   | 1.7   | 3.0   | 3.7   | 5.0   | 6.9    | 8.3         | F                |  |             |
| 1.5   | 4.5   | 9.4   | 20.0  | 27.1  | 41.6  | 56.4  | 71.8  | 91.1   | 96.8        | M                | Malignant neoplasm of pancreas   | C25         |
| 1.1   | 3.1   | 6.3   | 12.9  | 22.6  | 30.8  | 46.6  | 58.7  | 75.3   | 89.5        | F                |  |             |
| 0.2   | 0.3   | 0.7   | 1.0   | 1.8   | 2.7   | 3.2   | 5.0   | 10.1   | 19.8        | M                | Malignant neoplasm of other and ill-defined digestive organs   | C26         |
| 0.1   | 0.2   | 0.3   | 0.3   | 1.2   | 1.5   | 2.6   | 5.4   | 7.6    | 17.6        | F                |  |             |
| 0.4   | 0.2   | 0.5   | 0.6   | 0.6   | 1.1   | 1.4   | 2.0   | 2.5    | 1.7         | M                | Malignant neoplasm of nasal cavity and middle ear  | C30         |
| 0.1   | 0.3   | 0.3   | 0.5   | 0.9   | 1.4   | 1.2   | 1.1   | 0.8    | 0.9         | F                |  |             |
| 0.1   | 0.2   | 0.1   | 0.7   | 0.6   | 1.2   | 1.2   | 0.7   | 0.6    | 0.7         | M                | Malignant neoplasm of accessory sinuses  | C31         |
| 0.1   | 0.2   | 0.3   | 0.3   | 0.2   | 0.3   | 0.2   | 0.3   | 0.7    | 1.1         | F                |  |             |
| 1.0   | 3.1   | 7.2   | 13.2  | 18.7  | 20.1  | 21.9  | 24.2  | 27.7   | 25.5        | M                | Malignant neoplasm of larynx   | C32         |
| 0.3   | 0.9   | 1.6   | 2.1   | 3.3   | 3.2   | 3.1   | 5.3   | 4.1    | 2.7         | F                |  |             |
| 6.1   | 18.2  | 43.5  | 83.6  | 164.1 | 248.7 | 350.5 | 478.9 | 550.6  | 541.5       | M                | Malignant neoplasm of trachea, bronchus and lung   | C33-C34     |
| 6.5   | 15.5  | 36.6  | 62.0  | 102.8 | 149.5 | 199.3 | 265.9 | 259.9  | 193.2       | F                |  |             |
| -     | -     | 0.1   | 0.2   | 0.2   | 0.3   | 0.3   | 0.1   | 0.2    | -           | M                | Malignant neoplasm of trachea  | C33         |
| -     | 0.1   | -     | 0.2   | 0.2   | 0.1   | 0.4   | 0.7   | 0.3    | -           | F                |  |             |
| 6.1   | 18.2  | 43.4  | 83.5  | 163.8 | 248.4 | 350.2 | 478.7 | 550.4  | 541.5       | M                | Malignant neoplasm of bronchus and lung  | C34         |
| 6.5   | 15.4  | 36.6  | 61.7  | 102.6 | 149.4 | 198.9 | 265.2 | 259.6  | 193.2       | F                |  |             |
| 0.2   | 0.1   | 0.3   | 0.7   | 0.6   | 0.7   | 0.7   | 0.6   | 0.2    | -           | M                | Malignant neoplasm of thymus   | C37         |
| 0.1   | 0.2   | 0.1   | 0.3   | 0.3   | 0.8   | 0.5   | 0.4   | 0.5    | 0.1         | F                |  |             |
| 0.2   | 0.4   | 0.1   | 0.4   | 0.9   | 2.0   | 1.4   | 2.8   | 3.4    | 2.3         | M                | Malignant neoplasm of heart, mediastinum and pleura  | C38         |
| 0.1   | 0.2   | 0.1   | 0.3   | 0.5   | 0.5   | 0.7   | 2.1   | 1.8    | 2.6         | F                |  |             |
| -     | -     | -     | -     | -     | -     | -     | 0.3   | 0.2    | 0.3         | M                | Malignant neoplasm of other and ill-defined sites in the respiratory system and intrathoracic organs | C39         |
| -     | -     | -     | 0.1   | -     | -     | -     | -     | -      | 0.1         | F                |  |             |
| 0.3   | 0.4   | 0.4   | 0.3   | 0.4   | 0.4   | 0.3   | 1.3   | 0.4    | -           | M                | Malignant neoplasm of bone and articular cartilage of limbs  | C40         |
| 0.2   | 0.5   | 0.1   | 0.3   | 0.2   | 0.4   | 0.4   | 0.3   | 0.4    | 1.1         | F                |  |             |
| 0.5   | 0.4   | 0.4   | 0.6   | 1.3   | 1.7   | 1.0   | 1.3   | 1.0    | 2.3         | M                | Malignant neoplasm of bone and articular cartilage of other and unspecified sites                    | C41         |
| 0.2   | 0.2   | 0.3   | 0.5   | 0.2   | 0.7   | 0.3   | 0.8   | 1.7    | 0.6         | F                |  |             |
| 13.1  | 14.1  | 18.6  | 27.6  | 29.8  | 39.9  | 45.8  | 47.9  | 56.3   | 55.0        | M                | Malignant melanoma of skin   | C43         |
| 17.5  | 19.7  | 22.8  | 25.5  | 28.3  | 32.5  | 33.6  | 39.1  | 40.0   | 41.0        | F                |  |             |
| 33.7  | 56.1  | 96.0  | 162.8 | 266.4 | 418.8 | 586.3 | 835.6 | 1088.6 | 1328.2      | M                | Other malignant neoplasms of skin  | C44         |
| 40.0  | 60.9  | 88.2  | 124.4 | 190.5 | 248.3 | 336.5 | 446.8 | 562.8  | 732.9       | F                |  |             |
| 0.2   | 1.0   | 3.4   | 8.5   | 17.7  | 24.4  | 33.2  | 39.7  | 36.7   | 39.2        | M                | Mesothelioma   | C45         |
| -     | 0.2   | 0.7   | 1.1   | 2.3   | 4.3   | 3.3   | 6.1   | 6.1    | 5.2         | F                |  |             |

**Table 3 Series MBI no. 36**

To link to Excel version of the table - click on the red box surrounding the table title

**Table 3 Rates per 100,000 population - continued**

| ICD-10 code | Site description  |   | All ages     | Age group |     |     |       |       |       |       |       |       |     |
|-------------|---|---|--------------|-----------|-----|-----|-------|-------|-------|-------|-------|-------|-----|
|             |   |   |              | Under 1   | 1-4 | 5-9 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 |     |
| C46         | Kaposi's sarcoma  | M | <b>0.4</b>   | -         | -   | -   | -     | -     | -     | 0.1   | 0.6   | 0.9   | 0.9 |
|             |   | F | <b>0.1</b>   | -         | -   | -   | -     | -     | -     | 0.1   | 0.2   | 0.1   | 0.1 |
| C47         | Malignant neoplasm of peripheral nerves and autonomic nervous system    | M | <b>0.2</b>   | 0.6       | 0.6 | -   | 0.2   | 0.1   | 0.1   | 0.1   | 0.1   | 0.2   | 0.2 |
|             |   | F | <b>0.1</b>   | -         | 0.4 | 0.1 | 0.1   | -     | 0.1   | 0.1   | 0.1   | 0.1   | 0.2 |
| C48         | Malignant neoplasm of retroperitoneum and peritoneum                    | M | <b>0.4</b>   | 0.3       | -   | 0.1 | -     | -     | -     | -     | 0.1   | 0.1   | 0.2 |
|             |   | F | <b>1.4</b>   | 0.3       | -   | -   | -     | -     | -     | 0.1   | -     | 0.3   | 0.2 |
| C49         | Malignant neoplasm of other connective and soft tissue                  | M | <b>2.5</b>   | 1.0       | 0.7 | 0.5 | 0.4   | 0.5   | 0.9   | 1.0   | 1.2   | 1.6   |     |
|             |   | F | <b>2.0</b>   | 1.0       | 0.3 | 0.1 | 0.2   | 0.8   | 0.7   | 0.9   | 1.0   | 1.2   |     |
| C50         | Malignant neoplasm of breast  | M | <b>1.0</b>   | -         | -   | -   | -     | -     | -     | 0.1   | -     | 0.2   |     |
|             |   | F | <b>148.6</b> | -         | -   | -   | -     | 0.2   | 1.3   | 7.6   | 27.2  | 62.2  |     |
| C51         | Malignant neoplasm of vulva   | F | <b>3.3</b>   | -         | -   | -   | -     | 0.1   | 0.1   | 0.1   | 0.7   | 1.0   |     |
| C52         | Malignant neoplasm of vagina  | F | <b>0.8</b>   | 0.3       | -   | -   | -     | -     | -     | -     | 0.2   | 0.5   |     |
| C53         | Malignant neoplasm of cervix uteri                                      | F | <b>8.8</b>   | -         | -   | -   | -     | 0.2   | 2.4   | 12.1  | 16.7  | 14.3  |     |
| C54         | Malignant neoplasm of corpus uteri                                      | F | <b>21.2</b>  | -         | -   | -   | -     | 0.1   | 0.1   | 0.4   | 0.8   | 2.9   |     |
| C55         | Malignant neoplasm of uterus,part unspecified                           | F | <b>1.1</b>   | -         | -   | -   | -     | -     | -     | 0.1   | 0.1   | 0.3   |     |
| C56-C57     | Malignant neoplasm of ovary and other unspecified female genital organs | F | <b>21.7</b>  | 0.3       | 0.2 | 0.1 | 0.3   | 1.5   | 2.2   | 3.6   | 4.4   | 7.4   |     |
| C56         | Malignant neoplasm of ovary   | F | <b>21.2</b>  | 0.3       | 0.2 | 0.1 | 0.3   | 1.5   | 2.2   | 3.6   | 4.4   | 7.2   |     |
| C57         | Malignant neoplasm of other and unspecified female genital organs       | F | <b>0.5</b>   | -         | -   | -   | -     | -     | -     | -     | -     | 0.2   |     |
| C58         | Malignant neoplasm of placenta  | F | <b>0.0</b>   | -         | -   | -   | -     | -     | 0.1   | 0.2   | -     | 0.1   |     |
| C60         | Malignant neoplasm of penis   | M | <b>1.6</b>   | -         | -   | -   | -     | -     | 0.1   | 0.1   | 0.3   | 0.7   |     |
| C61         | Malignant neoplasm of prostate  | M | <b>116.7</b> | -         | 0.1 | -   | -     | 0.1   | -     | 0.1   | -     | 0.4   |     |
| C62         | Malignant neoplasm of testis  | M | <b>6.9</b>   | 1.6       | 0.2 | -   | 0.1   | 3.7   | 10.6  | 16.9  | 16.2  | 15.6  |     |
| C63         | Malignant neoplasm of other and unspecified male genital organs         | M | <b>0.2</b>   | -         | 0.1 | 0.1 | 0.1   | 0.1   | -     | -     | 0.2   | -     |     |
| C64         | Malignant neoplasm of kidney,except renal pelvis                        | M | <b>13.1</b>  | 2.3       | 2.1 | 0.3 | 0.1   | 0.1   | 0.2   | 0.4   | 1.4   | 2.4   |     |
|             |   | F | <b>7.5</b>   | 1.4       | 1.9 | 0.9 | 0.1   | 0.1   | 0.3   | 0.5   | 0.8   | 1.5   |     |
| C65         | Malignant neoplasm of renal pelvis                                      | M | <b>1.0</b>   | -         | 0.1 | -   | -     | -     | -     | -     | 0.1   | 0.1   |     |
|             |   | F | <b>0.6</b>   | -         | -   | -   | -     | -     | -     | -     | -     | -     |     |
| C66         | Malignant neoplasm of ureter  | M | <b>0.8</b>   | -         | -   | -   | -     | -     | -     | -     | -     | -     |     |
|             |   | F | <b>0.5</b>   | -         | -   | -   | -     | -     | -     | -     | 0.1   | -     |     |
| C67         | Malignant neoplasm of bladder   | M | <b>24.6</b>  | -         | 0.1 | -   | -     | 0.1   | -     | 0.1   | 0.5   | 0.8   |     |
|             |   | F | <b>9.3</b>   | -         | 0.1 | -   | -     | 0.1   | 0.1   | 0.1   | 0.3   | 0.7   |     |
| C68         | Malignant neoplasm of other and unspecified urinary organs              | M | <b>0.5</b>   | -         | -   | -   | -     | 0.1   | -     | -     | -     | -     |     |
|             |   | F | <b>0.2</b>   | -         | -   | -   | -     | -     | -     | 0.1   | -     | -     |     |
| C69         | Malignant neoplasm of eye and adnexa                                    | M | <b>0.8</b>   | 1.6       | 0.6 | 0.1 | 0.1   | -     | 0.1   | 0.1   | 0.2   | 0.2   |     |
|             |   | F | <b>0.6</b>   | 4.7       | 1.2 | 0.2 | -     | -     | -     | 0.1   | 0.5   | 0.3   |     |

|       |       |       |       |       |       |       |       |       |             | Site description | ICD-10 code   |         |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------------|------------------|---|---------|
| 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85 and over |                  |   |         |
| 1.0   | 0.7   | 0.3   | 0.1   | 0.5   | 0.2   | 0.3   | 0.3   | 0.6   | 0.3         | M                | Kaposi's sarcoma  | C46     |
| 0.1   | 0.1   | 0.1   | -     | 0.1   | 0.1   | 0.1   | -     | 0.3   | -           | F                |   |         |
| 0.2   | 0.2   | -     | 0.1   | 0.1   | 0.2   | 0.3   | 0.4   | 0.4   | 0.3         | M                | Malignant neoplasm of peripheral nerves and autonomic nervous system    | C47     |
| 0.1   | 0.1   | -     | -     | -     | 0.1   | 0.2   | 0.3   | 0.4   | 0.1         | F                |   |         |
| 0.3   | 0.5   | 0.6   | 0.6   | 1.0   | 1.1   | 2.0   | 1.1   | 2.7   | 2.0         | M                | Malignant neoplasm of retroperitoneum and peritoneum                    | C48     |
| 0.5   | 1.0   | 0.9   | 2.8   | 3.3   | 5.2   | 4.7   | 5.3   | 3.4   | 3.3         | F                |   |         |
| 1.1   | 1.9   | 2.0   | 3.8   | 4.2   | 5.3   | 6.2   | 9.4   | 13.0  | 20.4        | M                | Malignant neoplasm of other connective and soft tissue                  | C49     |
| 1.3   | 1.9   | 2.4   | 3.1   | 3.3   | 3.3   | 4.7   | 4.9   | 6.5   | 6.2         | F                |   |         |
| 0.5   | 0.5   | 1.0   | 1.8   | 2.2   | 2.6   | 5.2   | 4.1   | 4.2   | 11.1        | M                | Malignant neoplasm of breast  | C50     |
| 124.2 | 185.7 | 265.4 | 286.0 | 353.0 | 395.1 | 336.7 | 360.2 | 383.7 | 426.8       | F                |   |         |
| 1.6   | 2.6   | 3.6   | 3.7   | 3.8   | 6.8   | 9.7   | 11.2  | 13.7  | 25.2        | F                | Malignant neoplasm of vulva   | C51     |
| 0.2   | 0.5   | 1.2   | 1.2   | 1.4   | 1.5   | 2.2   | 2.5   | 3.7   | 5.7         | F                | Malignant neoplasm of vagina  | C52     |
| 13.7  | 11.3  | 10.8  | 8.7   | 10.4  | 12.6  | 10.5  | 9.3   | 12.2  | 14.6        | F                | Malignant neoplasm of cervix uteri                                      | C53     |
| 4.7   | 10.8  | 27.4  | 51.4  | 61.2  | 74.3  | 73.2  | 66.1  | 56.8  | 47.9        | F                | Malignant neoplasm of corpus uteri                                      | C54     |
| 0.5   | 1.2   | 1.8   | 1.6   | 1.2   | 2.6   | 3.4   | 3.4   | 4.6   | 5.7         | F                | Malignant neoplasm of uterus, part unspecified                          | C55     |
| 10.4  | 17.6  | 26.9  | 36.1  | 50.9  | 56.0  | 68.7  | 73.6  | 70.6  | 67.4        | F                | Malignant neoplasm of ovary and other unspecified female genital organs | C56-C57 |
| 10.3  | 17.0  | 26.1  | 34.6  | 50.0  | 54.9  | 67.6  | 72.1  | 69.1  | 64.8        | F                | Malignant neoplasm of ovary   | C56     |
| 0.1   | 0.6   | 0.8   | 1.5   | 0.9   | 1.1   | 1.2   | 1.5   | 1.6   | 2.6         | F                | Malignant neoplasm of other and unspecified female genital organs       | C57     |
| -     | -     | 0.1   | -     | -     | -     | -     | -     | -     | -           | F                | Malignant neoplasm of placenta  | C58     |
| 0.9   | 1.6   | 1.9   | 2.8   | 4.2   | 4.3   | 6.3   | 4.8   | 5.9   | 10.4        | M                | Malignant neoplasm of penis   | C60     |
| 1.6   | 10.8  | 43.0  | 144.0 | 290.5 | 502.8 | 622.7 | 721.7 | 745.1 | 784.4       | M                | Malignant neoplasm of prostate  | C61     |
| 12.6  | 9.1   | 4.8   | 2.7   | 2.5   | 1.9   | 2.4   | 1.3   | 1.5   | 2.0         | M                | Malignant neoplasm of testis  | C62     |
| -     | 0.1   | 0.2   | 0.2   | 0.3   | 0.6   | 0.6   | 2.0   | 2.1   | 1.0         | M                | Malignant neoplasm of other and unspecified male genital organs         | C63     |
| 4.2   | 8.1   | 15.7  | 23.5  | 30.0  | 42.2  | 55.9  | 63.3  | 67.2  | 61.7        | M                | Malignant neoplasm of kidney, except renal pelvis                       | C64     |
| 3.0   | 5.1   | 7.5   | 11.4  | 13.8  | 21.6  | 26.4  | 28.5  | 29.4  | 27.4        | F                |   |         |
| 0.2   | 0.4   | 0.6   | 1.3   | 2.4   | 2.4   | 5.8   | 7.1   | 7.1   | 5.0         | M                | Malignant neoplasm of renal pelvis                                      | C65     |
| 0.2   | 0.1   | 0.3   | 0.8   | 0.8   | 2.5   | 2.2   | 2.5   | 3.4   | 2.2         | F                |   |         |
| 0.1   | 0.3   | 0.7   | 0.7   | 2.2   | 3.0   | 3.9   | 6.7   | 6.1   | 2.7         | M                | Malignant neoplasm of ureter  | C66     |
| 0.1   | -     | 0.3   | 0.4   | 0.5   | 1.5   | 2.2   | 3.4   | 2.1   | 1.1         | F                |   |         |
| 2.0   | 5.1   | 10.3  | 21.7  | 44.2  | 73.9  | 117.8 | 170.7 | 210.2 | 271.7       | M                | Malignant neoplasm of bladder   | C67     |
| 1.3   | 2.2   | 3.4   | 6.1   | 13.7  | 21.1  | 32.8  | 45.7  | 62.3  | 71.6        | F                |   |         |
| 0.2   | 0.2   | 0.1   | 0.6   | 0.5   | 1.0   | 2.1   | 5.7   | 3.8   | 2.7         | M                | Malignant neoplasm of other and unspecified urinary organs              | C68     |
| 0.1   | -     | 0.3   | 0.1   | 0.3   | 0.3   | 0.3   | 1.0   | 1.2   | 1.3         | F                |   |         |
| 0.4   | 0.8   | 0.9   | 1.4   | 1.5   | 2.1   | 2.9   | 3.4   | 1.7   | 1.7         | M                | Malignant neoplasm of eye and adnexa                                    | C69     |
| 0.4   | 0.6   | 0.4   | 0.8   | 0.9   | 1.2   | 1.3   | 1.3   | 1.7   | 1.1         | F                |   |         |

**Table 3 Series MBI no. 36**

To link to Excel version of the table - click on the red box surrounding the table title

**Table 3 Rates per 100,000 population - continued**

| ICD-10 code | Site description   |   | All ages    | Age group |     |     |       |       |       |       |       |       |     |
|-------------|--|---|-------------|-----------|-----|-----|-------|-------|-------|-------|-------|-------|-----|
|             |  |   |             | Under 1   | 1-4 | 5-9 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 |     |
| C70         | Malignant neoplasm of meninges   | M | <b>0.1</b>  | -         | -   | -   | -     | -     | -     | -     | -     | 0.1   | 0.1 |
|             |  | F | <b>0.1</b>  | -         | -   | -   | -     | 0.1   | -     | -     | -     | 0.1   | 0.1 |
| C71         | Malignant neoplasm of brain  | M | <b>8.9</b>  | 2.6       | 3.7 | 3.2 | 2.1   | 2.2   | 1.9   | 2.6   | 4.5   | 4.7   |     |
|             |  | F | <b>5.8</b>  | 3.0       | 2.4 | 2.3 | 1.6   | 1.0   | 1.9   | 1.9   | 2.4   | 2.3   |     |
| C72         | Malignant neoplasm of spinal cord,cranial nerves and other parts of central nervous system | M | <b>0.2</b>  | -         | 0.4 | 0.5 | 0.1   | 0.1   | -     | 0.1   | 0.2   | 0.1   |     |
|             |  | F | <b>0.2</b>  | 0.3       | 0.8 | 0.1 | 0.1   | 0.1   | 0.2   | 0.2   | 0.2   | 0.1   |     |
| C73         | Malignant neoplasm of thyroid gland  | M | <b>1.5</b>  | -         | 0.1 | 0.1 | 0.1   | 0.2   | 0.4   | 1.1   | 1.4   | 2.0   |     |
|             |  | F | <b>4.3</b>  | -         | 0.1 | -   | 0.4   | 1.6   | 3.2   | 3.9   | 5.1   | 4.8   |     |
| C74         | Malignant neoplasm of adrenal gland  | M | <b>0.3</b>  | 2.3       | 1.3 | 0.1 | -     | 0.1   | -     | -     | 0.2   | 0.2   |     |
|             |  | F | <b>0.3</b>  | 1.7       | 1.3 | 0.3 | 0.1   | 0.1   | -     | 0.1   | 0.1   | 0.1   |     |
| C75         | Malignant neoplasm of other endocrine glands and related structures                        | M | <b>0.3</b>  | -         | 0.3 | -   | 0.3   | 0.5   | 0.2   | 0.2   | 0.3   | 0.2   |     |
|             |  | F | <b>0.1</b>  | -         | 0.1 | 0.2 | -     | -     | 0.1   | -     | 0.2   | -     |     |
| C76         | Malignant neoplasm of other and ill-defined sites  | M | <b>0.8</b>  | 0.3       | 0.3 | 0.1 | -     | 0.1   | 0.2   | 0.1   | 0.1   | 0.6   |     |
|             |  | F | <b>1.0</b>  | 1.7       | 0.3 | 0.1 | 0.1   | -     | 0.1   | 0.1   | 0.3   | 0.3   |     |
| C77         | Secondary and unspecified malignant neoplasm of lymph nodes                                | M | <b>1.3</b>  | -         | -   | -   | -     | -     | 0.1   | 0.1   | 0.1   | 0.3   |     |
|             |  | F | <b>1.1</b>  | -         | -   | -   | -     | -     | -     | 0.1   | 0.2   | 0.3   |     |
| C78         | Secondary malignant neoplasm of respiratory and digestive organs                           | M | <b>6.7</b>  | -         | -   | -   | -     | -     | -     | 0.3   | 0.5   | 0.6   |     |
|             |  | F | <b>7.4</b>  | -         | -   | -   | -     | -     | -     | 0.4   | 0.2   | 0.7   |     |
| C79         | Secondary malignant neoplasm of other sites  | M | <b>2.8</b>  | -         | -   | -   | -     | 0.1   | 0.1   | 0.1   | 0.1   | 0.3   |     |
|             |  | F | <b>2.6</b>  | -         | -   | -   | -     | -     | -     | 0.1   | 0.1   | 0.4   |     |
| C80         | Malignant neoplasm without specification of site   | M | <b>8.1</b>  | 0.3       | 0.1 | 0.1 | 0.1   | 0.2   | 0.4   | 0.3   | 0.7   | 0.7   |     |
|             |  | F | <b>9.5</b>  | -         | -   | -   | 0.1   | 0.1   | 0.1   | 0.1   | 0.4   | 0.6   |     |
| C81         | Hodgkin's disease  | M | <b>3.0</b>  | -         | 0.4 | 0.5 | 1.6   | 2.6   | 3.2   | 3.9   | 4.0   | 3.7   |     |
|             |  | F | <b>2.2</b>  | -         | 0.1 | 0.1 | 1.5   | 3.5   | 3.5   | 3.9   | 2.5   | 2.2   |     |
| C82-C85     | Non-Hodgkin's lymphoma   | M | <b>18.7</b> | -         | 0.8 | 1.2 | 1.7   | 2.0   | 2.2   | 2.8   | 5.0   | 6.8   |     |
|             |  | F | <b>15.2</b> | 1.0       | 0.1 | 0.4 | 0.7   | 1.2   | 1.4   | 1.7   | 2.8   | 4.0   |     |
| C82         | Follicular (nodular) non-Hodgkin's lymphoma  | M | <b>2.6</b>  | -         | -   | 0.1 | -     | 0.1   | 0.1   | 0.1   | 1.0   | 0.8   |     |
|             |  | F | <b>2.9</b>  | -         | -   | -   | -     | 0.1   | 0.1   | 0.1   | 0.4   | 1.2   |     |
| C83         | Diffuse non-Hodgkin's lymphoma   | M | <b>9.1</b>  | -         | 0.7 | 0.7 | 1.1   | 1.2   | 1.2   | 1.6   | 2.1   | 3.4   |     |
|             |  | F | <b>6.8</b>  | 0.3       | 0.1 | 0.3 | 0.5   | 0.6   | 0.7   | 1.0   | 1.5   | 1.4   |     |
| C84         | Peripheral and cutaneous T-cell lymphomas  | M | <b>1.1</b>  | -         | -   | 0.1 | 0.1   | 0.2   | 0.1   | 0.2   | 0.1   | 0.4   |     |
|             |  | F | <b>0.8</b>  | 0.3       | -   | -   | 0.1   | 0.1   | 0.2   | 0.1   | 0.1   | 0.2   |     |
| C85         | Other and unspecified types of non-Hodgkin's lymphoma                                      | M | <b>5.8</b>  | -         | 0.1 | 0.3 | 0.5   | 0.5   | 0.7   | 0.9   | 1.8   | 2.2   |     |
|             |  | F | <b>4.7</b>  | 0.3       | -   | 0.1 | 0.1   | 0.4   | 0.4   | 0.6   | 0.8   | 1.2   |     |
| C88         | Malignant immunoproliferative diseases   | M | <b>0.4</b>  | -         | -   | -   | -     | -     | -     | -     | -     | -     |     |
|             |  | F | <b>0.3</b>  | -         | -   | -   | -     | -     | -     | -     | -     | 0.1   |     |
| C90         | Multiple myeloma and malignant plasma cell neoplasms                                       | M | <b>7.0</b>  | -         | -   | -   | -     | -     | -     | 0.1   | 0.1   | 1.0   |     |
|             |  | F | <b>5.9</b>  | -         | 0.1 | -   | -     | -     | -     | -     | 0.1   | 0.2   |     |
| C91-C95     | All leukaemias   | M | <b>14.0</b> | 4.8       | 6.5 | 4.2 | 2.0   | 3.0   | 2.4   | 2.4   | 2.4   | 3.7   |     |
|             |  | F | <b>10.0</b> | 3.4       | 7.3 | 3.4 | 2.5   | 2.3   | 1.8   | 2.2   | 1.7   | 2.4   |     |
| C91         | Lymphoid leukaemia   | M | <b>7.1</b>  | 2.3       | 5.8 | 3.7 | 1.3   | 2.0   | 1.2   | 0.7   | 0.6   | 1.4   |     |
|             |  | F | <b>4.4</b>  | 1.7       | 5.8 | 2.7 | 1.9   | 1.4   | 0.3   | 0.4   | 0.4   | 0.5   |     |
| C92         | Myeloid leukaemia  | M | <b>6.2</b>  | 1.9       | 0.7 | 0.4 | 0.5   | 0.8   | 1.0   | 1.6   | 1.7   | 2.2   |     |
|             |  | F | <b>5.0</b>  | 1.7       | 1.2 | 0.8 | 0.6   | 0.9   | 1.2   | 1.6   | 1.2   | 1.8   |     |
| C93         | Monocytic leukaemia  | M | <b>0.1</b>  | 0.3       | -   | -   | -     | 0.1   | 0.1   | -     | -     | -     |     |
|             |  | F | <b>0.1</b>  | -         | -   | -   | -     | -     | 0.1   | -     | 0.1   | -     |     |

|            |             |              |              |              |              |              |              |              |               | Site description |  | ICD-10 code |
|------------|-------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|---------------|------------------|--|-------------|
| 40-44      | 45-49       | 50-54        | 55-59        | 60-64        | 65-69        | 70-74        | 75-79        | 80-84        | 85 and over   |                  |  |             |
| -<br>0.1   | 0.2<br>0.1  | 0.1<br>-     | 0.1<br>0.1   | 0.1<br>0.1   | 0.1<br>-     | 0.1<br>0.4   | 0.1<br>0.2   | 0.4<br>0.5   | 0.3<br>0.3    | M<br>F           | Malignant neoplasm of meninges   | C70         |
| 5.6<br>3.8 | 7.1<br>4.3  | 11.3<br>5.6  | 13.2<br>9.0  | 18.7<br>10.6 | 25.3<br>14.7 | 30.2<br>15.2 | 28.7<br>20.1 | 26.5<br>17.9 | 19.8<br>9.9   | M<br>F           | Malignant neoplasm of brain  | C71         |
| 0.1<br>0.1 | 0.1<br>-    | 0.2<br>0.2   | 0.2<br>0.4   | 0.6<br>0.4   | 0.1<br>0.1   | 0.9<br>0.1   | 0.4<br>0.3   | 0.6<br>0.3   | 0.7<br>0.3    | M<br>F           | Malignant neoplasm of spinal cord,cranial nerves and other parts of central nervous system | C72         |
| 1.6<br>6.0 | 1.7<br>6.0  | 1.9<br>5.5   | 2.2<br>6.1   | 2.5<br>4.8   | 3.1<br>6.6   | 3.2<br>5.7   | 4.7<br>7.6   | 3.8<br>6.3   | 4.4<br>6.9    | M<br>F           | Malignant neoplasm of thyroid gland  | C73         |
| 0.2<br>0.3 | 0.2<br>0.2  | 0.2<br>0.2   | 0.2<br>0.4   | 0.4<br>0.4   | 0.5<br>0.4   | 1.2<br>0.6   | 0.9<br>0.7   | 0.6<br>0.3   | 0.3<br>0.6    | M<br>F           | Malignant neoplasm of adrenal gland  | C74         |
| 0.1<br>-   | 0.1<br>0.1  | 0.3<br>0.3   | 0.2<br>0.2   | 0.2<br>0.2   | 0.5<br>0.2   | 1.0<br>0.3   | 0.4<br>0.3   | 0.8<br>0.3   | 0.3<br>0.4    | M<br>F           | Malignant neoplasm of other endocrine glands and related structures                        | C75         |
| 0.5<br>0.4 | 0.5<br>0.5  | 0.5<br>0.6   | 0.7<br>0.9   | 1.0<br>0.8   | 1.8<br>1.1   | 2.4<br>1.9   | 4.7<br>3.0   | 5.9<br>6.0   | 8.4<br>12.1   | M<br>F           | Malignant neoplasm of other and ill-defined sites  | C76         |
| 0.9<br>0.5 | 1.0<br>0.8  | 2.2<br>1.4   | 3.2<br>1.7   | 2.8<br>2.7   | 3.4<br>3.4   | 4.3<br>3.3   | 4.3<br>3.7   | 5.2<br>3.9   | 8.7<br>4.7    | M<br>F           | Secondary and unspecified malignant neoplasm of lymph nodes                                | C77         |
| 0.8<br>1.2 | 2.2<br>2.3  | 4.5<br>3.9   | 6.7<br>7.1   | 10.8<br>11.2 | 17.6<br>14.4 | 25.7<br>22.4 | 41.3<br>37.8 | 63.4<br>45.4 | 82.1<br>58.1  | M<br>F           | Secondary malignant neoplasm of respiratory and digestive organs                           | C78         |
| 0.6<br>0.7 | 0.8<br>0.8  | 1.6<br>1.7   | 2.6<br>2.2   | 5.4<br>4.3   | 8.6<br>6.2   | 12.1<br>7.7  | 19.5<br>13.5 | 22.3<br>17.8 | 26.5<br>15.5  | M<br>F           | Secondary malignant neoplasm of other sites  | C79         |
| 1.3<br>1.2 | 1.7<br>2.1  | 4.1<br>3.8   | 6.6<br>6.8   | 12.2<br>11.0 | 23.1<br>15.5 | 32.9<br>25.1 | 50.1<br>44.4 | 76.2<br>68.1 | 111.6<br>97.6 | M<br>F           | Malignant neoplasm without specification of site   | C80         |
| 3.1<br>1.5 | 3.4<br>1.3  | 3.5<br>1.5   | 3.4<br>1.9   | 3.2<br>2.0   | 2.8<br>4.0   | 3.8<br>3.3   | 5.7<br>2.6   | 5.0<br>3.0   | 5.0<br>2.3    | M<br>F           | Hodgkin's disease  | C81         |
| 9.1<br>5.7 | 14.7<br>8.5 | 18.1<br>14.8 | 27.9<br>21.1 | 39.9<br>31.1 | 54.7<br>42.3 | 68.7<br>53.5 | 89.2<br>54.0 | 97.6<br>64.3 | 94.5<br>58.5  | M<br>F           | Non-Hodgkin's lymphoma   | C82-C85     |
| 1.9<br>1.6 | 2.6<br>2.3  | 3.2<br>4.5   | 5.6<br>5.9   | 7.0<br>8.2   | 8.5<br>9.3   | 7.6<br>8.0   | 10.2<br>6.7  | 7.8<br>8.2   | 6.0<br>4.9    | M<br>F           | Follicular (nodular) non-Hodgkin's lymphoma  | C82         |
| 4.1<br>1.8 | 7.0<br>3.0  | 8.5<br>5.6   | 13.3<br>9.3  | 19.7<br>13.3 | 27.6<br>20.3 | 35.7<br>25.5 | 42.1<br>26.3 | 48.3<br>28.8 | 41.2<br>26.1  | M<br>F           | Diffuse non-Hodgkin's lymphoma   | C83         |
| 0.6<br>0.3 | 0.7<br>0.8  | 1.5<br>0.6   | 2.1<br>1.1   | 3.4<br>2.4   | 3.3<br>1.9   | 4.2<br>3.9   | 5.3<br>2.6   | 3.1<br>2.7   | 3.4<br>1.7    | M<br>F           | Peripheral and cutaneous T-cell lymphomas  | C84         |
| 2.5<br>2.0 | 4.4<br>2.4  | 4.9<br>4.0   | 6.8<br>4.7   | 9.7<br>7.2   | 15.3<br>10.8 | 21.2<br>16.2 | 31.6<br>18.4 | 38.4<br>24.6 | 43.9<br>25.8  | M<br>F           | Other and unspecified types of non-Hodgkin's lymphoma                                      | C85         |
| -<br>0.1   | 0.2<br>0.1  | 0.3<br>0.1   | 0.2<br>0.2   | 0.5<br>0.5   | 1.0<br>0.3   | 1.9<br>0.9   | 4.7<br>1.4   | 4.4<br>1.8   | 3.7<br>1.7    | M<br>F           | Malignant immunoproliferative diseases   | C88         |
| 1.6<br>0.7 | 3.5<br>2.1  | 6.0<br>4.3   | 8.4<br>6.7   | 15.3<br>11.4 | 23.9<br>16.4 | 31.9<br>20.7 | 37.8<br>26.0 | 51.9<br>33.5 | 49.6<br>31.7  | M<br>F           | Multiple myeloma and malignant plasma cell neoplasms                                       | C90         |
| 4.7<br>3.9 | 6.2<br>3.7  | 9.9<br>6.7   | 18.1<br>9.2  | 24.2<br>11.1 | 40.4<br>17.6 | 54.1<br>29.4 | 64.4<br>39.1 | 85.7<br>48.1 | 100.2<br>61.3 | M<br>F           | All leukaemias   | C91-C95     |
| 1.8<br>1.1 | 3.0<br>1.5  | 5.9<br>2.4   | 10.4<br>4.5  | 12.5<br>5.2  | 20.0<br>8.1  | 26.2<br>13.5 | 32.6<br>16.8 | 36.5<br>23.5 | 47.6<br>22.5  | M<br>F           | Lymphoid leukaemia   | C91         |
| 2.5<br>2.5 | 2.9<br>2.1  | 3.8<br>4.2   | 7.1<br>4.2   | 10.7<br>5.4  | 18.6<br>9.2  | 25.1<br>14.0 | 28.6<br>20.2 | 44.3<br>21.4 | 43.6<br>32.7  | M<br>F           | Myeloid leukaemia  | C92         |
| 0.1<br>0.1 | -<br>0.1    | 0.1<br>0.1   | 0.2<br>0.1   | 0.2<br>0.1   | 0.5<br>0.2   | 0.3<br>0.7   | 0.3<br>0.3   | 0.8<br>0.7   | 0.7<br>0.3    | M<br>F           | Monocytic leukaemia  | C93         |

Table 3 Series MB1 no. 36

To link to Excel version of the table - click on the red box surrounding the table title

Table 3 Rates per 100,000 population - continued

| ICD-10 code | Site description  |   | All ages    | Age group |     |     |       |       |       |       |       |       |  |
|-------------|---|---|-------------|-----------|-----|-----|-------|-------|-------|-------|-------|-------|--|
|             |   |   |             | Under 1   | 1-4 | 5-9 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 |  |
| C94         | Other leukaemias of specified cell type   | M | <b>0.1</b>  | 0.3       | -   | -   | 0.1   | -     | -     | 0.1   | 0.1   | 0.1   |  |
|             |   | F | <b>0.1</b>  | -         | 0.3 | -   | -     | -     | -     | -     | -     | -     |  |
| C95         | Leukaemia of unspecified cell type  | M | <b>0.5</b>  | -         | -   | 0.1 | 0.1   | 0.2   | 0.2   | 0.1   | -     | 0.1   |  |
|             |   | F | <b>0.4</b>  | -         | 0.1 | -   | -     | 0.1   | 0.1   | 0.2   | 0.1   | 0.1   |  |
| C96         | Other and unspecified malignant neoplasms of lymphoid,haematopoietic and related tissue           | M | <b>0.1</b>  | 0.3       | 0.2 | -   | 0.1   | -     | -     | -     | 0.1   | -     |  |
|             |   | F | <b>0.0</b>  | -         | -   | -   | -     | -     | 0.1   | 0.1   | -     | -     |  |
| C97         | Malignant neoplasms of independent(primary) multiple sites  | M | <b>0.0</b>  | -         | -   | -   | -     | -     | -     | -     | -     | -     |  |
|             |   | F | -           | -         | -   | -   | -     | -     | -     | -     | -     | -     |  |
| D00         | Carcinoma in situ of oral cavity,oesophagus and stomach   | M | <b>0.8</b>  | -         | -   | -   | -     | -     | -     | -     | -     | 0.1   |  |
|             |   | F | <b>0.4</b>  | -         | -   | -   | -     | -     | -     | -     | -     | 0.1   |  |
| D01         | Carcinoma in situ of other and unspecified digestive organs                                       | M | <b>2.2</b>  | -         | -   | -   | -     | 0.1   | 0.1   | 0.1   | 0.1   | 0.6   |  |
|             |   | F | <b>1.6</b>  | -         | -   | -   | -     | -     | -     | 0.2   | 0.3   | 0.2   |  |
| D02         | Carcinoma in situ of middle ear and respiratory system  | M | <b>0.8</b>  | -         | -   | -   | -     | -     | -     | -     | -     | 0.1   |  |
|             |   | F | <b>0.2</b>  | -         | -   | -   | -     | -     | -     | -     | -     | 0.1   |  |
| D03         | Melanoma in situ  | M | <b>4.8</b>  | -         | -   | -   | 0.1   | 0.4   | 0.4   | 1.3   | 1.3   | 2.5   |  |
|             |   | F | <b>5.8</b>  | -         | 0.1 | -   | 0.1   | 0.9   | 1.5   | 2.2   | 4.1   | 5.1   |  |
| D04         | Carcinoma in situ of skin   | M | <b>13.2</b> | -         | -   | -   | -     | 0.1   | 0.1   | 0.1   | 0.4   | 0.7   |  |
|             |   | F | <b>21.4</b> | -         | -   | -   | -     | 0.1   | 0.1   | 0.2   | 0.5   | 1.0   |  |
| D05         | Carcinoma in situ of breast   | M | <b>0.1</b>  | -         | -   | -   | -     | -     | -     | 0.1   | -     | -     |  |
|             |   | F | <b>16.3</b> | -         | -   | -   | 0.1   | -     | 0.1   | 0.4   | 1.1   | 4.8   |  |
| D06         | Carcinoma in situ of cervix uteri   | F | <b>77.7</b> | -         | -   | -   | -     | 3.9   | 197.9 | 350.3 | 257.6 | 157.5 |  |
| D07         | Carcinoma in situ of other and unspecified genital organs   | M | <b>3.5</b>  | -         | -   | -   | -     | 0.1   | 0.1   | 0.1   | 0.3   | 0.3   |  |
|             |   | F | <b>2.1</b>  | -         | -   | -   | -     | 0.1   | 0.4   | 1.2   | 1.9   | 3.6   |  |
| D09         | Carcinoma in situ of other and unspecified sites  | M | <b>10.5</b> | -         | -   | -   | 0.1   | -     | 0.2   | 0.4   | 0.5   | 1.0   |  |
|             |   | F | <b>2.9</b>  | -         | -   | -   | -     | -     | 0.1   | 0.1   | 0.2   | 0.3   |  |
| D33         | Benign neoplasm of brain and other parts of central nervous system                                | M | <b>1.1</b>  | 1.0       | 0.2 | 0.5 | 0.2   | 0.4   | 0.7   | 0.3   | 0.9   | 1.3   |  |
|             |   | F | <b>1.1</b>  | -         | 0.1 | 0.1 | 0.3   | 0.2   | 0.5   | 0.4   | 0.8   | 1.1   |  |
| D35.2       | Benign neoplasm of pituitary gland  | M | <b>1.4</b>  | -         | -   | -   | -     | 0.2   | 0.2   | 0.6   | 0.8   | 1.1   |  |
|             |   | F | <b>1.0</b>  | -         | -   | 0.1 | 0.3   | 0.2   | 0.4   | 0.3   | 1.2   | 1.3   |  |
| D35.3       | Benign neoplasm of craniopharyngeal duct  | M | -           | -         | -   | -   | -     | -     | -     | -     | -     | -     |  |
|             |   | F | -           | -         | -   | -   | -     | -     | -     | -     | -     | -     |  |
| D35.4       | Benign neoplasm of pineal gland   | M | -           | -         | -   | -   | -     | -     | -     | -     | -     | -     |  |
|             |   | F | -           | -         | -   | -   | -     | -     | -     | -     | -     | -     |  |
| D37         | Neoplasm of uncertain or unknown behaviour of oral cavity and digestive organs                    | M | <b>3.3</b>  | 0.3       | -   | 0.1 | 0.5   | 0.7   | 0.8   | 0.3   | 0.6   | 0.6   |  |
|             |   | F | <b>3.3</b>  | -         | 0.1 | 0.2 | 0.9   | 1.2   | 1.2   | 1.3   | 0.8   | 1.0   |  |
| D38         | Neoplasm of uncertain or unknown behaviour of middle ear and respiratory and intrathoracic organs | M | <b>0.3</b>  | -         | -   | -   | -     | -     | -     | 0.1   | -     | 0.1   |  |
|             |   | F | <b>0.2</b>  | -         | -   | -   | 0.1   | -     | -     | -     | 0.1   | 0.1   |  |
| D39         | Neoplasm of uncertain or unknown behaviour of female genital organs                               | F | <b>1.1</b>  | -         | -   | -   | -     | 0.6   | 0.9   | 0.9   | 1.1   | 1.4   |  |
| D40         | Neoplasm of uncertain or unknown behaviour of male genital organs                                 | M | <b>0.2</b>  | 0.3       | 0.2 | -   | 0.1   | 0.1   | 0.2   | 0.4   | 0.2   | 0.6   |  |

|       |       |       |       |       |       |       |       |       |             | Site description | ICD-10 code   |       |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------------|------------------|---|-------|
| 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85 and over |                  |   |       |
| 0.1   | 0.2   | -     | -     | 0.2   | 0.2   | 0.2   | 0.1   | 0.6   | 0.3         | M                | Other leukaemias of specified cell type   | C94   |
| 0.1   | -     | -     | -     | 0.1   | -     | 0.2   | 0.4   | 0.5   | 0.1         | F                |   |       |
| 0.2   | 0.1   | 0.1   | 0.4   | 0.6   | 1.1   | 2.2   | 2.8   | 3.4   | 8.0         | M                | Leukaemia of unspecified cell type  | C95   |
| 0.2   | 0.1   | 0.1   | 0.4   | 0.4   | 0.2   | 1.1   | 1.3   | 2.0   | 5.6         | F                |   |       |
| 0.1   | 0.1   | 0.1   | 0.1   | -     | 0.2   | 0.2   | 0.3   | 0.2   | -           | M                | Other and unspecified malignant neoplasms of lymphoid,haematopoietic and related tissue           | C96   |
| -     | -     | 0.1   | 0.2   | 0.1   | -     | 0.1   | -     | 0.1   | -           | F                |   |       |
| -     | -     | -     | -     | -     | -     | -     | -     | -     | 0.3         | M                | Malignant neoplasms of independent(primary) multiple sites  | C97   |
| -     | -     | -     | -     | -     | -     | -     | -     | -     | -           | F                |   |       |
| 0.2   | 0.5   | 1.3   | 1.2   | 1.9   | 2.9   | 2.9   | 3.4   | 4.0   | 2.7         | M                | Carcinoma in situ of oral cavity,oesophagus and stomach   | D00   |
| 0.2   | 0.3   | 0.3   | 0.4   | 0.7   | 0.6   | 1.3   | 2.1   | 2.9   | 1.6         | F                |   |       |
| 0.5   | 0.9   | 2.3   | 3.5   | 5.5   | 6.2   | 10.8  | 14.1  | 12.6  | 10.7        | M                | Carcinoma in situ of other and unspecified digestive organs                                       | D01   |
| 0.7   | 1.0   | 2.0   | 2.4   | 2.4   | 4.3   | 5.4   | 6.8   | 7.3   | 6.9         | F                |   |       |
| 0.2   | 0.2   | 0.9   | 1.3   | 2.2   | 3.0   | 3.7   | 4.3   | 3.1   | 3.0         | M                | Carcinoma in situ of middle ear and respiratory system  | D02   |
| -     | 0.2   | 0.2   | 0.4   | 0.6   | 0.7   | 0.9   | 1.4   | 0.4   | 0.6         | F                |   |       |
| 2.5   | 2.6   | 4.0   | 7.8   | 9.7   | 13.8  | 19.3  | 22.8  | 27.7  | 25.1        | M                | Melanoma in situ  | D03   |
| 4.5   | 6.4   | 6.0   | 9.8   | 10.1  | 13.4  | 12.7  | 15.1  | 16.2  | 15.4        | F                |   |       |
| 1.2   | 3.2   | 6.2   | 12.5  | 21.6  | 41.0  | 58.0  | 87.2  | 118.9 | 152.8       | M                | Carcinoma in situ of skin   | D04   |
| 1.9   | 4.6   | 6.4   | 12.9  | 25.8  | 45.8  | 78.6  | 115.7 | 141.1 | 172.4       | F                |   |       |
| 0.1   | 0.2   | 0.1   | 0.2   | 0.3   | 0.4   | 0.1   | 0.1   | 0.4   | -           | M                | Carcinoma in situ of breast   | D05   |
| 9.2   | 19.8  | 53.6  | 42.6  | 54.3  | 57.2  | 28.8  | 18.9  | 16.0  | 7.6         | F                |   |       |
| 87.9  | 46.4  | 22.9  | 17.8  | 14.6  | 5.8   | 2.7   | 1.4   | 1.0   | 0.6         | F                | Carcinoma in situ of cervix uteri   | D06   |
| 0.6   | 1.0   | 2.8   | 8.2   | 10.7  | 16.9  | 16.0  | 15.5  | 10.9  | 5.7         | M                | Carcinoma in situ of other and unspecified genital organs   | D07   |
| 5.0   | 4.4   | 3.6   | 3.4   | 2.6   | 2.6   | 2.5   | 1.5   | 2.6   | 1.6         | F                |   |       |
| 2.4   | 3.2   | 7.2   | 13.0  | 23.1  | 37.4  | 52.1  | 68.7  | 67.6  | 56.0        | M                | Carcinoma in situ of other and unspecified sites  | D09   |
| 0.4   | 0.8   | 1.9   | 3.9   | 5.1   | 8.7   | 10.3  | 15.4  | 15.3  | 13.1        | F                |   |       |
| 1.5   | 1.0   | 1.9   | 1.9   | 2.1   | 2.1   | 1.8   | 1.6   | 1.0   | 0.3         | M                | Benign neoplasm of brain and other parts of central nervous system                                | D33   |
| 1.2   | 1.5   | 2.3   | 2.0   | 2.0   | 2.1   | 1.4   | 1.6   | 1.2   | 0.7         | F                |   |       |
| 0.8   | 1.9   | 1.8   | 2.5   | 2.4   | 3.7   | 5.1   | 4.3   | 4.2   | 2.3         | M                | Benign neoplasm of pituitary gland  | D35.2 |
| 1.3   | 1.2   | 1.9   | 1.7   | 1.7   | 2.2   | 1.9   | 1.3   | 1.3   | 1.0         | F                |   |       |
| -     | -     | -     | -     | -     | -     | -     | -     | -     | -           | M                | Benign neoplasm of craniopharyngeal duct  | D35.3 |
| -     | -     | -     | -     | -     | -     | -     | -     | -     | -           | F                |   |       |
| -     | -     | -     | -     | -     | -     | -     | -     | -     | -           | M                | Benign neoplasm of pineal gland   | D35.4 |
| -     | -     | -     | -     | -     | -     | -     | -     | -     | -           | F                |   |       |
| 0.6   | 1.2   | 3.6   | 4.5   | 7.7   | 10.2  | 12.9  | 17.6  | 20.2  | 21.4        | M                | Neoplasm of uncertain or unknown behaviour of oral cavity and digestive organs                    | D37   |
| 1.3   | 2.0   | 2.9   | 3.5   | 5.5   | 7.4   | 9.0   | 11.5  | 17.0  | 12.3        | F                |   |       |
| 0.2   | 0.2   | 0.3   | 0.5   | 0.6   | 0.6   | 1.1   | 2.1   | 2.1   | 2.0         | M                | Neoplasm of uncertain or unknown behaviour of middle ear and respiratory and intrathoracic organs | D38   |
| 0.1   | -     | 0.3   | 0.2   | 0.3   | 0.3   | 0.9   | 0.7   | 1.4   | 0.7         | F                |   |       |
| 1.4   | 1.1   | 1.8   | 1.9   | 2.0   | 1.3   | 2.0   | 1.5   | 1.4   | 1.7         | F                | Neoplasm of uncertain or unknown behaviour of female genital organs                               | D39   |
| 0.3   | 0.2   | 0.1   | 0.2   | 0.2   | 0.1   | 0.2   | -     | 0.4   | 0.7         | M                | Neoplasm of uncertain or unknown behaviour of male genital organs                                 | D40   |

Table 3 Series MBI no. 36

To link to Excel version of the table - click on the red box surrounding the table title

Table 3 Rates per 100,000 population - continued

| ICD-10 code | Site description   |   | All ages    | Age group |     |     |       |       |       |       |       |       |  |
|-------------|--|---|-------------|-----------|-----|-----|-------|-------|-------|-------|-------|-------|--|
|             |  |   |             | Under 1   | 1-4 | 5-9 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 |  |
| D41         | Neoplasm of uncertain or unknown behaviour of urinary organs                                     | M | <b>10.9</b> | -         | -   | 0.1 | -     | 0.1   | 0.4   | 0.3   | 0.5   | 1.4   |  |
|             |  | F | <b>3.4</b>  | -         | -   | -   | -     | -     | -     | 0.1   | 0.2   | 0.5   |  |
| D42         | Neoplasm of uncertain or unknown behaviour of meninges   | M | <b>0.1</b>  | -         | 0.1 | -   | -     | -     | 0.1   | 0.1   | 0.1   | 0.1   |  |
|             |  | F | <b>0.1</b>  | -         | -   | -   | -     | 0.1   | -     | 0.1   | 0.1   | -     |  |
| D43         | Neoplasm of uncertain or unknown behaviour of brain and central nervous system                   | M | <b>1.1</b>  | 0.6       | 0.5 | 0.2 | 0.6   | 0.3   | 0.1   | 0.5   | 0.3   | 0.8   |  |
|             |  | F | <b>1.1</b>  | 1.0       | 0.4 | 0.4 | 0.5   | 0.4   | 0.3   | 0.5   | 0.5   | 0.4   |  |
| D44         | Neoplasm of uncertain or unknown behaviour of endocrine glands                                   | M | <b>0.4</b>  | -         | -   | 0.1 | 0.2   | 0.2   | 0.3   | 0.2   | 0.3   | 0.1   |  |
|             |  | F | <b>0.4</b>  | -         | 0.1 | 0.3 | -     | 0.1   | 0.2   | 0.6   | 0.3   | 0.4   |  |
| D45         | Polycythaemia vera   | M | <b>2.4</b>  | -         | -   | -   | -     | 0.1   | 0.4   | 0.7   | 1.0   | 1.3   |  |
|             |  | F | <b>1.3</b>  | -         | -   | -   | 0.1   | -     | 0.1   | 0.2   | 0.1   | 0.4   |  |
| D46         | Myelodysplastic syndromes  | M | <b>4.6</b>  | -         | 0.1 | 0.1 | 0.1   | -     | 0.1   | 0.1   | 0.2   | 0.3   |  |
|             |  | F | <b>3.7</b>  | -         | 0.2 | 0.1 | 0.1   | 0.2   | 0.2   | 0.1   | -     | 0.3   |  |
| D47         | Other neoplasms of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue | M | <b>4.1</b>  | 0.3       | 0.1 | -   | 0.1   | 0.4   | 0.1   | 0.3   | 0.9   | 0.6   |  |
|             |  | F | <b>4.0</b>  | -         | 0.1 | 0.2 | 0.1   | 0.2   | 0.1   | 0.4   | 0.5   | 1.0   |  |
| D48         | Neoplasm of uncertain or unknown behaviour of other and unspecified sites                        | M | <b>1.5</b>  | 1.3       | 0.2 | 0.5 | 0.7   | 0.4   | 1.3   | 0.6   | 1.2   | 1.3   |  |
|             |  | F | <b>1.7</b>  | 1.7       | 0.5 | 0.2 | 0.5   | 0.6   | 1.0   | 0.7   | 1.1   | 2.2   |  |
| O01         | Hydatidiform mole  | F | <b>1.0</b>  | -         | -   | -   | 0.1   | 2.1   | 2.8   | 3.6   | 3.2   | 1.9   |  |

|            |            |            |             |             |             |              |              |              |              | Site description | ICD-10 code  |     |
|------------|------------|------------|-------------|-------------|-------------|--------------|--------------|--------------|--------------|------------------|--|-----|
| 40-44      | 45-49      | 50-54      | 55-59       | 60-64       | 65-69       | 70-74        | 75-79        | 80-84        | 85 and over  |                  |  |     |
| 2.5<br>0.9 | 4.6<br>1.5 | 7.8<br>2.5 | 14.3<br>4.7 | 22.3<br>6.9 | 32.7<br>9.9 | 50.9<br>11.4 | 69.1<br>14.9 | 80.8<br>17.3 | 67.3<br>16.9 | M<br>F           | Neoplasm of uncertain or unknown behaviour of urinary organs                                     | D41 |
| -<br>0.1   | 0.1<br>0.1 | 0.1<br>0.1 | 0.1<br>0.1  | 0.2<br>0.5  | 0.3<br>0.3  | 0.2<br>0.7   | 0.4<br>-     | 0.4<br>-     | -<br>0.4     | M<br>F           | Neoplasm of uncertain or unknown behaviour of meninges   | D42 |
| 0.7<br>0.4 | 1.0<br>0.7 | 1.1<br>0.6 | 0.9<br>1.0  | 1.6<br>1.1  | 2.2<br>1.7  | 2.8<br>2.3   | 3.6<br>2.8   | 8.8<br>5.0   | 6.4<br>6.5   | M<br>F           | Neoplasm of uncertain or unknown behaviour of brain and central nervous system                   | D43 |
| 0.5<br>0.5 | 0.4<br>0.6 | 0.4<br>0.3 | 0.4<br>0.4  | 0.6<br>0.8  | 0.4<br>0.7  | 0.9<br>0.9   | 0.9<br>0.8   | 1.0<br>1.3   | 1.0<br>0.7   | M<br>F           | Neoplasm of uncertain or unknown behaviour of endocrine glands                                   | D44 |
| 2.0<br>0.5 | 2.5<br>1.1 | 4.2<br>1.8 | 3.9<br>1.6  | 5.7<br>2.3  | 5.5<br>2.7  | 8.1<br>4.4   | 8.5<br>5.4   | 8.4<br>4.4   | 4.7<br>5.0   | M<br>F           | Polycythaemia vera   | D45 |
| 0.3<br>0.3 | 0.5<br>0.4 | 0.9<br>0.8 | 2.8<br>1.2  | 4.0<br>2.7  | 10.1<br>4.7 | 18.2<br>9.3  | 32.2<br>18.2 | 55.2<br>25.5 | 82.8<br>48.6 | M<br>F           | Myelodysplastic syndromes  | D46 |
| 1.5<br>1.2 | 1.9<br>2.0 | 2.8<br>3.6 | 4.0<br>3.6  | 7.5<br>5.8  | 11.1<br>9.8 | 18.7<br>12.5 | 22.9<br>17.4 | 32.1<br>24.3 | 36.9<br>22.5 | M<br>F           | Other neoplasms of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue | D47 |
| 1.2<br>2.1 | 1.3<br>2.7 | 0.7<br>1.9 | 1.7<br>2.4  | 1.9<br>3.0  | 2.8<br>2.8  | 4.0<br>2.5   | 4.6<br>2.5   | 6.5<br>2.6   | 10.1<br>3.3  | M<br>F           | Neoplasm of uncertain or unknown behaviour of other and unspecified sites                        | D48 |
| 1.4        | 0.2        | 0.1        | -           | -           | -           | -            | -            | -            | -            | F                | Hydatidiform mole  | O01 |

Table 4 Series MBI no. 36

To link to Excel version of the table - click on the red box surrounding the table title

**Table 4 Registrations of newly diagnosed cases of cancer: site, sex and Government Office Region of residence, 2005** **England, Government Office Regions Registered by October 2007**

| ICD-10 code                  | Site description  |          | Government Office Region |               |               |                          |               |               |               |               |               |               |
|------------------------------|---|----------|--------------------------|---------------|---------------|--------------------------|---------------|---------------|---------------|---------------|---------------|---------------|
|                              |   |          | England                  | North East    | North West    | Yorkshire and The Humber | East Midlands | West Midlands | East          | London        | South East    | South West    |
| <b>C00-C97, D00-D48, O01</b> | <b>All registrations</b>  | <b>M</b> | <b>171,255</b>           | <b>9,529</b>  | <b>25,803</b> | <b>18,221</b>            | <b>16,800</b> | <b>18,435</b> | <b>18,321</b> | <b>14,954</b> | <b>25,530</b> | <b>23,662</b> |
|                              |   | <b>F</b> | <b>187,931</b>           | <b>10,924</b> | <b>27,990</b> | <b>19,963</b>            | <b>17,628</b> | <b>20,043</b> | <b>19,701</b> | <b>17,404</b> | <b>28,919</b> | <b>25,359</b> |
| C00-C97                      | All cancers   | M        | 154,191                  | 8,803         | 23,135        | 16,553                   | 15,110        | 16,850        | 16,339        | 13,688        | 22,850        | 20,863        |
|                              |   | F        | 147,854                  | 8,606         | 22,253        | 16,073                   | 13,797        | 15,750        | 15,361        | 13,459        | 22,774        | 19,781        |
| C00-C97 excl.C44             | All cancers excluding nmisc <sup>1</sup>  | M        | 119,625                  | 6,611         | 17,789        | 12,329                   | 10,972        | 12,948        | 13,262        | 12,901        | 18,607        | 14,206        |
|                              |   | F        | 119,352                  | 6,694         | 17,377        | 12,449                   | 10,661        | 12,460        | 13,106        | 12,917        | 19,312        | 14,376        |
| C00-C14                      | Malignant neoplasm of lip, mouth and pharynx  | M        | 2,934                    | 193           | 451           | 286                      | 268           | 315           | 270           | 391           | 415           | 345           |
|                              |   | F        | 1,625                    | 85            | 246           | 147                      | 166           | 161           | 198           | 204           | 241           | 177           |
| C00                          | Malignant neoplasm of lip   | M        | 150                      | 8             | 7             | 14                       | 17            | 17            | 29            | 11            | 30            | 17            |
|                              |   | F        | 82                       | 10            | 13            | 7                        | 10            | 7             | 13            | 3             | 13            | 6             |
| C01                          | Malignant neoplasm of base of tongue  | M        | 241                      | 12            | 43            | 16                       | 26            | 29            | 23            | 21            | 37            | 34            |
|                              |   | F        | 81                       | 1             | 14            | 6                        | 7             | 10            | 12            | 8             | 9             | 14            |
| C02                          | Malignant neoplasm of other and unspecified parts of tongue                           | M        | 481                      | 30            | 83            | 40                       | 43            | 51            | 43            | 69            | 61            | 61            |
|                              |   | F        | 342                      | 9             | 50            | 36                       | 32            | 31            | 46            | 48            | 54            | 36            |
| C03                          | Malignant neoplasm of gum   | M        | 130                      | 3             | 16            | 14                       | 15            | 12            | 11            | 25            | 18            | 16            |
|                              |   | F        | 112                      | 3             | 17            | 7                        | 10            | 11            | 18            | 13            | 19            | 14            |
| C04                          | Malignant neoplasm of floor of mouth  | M        | 239                      | 21            | 41            | 26                       | 17            | 25            | 21            | 35            | 32            | 21            |
|                              |   | F        | 105                      | 7             | 19            | 10                       | 12            | 11            | 15            | 19            | 6             | 6             |
| C05                          | Malignant neoplasm of palate  | M        | 135                      | 9             | 20            | 15                       | 15            | 16            | 13            | 22            | 10            | 15            |
|                              |   | F        | 122                      | 7             | 19            | 11                       | 8             | 12            | 11            | 19            | 17            | 18            |
| C06                          | Malignant neoplasm of other and unspecified parts of mouth                            | M        | 182                      | 16            | 26            | 11                       | 15            | 26            | 12            | 27            | 28            | 21            |
|                              |   | F        | 161                      | 8             | 25            | 15                       | 16            | 21            | 12            | 20            | 28            | 16            |
| C07                          | Malignant neoplasm of parotid gland   | M        | 194                      | 8             | 30            | 16                       | 18            | 19            | 17            | 24            | 32            | 30            |
|                              |   | F        | 145                      | 13            | 15            | 15                       | 22            | 16            | 15            | 11            | 19            | 19            |
| C08                          | Malignant neoplasm of other and unspecified major salivary glands                     | M        | 56                       | 6             | 8             | 6                        | 6             | 4             | 4             | 6             | 9             | 7             |
|                              |   | F        | 60                       | 1             | 9             | 6                        | 4             | 5             | 10            | 7             | 9             | 9             |
| C09                          | Malignant neoplasm of tonsil  | M        | 468                      | 35            | 54            | 55                       | 39            | 48            | 44            | 67            | 70            | 56            |
|                              |   | F        | 158                      | 11            | 23            | 15                       | 18            | 13            | 16            | 21            | 32            | 9             |
| C10                          | Malignant neoplasm of oropharynx  | M        | 121                      | 1             | 30            | 15                       | 8             | 16            | 8             | 16            | 16            | 11            |
|                              |   | F        | 36                       | 3             | 8             | 3                        | 3             | 4             | 4             | 5             | 3             | 3             |
| C11                          | Malignant neoplasm of nasopharynx   | M        | 152                      | 11            | 25            | 11                       | 11            | 11            | 17            | 25            | 25            | 16            |
|                              |   | F        | 62                       | 3             | 7             | 3                        | 6             | 9             | 4             | 8             | 11            | 11            |
| C12                          | Malignant neoplasm of pyriform sinus  | M        | 164                      | 15            | 30            | 15                       | 17            | 23            | 14            | 19            | 18            | 13            |
|                              |   | F        | 37                       | 2             | 3             | 2                        | 5             | 2             | 9             | 7             | 4             | 3             |
| C13                          | Malignant neoplasm of hypopharynx   | M        | 81                       | 7             | 16            | 13                       | 6             | 9             | 4             | 6             | 9             | 11            |
|                              |   | F        | 48                       | 2             | 10            | 4                        | 5             | 4             | 8             | 5             | 5             | 5             |
| C14                          | Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynx | M        | 140                      | 11            | 22            | 19                       | 15            | 9             | 10            | 18            | 20            | 16            |
|                              |   | F        | 74                       | 5             | 14            | 7                        | 8             | 5             | 5             | 10            | 12            | 8             |
| C15                          | Malignant neoplasm of oesophagus  | M        | 4,147                    | 192           | 652           | 436                      | 402           | 462           | 395           | 392           | 711           | 505           |
|                              |   | F        | 2,290                    | 115           | 411           | 245                      | 215           | 234           | 245           | 202           | 333           | 290           |
| C16                          | Malignant neoplasm of stomach   | M        | 4,247                    | 293           | 667           | 529                      | 418           | 480           | 461           | 481           | 540           | 378           |
|                              |   | F        | 2,241                    | 162           | 347           | 269                      | 190           | 281           | 224           | 249           | 278           | 241           |
| C17                          | Malignant neoplasm of small intestine   | M        | 379                      | 11            | 54            | 39                       | 49            | 41            | 44            | 38            | 52            | 51            |
|                              |   | F        | 323                      | 11            | 40            | 33                       | 33            | 26            | 33            | 47            | 50            | 50            |
| C18-C20                      | Malignant neoplasm of colon and rectum  | M        | 16,282                   | 1,000         | 2,315         | 1,655                    | 1,580         | 1,859         | 1,900         | 1,587         | 2,493         | 1,893         |
|                              |   | F        | 13,283                   | 752           | 1,848         | 1,330                    | 1,153         | 1,407         | 1,560         | 1,349         | 2,216         | 1,668         |

1. These figures exclude non-melanoma skin cancer (ICD-10 C44) - see section 4.2.

To link to Excel version of the table - click on the red box surrounding the table title

Table 4 Registrations in Government Office Regions - *continued*

| ICD-10 code | Site description   |   | Government Office Region |            |            |                          |               |               |       |        |            |            |
|-------------|--|---|--------------------------|------------|------------|--------------------------|---------------|---------------|-------|--------|------------|------------|
|             |  |   | England                  | North East | North West | Yorkshire and The Humber | East Midlands | West Midlands | East  | London | South East | South West |
| C18         | Malignant neoplasm of colon  | M | <b>9,640</b>             | 611        | 1,336      | 944                      | 922           | 1,107         | 1,105 | 922    | 1,496      | 1,197      |
|             |  | F | <b>9,022</b>             | 512        | 1,238      | 886                      | 758           | 967           | 1,040 | 917    | 1,493      | 1,211      |
| C19         | Malignant neoplasm of rectosigmoid junction  | M | <b>1,455</b>             | 98         | 215        | 146                      | 135           | 140           | 196   | 177    | 217        | 131        |
|             |  | F | <b>1,021</b>             | 51         | 172        | 105                      | 85            | 98            | 127   | 132    | 167        | 84         |
| C20         | Malignant neoplasm of rectum   | M | <b>5,187</b>             | 291        | 764        | 565                      | 523           | 612           | 599   | 488    | 780        | 565        |
|             |  | F | <b>3,240</b>             | 189        | 438        | 339                      | 310           | 342           | 393   | 300    | 556        | 373        |
| C21         | Malignant neoplasm of anus and anal canal  | M | <b>265</b>               | 21         | 29         | 30                       | 13            | 25            | 28    | 41     | 45         | 33         |
|             |  | F | <b>438</b>               | 19         | 66         | 55                       | 32            | 36            | 49    | 53     | 86         | 42         |
| C22         | Malignant neoplasm of liver and intrahepatic bile ducts  | M | <b>1,599</b>             | 92         | 296        | 151                      | 115           | 170           | 137   | 235    | 220        | 183        |
|             |  | F | <b>985</b>               | 53         | 245        | 84                       | 91            | 83            | 77    | 119    | 117        | 116        |
| C23         | Malignant neoplasm of gallbladder  | M | <b>136</b>               | 13         | 16         | 9                        | 16            | 11            | 21    | 17     | 20         | 13         |
|             |  | F | <b>350</b>               | 24         | 48         | 32                       | 45            | 45            | 35    | 38     | 43         | 40         |
| C24         | Malignant neoplasm of other and unspecified parts of biliary tract                                   | M | <b>324</b>               | 8          | 44         | 30                       | 35            | 45            | 45    | 34     | 49         | 34         |
|             |  | F | <b>301</b>               | 14         | 42         | 21                       | 32            | 27            | 48    | 41     | 41         | 35         |
| C25         | Malignant neoplasm of pancreas   | M | <b>3,133</b>             | 146        | 438        | 306                      | 298           | 339           | 365   | 376    | 500        | 365        |
|             |  | F | <b>3,289</b>             | 181        | 448        | 302                      | 291           | 318           | 358   | 377    | 588        | 426        |
| C26         | Malignant neoplasm of other and ill-defined digestive organs   | M | <b>265</b>               | 1          | 42         | 10                       | 32            | 25            | 25    | 32     | 42         | 56         |
|             |  | F | <b>314</b>               | 3          | 46         | 13                       | 34            | 37            | 24    | 47     | 58         | 52         |
| C30         | Malignant neoplasm of nasal cavity and middle ear  | M | <b>100</b>               | 12         | 11         | 13                       | 10            | 11            | 13    | 10     | 13         | 7          |
|             |  | F | <b>85</b>                | 8          | 13         | 9                        | 7             | 6             | 6     | 10     | 18         | 8          |
| C31         | Malignant neoplasm of accessory sinuses  | M | <b>65</b>                | 3          | 9          | 7                        | 2             | 9             | 6     | 9      | 8          | 12         |
|             |  | F | <b>43</b>                | 5          | 9          | 5                        | 5             | 3             | 4     | 5      | 2          | 5          |
| C32         | Malignant neoplasm of larynx   | M | <b>1,432</b>             | 106        | 264        | 175                      | 133           | 120           | 134   | 175    | 193        | 132        |
|             |  | F | <b>297</b>               | 26         | 57         | 33                       | 28            | 24            | 23    | 38     | 39         | 29         |
| C33-C34     | Malignant neoplasm of trachea, bronchus and lung   | M | <b>18,037</b>            | 1,272      | 3,019      | 2,008                    | 1,635         | 1,995         | 1,833 | 2,020  | 2,498      | 1,757      |
|             |  | F | <b>13,000</b>            | 1,028      | 2,377      | 1,581                    | 1,083         | 1,228         | 1,259 | 1,495  | 1,753      | 1,196      |
| C33         | Malignant neoplasm of trachea  | M | <b>17</b>                | 1          | 5          | -                        | 3             | 3             | 1     | 2      | 1          | 1          |
|             |  | F | <b>23</b>                | 2          | 7          | 3                        | 1             | 3             | 1     | 2      | 2          | 2          |
| C34         | Malignant neoplasm of bronchus and lung  | M | <b>18,020</b>            | 1,271      | 3,014      | 2,008                    | 1,632         | 1,992         | 1,832 | 2,018  | 2,497      | 1,756      |
|             |  | F | <b>12,977</b>            | 1,026      | 2,370      | 1,578                    | 1,082         | 1,225         | 1,258 | 1,493  | 1,751      | 1,194      |
| C37         | Malignant neoplasm of thymus   | M | <b>50</b>                | 2          | 13         | 6                        | 6             | 2             | 3     | 7      | 7          | 4          |
|             |  | F | <b>42</b>                | 2          | 4          | 8                        | 2             | 2             | 4     | 6      | 10         | 4          |
| C38         | Malignant neoplasm of heart, mediastinum and pleura  | M | <b>120</b>               | 7          | 28         | 12                       | 18            | 10            | 10    | 8      | 11         | 16         |
|             |  | F | <b>86</b>                | 3          | 26         | 5                        | 3             | 6             | 3     | 14     | 15         | 11         |
| C39         | Malignant neoplasm of other and ill-defined sites in the respiratory system and intrathoracic organs | M | <b>4</b>                 | -          | -          | -                        | -             | 1             | -     | -      | -          | 3          |
|             |  | F | <b>2</b>                 | -          | -          | -                        | -             | -             | 1     | -      | -          | 1          |
| C40         | Malignant neoplasm of bone and articular cartilage of limbs  | M | <b>99</b>                | 7          | 8          | 10                       | 7             | 14            | 13    | 15     | 14         | 11         |
|             |  | F | <b>87</b>                | 2          | 11         | 8                        | 10            | 12            | 8     | 9      | 18         | 9          |
| C41         | Malignant neoplasm of bone and articular cartilage of other and unspecified sites                    | M | <b>145</b>               | 4          | 36         | 19                       | 9             | 6             | 19    | 15     | 19         | 18         |
|             |  | F | <b>83</b>                | 3          | 27         | 8                        | 4             | 4             | 8     | 8      | 12         | 9          |
| C43         | Malignant melanoma of skin   | M | <b>3,663</b>             | 125        | 466        | 386                      | 307           | 358           | 392   | 271    | 766        | 592        |
|             |  | F | <b>4,362</b>             | 201        | 583        | 464                      | 357           | 436           | 514   | 329    | 822        | 656        |
| C44         | Other malignant neoplasms of skin  | M | <b>34,566</b>            | 2,192      | 5,346      | 4,224                    | 4,138         | 3,902         | 3,077 | 787    | 4,243      | 6,657      |
|             |  | F | <b>28,502</b>            | 1,912      | 4,876      | 3,624                    | 3,136         | 3,290         | 2,255 | 542    | 3,462      | 5,405      |
| C45         | Mesothelioma   | M | <b>1,569</b>             | 108        | 243        | 133                      | 114           | 139           | 187   | 147    | 311        | 187        |
|             |  | F | <b>289</b>               | 26         | 35         | 33                       | 19            | 27            | 31    | 34     | 50         | 34         |

Table 4 Series MB1 no. 36

To link to Excel version of the table - click on the red box surrounding the table title

Table 4 Registrations in Government Office Regions - *continued*

| ICD-10 code | Site description  |   | Government Office Region |            |            |                          |               |               |       |        |            |            |
|-------------|---|---|--------------------------|------------|------------|--------------------------|---------------|---------------|-------|--------|------------|------------|
|             |   |   | England                  | North East | North West | Yorkshire and The Humber | East Midlands | West Midlands | East  | London | South East | South West |
| C46         | Kaposi's sarcoma  | M | <b>98</b>                | 3          | 13         | 4                        | 2             | 1             | 8     | 53     | 10         | 4          |
|             |   | F | <b>17</b>                | 2          | 1          | 2                        | 2             | 1             | -     | 7      | 1          | 1          |
| C47         | Malignant neoplasm of peripheral nerves and autonomic nervous system    | M | <b>42</b>                | 4          | 3          | 5                        | 4             | 4             | 6     | 5      | 5          | 6          |
|             |   | F | <b>29</b>                | 1          | 4          | 1                        | 2             | 5             | 3     | 4      | 4          | 5          |
| C48         | Malignant neoplasm of retroperitoneum and peritoneum                    | M | <b>111</b>               | 4          | 18         | 11                       | 10            | 6             | 18    | 18     | 17         | 9          |
|             |   | F | <b>348</b>               | 37         | 53         | 57                       | 27            | 18            | 38    | 40     | 47         | 31         |
| C49         | Malignant neoplasm of other connective and soft tissue                  | M | <b>615</b>               | 35         | 107        | 75                       | 59            | 50            | 51    | 64     | 82         | 92         |
|             |   | F | <b>506</b>               | 29         | 87         | 53                       | 46            | 56            | 41    | 51     | 73         | 70         |
| C50         | Malignant neoplasm of breast  | M | <b>250</b>               | 17         | 35         | 20                       | 18            | 23            | 21    | 41     | 40         | 35         |
|             |   | F | <b>38,212</b>            | 1,968      | 5,323      | 3,844                    | 3,375         | 4,224         | 4,310 | 4,139  | 6,410      | 4,619      |
| C51         | Malignant neoplasm of vulva   | F | <b>842</b>               | 60         | 102        | 102                      | 87            | 106           | 76    | 72     | 130        | 107        |
| C52         | Malignant neoplasm of vagina  | F | <b>216</b>               | 11         | 25         | 22                       | 32            | 23            | 14    | 33     | 32         | 24         |
| C53         | Malignant neoplasm of cervix uteri                                      | F | <b>2,253</b>             | 124        | 349        | 278                      | 219           | 240           | 192   | 279    | 325        | 247        |
| C54         | Malignant neoplasm of corpus uteri                                      | F | <b>5,438</b>             | 253        | 746        | 554                      | 496           | 588           | 641   | 608    | 869        | 683        |
| C55         | Malignant neoplasm of uterus, part unspecified                          | F | <b>281</b>               | 14         | 43         | 29                       | 27            | 39            | 52    | 21     | 40         | 16         |
| C56-C57     | Malignant neoplasm of ovary and other unspecified female genital organs | F | <b>5,589</b>             | 298        | 799        | 512                      | 540           | 593           | 633   | 544    | 910        | 760        |
| C56         | Malignant neoplasm of ovary   | F | <b>5,456</b>             | 293        | 778        | 506                      | 521           | 577           | 622   | 531    | 888        | 740        |
| C57         | Malignant neoplasm of other and unspecified female genital organs       | F | <b>133</b>               | 5          | 21         | 6                        | 19            | 16            | 11    | 13     | 22         | 20         |
| C58         | Malignant neoplasm of placenta  | F | <b>9</b>                 | 2          | -          | -                        | 3             | -             | -     | 1      | 2          | 1          |
| C60         | Malignant neoplasm of penis   | M | <b>389</b>               | 28         | 53         | 39                       | 36            | 45            | 51    | 36     | 52         | 49         |
| C61         | Malignant neoplasm of prostate  | M | <b>28,886</b>            | 1,403      | 4,293      | 2,729                    | 2,619         | 3,350         | 3,453 | 2,875  | 4,486      | 3,678      |
| C62         | Malignant neoplasm of testis  | M | <b>1,715</b>             | 80         | 240        | 167                      | 156           | 170           | 189   | 191    | 335        | 187        |
| C63         | Malignant neoplasm of other and unspecified male genital organs         | M | <b>61</b>                | 3          | 10         | 8                        | 4             | 3             | 15    | 5      | 8          | 5          |
| C64         | Malignant neoplasm of kidney, except renal pelvis                       | M | <b>3,243</b>             | 195        | 423        | 336                      | 285           | 315           | 372   | 344    | 521        | 452        |
|             |   | F | <b>1,934</b>             | 130        | 251        | 212                      | 183           | 195           | 227   | 182    | 320        | 234        |
| C65         | Malignant neoplasm of renal pelvis                                      | M | <b>251</b>               | 23         | 41         | 44                       | 19            | 18            | 30    | 18     | 34         | 24         |
|             |   | F | <b>148</b>               | 12         | 22         | 20                       | 5             | 18            | 24    | 10     | 21         | 16         |
| C66         | Malignant neoplasm of ureter  | M | <b>207</b>               | 17         | 22         | 22                       | 20            | 16            | 22    | 30     | 25         | 33         |
|             |   | F | <b>116</b>               | 6          | 12         | 17                       | 6             | 9             | 21    | 6      | 22         | 17         |
| C67         | Malignant neoplasm of bladder   | M | <b>6,091</b>             | 312        | 964        | 682                      | 509           | 620           | 642   | 667    | 1,002      | 693        |
|             |   | F | <b>2,403</b>             | 145        | 381        | 292                      | 211           | 224           | 243   | 254    | 395        | 258        |
| C68         | Malignant neoplasm of other and unspecified urinary organs              | M | <b>121</b>               | 2          | 9          | 9                        | 18            | 13            | 11    | 9      | 13         | 37         |
|             |   | F | <b>46</b>                | 2          | 5          | 3                        | 7             | 7             | 4     | 5      | 5          | 8          |
| C69         | Malignant neoplasm of eye and adnexa                                    | M | <b>188</b>               | 9          | 29         | 16                       | 18            | 9             | 22    | 31     | 31         | 23         |
|             |   | F | <b>155</b>               | 3          | 37         | 13                       | 8             | 12            | 14    | 17     | 28         | 23         |

To link to Excel version of the table - click on the red box surrounding the table title

**Table 4 Registrations in Government Office Regions - *continued***

| ICD-10 code | Site description  |   | Government Office Region |            |            |                          |               |               |      |        |            |            |
|-------------|---|---|--------------------------|------------|------------|--------------------------|---------------|---------------|------|--------|------------|------------|
|             |   |   | England                  | North East | North West | Yorkshire and The Humber | East Midlands | West Midlands | East | London | South East | South West |
| C70         | Malignant neoplasm of meninges  | M | 16                       | -          | 2          | 2                        | -             | 2             | 4    | 1      | 2          | 3          |
|             |   | F | 22                       | -          | 2          | -                        | 1             | 1             | 3    | 4      | 3          | 8          |
| C71         | Malignant neoplasm of brain   | M | 2,192                    | 133        | 313        | 204                      | 205           | 209           | 255  | 252    | 342        | 279        |
|             |   | F | 1,501                    | 86         | 186        | 171                      | 133           | 164           | 155  | 181    | 248        | 177        |
| C72         | Malignant neoplasm of spinal cord, cranial nerves and other parts of central nervous system | M | 56                       | 1          | 9          | 3                        | 5             | 3             | 9    | 9      | 11         | 6          |
|             |   | F | 50                       | 2          | 5          | 5                        | 6             | 4             | 8    | 9      | 5          | 6          |
| C73         | Malignant neoplasm of thyroid gland   | M | 376                      | 15         | 51         | 38                       | 42            | 48            | 49   | 44     | 49         | 40         |
|             |   | F | 1,099                    | 69         | 143        | 112                      | 101           | 90            | 130  | 149    | 176        | 129        |
| C74         | Malignant neoplasm of adrenal gland   | M | 78                       | 3          | 14         | 11                       | 5             | 8             | 8    | 13     | 10         | 6          |
|             |   | F | 81                       | 4          | 17         | 6                        | 11            | 4             | 8    | 1      | 18         | 12         |
| C75         | Malignant neoplasm of other endocrine glands and related structures                         | M | 68                       | 1          | 11         | 9                        | 2             | 9             | 8    | 8      | 8          | 12         |
|             |   | F | 34                       | 1          | 8          | 2                        | 2             | 1             | 1    | 8      | 8          | 3          |
| C76         | Malignant neoplasm of other and ill-defined sites   | M | 205                      | 3          | 17         | 10                       | 12            | 8             | 29   | 49     | 54         | 23         |
|             |   | F | 268                      | 11         | 20         | 27                       | 17            | 18            | 29   | 44     | 60         | 42         |
| C77         | Secondary and unspecified malignant neoplasm of lymph nodes                                 | M | 321                      | 26         | 43         | 42                       | 38            | 34            | 29   | 29     | 45         | 35         |
|             |   | F | 288                      | 12         | 30         | 30                       | 37            | 30            | 37   | 21     | 53         | 38         |
| C78         | Secondary malignant neoplasm of respiratory and digestive organs                            | M | 1,648                    | 102        | 198        | 202                      | 204           | 141           | 175  | 146    | 275        | 205        |
|             |   | F | 1,912                    | 130        | 141        | 232                      | 264           | 181           | 204  | 176    | 337        | 247        |
| C79         | Secondary malignant neoplasm of other sites   | M | 692                      | 35         | 56         | 97                       | 100           | 61            | 76   | 72     | 127        | 68         |
|             |   | F | 678                      | 39         | 56         | 77                       | 87            | 63            | 84   | 65     | 130        | 77         |
| C80         | Malignant neoplasm without specification of site  | M | 2,012                    | 134        | 398        | 195                      | 127           | 279           | 209  | 252    | 259        | 159        |
|             |   | F | 2,449                    | 159        | 471        | 242                      | 147           | 317           | 268  | 275    | 360        | 210        |
| C81         | Hodgkin's disease   | M | 749                      | 37         | 90         | 74                       | 73            | 61            | 88   | 95     | 145        | 86         |
|             |   | F | 563                      | 32         | 85         | 70                       | 45            | 45            | 65   | 73     | 91         | 57         |
| C82-C85     | Non-Hodgkin's lymphoma  | M | 4,622                    | 169        | 570        | 423                      | 431           | 468           | 560  | 562    | 797        | 642        |
|             |   | F | 3,907                    | 170        | 513        | 367                      | 374           | 379           | 427  | 464    | 665        | 548        |
| C82         | Follicular (nodular) non-Hodgkin's lymphoma   | M | 637                      | 24         | 67         | 63                       | 69            | 70            | 75   | 69     | 118        | 82         |
|             |   | F | 733                      | 29         | 109        | 82                       | 62            | 59            | 82   | 80     | 120        | 110        |
| C83         | Diffuse non-Hodgkin's lymphoma  | M | 2,262                    | 84         | 256        | 231                      | 232           | 260           | 261  | 197    | 403        | 338        |
|             |   | F | 1,751                    | 83         | 207        | 185                      | 191           | 211           | 183  | 137    | 320        | 234        |
| C84         | Peripheral and cutaneous T-cell lymphomas   | M | 280                      | 13         | 28         | 34                       | 29            | 32            | 33   | 24     | 45         | 42         |
|             |   | F | 215                      | 8          | 13         | 26                       | 31            | 26            | 26   | 26     | 22         | 37         |
| C85         | Other and unspecified types of non-Hodgkin's lymphoma                                       | M | 1,443                    | 48         | 219        | 95                       | 101           | 106           | 191  | 272    | 231        | 180        |
|             |   | F | 1,208                    | 50         | 184        | 74                       | 90            | 83            | 136  | 221    | 203        | 167        |
| C88         | Malignant immunoproliferative diseases  | M | 110                      | 1          | 10         | 5                        | 6             | 19            | 9    | 14     | 26         | 20         |
|             |   | F | 65                       | 1          | 5          | 1                        | 6             | 11            | 7    | 5      | 16         | 13         |
| C90         | Multiple myeloma and malignant plasma cell neoplasms  | M | 1,739                    | 67         | 227        | 185                      | 148           | 169           | 189  | 220    | 278        | 256        |
|             |   | F | 1,504                    | 72         | 207        | 130                      | 139           | 153           | 171  | 155    | 238        | 239        |
| C91-C95     | All leukaemias  | M | 3,459                    | 133        | 417        | 412                      | 329           | 348           | 351  | 440    | 589        | 440        |
|             |   | F | 2,565                    | 85         | 319        | 280                      | 215           | 238           | 264  | 334    | 479        | 351        |
| C91         | Lymphoid leukaemia  | M | 1,753                    | 60         | 204        | 237                      | 167           | 178           | 161  | 207    | 311        | 228        |
|             |   | F | 1,142                    | 28         | 132        | 148                      | 98            | 107           | 101  | 136    | 227        | 165        |
| C92         | Myeloid leukaemia   | M | 1,532                    | 71         | 186        | 166                      | 148           | 153           | 172  | 203    | 241        | 192        |
|             |   | F | 1,273                    | 53         | 164        | 126                      | 107           | 108           | 155  | 173    | 226        | 161        |
| C93         | Monocytic leukaemia   | M | 27                       | -          | 2          | -                        | 2             | 4             | 2    | 4      | 10         | 3          |
|             |   | F | 29                       | -          | 1          | -                        | 1             | 11            | 1    | 1      | 11         | 3          |

Table 4 Series MB1 no. 36

To link to Excel version of the table - click on the red box surrounding the table title

Table 4 Registrations in Government Office Regions - *continued*

| ICD-10 code | Site description  |   | Government Office Region |            |            |                          |               |               |       |        |            |            |
|-------------|---|---|--------------------------|------------|------------|--------------------------|---------------|---------------|-------|--------|------------|------------|
|             |   |   | England                  | North East | North West | Yorkshire and The Humber | East Midlands | West Midlands | East  | London | South East | South West |
| C94         | Other leukaemias of specified cell type   | M | 22                       | -          | 3          | -                        | 2             | 5             | -     | 5      | 7          | -          |
|             |   | F | 16                       | -          | 1          | -                        | 1             | 1             | 2     | 3      | 2          | 6          |
| C95         | Leukaemia of unspecified cell type  | M | 125                      | 2          | 22         | 9                        | 10            | 8             | 16    | 21     | 20         | 17         |
|             |   | F | 105                      | 4          | 21         | 6                        | 8             | 11            | 5     | 21     | 13         | 16         |
| C96         | Other and unspecified malignant neoplasms of lymphoid,haematopoietic and related tissue           | M | 18                       | -          | 2          | -                        | 1             | 1             | 2     | 7      | 2          | 3          |
|             |   | F | 9                        | 1          | -          | 1                        | -             | -             | -     | 6      | 1          | -          |
| C97         | Malignant neoplasms of independent(primary) multiple sites  | M | 1                        | -          | -          | -                        | -             | -             | -     | -      | -          | 1          |
|             |   | F | -                        | -          | -          | -                        | -             | -             | -     | -      | -          | -          |
| D00         | Carcinoma in situ of oral cavity,oesophagus and stomach   | M | 186                      | 11         | 27         | 17                       | 13            | 16            | 26    | 16     | 28         | 32         |
|             |   | F | 102                      | 4          | 14         | 6                        | 7             | 6             | 14    | 12     | 25         | 14         |
| D01         | Carcinoma in situ of other and unspecified digestive organs                                       | M | 556                      | 13         | 56         | 18                       | 11            | 77            | 97    | 50     | 78         | 156        |
|             |   | F | 419                      | 7          | 54         | 19                       | 9             | 63            | 66    | 32     | 53         | 116        |
| D02         | Carcinoma in situ of middle ear and respiratory system  | M | 190                      | 6          | 39         | 15                       | 23            | 21            | 21    | 11     | 21         | 33         |
|             |   | F | 59                       | 3          | 10         | 5                        | 6             | 7             | 4     | 8      | 8          | 8          |
| D03         | Melanoma in situ  | M | 1,198                    | 55         | 145        | 94                       | 134           | 81            | 144   | 62     | 248        | 235        |
|             |   | F | 1,489                    | 66         | 153        | 159                      | 148           | 108           | 187   | 98     | 274        | 296        |
| D04         | Carcinoma in situ of skin   | M | 3,269                    | 140        | 565        | 381                      | 425           | 302           | 391   | 153    | 444        | 468        |
|             |   | F | 5,496                    | 312        | 955        | 669                      | 607           | 521           | 683   | 234    | 682        | 833        |
| D05         | Carcinoma in situ of breast   | M | 22                       | 2          | 2          | -                        | 1             | 5             | 4     | 5      | 1          | 2          |
|             |   | F | 4,197                    | 203        | 454        | 426                      | 400           | 393           | 486   | 433    | 751        | 651        |
| D06         | Carcinoma in situ of cervix uteri   | F | 19,984                   | 1,365      | 2,618      | 1,853                    | 1,860         | 2,561         | 2,152 | 2,281  | 2,967      | 2,327      |
| D07         | Carcinoma in situ of other and unspecified genital organs   | M | 859                      | 13         | 91         | 127                      | 123           | 97            | 134   | 67     | 82         | 125        |
|             |   | F | 551                      | 15         | 92         | 53                       | 53            | 75            | 43    | 65     | 73         | 82         |
| D09         | Carcinoma in situ of other and unspecified sites  | M | 2,592                    | 310        | 503        | 411                      | 102           | 119           | 162   | 368    | 468        | 149        |
|             |   | F | 753                      | 95         | 171        | 126                      | 15            | 27            | 42    | 105    | 146        | 26         |
| D33         | Benign neoplasm of brain and other parts of central nervous system                                | M | 269                      | 14         | 45         | 14                       | 28            | 28            | 34    | 19     | 56         | 31         |
|             |   | F | 273                      | 17         | 27         | 17                       | 22            | 27            | 33    | 27     | 59         | 44         |
| D35.2       | Benign neoplasm of pituitary gland  | M | 339                      | 12         | 56         | 21                       | 31            | 25            | 42    | 33     | 55         | 64         |
|             |   | F | 269                      | 5          | 52         | 21                       | 18            | 29            | 24    | 31     | 42         | 47         |
| D35.3       | Benign neoplasm of craniopharyngeal duct  | M | -                        | -          | -          | -                        | -             | -             | -     | -      | -          | -          |
|             |   | F | -                        | -          | -          | -                        | -             | -             | -     | -      | -          | -          |
| D35.4       | Benign neoplasm of pineal gland   | M | -                        | -          | -          | -                        | -             | -             | -     | -      | -          | -          |
|             |   | F | -                        | -          | -          | -                        | -             | -             | -     | -      | -          | -          |
| D37         | Neoplasm of uncertain or unknown behaviour of oral cavity and digestive organs                    | M | 829                      | 44         | 285        | 54                       | 83            | 40            | 82    | 45     | 102        | 94         |
|             |   | F | 848                      | 32         | 238        | 60                       | 119           | 43            | 95    | 47     | 111        | 103        |
| D38         | Neoplasm of uncertain or unknown behaviour of middle ear and respiratory and intrathoracic organs | M | 78                       | 2          | 19         | 4                        | 7             | 7             | 7     | 3      | 3          | 26         |
|             |   | F | 51                       | 1          | 10         | 1                        | 6             | 5             | 5     | 1      | 9          | 13         |
| D39         | Neoplasm of uncertain or unknown behaviour of female genital organs                               | F | 289                      | 7          | 78         | 7                        | 31            | 20            | 8     | 47     | 48         | 43         |
| D40         | Neoplasm of uncertain or unknown behaviour of male genital organs                                 | M | 52                       | 1          | 16         | 3                        | 4             | 2             | 3     | 6      | 8          | 9          |

To link to Excel version of the table - click on the red box surrounding the table title

**Table 4 Registrations in Government Office Regions - *continued***

| ICD-10 code | Site description   |   | Government Office Region |            |            |                          |               |               |      |        |            |            |
|-------------|--|---|--------------------------|------------|------------|--------------------------|---------------|---------------|------|--------|------------|------------|
|             |  |   | England                  | North East | North West | Yorkshire and The Humber | East Midlands | West Midlands | East | London | South East | South West |
| D41         | Neoplasm of uncertain or unknown behaviour of urinary organs                                     | M | <b>2,690</b>             | 1          | 177        | 140                      | 421           | 491           | 528  | 6      | 366        | 560        |
|             |  | F | <b>885</b>               | -          | 74         | 53                       | 161           | 163           | 141  | 5      | 107        | 181        |
| D42         | Neoplasm of uncertain or unknown behaviour of meninges   | M | <b>24</b>                | -          | 3          | 2                        | 3             | 6             | 6    | -      | 2          | 2          |
|             |  | F | <b>30</b>                | -          | 5          | 2                        | 5             | 7             | 3    | -      | 5          | 3          |
| D43         | Neoplasm of uncertain or unknown behaviour of brain and central nervous system                   | M | <b>273</b>               | 6          | 78         | 14                       | 24            | 29            | 24   | 27     | 39         | 32         |
|             |  | F | <b>270</b>               | 3          | 54         | 10                       | 12            | 37            | 31   | 27     | 62         | 34         |
| D44         | Neoplasm of uncertain or unknown behaviour of endocrine glands                                   | M | <b>87</b>                | 2          | 27         | 4                        | 5             | 7             | 8    | 8      | 9          | 17         |
|             |  | F | <b>112</b>               | 6          | 27         | 5                        | 9             | 4             | 13   | 6      | 27         | 15         |
| D45         | Polycythaemia vera   | M | <b>588</b>               | 4          | 117        | 15                       | 17            | 13            | 25   | 54     | 119        | 224        |
|             |  | F | <b>323</b>               | 5          | 54         | 11                       | 13            | 14            | 23   | 27     | 72         | 104        |
| D46         | Myelodysplastic syndromes  | M | <b>1,150</b>             | 37         | 129        | 97                       | 100           | 106           | 101  | 123    | 200        | 257        |
|             |  | F | <b>951</b>               | 43         | 135        | 82                       | 74            | 63            | 94   | 91     | 164        | 205        |
| D47         | Other neoplasms of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue | M | <b>1,019</b>             | 25         | 83         | 177                      | 51            | 99            | 90   | 133    | 208        | 153        |
|             |  | F | <b>1,041</b>             | 32         | 82         | 171                      | 53            | 80            | 82   | 143    | 214        | 184        |
| D48         | Neoplasm of uncertain or unknown behaviour of other and unspecified sites                        | M | <b>375</b>               | 5          | 113        | 23                       | 39            | 14            | 25   | 24     | 61         | 71         |
|             |  | F | <b>441</b>               | 11         | 125        | 17                       | 53            | 38            | 26   | 35     | 44         | 92         |
| O01         | Hydatidiform mole  | F | <b>264</b>               | 42         | 49         | 22                       | 45            | -             | -    | 46     | 26         | 34         |

Table 5 Series MB1 no. 36

To link to Excel version of the table - click on the red box surrounding the table title

**Table 5 Rates per 100,000 population of newly diagnosed cases of cancer: site, sex and Government Office Region of residence, 2005** **England, Government Office Regions Registered by October 2007**

| ICD-10 code                  | Site description  |          | Government Office Region |              |              |                          |               |               |              |              |              |              |
|------------------------------|---|----------|--------------------------|--------------|--------------|--------------------------|---------------|---------------|--------------|--------------|--------------|--------------|
|                              |   |          | England                  | North East   | North West   | Yorkshire and The Humber | East Midlands | West Midlands | East         | London       | South East   | South West   |
| <b>C00-C97, D00-D48, O01</b> | <b>All registrations</b>  | <b>M</b> | <b>691.7</b>             | <b>768.1</b> | <b>772.2</b> | <b>727.9</b>             | <b>786.6</b>  | <b>700.8</b>  | <b>671.4</b> | <b>405.8</b> | <b>637.3</b> | <b>951.6</b> |
|                              |   | <b>F</b> | <b>731.0</b>             | <b>834.4</b> | <b>800.1</b> | <b>766.5</b>             | <b>804.3</b>  | <b>736.8</b>  | <b>695.1</b> | <b>461.5</b> | <b>692.0</b> | <b>975.3</b> |
| C00-C97                      | All cancers   | M        | 622.8                    | 709.6        | 692.4        | 661.3                    | 707.5         | 640.5         | 598.7        | 371.4        | 570.4        | 839.0        |
|                              |   | F        | 575.1                    | 657.4        | 636.1        | 617.2                    | 629.5         | 579.0         | 542.0        | 356.9        | 545.0        | 760.8        |
| C00-C97 excl.C44             | All cancers excluding nmse <sup>1</sup>   | M        | 483.2                    | 532.9        | 532.4        | 492.5                    | 513.7         | 492.2         | 486.0        | 350.1        | 464.5        | 571.3        |
|                              |   | F        | 464.3                    | 511.3        | 496.7        | 478.0                    | 486.4         | 458.1         | 462.4        | 342.5        | 462.1        | 552.9        |
| C00-C14                      | Malignant neoplasm of lip, mouth and pharynx  | M        | 11.9                     | 15.6         | 13.5         | 11.4                     | 12.5          | 12.0          | 9.9          | 10.6         | 10.4         | 13.9         |
|                              |   | F        | 6.3                      | 6.5          | 7.0          | 5.6                      | 7.6           | 5.9           | 7.0          | 5.4          | 5.8          | 6.8          |
| C00                          | Malignant neoplasm of lip   | M        | 0.6                      | 0.6          | 0.2          | 0.6                      | 0.8           | 0.6           | 1.1          | 0.3          | 0.7          | 0.7          |
|                              |   | F        | 0.3                      | 0.8          | 0.4          | 0.3                      | 0.5           | 0.3           | 0.5          | 0.1          | 0.3          | 0.2          |
| C01                          | Malignant neoplasm of base of tongue  | M        | 1.0                      | 1.0          | 1.3          | 0.6                      | 1.2           | 1.1           | 0.8          | 0.6          | 0.9          | 1.4          |
|                              |   | F        | 0.3                      | 0.1          | 0.4          | 0.2                      | 0.3           | 0.4           | 0.4          | 0.2          | 0.2          | 0.5          |
| C02                          | Malignant neoplasm of other and unspecified parts of tongue                           | M        | 1.9                      | 2.4          | 2.5          | 1.6                      | 2.0           | 1.9           | 1.6          | 1.9          | 1.5          | 2.5          |
|                              |   | F        | 1.3                      | 0.7          | 1.4          | 1.4                      | 1.5           | 1.1           | 1.6          | 1.3          | 1.3          | 1.4          |
| C03                          | Malignant neoplasm of gum   | M        | 0.5                      | 0.2          | 0.5          | 0.6                      | 0.7           | 0.5           | 0.4          | 0.7          | 0.4          | 0.6          |
|                              |   | F        | 0.4                      | 0.2          | 0.5          | 0.3                      | 0.5           | 0.4           | 0.6          | 0.3          | 0.5          | 0.5          |
| C04                          | Malignant neoplasm of floor of mouth  | M        | 1.0                      | 1.7          | 1.2          | 1.0                      | 0.8           | 1.0           | 0.8          | 0.9          | 0.8          | 0.8          |
|                              |   | F        | 0.4                      | 0.5          | 0.5          | 0.4                      | 0.5           | 0.4           | 0.5          | 0.5          | 0.1          | 0.2          |
| C05                          | Malignant neoplasm of palate  | M        | 0.5                      | 0.7          | 0.6          | 0.6                      | 0.7           | 0.6           | 0.5          | 0.6          | 0.2          | 0.6          |
|                              |   | F        | 0.5                      | 0.5          | 0.5          | 0.4                      | 0.4           | 0.4           | 0.4          | 0.5          | 0.4          | 0.7          |
| C06                          | Malignant neoplasm of other and unspecified parts of mouth                            | M        | 0.7                      | 1.3          | 0.8          | 0.4                      | 0.7           | 1.0           | 0.4          | 0.7          | 0.7          | 0.8          |
|                              |   | F        | 0.6                      | 0.6          | 0.7          | 0.6                      | 0.7           | 0.8           | 0.4          | 0.5          | 0.7          | 0.6          |
| C07                          | Malignant neoplasm of parotid gland   | M        | 0.8                      | 0.6          | 0.9          | 0.6                      | 0.8           | 0.7           | 0.6          | 0.7          | 0.8          | 1.2          |
|                              |   | F        | 0.6                      | 1.0          | 0.4          | 0.6                      | 1.0           | 0.6           | 0.5          | 0.3          | 0.5          | 0.7          |
| C08                          | Malignant neoplasm of other and unspecified major salivary glands                     | M        | 0.2                      | 0.5          | 0.2          | 0.2                      | 0.3           | 0.2           | 0.1          | 0.2          | 0.2          | 0.3          |
|                              |   | F        | 0.2                      | 0.1          | 0.3          | 0.2                      | 0.2           | 0.2           | 0.4          | 0.2          | 0.2          | 0.3          |
| C09                          | Malignant neoplasm of tonsil  | M        | 1.9                      | 2.8          | 1.6          | 2.2                      | 1.8           | 1.8           | 1.6          | 1.8          | 1.7          | 2.3          |
|                              |   | F        | 0.6                      | 0.8          | 0.7          | 0.6                      | 0.8           | 0.5           | 0.6          | 0.6          | 0.8          | 0.3          |
| C10                          | Malignant neoplasm of oropharynx  | M        | 0.5                      | 0.1          | 0.9          | 0.6                      | 0.4           | 0.6           | 0.3          | 0.4          | 0.4          | 0.4          |
|                              |   | F        | 0.1                      | 0.2          | 0.2          | 0.1                      | 0.1           | 0.1           | 0.1          | 0.1          | 0.1          | 0.1          |
| C11                          | Malignant neoplasm of nasopharynx   | M        | 0.6                      | 0.9          | 0.7          | 0.4                      | 0.5           | 0.4           | 0.6          | 0.7          | 0.6          | 0.6          |
|                              |   | F        | 0.2                      | 0.2          | 0.2          | 0.1                      | 0.3           | 0.3           | 0.1          | 0.2          | 0.3          | 0.4          |
| C12                          | Malignant neoplasm of pyriform sinus  | M        | 0.7                      | 1.2          | 0.9          | 0.6                      | 0.8           | 0.9           | 0.5          | 0.5          | 0.4          | 0.5          |
|                              |   | F        | 0.1                      | 0.2          | 0.1          | 0.1                      | 0.2           | 0.1           | 0.3          | 0.2          | 0.1          | 0.1          |
| C13                          | Malignant neoplasm of hypopharynx   | M        | 0.3                      | 0.6          | 0.5          | 0.5                      | 0.3           | 0.3           | 0.1          | 0.2          | 0.2          | 0.4          |
|                              |   | F        | 0.2                      | 0.2          | 0.3          | 0.2                      | 0.2           | 0.1           | 0.3          | 0.1          | 0.1          | 0.2          |
| C14                          | Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynx | M        | 0.6                      | 0.9          | 0.7          | 0.8                      | 0.7           | 0.3           | 0.4          | 0.5          | 0.5          | 0.6          |
|                              |   | F        | 0.3                      | 0.4          | 0.4          | 0.3                      | 0.4           | 0.2           | 0.2          | 0.3          | 0.3          | 0.3          |
| C15                          | Malignant neoplasm of oesophagus  | M        | 16.8                     | 15.5         | 19.5         | 17.4                     | 18.8          | 17.6          | 14.5         | 10.6         | 17.7         | 20.3         |
|                              |   | F        | 8.9                      | 8.8          | 11.7         | 9.4                      | 9.8           | 8.6           | 8.6          | 5.4          | 8.0          | 11.2         |
| C16                          | Malignant neoplasm of stomach   | M        | 17.2                     | 23.6         | 20.0         | 21.1                     | 19.6          | 18.2          | 16.9         | 13.1         | 13.5         | 15.2         |
|                              |   | F        | 8.7                      | 12.4         | 9.9          | 10.3                     | 8.7           | 10.3          | 7.9          | 6.6          | 6.7          | 9.3          |
| C17                          | Malignant neoplasm of small intestine   | M        | 1.5                      | 0.9          | 1.6          | 1.6                      | 2.3           | 1.6           | 1.6          | 1.0          | 1.3          | 2.1          |
|                              |   | F        | 1.3                      | 0.8          | 1.1          | 1.3                      | 1.5           | 1.0           | 1.2          | 1.2          | 1.2          | 1.9          |
| C18-C20                      | Malignant neoplasm of colon and rectum  | M        | 65.8                     | 80.6         | 69.3         | 66.1                     | 74.0          | 70.7          | 69.6         | 43.1         | 62.2         | 76.1         |
|                              |   | F        | 51.7                     | 57.4         | 52.8         | 51.1                     | 52.6          | 51.7          | 55.0         | 35.8         | 53.0         | 64.1         |

1. These figures exclude non-melanoma skin cancer (ICD-10 C44) - see section 4.2.

To link to Excel version of the table - click on the red box surrounding the table title

Table 5 Rates per 100,000 population in Government Office Regions - continued

| ICD-10 code | Site description   |   | Government Office Region |            |            |                          |               |               |       |        |            |            |
|-------------|--|---|--------------------------|------------|------------|--------------------------|---------------|---------------|-------|--------|------------|------------|
|             |  |   | England                  | North East | North West | Yorkshire and The Humber | East Midlands | West Midlands | East  | London | South East | South West |
| C18         | Malignant neoplasm of colon  | M | <b>38.9</b>              | 49.3       | 40.0       | 37.7                     | 43.2          | 42.1          | 40.5  | 25.0   | 37.3       | 48.1       |
|             |  | F | <b>35.1</b>              | 39.1       | 35.4       | 34.0                     | 34.6          | 35.5          | 36.7  | 24.3   | 35.7       | 46.6       |
| C19         | Malignant neoplasm of rectosigmoid junction  | M | <b>5.9</b>               | 7.9        | 6.4        | 5.8                      | 6.3           | 5.3           | 7.2   | 4.8    | 5.4        | 5.3        |
|             |  | F | <b>4.0</b>               | 3.9        | 4.9        | 4.0                      | 3.9           | 3.6           | 4.5   | 3.5    | 4.0        | 3.2        |
| C20         | Malignant neoplasm of rectum   | M | <b>21.0</b>              | 23.5       | 22.9       | 22.6                     | 24.5          | 23.3          | 22.0  | 13.2   | 19.5       | 22.7       |
|             |  | F | <b>12.6</b>              | 14.4       | 12.5       | 13.0                     | 14.1          | 12.6          | 13.9  | 8.0    | 13.3       | 14.3       |
| C21         | Malignant neoplasm of anus and anal canal  | M | <b>1.1</b>               | 1.7        | 0.9        | 1.2                      | 0.6           | 1.0           | 1.0   | 1.1    | 1.1        | 1.3        |
|             |  | F | <b>1.7</b>               | 1.5        | 1.9        | 2.1                      | 1.5           | 1.3           | 1.7   | 1.4    | 2.1        | 1.6        |
| C22         | Malignant neoplasm of liver and intrahepatic bile ducts  | M | <b>6.5</b>               | 7.4        | 8.9        | 6.0                      | 5.4           | 6.5           | 5.0   | 6.4    | 5.5        | 7.4        |
|             |  | F | <b>3.8</b>               | 4.0        | 7.0        | 3.2                      | 4.2           | 3.1           | 2.7   | 3.2    | 2.8        | 4.5        |
| C23         | Malignant neoplasm of gallbladder  | M | <b>0.5</b>               | 1.0        | 0.5        | 0.4                      | 0.7           | 0.4           | 0.8   | 0.5    | 0.5        | 0.5        |
|             |  | F | <b>1.4</b>               | 1.8        | 1.4        | 1.2                      | 2.1           | 1.7           | 1.2   | 1.0    | 1.0        | 1.5        |
| C24         | Malignant neoplasm of other and unspecified parts of biliary tract                                   | M | <b>1.3</b>               | 0.6        | 1.3        | 1.2                      | 1.6           | 1.7           | 1.6   | 0.9    | 1.2        | 1.4        |
|             |  | F | <b>1.2</b>               | 1.1        | 1.2        | 0.8                      | 1.5           | 1.0           | 1.7   | 1.1    | 1.0        | 1.3        |
| C25         | Malignant neoplasm of pancreas   | M | <b>12.7</b>              | 11.8       | 13.1       | 12.2                     | 14.0          | 12.9          | 13.4  | 10.2   | 12.5       | 14.7       |
|             |  | F | <b>12.8</b>              | 13.8       | 12.8       | 11.6                     | 13.3          | 11.7          | 12.6  | 10.0   | 14.1       | 16.4       |
| C26         | Malignant neoplasm of other and ill-defined digestive organs   | M | <b>1.1</b>               | 0.1        | 1.3        | 0.4                      | 1.5           | 1.0           | 0.9   | 0.9    | 1.0        | 2.3        |
|             |  | F | <b>1.2</b>               | 0.2        | 1.3        | 0.5                      | 1.6           | 1.4           | 0.8   | 1.2    | 1.4        | 2.0        |
| C30         | Malignant neoplasm of nasal cavity and middle ear  | M | <b>0.4</b>               | 1.0        | 0.3        | 0.5                      | 0.5           | 0.4           | 0.5   | 0.3    | 0.3        | 0.3        |
|             |  | F | <b>0.3</b>               | 0.6        | 0.4        | 0.3                      | 0.3           | 0.2           | 0.2   | 0.3    | 0.4        | 0.3        |
| C31         | Malignant neoplasm of accessory sinuses  | M | <b>0.3</b>               | 0.2        | 0.3        | 0.3                      | 0.1           | 0.3           | 0.2   | 0.2    | 0.2        | 0.5        |
|             |  | F | <b>0.2</b>               | 0.4        | 0.3        | 0.2                      | 0.2           | 0.1           | 0.1   | 0.1    | 0.0        | 0.2        |
| C32         | Malignant neoplasm of larynx   | M | <b>5.8</b>               | 8.5        | 7.9        | 7.0                      | 6.2           | 4.6           | 4.9   | 4.7    | 4.8        | 5.3        |
|             |  | F | <b>1.2</b>               | 2.0        | 1.6        | 1.3                      | 1.3           | 0.9           | 0.8   | 1.0    | 0.9        | 1.1        |
| C33-C34     | Malignant neoplasm of trachea, bronchus and lung   | M | <b>72.9</b>              | 102.5      | 90.3       | 80.2                     | 76.6          | 75.8          | 67.2  | 54.8   | 62.4       | 70.7       |
|             |  | F | <b>50.6</b>              | 78.5       | 67.9       | 60.7                     | 49.4          | 45.1          | 44.4  | 39.6   | 41.9       | 46.0       |
| C33         | Malignant neoplasm of trachea  | M | <b>0.1</b>               | 0.1        | 0.1        | -                        | 0.1           | 0.1           | 0.0   | 0.1    | 0.0        | 0.0        |
|             |  | F | <b>0.1</b>               | 0.2        | 0.2        | 0.1                      | 0.0           | 0.1           | 0.0   | 0.1    | 0.0        | 0.1        |
| C34         | Malignant neoplasm of bronchus and lung  | M | <b>72.8</b>              | 102.5      | 90.2       | 80.2                     | 76.4          | 75.7          | 67.1  | 54.8   | 62.3       | 70.6       |
|             |  | F | <b>50.5</b>              | 78.4       | 67.7       | 60.6                     | 49.4          | 45.0          | 44.4  | 39.6   | 41.9       | 45.9       |
| C37         | Malignant neoplasm of thymus   | M | <b>0.2</b>               | 0.2        | 0.4        | 0.2                      | 0.3           | 0.1           | 0.1   | 0.2    | 0.2        | 0.2        |
|             |  | F | <b>0.2</b>               | 0.2        | 0.1        | 0.3                      | 0.1           | 0.1           | 0.1   | 0.2    | 0.2        | 0.2        |
| C38         | Malignant neoplasm of heart, mediastinum and pleura  | M | <b>0.5</b>               | 0.6        | 0.8        | 0.5                      | 0.8           | 0.4           | 0.4   | 0.2    | 0.3        | 0.6        |
|             |  | F | <b>0.3</b>               | 0.2        | 0.7        | 0.2                      | 0.1           | 0.2           | 0.1   | 0.4    | 0.4        | 0.4        |
| C39         | Malignant neoplasm of other and ill-defined sites in the respiratory system and intrathoracic organs | M | <b>0.0</b>               | -          | -          | -                        | -             | 0.0           | -     | -      | -          | 0.1        |
|             |  | F | <b>0.0</b>               | -          | -          | -                        | -             | -             | 0.0   | -      | -          | 0.0        |
| C40         | Malignant neoplasm of bone and articular cartilage of limbs  | M | <b>0.4</b>               | 0.6        | 0.2        | 0.4                      | 0.3           | 0.5           | 0.5   | 0.4    | 0.3        | 0.4        |
|             |  | F | <b>0.3</b>               | 0.2        | 0.3        | 0.3                      | 0.5           | 0.4           | 0.3   | 0.2    | 0.4        | 0.3        |
| C41         | Malignant neoplasm of bone and articular cartilage of other and unspecified sites                    | M | <b>0.6</b>               | 0.3        | 1.1        | 0.8                      | 0.4           | 0.2           | 0.7   | 0.4    | 0.5        | 0.7        |
|             |  | F | <b>0.3</b>               | 0.2        | 0.8        | 0.3                      | 0.2           | 0.1           | 0.3   | 0.2    | 0.3        | 0.3        |
| C43         | Malignant melanoma of skin   | M | <b>14.8</b>              | 10.1       | 13.9       | 15.4                     | 14.4          | 13.6          | 14.4  | 7.4    | 19.1       | 23.8       |
|             |  | F | <b>17.0</b>              | 15.4       | 16.7       | 17.8                     | 16.3          | 16.0          | 18.1  | 8.7    | 19.7       | 25.2       |
| C44         | Other malignant neoplasms of skin  | M | <b>139.6</b>             | 176.7      | 160.0      | 168.7                    | 193.8         | 148.3         | 112.8 | 21.4   | 105.9      | 267.7      |
|             |  | F | <b>110.9</b>             | 146.0      | 139.4      | 139.2                    | 143.1         | 120.9         | 79.6  | 14.4   | 82.8       | 207.9      |
| C45         | Mesothelioma   | M | <b>6.3</b>               | 8.7        | 7.3        | 5.3                      | 5.3           | 5.3           | 6.9   | 4.0    | 7.8        | 7.5        |
|             |  | F | <b>1.1</b>               | 2.0        | 1.0        | 1.3                      | 0.9           | 1.0           | 1.1   | 0.9    | 1.2        | 1.3        |

Table 5 Series MB1 no. 36

To link to Excel version of the table - click on the red box surrounding the table title

Table 5 Rates per 100,000 population in Government Office Regions - *continued*

| ICD-10 code | Site description  |   | Government Office Region |            |            |                          |               |               |       |        |            |            |
|-------------|---|---|--------------------------|------------|------------|--------------------------|---------------|---------------|-------|--------|------------|------------|
|             |   |   | England                  | North East | North West | Yorkshire and The Humber | East Midlands | West Midlands | East  | London | South East | South West |
| C46         | Kaposi's sarcoma  | M | <b>0.4</b>               | 0.2        | 0.4        | 0.2                      | 0.1           | 0.0           | 0.3   | 1.4    | 0.2        | 0.2        |
|             |   | F | <b>0.1</b>               | 0.2        | 0.0        | 0.1                      | 0.1           | 0.0           | -     | 0.2    | 0.0        | 0.0        |
| C47         | Malignant neoplasm of peripheral nerves and autonomic nervous system    | M | <b>0.2</b>               | 0.3        | 0.1        | 0.2                      | 0.2           | 0.2           | 0.2   | 0.1    | 0.1        | 0.2        |
|             |   | F | <b>0.1</b>               | 0.1        | 0.1        | 0.0                      | 0.1           | 0.2           | 0.1   | 0.1    | 0.1        | 0.2        |
| C48         | Malignant neoplasm of retroperitoneum and peritoneum                    | M | <b>0.4</b>               | 0.3        | 0.5        | 0.4                      | 0.5           | 0.2           | 0.7   | 0.5    | 0.4        | 0.4        |
|             |   | F | <b>1.4</b>               | 2.8        | 1.5        | 2.2                      | 1.2           | 0.7           | 1.3   | 1.1    | 1.1        | 1.2        |
| C49         | Malignant neoplasm of other connective and soft tissue                  | M | <b>2.5</b>               | 2.8        | 3.2        | 3.0                      | 2.8           | 1.9           | 1.9   | 1.7    | 2.0        | 3.7        |
|             |   | F | <b>2.0</b>               | 2.2        | 2.5        | 2.0                      | 2.1           | 2.1           | 1.4   | 1.4    | 1.7        | 2.7        |
| C50         | Malignant neoplasm of breast  | M | <b>1.0</b>               | 1.4        | 1.0        | 0.8                      | 0.8           | 0.9           | 0.8   | 1.1    | 1.0        | 1.4        |
|             |   | F | <b>148.6</b>             | 150.3      | 152.2      | 147.6                    | 154.0         | 155.3         | 152.1 | 109.8  | 153.4      | 177.6      |
| C51         | Malignant neoplasm of vulva   | F | <b>3.3</b>               | 4.6        | 2.9        | 3.9                      | 4.0           | 3.9           | 2.7   | 1.9    | 3.1        | 4.1        |
| C52         | Malignant neoplasm of vagina  | F | <b>0.8</b>               | 0.8        | 0.7        | 0.8                      | 1.5           | 0.8           | 0.5   | 0.9    | 0.8        | 0.9        |
| C53         | Malignant neoplasm of cervix uteri                                      | F | <b>8.8</b>               | 9.5        | 10.0       | 10.7                     | 10.0          | 8.8           | 6.8   | 7.4    | 7.8        | 9.5        |
| C54         | Malignant neoplasm of corpus uteri                                      | F | <b>21.2</b>              | 19.3       | 21.3       | 21.3                     | 22.6          | 21.6          | 22.6  | 16.1   | 20.8       | 26.3       |
| C55         | Malignant neoplasm of uterus,part unspecified                           | F | <b>1.1</b>               | 1.1        | 1.2        | 1.1                      | 1.2           | 1.4           | 1.8   | 0.6    | 1.0        | 0.6        |
| C56-C57     | Malignant neoplasm of ovary and other unspecified female genital organs | F | <b>21.7</b>              | 22.8       | 22.8       | 19.7                     | 24.6          | 21.8          | 22.3  | 14.4   | 21.8       | 29.2       |
| C56         | Malignant neoplasm of ovary   | F | <b>21.2</b>              | 22.4       | 22.2       | 19.4                     | 23.8          | 21.2          | 21.9  | 14.1   | 21.2       | 28.5       |
| C57         | Malignant neoplasm of other and unspecified female genital organs       | F | <b>0.5</b>               | 0.4        | 0.6        | 0.2                      | 0.9           | 0.6           | 0.4   | 0.3    | 0.5        | 0.8        |
| C58         | Malignant neoplasm of placenta  | F | <b>0.0</b>               | 0.2        | -          | -                        | 0.1           | -             | -     | 0.0    | 0.0        | 0.0        |
| C60         | Malignant neoplasm of penis   | M | <b>1.6</b>               | 2.3        | 1.6        | 1.6                      | 1.7           | 1.7           | 1.9   | 1.0    | 1.3        | 2.0        |
| C61         | Malignant neoplasm of prostate  | M | <b>116.7</b>             | 113.1      | 128.5      | 109.0                    | 122.6         | 127.3         | 126.5 | 78.0   | 112.0      | 147.9      |
| C62         | Malignant neoplasm of testis  | M | <b>6.9</b>               | 6.4        | 7.2        | 6.7                      | 7.3           | 6.5           | 6.9   | 5.2    | 8.4        | 7.5        |
| C63         | Malignant neoplasm of other and unspecified male genital organs         | M | <b>0.2</b>               | 0.2        | 0.3        | 0.3                      | 0.2           | 0.1           | 0.5   | 0.1    | 0.2        | 0.2        |
| C64         | Malignant neoplasm of kidney,except renal pelvis                        | M | <b>13.1</b>              | 15.7       | 12.7       | 13.4                     | 13.3          | 12.0          | 13.6  | 9.3    | 13.0       | 18.2       |
|             |   | F | <b>7.5</b>               | 9.9        | 7.2        | 8.1                      | 8.3           | 7.2           | 8.0   | 4.8    | 7.7        | 9.0        |
| C65         | Malignant neoplasm of renal pelvis                                      | M | <b>1.0</b>               | 1.9        | 1.2        | 1.8                      | 0.9           | 0.7           | 1.1   | 0.5    | 0.8        | 1.0        |
|             |   | F | <b>0.6</b>               | 0.9        | 0.6        | 0.8                      | 0.2           | 0.7           | 0.8   | 0.3    | 0.5        | 0.6        |
| C66         | Malignant neoplasm of ureter  | M | <b>0.8</b>               | 1.4        | 0.7        | 0.9                      | 0.9           | 0.6           | 0.8   | 0.8    | 0.6        | 1.3        |
|             |   | F | <b>0.5</b>               | 0.5        | 0.3        | 0.7                      | 0.3           | 0.3           | 0.7   | 0.2    | 0.5        | 0.7        |
| C67         | Malignant neoplasm of bladder   | M | <b>24.6</b>              | 25.2       | 28.8       | 27.2                     | 23.8          | 23.6          | 23.5  | 18.1   | 25.0       | 27.9       |
|             |   | F | <b>9.3</b>               | 11.1       | 10.9       | 11.2                     | 9.6           | 8.2           | 8.6   | 6.7    | 9.5        | 9.9        |
| C68         | Malignant neoplasm of other and unspecified urinary organs              | M | <b>0.5</b>               | 0.2        | 0.3        | 0.4                      | 0.8           | 0.5           | 0.4   | 0.2    | 0.3        | 1.5        |
|             |   | F | <b>0.2</b>               | 0.2        | 0.1        | 0.1                      | 0.3           | 0.3           | 0.1   | 0.1    | 0.1        | 0.3        |
| C69         | Malignant neoplasm of eye and adnexa                                    | M | <b>0.8</b>               | 0.7        | 0.9        | 0.6                      | 0.8           | 0.3           | 0.8   | 0.8    | 0.8        | 0.9        |
|             |   | F | <b>0.6</b>               | 0.2        | 1.1        | 0.5                      | 0.4           | 0.4           | 0.5   | 0.5    | 0.7        | 0.9        |

To link to Excel version of the table - click on the red box surrounding the table title

**Table 5 Rates per 100,000 population in Government Office Regions - continued**

| ICD-10 code | Site description   |   | Government Office Region |            |            |                          |               |               |      |        |            |            |
|-------------|--|---|--------------------------|------------|------------|--------------------------|---------------|---------------|------|--------|------------|------------|
|             |  |   | England                  | North East | North West | Yorkshire and The Humber | East Midlands | West Midlands | East | London | South East | South West |
| C70         | Malignant neoplasm of meninges   | M | <b>0.1</b>               | -          | 0.1        | 0.1                      | -             | 0.1           | 0.1  | 0.0    | 0.0        | 0.1        |
|             |  | F | <b>0.1</b>               | -          | 0.1        | -                        | 0.0           | 0.0           | 0.1  | 0.1    | 0.1        | 0.3        |
| C71         | Malignant neoplasm of brain  | M | <b>8.9</b>               | 10.7       | 9.4        | 8.1                      | 9.6           | 7.9           | 9.3  | 6.8    | 8.5        | 11.2       |
|             |  | F | <b>5.8</b>               | 6.6        | 5.3        | 6.6                      | 6.1           | 6.0           | 5.5  | 4.8    | 5.9        | 6.8        |
| C72         | Malignant neoplasm of spinal cord,cranial nerves and other parts of central nervous system | M | <b>0.2</b>               | 0.1        | 0.3        | 0.1                      | 0.2           | 0.1           | 0.3  | 0.2    | 0.3        | 0.2        |
|             |  | F | <b>0.2</b>               | 0.2        | 0.1        | 0.2                      | 0.3           | 0.1           | 0.3  | 0.2    | 0.1        | 0.2        |
| C73         | Malignant neoplasm of thyroid gland  | M | <b>1.5</b>               | 1.2        | 1.5        | 1.5                      | 2.0           | 1.8           | 1.8  | 1.2    | 1.2        | 1.6        |
|             |  | F | <b>4.3</b>               | 5.3        | 4.1        | 4.3                      | 4.6           | 3.3           | 4.6  | 4.0    | 4.2        | 5.0        |
| C74         | Malignant neoplasm of adrenal gland  | M | <b>0.3</b>               | 0.2        | 0.4        | 0.4                      | 0.2           | 0.3           | 0.3  | 0.4    | 0.2        | 0.2        |
|             |  | F | <b>0.3</b>               | 0.3        | 0.5        | 0.2                      | 0.5           | 0.1           | 0.3  | 0.0    | 0.4        | 0.5        |
| C75         | Malignant neoplasm of other endocrine glands and related structures                        | M | <b>0.3</b>               | 0.1        | 0.3        | 0.4                      | 0.1           | 0.3           | 0.3  | 0.2    | 0.2        | 0.5        |
|             |  | F | <b>0.1</b>               | 0.1        | 0.2        | 0.1                      | 0.1           | 0.0           | 0.0  | 0.2    | 0.2        | 0.1        |
| C76         | Malignant neoplasm of other and ill-defined sites  | M | <b>0.8</b>               | 0.2        | 0.5        | 0.4                      | 0.6           | 0.3           | 1.1  | 1.3    | 1.3        | 0.9        |
|             |  | F | <b>1.0</b>               | 0.8        | 0.6        | 1.0                      | 0.8           | 0.7           | 1.0  | 1.2    | 1.4        | 1.6        |
| C77         | Secondary and unspecified malignant neoplasm of lymph nodes                                | M | <b>1.3</b>               | 2.1        | 1.3        | 1.7                      | 1.8           | 1.3           | 1.1  | 0.8    | 1.1        | 1.4        |
|             |  | F | <b>1.1</b>               | 0.9        | 0.9        | 1.2                      | 1.7           | 1.1           | 1.3  | 0.6    | 1.3        | 1.5        |
| C78         | Secondary malignant neoplasm of respiratory and digestive organs                           | M | <b>6.7</b>               | 8.2        | 5.9        | 8.1                      | 9.6           | 5.4           | 6.4  | 4.0    | 6.9        | 8.2        |
|             |  | F | <b>7.4</b>               | 9.9        | 4.0        | 8.9                      | 12.0          | 6.7           | 7.2  | 4.7    | 8.1        | 9.5        |
| C79         | Secondary malignant neoplasm of other sites  | M | <b>2.8</b>               | 2.8        | 1.7        | 3.9                      | 4.7           | 2.3           | 2.8  | 2.0    | 3.2        | 2.7        |
|             |  | F | <b>2.6</b>               | 3.0        | 1.6        | 3.0                      | 4.0           | 2.3           | 3.0  | 1.7    | 3.1        | 3.0        |
| C80         | Malignant neoplasm without specification of site   | M | <b>8.1</b>               | 10.8       | 11.9       | 7.8                      | 5.9           | 10.6          | 7.7  | 6.8    | 6.5        | 6.4        |
|             |  | F | <b>9.5</b>               | 12.1       | 13.5       | 9.3                      | 6.7           | 11.7          | 9.5  | 7.3    | 8.6        | 8.1        |
| C81         | Hodgkin's disease  | M | <b>3.0</b>               | 3.0        | 2.7        | 3.0                      | 3.4           | 2.3           | 3.2  | 2.6    | 3.6        | 3.5        |
|             |  | F | <b>2.2</b>               | 2.4        | 2.4        | 2.7                      | 2.1           | 1.7           | 2.3  | 1.9    | 2.2        | 2.2        |
| C82-C85     | Non-Hodgkin's lymphoma   | M | <b>18.7</b>              | 13.6       | 17.1       | 16.9                     | 20.2          | 17.8          | 20.5 | 15.3   | 19.9       | 25.8       |
|             |  | F | <b>15.2</b>              | 13.0       | 14.7       | 14.1                     | 17.1          | 13.9          | 15.1 | 12.3   | 15.9       | 21.1       |
| C82         | Follicular (nodular) non-Hodgkin's lymphoma  | M | <b>2.6</b>               | 1.9        | 2.0        | 2.5                      | 3.2           | 2.7           | 2.7  | 1.9    | 2.9        | 3.3        |
|             |  | F | <b>2.9</b>               | 2.2        | 3.1        | 3.1                      | 2.8           | 2.2           | 2.9  | 2.1    | 2.9        | 4.2        |
| C83         | Diffuse non-Hodgkin's lymphoma   | M | <b>9.1</b>               | 6.8        | 7.7        | 9.2                      | 10.9          | 9.9           | 9.6  | 5.3    | 10.1       | 13.6       |
|             |  | F | <b>6.8</b>               | 6.3        | 5.9        | 7.1                      | 8.7           | 7.8           | 6.5  | 3.6    | 7.7        | 9.0        |
| C84         | Peripheral and cutaneous T-cell lymphomas  | M | <b>1.1</b>               | 1.0        | 0.8        | 1.4                      | 1.4           | 1.2           | 1.2  | 0.7    | 1.1        | 1.7        |
|             |  | F | <b>0.8</b>               | 0.6        | 0.4        | 1.0                      | 1.4           | 1.0           | 0.9  | 0.7    | 0.5        | 1.4        |
| C85         | Other and unspecified types of non-Hodgkin's lymphoma                                      | M | <b>5.8</b>               | 3.9        | 6.6        | 3.8                      | 4.7           | 4.0           | 7.0  | 7.4    | 5.8        | 7.2        |
|             |  | F | <b>4.7</b>               | 3.8        | 5.3        | 2.8                      | 4.1           | 3.1           | 4.8  | 5.9    | 4.9        | 6.4        |
| C88         | Malignant immunoproliferative diseases   | M | <b>0.4</b>               | 0.1        | 0.3        | 0.2                      | 0.3           | 0.7           | 0.3  | 0.4    | 0.6        | 0.8        |
|             |  | F | <b>0.3</b>               | 0.1        | 0.1        | 0.0                      | 0.3           | 0.4           | 0.2  | 0.1    | 0.4        | 0.5        |
| C90         | Multiple myeloma and malignant plasma cell neoplasms                                       | M | <b>7.0</b>               | 5.4        | 6.8        | 7.4                      | 6.9           | 6.4           | 6.9  | 6.0    | 6.9        | 10.3       |
|             |  | F | <b>5.9</b>               | 5.5        | 5.9        | 5.0                      | 6.3           | 5.6           | 6.0  | 4.1    | 5.7        | 9.2        |
| C91-C95     | All leukaemias   | M | <b>14.0</b>              | 10.7       | 12.5       | 16.5                     | 15.4          | 13.2          | 12.9 | 11.9   | 14.7       | 17.7       |
|             |  | F | <b>10.0</b>              | 6.5        | 9.1        | 10.8                     | 9.8           | 8.7           | 9.3  | 8.9    | 11.5       | 13.5       |
| C91         | Lymphoid leukaemia   | M | <b>7.1</b>               | 4.8        | 6.1        | 9.5                      | 7.8           | 6.8           | 5.9  | 5.6    | 7.8        | 9.2        |
|             |  | F | <b>4.4</b>               | 2.1        | 3.8        | 5.7                      | 4.5           | 3.9           | 3.6  | 3.6    | 5.4        | 6.3        |
| C92         | Myeloid leukaemia  | M | <b>6.2</b>               | 5.7        | 5.6        | 6.6                      | 6.9           | 5.8           | 6.3  | 5.5    | 6.0        | 7.7        |
|             |  | F | <b>5.0</b>               | 4.0        | 4.7        | 4.8                      | 4.9           | 4.0           | 5.5  | 4.6    | 5.4        | 6.2        |
| C93         | Monocytic leukaemia  | M | <b>0.1</b>               | -          | 0.1        | -                        | 0.1           | 0.2           | 0.1  | 0.1    | 0.2        | 0.1        |
|             |  | F | <b>0.1</b>               | -          | 0.0        | -                        | 0.0           | 0.4           | 0.0  | 0.0    | 0.3        | 0.1        |

Table 5 Series MB1 no. 36

To link to Excel version of the table - click on the red box surrounding the table title

Table 5 Rates per 100,000 population in Government Office Regions - continued

| ICD-10 code | Site description  |   | Government Office Region |            |            |                          |               |               |      |        |            |            |
|-------------|---|---|--------------------------|------------|------------|--------------------------|---------------|---------------|------|--------|------------|------------|
|             |   |   | England                  | North East | North West | Yorkshire and The Humber | East Midlands | West Midlands | East | London | South East | South West |
| C94         | Other leukaemias of specified cell type   | M | <b>0.1</b>               | -          | 0.1        | -                        | 0.1           | 0.2           | -    | 0.1    | 0.2        | -          |
|             |   | F | <b>0.1</b>               | -          | 0.0        | -                        | 0.0           | 0.0           | 0.1  | 0.1    | 0.0        | -          |
| C95         | Leukaemia of unspecified cell type  | M | <b>0.5</b>               | 0.2        | 0.7        | 0.4                      | 0.5           | 0.3           | 0.6  | 0.6    | 0.5        | 0.7        |
|             |   | F | <b>0.4</b>               | 0.3        | 0.6        | 0.2                      | 0.4           | 0.4           | 0.2  | 0.6    | 0.3        | 0.6        |
| C96         | Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue          | M | <b>0.1</b>               | -          | 0.1        | -                        | 0.0           | 0.0           | 0.1  | 0.2    | 0.0        | 0.1        |
|             |   | F | <b>0.0</b>               | 0.1        | -          | 0.0                      | -             | -             | -    | 0.2    | 0.0        | -          |
| C97         | Malignant neoplasms of independent(primary) multiple sites  | M | <b>0.0</b>               | -          | -          | -                        | -             | -             | -    | -      | -          | 0.0        |
|             |   | F | -                        | -          | -          | -                        | -             | -             | -    | -      | -          | -          |
| D00         | Carcinoma in situ of oral cavity, oesophagus and stomach  | M | <b>0.8</b>               | 0.9        | 0.8        | 0.7                      | 0.6           | 0.6           | 1.0  | 0.4    | 0.7        | 1.3        |
|             |   | F | <b>0.4</b>               | 0.3        | 0.4        | 0.2                      | 0.3           | 0.2           | 0.5  | 0.3    | 0.6        | 0.5        |
| D01         | Carcinoma in situ of other and unspecified digestive organs                                       | M | <b>2.2</b>               | 1.0        | 1.7        | 0.7                      | 0.5           | 2.9           | 3.6  | 1.4    | 1.9        | 6.3        |
|             |   | F | <b>1.6</b>               | 0.5        | 1.5        | 0.7                      | 0.4           | 2.3           | 2.3  | 0.8    | 1.3        | 4.5        |
| D02         | Carcinoma in situ of middle ear and respiratory system  | M | <b>0.8</b>               | 0.5        | 1.2        | 0.6                      | 1.1           | 0.8           | 0.8  | 0.3    | 0.5        | 1.3        |
|             |   | F | <b>0.2</b>               | 0.2        | 0.3        | 0.2                      | 0.3           | 0.3           | 0.1  | 0.2    | 0.2        | 0.3        |
| D03         | Melanoma in situ  | M | <b>4.8</b>               | 4.4        | 4.3        | 3.8                      | 6.3           | 3.1           | 5.3  | 1.7    | 6.2        | 9.5        |
|             |   | F | <b>5.8</b>               | 5.0        | 4.4        | 6.1                      | 6.8           | 4.0           | 6.6  | 2.6    | 6.6        | 11.4       |
| D04         | Carcinoma in situ of skin   | M | <b>13.2</b>              | 11.3       | 16.9       | 15.2                     | 19.9          | 11.5          | 14.3 | 4.2    | 11.1       | 18.8       |
|             |   | F | <b>21.4</b>              | 23.8       | 27.3       | 25.7                     | 27.7          | 19.2          | 24.1 | 6.2    | 16.3       | 32.0       |
| D05         | Carcinoma in situ of breast   | M | <b>0.1</b>               | 0.2        | 0.1        | -                        | 0.0           | 0.2           | 0.1  | 0.1    | 0.0        | 0.1        |
|             |   | F | <b>16.3</b>              | 15.5       | 13.0       | 16.4                     | 18.2          | 14.4          | 17.1 | 11.5   | 18.0       | 25.0       |
| D06         | Carcinoma in situ of cervix uteri   | F | <b>77.7</b>              | 104.3      | 74.8       | 71.2                     | 84.9          | 94.1          | 75.9 | 60.5   | 71.0       | 89.5       |
| D07         | Carcinoma in situ of other and unspecified genital organs   | M | <b>3.5</b>               | 1.0        | 2.7        | 5.1                      | 5.8           | 3.7           | 4.9  | 1.8    | 2.0        | 5.0        |
|             |   | F | <b>2.1</b>               | 1.1        | 2.6        | 2.0                      | 2.4           | 2.8           | 1.5  | 1.7    | 1.7        | 3.2        |
| D09         | Carcinoma in situ of other and unspecified sites  | M | <b>10.5</b>              | 25.0       | 15.1       | 16.4                     | 4.8           | 4.5           | 5.9  | 10.0   | 11.7       | 6.0        |
|             |   | F | <b>2.9</b>               | 7.3        | 4.9        | 4.8                      | 0.7           | 1.0           | 1.5  | 2.8    | 3.5        | 1.0        |
| D33         | Benign neoplasm of brain and other parts of central nervous system                                | M | <b>1.1</b>               | 1.1        | 1.3        | 0.6                      | 1.3           | 1.1           | 1.2  | 0.5    | 1.4        | 1.2        |
|             |   | F | <b>1.1</b>               | 1.3        | 0.8        | 0.7                      | 1.0           | 1.0           | 1.2  | 0.7    | 1.4        | 1.7        |
| D35.2       | Benign neoplasm of pituitary gland  | M | <b>1.4</b>               | 1.0        | 1.7        | 0.8                      | 1.5           | 1.0           | 1.5  | 0.9    | 1.4        | 2.6        |
|             |   | F | <b>1.0</b>               | 0.4        | 1.5        | 0.8                      | 0.8           | 1.1           | 0.8  | 0.8    | 1.0        | 1.8        |
| D35.3       | Benign neoplasm of craniopharyngeal duct  | M | -                        | -          | -          | -                        | -             | -             | -    | -      | -          | -          |
|             |   | F | -                        | -          | -          | -                        | -             | -             | -    | -      | -          | -          |
| D35.4       | Benign neoplasm of pineal gland   | M | -                        | -          | -          | -                        | -             | -             | -    | -      | -          | -          |
|             |   | F | -                        | -          | -          | -                        | -             | -             | -    | -      | -          | -          |
| D37         | Neoplasm of uncertain or unknown behaviour of oral cavity and digestive organs                    | M | <b>3.3</b>               | 3.5        | 8.5        | 2.2                      | 3.9           | 1.5           | 3.0  | 1.2    | 2.5        | 3.8        |
|             |   | F | <b>3.3</b>               | 2.4        | 6.8        | 2.3                      | 5.4           | 1.6           | 3.4  | 1.2    | 2.7        | 4.0        |
| D38         | Neoplasm of uncertain or unknown behaviour of middle ear and respiratory and intrathoracic organs | M | <b>0.3</b>               | 0.2        | 0.6        | 0.2                      | 0.3           | 0.3           | 0.3  | 0.1    | 0.1        | 1.0        |
|             |   | F | <b>0.2</b>               | 0.1        | 0.3        | 0.0                      | 0.3           | 0.2           | 0.2  | 0.0    | 0.2        | 0.5        |
| D39         | Neoplasm of uncertain or unknown behaviour of female genital organs                               | F | <b>1.1</b>               | 0.5        | 2.2        | 0.3                      | 1.4           | 0.7           | 0.3  | 1.2    | 1.1        | 1.7        |
| D40         | Neoplasm of uncertain or unknown behaviour of male genital organs                                 | M | <b>0.2</b>               | 0.1        | 0.5        | 0.1                      | 0.2           | 0.1           | 0.1  | 0.2    | 0.2        | 0.4        |

To link to Excel version of the table - click on the red box surrounding the table title

**Table 5 Rates per 100,000 population in Government Office Regions - continued**

| ICD-10 code | Site description   |   | Government Office Region |            |            |                          |               |               |      |        |            |            |
|-------------|--|---|--------------------------|------------|------------|--------------------------|---------------|---------------|------|--------|------------|------------|
|             |  |   | England                  | North East | North West | Yorkshire and The Humber | East Midlands | West Midlands | East | London | South East | South West |
| D41         | Neoplasm of uncertain or unknown behaviour of urinary organs                                     | M | <b>10.9</b>              | 0.1        | 5.3        | 5.6                      | 19.7          | 18.7          | 19.3 | 0.2    | 9.1        | 22.5       |
|             |  | F | <b>3.4</b>               | -          | 2.1        | 2.0                      | 7.3           | 6.0           | 5.0  | 0.1    | 2.6        | 7.0        |
| D42         | Neoplasm of uncertain or unknown behaviour of meninges   | M | <b>0.1</b>               | -          | 0.1        | 0.1                      | 0.1           | 0.2           | 0.2  | -      | 0.0        | 0.1        |
|             |  | F | <b>0.1</b>               | -          | 0.1        | 0.1                      | 0.2           | 0.3           | 0.1  | -      | 0.1        | 0.1        |
| D43         | Neoplasm of uncertain or unknown behaviour of brain and central nervous system                   | M | <b>1.1</b>               | 0.5        | 2.3        | 0.6                      | 1.1           | 1.1           | 0.9  | 0.7    | 1.0        | 1.3        |
|             |  | F | <b>1.1</b>               | 0.2        | 1.5        | 0.4                      | 0.5           | 1.4           | 1.1  | 0.7    | 1.5        | 1.3        |
| D44         | Neoplasm of uncertain or unknown behaviour of endocrine glands                                   | M | <b>0.4</b>               | 0.2        | 0.8        | 0.2                      | 0.2           | 0.3           | 0.3  | 0.2    | 0.2        | 0.7        |
|             |  | F | <b>0.4</b>               | 0.5        | 0.8        | 0.2                      | 0.4           | 0.1           | 0.5  | 0.2    | 0.6        | 0.6        |
| D45         | Polycythaemia vera   | M | <b>2.4</b>               | 0.3        | 3.5        | 0.6                      | 0.8           | 0.5           | 0.9  | 1.5    | 3.0        | 9.0        |
|             |  | F | <b>1.3</b>               | 0.4        | 1.5        | 0.4                      | 0.6           | 0.5           | 0.8  | 0.7    | 1.7        | 4.0        |
| D46         | Myelodysplastic syndromes  | M | <b>4.6</b>               | 3.0        | 3.9        | 3.9                      | 4.7           | 4.0           | 3.7  | 3.3    | 5.0        | 10.3       |
|             |  | F | <b>3.7</b>               | 3.3        | 3.9        | 3.1                      | 3.4           | 2.3           | 3.3  | 2.4    | 3.9        | 7.9        |
| D47         | Other neoplasms of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue | M | <b>4.1</b>               | 2.0        | 2.5        | 7.1                      | 2.4           | 3.8           | 3.3  | 3.6    | 5.2        | 6.2        |
|             |  | F | <b>4.0</b>               | 2.4        | 2.3        | 6.6                      | 2.4           | 2.9           | 2.9  | 3.8    | 5.1        | 7.1        |
| D48         | Neoplasm of uncertain or unknown behaviour of other and unspecified sites                        | M | <b>1.5</b>               | 0.4        | 3.4        | 0.9                      | 1.8           | 0.5           | 0.9  | 0.7    | 1.5        | 2.9        |
|             |  | F | <b>1.7</b>               | 0.8        | 3.6        | 0.7                      | 2.4           | 1.4           | 0.9  | 0.9    | 1.1        | 3.5        |
| O01         | Hydatidiform mole  | F | <b>1.0</b>               | 3.2        | 1.4        | 0.8                      | 2.1           | -             | -    | 1.2    | 0.6        | 1.3        |

Table 6 Series MBI no. 36

To link to Excel version of the table - click on the red box surrounding the table title

**Table 6 Standardised registration ratios<sup>1</sup>: site, sex and Government Office Region of residence, 2005** **England,  
Government Office Regions  
Registered by October 2007**

| ICD-10 code                  | Site description  |          | Government Office Region |            |                          |               |               |           |           |            |            |
|------------------------------|---|----------|--------------------------|------------|--------------------------|---------------|---------------|-----------|-----------|------------|------------|
|                              |   |          | North East               | North West | Yorkshire and The Humber | East Midlands | West Midlands | East      | London    | South East | South West |
| <b>C00-C97, D00-D48, O01</b> | <b>All registrations</b>  | <b>M</b> | <b>107</b>               | <b>112</b> | <b>105</b>               | <b>110</b>    | <b>100</b>    | <b>92</b> | <b>76</b> | <b>89</b>  | <b>119</b> |
|                              |   | <b>F</b> | <b>112</b>               | <b>109</b> | <b>105</b>               | <b>109</b>    | <b>100</b>    | <b>93</b> | <b>73</b> | <b>92</b>  | <b>121</b> |
| <b>C00-C97</b>               | <b>All cancers</b>  | <b>M</b> | <b>110</b>               | <b>111</b> | <b>106</b>               | <b>110</b>    | <b>101</b>    | <b>91</b> | <b>78</b> | <b>88</b>  | <b>116</b> |
|                              |   | <b>F</b> | <b>111</b>               | <b>110</b> | <b>107</b>               | <b>108</b>    | <b>100</b>    | <b>91</b> | <b>77</b> | <b>92</b>  | <b>117</b> |
| <b>C00-C97 excl.C44</b>      | <b>All cancers excluding nmse<sup>2</sup></b>   | <b>M</b> | <b>106</b>               | <b>110</b> | <b>102</b>               | <b>103</b>    | <b>100</b>    | <b>95</b> | <b>94</b> | <b>93</b>  | <b>102</b> |
|                              |   | <b>F</b> | <b>107</b>               | <b>106</b> | <b>103</b>               | <b>103</b>    | <b>98</b>     | <b>96</b> | <b>91</b> | <b>96</b>  | <b>106</b> |
| C00-C14                      | Malignant neoplasm of lip, mouth and pharynx  | M        | 125                      | 112        | 96                       | 102           | 99            | 80        | 112       | 85         | 106        |
|                              |   | F        | 99                       | 110        | 89                       | 118           | 93            | 107       | 105       | 88         | 96         |
| C00                          | Malignant neoplasm of lip   | M        | 103                      | 35         | 93                       | 128           | 105           | 167       | 62        | 119        | 98         |
|                              |   | F        | 234                      | 116        | 84                       | 142           | 80            | 138       | 33        | 93         | 62         |
| C01                          | Malignant neoplasm of base of tongue  | M        | 94                       | 129        | 65                       | 120           | 111           | 83        | 74        | 92         | 128        |
|                              |   | F        | 23                       | 125        | 73                       | 99            | 115           | 130       | 83        | 66         | 153        |
| C02                          | Malignant neoplasm of other and unspecified parts of tongue                           | M        | 119                      | 126        | 82                       | 100           | 98            | 78        | 119       | 76         | 114        |
|                              |   | F        | 50                       | 107        | 104                      | 108           | 85            | 118       | 117       | 94         | 93         |
| C03                          | Malignant neoplasm of gum   | M        | 44                       | 91         | 107                      | 129           | 85            | 73        | 165       | 83         | 107        |
|                              |   | F        | 51                       | 110        | 61                       | 103           | 91            | 141       | 100       | 101        | 108        |
| C04                          | Malignant neoplasm of floor of mouth  | M        | 166                      | 125        | 107                      | 79            | 96            | 76        | 124       | 81         | 80         |
|                              |   | F        | 126                      | 131        | 94                       | 131           | 98            | 125       | 151       | 34         | 51         |
| C05                          | Malignant neoplasm of palate  | M        | 126                      | 108        | 109                      | 124           | 109           | 84        | 139       | 45         | 100        |
|                              |   | F        | 109                      | 114        | 89                       | 76            | 92            | 79        | 126       | 83         | 132        |
| C06                          | Malignant neoplasm of other and unspecified parts of mouth                            | M        | 168                      | 105        | 60                       | 93            | 133           | 57        | 124       | 92         | 103        |
|                              |   | F        | 95                       | 113        | 92                       | 115           | 122           | 65        | 105       | 103        | 87         |
| C07                          | Malignant neoplasm of parotid gland   | M        | 81                       | 116        | 82                       | 105           | 92            | 76        | 101       | 98         | 135        |
|                              |   | F        | 172                      | 76         | 102                      | 176           | 104           | 92        | 60        | 78         | 118        |
| C08                          | Malignant neoplasm of other and unspecified major salivary glands                     | M        | 206                      | 105        | 106                      | 121           | 67            | 62        | 88        | 96         | 112        |
|                              |   | F        | 32                       | 109        | 98                       | 77            | 78            | 147       | 97        | 89         | 132        |
| C09                          | Malignant neoplasm of tonsil  | M        | 142                      | 84         | 115                      | 93            | 95            | 82        | 118       | 90         | 110        |
|                              |   | F        | 131                      | 106        | 93                       | 130           | 77            | 89        | 108       | 122        | 52         |
| C10                          | Malignant neoplasm of oropharynx  | M        | 16                       | 180        | 122                      | 74            | 122           | 57        | 114       | 80         | 82         |
|                              |   | F        | 160                      | 162        | 82                       | 96            | 104           | 97        | 116       | 49         | 74         |
| C11                          | Malignant neoplasm of nasopharynx   | M        | 138                      | 120        | 71                       | 81            | 67            | 98        | 133       | 100        | 97         |
|                              |   | F        | 92                       | 82         | 47                       | 112           | 136           | 57        | 102       | 107        | 162        |
| C12                          | Malignant neoplasm of pyriform sinus  | M        | 174                      | 134        | 90                       | 115           | 129           | 74        | 100       | 66         | 70         |
|                              |   | F        | 101                      | 59         | 53                       | 155           | 50            | 213       | 161       | 65         | 72         |
| C13                          | Malignant neoplasm of hypopharynx   | M        | 164                      | 145        | 158                      | 83            | 102           | 43        | 65        | 67         | 119        |
|                              |   | F        | 78                       | 151        | 82                       | 120           | 77            | 145       | 92        | 62         | 90         |
| C14                          | Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynx | M        | 150                      | 115        | 134                      | 119           | 59            | 62        | 112       | 86         | 101        |
|                              |   | F        | 127                      | 138        | 93                       | 125           | 63            | 59        | 118       | 96         | 93         |
| C15                          | Malignant neoplasm of oesophagus  | M        | 88                       | 116        | 104                      | 108           | 103           | 82        | 84        | 102        | 104        |
|                              |   | F        | 96                       | 131        | 105                      | 109           | 96            | 93        | 78        | 85         | 107        |
| C16                          | Malignant neoplasm of stomach   | M        | 133                      | 117        | 124                      | 110           | 105           | 93        | 101       | 76         | 75         |
|                              |   | F        | 139                      | 113        | 118                      | 99            | 118           | 87        | 98        | 73         | 91         |
| C17                          | Malignant neoplasm of small intestine   | M        | 56                       | 105        | 102                      | 145           | 100           | 100       | 87        | 82         | 116        |
|                              |   | F        | 64                       | 90         | 100                      | 118           | 75            | 90        | 123       | 92         | 135        |
| C18-C20                      | Malignant neoplasm of colon and rectum  | M        | 118                      | 105        | 101                      | 109           | 105           | 100       | 87        | 91         | 99         |
|                              |   | F        | 107                      | 101        | 98                       | 101           | 99            | 103       | 89        | 99         | 107        |

1. See sections 4.3 and 5.7.

2. These figures exclude non-melanoma skin cancer (ICD-10 C44) - see section 4.2.

To link to Excel version of the table - click on the red box surrounding the table title

Table 6 Standardised registration ratios - *continued*

| ICD-10 code | Site description   |   | Government Office Region |            |                          |               |               |      |        |            |            |
|-------------|--|---|--------------------------|------------|--------------------------|---------------|---------------|------|--------|------------|------------|
|             |  |   | North East               | North West | Yorkshire and The Humber | East Midlands | West Midlands | East | London | South East | South West |
| C18         | Malignant neoplasm of colon  | M | 122                      | 103        | 97                       | 107           | 106           | 98   | 85     | 92         | 106        |
|             |  | F | 108                      | 100        | 96                       | 97            | 100           | 101  | 90     | 98         | 114        |
| C19         | Malignant neoplasm of rectosigmoid junction  | M | 128                      | 109        | 99                       | 104           | 89            | 115  | 109    | 89         | 77         |
|             |  | F | 94                       | 122        | 101                      | 96            | 90            | 109  | 113    | 97         | 71         |
| C20         | Malignant neoplasm of rectum   | M | 107                      | 109        | 108                      | 113           | 109           | 99   | 84     | 90         | 94         |
|             |  | F | 111                      | 98         | 103                      | 111           | 99            | 106  | 81     | 102        | 99         |
| C21         | Malignant neoplasm of anus and anal canal  | M | 152                      | 81         | 112                      | 55            | 88            | 92   | 130    | 102        | 111        |
|             |  | F | 83                       | 110        | 124                      | 84            | 77            | 98   | 102    | 116        | 84         |
| C22         | Malignant neoplasm of liver and intrahepatic bile ducts  | M | 110                      | 137        | 93                       | 81            | 98            | 74   | 129    | 82         | 99         |
|             |  | F | 102                      | 181        | 84                       | 107           | 79            | 68   | 106    | 70         | 100        |
| C23         | Malignant neoplasm of gallbladder  | M | 183                      | 87         | 66                       | 132           | 75            | 132  | 112    | 88         | 81         |
|             |  | F | 130                      | 100        | 90                       | 149           | 120           | 87   | 96     | 73         | 98         |
| C24         | Malignant neoplasm of other and unspecified parts of biliary tract                                   | M | 47                       | 100        | 92                       | 121           | 128           | 119  | 93     | 90         | 90         |
|             |  | F | 89                       | 102        | 69                       | 123           | 84            | 139  | 119    | 80         | 99         |
| C25         | Malignant neoplasm of pancreas   | M | 89                       | 103        | 97                       | 106           | 100           | 100  | 107    | 95         | 100        |
|             |  | F | 105                      | 99         | 90                       | 103           | 90            | 95   | 102    | 105        | 110        |
| C26         | Malignant neoplasm of other and ill-defined digestive organs   | M | 7                        | 120        | 38                       | 136           | 88            | 81   | 105    | 93         | 177        |
|             |  | F | 19                       | 108        | 41                       | 127           | 111           | 67   | 133    | 107        | 137        |
| C30         | Malignant neoplasm of nasal cavity and middle ear  | M | 231                      | 81         | 129                      | 113           | 102           | 113  | 83     | 78         | 62         |
|             |  | F | 177                      | 111        | 104                      | 95            | 66            | 62   | 100    | 127        | 83         |
| C31         | Malignant neoplasm of accessory sinuses  | M | 88                       | 101        | 106                      | 34            | 128           | 80   | 116    | 74         | 165        |
|             |  | F | 223                      | 153        | 114                      | 135           | 66            | 82   | 96     | 28         | 103        |
| C32         | Malignant neoplasm of larynx   | M | 141                      | 135        | 120                      | 103           | 77            | 81   | 108    | 81         | 80         |
|             |  | F | 165                      | 139        | 109                      | 108           | 75            | 68   | 110    | 78         | 85         |
| C33-C34     | Malignant neoplasm of trachea, bronchus and lung   | M | 135                      | 124        | 110                      | 101           | 102           | 87   | 101    | 83         | 83         |
|             |  | F | 149                      | 133        | 119                      | 96            | 88            | 85   | 102    | 80         | 79         |
| C33         | Malignant neoplasm of trachea  | M | 113                      | 215        | -                        | 198           | 162           | 51   | 98     | 36         | 53         |
|             |  | F | 162                      | 220        | 127                      | 50            | 122           | 38   | 72     | 53         | 77         |
| C34         | Malignant neoplasm of bronchus and lung  | M | 135                      | 124        | 110                      | 101           | 102           | 87   | 101    | 83         | 83         |
|             |  | F | 149                      | 132        | 119                      | 96            | 88            | 85   | 102    | 80         | 79         |
| C37         | Malignant neoplasm of thymus   | M | 76                       | 189        | 118                      | 134           | 37            | 52   | 118    | 85         | 72         |
|             |  | F | 90                       | 69         | 187                      | 55            | 44            | 84   | 116    | 144        | 86         |
| C38         | Malignant neoplasm of heart, mediastinum and pleura  | M | 113                      | 173        | 99                       | 169           | 77            | 72   | 55     | 55         | 117        |
|             |  | F | 67                       | 222        | 57                       | 41            | 65            | 31   | 140    | 103        | 109        |
| C39         | Malignant neoplasm of other and ill-defined sites in the respiratory system and intrathoracic organs | M | -                        | -          | -                        | -             | 235           | -    | -      | -          | 602        |
|             |  | F | -                        | -          | -                        | -             | -             | 430  | -      | -          | 419        |
| C40         | Malignant neoplasm of bone and articular cartilage of limbs  | M | 138                      | 59         | 98                       | 81            | 132           | 119  | 108    | 87         | 108        |
|             |  | F | 45                       | 92         | 90                       | 134           | 130           | 83   | 74     | 126        | 100        |
| C41         | Malignant neoplasm of bone and articular cartilage of other and unspecified sites                    | M | 54                       | 183        | 129                      | 71            | 39            | 117  | 77     | 80         | 116        |
|             |  | F | 69                       | 236        | 94                       | 56            | 45            | 87   | 74     | 88         | 101        |
| C43         | Malignant melanoma of skin   | M | 66                       | 94         | 104                      | 95            | 91            | 94   | 59     | 126        | 147        |
|             |  | F | 89                       | 98         | 105                      | 95            | 95            | 105  | 57     | 114        | 139        |
| C44         | Other malignant neoplasms of skin  | M | 122                      | 115        | 121                      | 134           | 105           | 76   | 20     | 73         | 164        |
|             |  | F | 128                      | 125        | 125                      | 128           | 108           | 69   | 16     | 72         | 163        |
| C45         | Mesothelioma   | M | 131                      | 114        | 84                       | 81            | 81            | 102  | 85     | 118        | 102        |
|             |  | F | 170                      | 88         | 112                      | 76            | 87            | 94   | 104    | 103        | 101        |

**Table 6 Series MB1 no. 36**

To link to Excel version of the table - click on the red box surrounding the table title

**Table 6 Standardised registration ratios - continued**

| ICD-10 code | Site description  |   | Government Office Region |            |                          |               |               |      |        |            |            |
|-------------|---|---|--------------------------|------------|--------------------------|---------------|---------------|------|--------|------------|------------|
|             |   |   | North East               | North West | Yorkshire and The Humber | East Midlands | West Midlands | East | London | South East | South West |
| C46         | Kaposi's sarcoma  | M | 63                       | 101        | 42                       | 24            | 10            | 74   | 330    | 63         | 42         |
|             |   | F | 234                      | 44         | 118                      | 140           | 57            | -    | 258    | 37         | 59         |
| C47         | Malignant neoplasm of peripheral nerves and autonomic nervous system    | M | 193                      | 53         | 119                      | 111           | 90            | 129  | 79     | 73         | 141        |
|             |   | F | 68                       | 102        | 34                       | 82            | 163           | 93   | 95     | 84         | 168        |
| C48         | Malignant neoplasm of retroperitoneum and peritoneum                    | M | 69                       | 120        | 98                       | 102           | 50            | 141  | 134    | 92         | 72         |
|             |   | F | 199                      | 110        | 160                      | 89            | 48            | 96   | 98     | 81         | 78         |
| C49         | Malignant neoplasm of other connective and soft tissue                  | M | 112                      | 130        | 121                      | 109           | 76            | 72   | 82     | 80         | 134        |
|             |   | F | 110                      | 126        | 103                      | 105           | 104           | 72   | 79     | 87         | 126        |
| C50         | Malignant neoplasm of breast  | M | 131                      | 104        | 79                       | 81            | 85            | 72   | 143    | 95         | 121        |
|             |   | F | 98                       | 101        | 99                       | 102           | 104           | 99   | 89     | 100        | 108        |
| C51         | Malignant neoplasm of vulva   | F | 137                      | 89         | 119                      | 120           | 118           | 79   | 72     | 91         | 110        |
| C52         | Malignant neoplasm of vagina  | F | 98                       | 85         | 101                      | 172           | 100           | 57   | 128    | 87         | 97         |
| C53         | Malignant neoplasm of cervix uteri                                      | F | 109                      | 115        | 124                      | 115           | 102           | 77   | 83     | 88         | 107        |
| C54         | Malignant neoplasm of corpus uteri                                      | F | 87                       | 99         | 100                      | 104           | 100           | 103  | 97     | 96         | 110        |
| C55         | Malignant neoplasm of uterus,part unspecified                           | F | 95                       | 112        | 102                      | 111           | 130           | 162  | 63     | 84         | 50         |
| C56-C57     | Malignant neoplasm of ovary and other unspecified female genital organs | F | 101                      | 104        | 90                       | 111           | 99            | 100  | 81     | 97         | 120        |
| C56         | Malignant neoplasm of ovary   | F | 102                      | 104        | 91                       | 110           | 99            | 100  | 81     | 97         | 120        |
| C57         | Malignant neoplasm of other and unspecified female genital organs       | F | 71                       | 115        | 44                       | 164           | 113           | 72   | 83     | 98         | 132        |
| C58         | Malignant neoplasm of placenta  | F | 456                      | -          | -                        | 410           | -             | -    | 58     | 144        | 125        |
| C60         | Malignant neoplasm of penis   | M | 139                      | 101        | 99                       | 104           | 107           | 114  | 77     | 80         | 112        |
| C61         | Malignant neoplasm of prostate  | M | 92                       | 110        | 93                       | 101           | 107           | 102  | 90     | 93         | 108        |
| C62         | Malignant neoplasm of testis  | M | 97                       | 107        | 98                       | 108           | 96            | 103  | 64     | 124        | 115        |
| C63         | Malignant neoplasm of other and unspecified male genital organs         | M | 95                       | 122        | 130                      | 74            | 46            | 212  | 69     | 79         | 72         |
| C64         | Malignant neoplasm of kidney,except renal pelvis                        | M | 115                      | 96         | 102                      | 98            | 90            | 99   | 92     | 96         | 122        |
|             |   | F | 127                      | 94         | 108                      | 109           | 94            | 103  | 80     | 99         | 106        |
| C65         | Malignant neoplasm of renal pelvis                                      | M | 175                      | 121        | 173                      | 85            | 66            | 102  | 64     | 81         | 82         |
|             |   | F | 152                      | 108        | 132                      | 39            | 113           | 142  | 60     | 84         | 93         |
| C66         | Malignant neoplasm of ureter  | M | 156                      | 78         | 105                      | 108           | 71            | 91   | 131    | 72         | 136        |
|             |   | F | 96                       | 75         | 143                      | 60            | 72            | 158  | 46     | 113        | 126        |
| C67         | Malignant neoplasm of bladder   | M | 99                       | 118        | 111                      | 94            | 94            | 90   | 98     | 97         | 96         |
|             |   | F | 115                      | 116        | 119                      | 102           | 87            | 88   | 94     | 97         | 90         |
| C68         | Malignant neoplasm of other and unspecified urinary organs              | M | 32                       | 55         | 74                       | 167           | 99            | 78   | 66     | 64         | 259        |
|             |   | F | 84                       | 80         | 64                       | 177           | 143           | 76   | 94     | 64         | 148        |
| C69         | Malignant neoplasm of eye and adnexa                                    | M | 92                       | 113        | 84                       | 108           | 44            | 102  | 133    | 100        | 111        |
|             |   | F | 38                       | 175        | 83                       | 60            | 73            | 80   | 81     | 110        | 139        |

To link to Excel version of the table - click on the red box surrounding the table title

Table 6 Standardised registration ratios - continued

| ICD-10 code | Site description  |   | Government Office Region |            |                          |               |               |      |        |            |            |
|-------------|---|---|--------------------------|------------|--------------------------|---------------|---------------|------|--------|------------|------------|
|             |   |   | North East               | North West | Yorkshire and The Humber | East Midlands | West Midlands | East | London | South East | South West |
| C70         | Malignant neoplasm of meninges  | M | -                        | 93         | 125                      | -             | 118           | 219  | 48     | 75         | 172        |
|             |   | F | -                        | 67         | -                        | 53            | 43            | 121  | 145    | 81         | 325        |
| C71         | Malignant neoplasm of brain   | M | 117                      | 105        | 92                       | 106           | 88            | 102  | 91     | 95         | 117        |
|             |   | F | 109                      | 90         | 112                      | 103           | 102           | 91   | 95     | 100        | 107        |
| C72         | Malignant neoplasm of spinal cord, cranial nerves and other parts of central nervous system | M | 35                       | 119        | 53                       | 102           | 50            | 141  | 121    | 119        | 101        |
|             |   | F | 80                       | 74         | 99                       | 141           | 75            | 144  | 123    | 61         | 117        |
| C73         | Malignant neoplasm of thyroid gland   | M | 79                       | 101        | 101                      | 128           | 120           | 115  | 85     | 79         | 100        |
|             |   | F | 122                      | 96         | 101                      | 107           | 78            | 107  | 96     | 98         | 112        |
| C74         | Malignant neoplasm of adrenal gland   | M | 77                       | 133        | 141                      | 74            | 95            | 91   | 119    | 79         | 74         |
|             |   | F | 98                       | 154        | 73                       | 160           | 46            | 88   | 9      | 135        | 143        |
| C75         | Malignant neoplasm of other endocrine glands and related structures                         | M | 29                       | 119        | 130                      | 34            | 123           | 106  | 85     | 72         | 168        |
|             |   | F | 57                       | 172        | 58                       | 68            | 28            | 26   | 182    | 142        | 81         |
| C76         | Malignant neoplasm of other and ill-defined sites   | M | 29                       | 62         | 49                       | 66            | 36            | 122  | 196    | 157        | 98         |
|             |   | F | 81                       | 55         | 100                      | 75            | 64            | 95   | 137    | 131        | 134        |
| C77         | Secondary and unspecified malignant neoplasm of lymph nodes                                 | M | 155                      | 99         | 129                      | 133           | 98            | 78   | 76     | 84         | 96         |
|             |   | F | 79                       | 76         | 102                      | 148           | 97            | 113  | 62     | 110        | 116        |
| C78         | Secondary malignant neoplasm of respiratory and digestive organs                            | M | 120                      | 90         | 122                      | 139           | 80            | 91   | 78     | 99         | 105        |
|             |   | F | 130                      | 54         | 119                      | 160           | 89            | 93   | 81     | 103        | 109        |
| C79         | Secondary malignant neoplasm of other sites   | M | 97                       | 60         | 139                      | 162           | 82            | 94   | 92     | 109        | 83         |
|             |   | F | 109                      | 60         | 112                      | 149           | 87            | 108  | 84     | 113        | 97         |
| C80         | Malignant neoplasm without specification of site  | M | 130                      | 149        | 97                       | 71            | 129           | 89   | 110    | 76         | 66         |
|             |   | F | 125                      | 141        | 97                       | 70            | 122           | 95   | 100    | 86         | 72         |
| C81         | Hodgkin's disease   | M | 98                       | 90         | 98                       | 113           | 77            | 106  | 85     | 120        | 113        |
|             |   | F | 111                      | 111        | 122                      | 94            | 76            | 106  | 87     | 100        | 100        |
| C82-C85     | Non-Hodgkin's lymphoma  | M | 70                       | 91         | 91                       | 105           | 94            | 105  | 101    | 104        | 123        |
|             |   | F | 82                       | 95         | 92                       | 110           | 91            | 96   | 101    | 101        | 123        |
| C82         | Follicular (nodular) non-Hodgkin's lymphoma   | M | 72                       | 77         | 98                       | 121           | 102           | 102  | 90     | 112        | 116        |
|             |   | F | 75                       | 108        | 110                      | 97            | 75            | 98   | 91     | 98         | 134        |
| C83         | Diffuse non-Hodgkin's lymphoma  | M | 71                       | 83         | 101                      | 115           | 107           | 100  | 73     | 107        | 132        |
|             |   | F | 90                       | 86         | 104                      | 126           | 112           | 92   | 66     | 109        | 117        |
| C84         | Peripheral and cutaneous T-cell lymphomas   | M | 89                       | 73         | 120                      | 116           | 105           | 102  | 72     | 97         | 134        |
|             |   | F | 70                       | 44         | 118                      | 166           | 113           | 106  | 102    | 61         | 153        |
| C85         | Other and unspecified types of non-Hodgkin's lymphoma                                       | M | 64                       | 113        | 65                       | 79            | 68            | 114  | 157    | 96         | 109        |
|             |   | F | 79                       | 111        | 60                       | 86            | 64            | 99   | 156    | 100        | 120        |
| C88         | Malignant immunoproliferative diseases  | M | 17                       | 68         | 45                       | 61            | 160           | 70   | 115    | 140        | 152        |
|             |   | F | 29                       | 56         | 15                       | 107           | 158           | 94   | 68     | 145        | 169        |
| C90         | Multiple myeloma and malignant plasma cell neoplasms  | M | 74                       | 97         | 105                      | 95            | 90            | 93   | 112    | 95         | 126        |
|             |   | F | 91                       | 100        | 85                       | 107           | 95            | 99   | 91     | 94         | 136        |
| C91-C95     | All leukaemias  | M | 74                       | 89         | 118                      | 107           | 93            | 88   | 106    | 102        | 112        |
|             |   | F | 64                       | 91         | 107                      | 98            | 87            | 91   | 107    | 111        | 120        |
| C91         | Lymphoid leukaemia  | M | 66                       | 86         | 134                      | 107           | 94            | 80   | 99     | 106        | 115        |
|             |   | F | 47                       | 84         | 127                      | 100           | 87            | 78   | 99     | 118        | 127        |
| C92         | Myeloid leukaemia   | M | 90                       | 90         | 108                      | 109           | 93            | 97   | 110    | 94         | 110        |
|             |   | F | 80                       | 94         | 97                       | 98            | 80            | 107  | 111    | 105        | 111        |
| C93         | Monocytic leukaemia   | M | -                        | 55         | -                        | 83            | 137           | 64   | 126    | 223        | 98         |
|             |   | F | -                        | 25         | -                        | 40            | 356           | 31   | 28     | 228        | 92         |

Table 6 Series MBI no. 36

To link to Excel version of the table - click on the red box surrounding the table title

Table 6 Standardised registration ratios - *continued*

| ICD-10 code | Site description  |   | Government Office Region |            |                          |               |               |      |        |            |            |
|-------------|---|---|--------------------------|------------|--------------------------|---------------|---------------|------|--------|------------|------------|
|             |   |   | North East               | North West | Yorkshire and The Humber | East Midlands | West Midlands | East | London | South East | South West |
| C94         | Other leukaemias of specified cell type   | M | -                        | 102        | -                        | 104           | 213           | -    | 168    | 193        | -          |
|             |   | F | -                        | 46         | -                        | 73            | 58            | 110  | 152    | 75         | 331        |
| C95         | Leukaemia of unspecified cell type  | M | 31                       | 132        | 72                       | 91            | 60            | 110  | 143    | 95         | 116        |
|             |   | F | 75                       | 148        | 57                       | 90            | 99            | 42   | 167    | 72         | 129        |
| C96         | Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue          | M | -                        | 82         | -                        | 64            | 52            | 98   | 287    | 68         | 159        |
|             |   | F | 213                      | -          | 109                      | -             | -             | -    | 497    | 68         | -          |
| C97         | Malignant neoplasms of independent(primary) multiple sites  | M | -                        | -          | -                        | -             | -             | -    | -      | -          | 765        |
|             |   | F | -                        | -          | -                        | -             | -             | -    | -      | -          | -          |
| D00         | Carcinoma in situ of oral cavity, oesophagus and stomach  | M | 112                      | 106        | 90                       | 78            | 79            | 120  | 76     | 90         | 150        |
|             |   | F | 74                       | 100        | 58                       | 79            | 55            | 120  | 102    | 145        | 118        |
| D01         | Carcinoma in situ of other and unspecified digestive organs                                       | M | 45                       | 74         | 32                       | 22            | 128           | 150  | 79     | 84         | 243        |
|             |   | F | 32                       | 94         | 45                       | 25            | 141           | 138  | 65     | 75         | 241        |
| D02         | Carcinoma in situ of middle ear and respiratory system  | M | 60                       | 150        | 78                       | 135           | 101           | 95   | 52     | 66         | 151        |
|             |   | F | 95                       | 122        | 83                       | 117           | 110           | 59   | 118    | 81         | 119        |
| D03         | Melanoma in situ  | M | 89                       | 90         | 78                       | 126           | 63            | 104  | 43     | 124        | 173        |
|             |   | F | 85                       | 75         | 105                      | 115           | 68            | 111  | 51     | 111        | 181        |
| D04         | Carcinoma in situ of skin   | M | 83                       | 129        | 116                      | 146           | 86            | 102  | 42     | 80         | 120        |
|             |   | F | 108                      | 127        | 120                      | 129           | 89            | 108  | 38     | 73         | 127        |
| D05         | Carcinoma in situ of breast   | M | 175                      | 67         | -                        | 51            | 211           | 160  | 180    | 28         | 83         |
|             |   | F | 91                       | 78         | 100                      | 108           | 87            | 102  | 85     | 108        | 141        |
| D06         | Carcinoma in situ of cervix uteri   | F | 141                      | 100        | 94                       | 114           | 127           | 102  | 61     | 95         | 129        |
| D07         | Carcinoma in situ of other and unspecified genital organs   | M | 29                       | 77         | 145                      | 159           | 103           | 134  | 69     | 58         | 127        |
|             |   | F | 53                       | 123        | 96                       | 112           | 130           | 70   | 83     | 80         | 143        |
| D09         | Carcinoma in situ of other and unspecified sites  | M | 228                      | 143        | 157                      | 44            | 42            | 54   | 126    | 108        | 49         |
|             |   | F | 238                      | 165        | 164                      | 23            | 33            | 49   | 123    | 115        | 30         |
| D33         | Benign neoplasm of brain and other parts of central nervous system                                | M | 102                      | 123        | 51                       | 119           | 97            | 113  | 51     | 128        | 111        |
|             |   | F | 119                      | 72         | 62                       | 93            | 93            | 108  | 73     | 131        | 152        |
| D35.2       | Benign neoplasm of pituitary gland  | M | 68                       | 122        | 61                       | 104           | 69            | 109  | 76     | 98         | 173        |
|             |   | F | 36                       | 142        | 77                       | 77            | 102           | 80   | 85     | 95         | 165        |
| D35.3       | Benign neoplasm of craniopharyngeal duct  | M | -                        | -          | -                        | -             | -             | -    | -      | -          | -          |
|             |   | F | -                        | -          | -                        | -             | -             | -    | -      | -          | -          |
| D35.4       | Benign neoplasm of pineal gland   | M | -                        | -          | -                        | -             | -             | -    | -      | -          | -          |
|             |   | F | -                        | -          | -                        | -             | -             | -    | -      | -          | -          |
| D37         | Neoplasm of uncertain or unknown behaviour of oral cavity and digestive organs                    | M | 102                      | 254        | 64                       | 112           | 45            | 85   | 47     | 74         | 99         |
|             |   | F | 72                       | 205        | 70                       | 163           | 47            | 99   | 45     | 78         | 108        |
| D38         | Neoplasm of uncertain or unknown behaviour of middle ear and respiratory and intrathoracic organs | M | 49                       | 181        | 51                       | 101           | 83            | 77   | 32     | 23         | 290        |
|             |   | F | 37                       | 143        | 19                       | 136           | 92            | 86   | 17     | 105        | 221        |
| D39         | Neoplasm of uncertain or unknown behaviour of female genital organs                               | F | 47                       | 198        | 24                       | 125           | 66            | 25   | 117    | 101        | 142        |
| D40         | Neoplasm of uncertain or unknown behaviour of male genital organs                                 | M | 39                       | 232        | 58                       | 90            | 37            | 52   | 73     | 95         | 174        |

To link to Excel version of the table - click on the red box surrounding the table title

Table 6 Standardised registration ratios - *continued*

| ICD-10 code | Site description   |   | Government Office Region |            |                          |               |               |      |        |            |            |
|-------------|--|---|--------------------------|------------|--------------------------|---------------|---------------|------|--------|------------|------------|
|             |  |   | North East               | North West | Yorkshire and The Humber | East Midlands | West Midlands | East | London | South East | South West |
| D41         | Neoplasm of uncertain or unknown behaviour of urinary organs                                     | M | 1                        | 49         | 52                       | 175           | 169           | 168  | 2      | 81         | 179        |
|             |  | F | -                        | 61         | 59                       | 210           | 172           | 139  | 5      | 72         | 176        |
| D42         | Neoplasm of uncertain or unknown behaviour of meninges   | M | -                        | 92         | 82                       | 142           | 232           | 220  | -      | 51         | 77         |
|             |  | F | -                        | 121        | 66                       | 192           | 218           | 88   | -      | 100        | 91         |
| D43         | Neoplasm of uncertain or unknown behaviour of brain and central nervous system                   | M | 43                       | 213        | 51                       | 100           | 99            | 77   | 77     | 86         | 106        |
|             |  | F | 22                       | 147        | 37                       | 52            | 129           | 102  | 79     | 137        | 112        |
| D44         | Neoplasm of uncertain or unknown behaviour of endocrine glands                                   | M | 45                       | 229        | 45                       | 66            | 75            | 82   | 68     | 63         | 184        |
|             |  | F | 104                      | 178        | 44                       | 94            | 34            | 104  | 38     | 147        | 126        |
| D45         | Polycythaemia vera   | M | 13                       | 146        | 25                       | 33            | 21            | 37   | 74     | 122        | 346        |
|             |  | F | 29                       | 122        | 33                       | 46            | 41            | 63   | 70     | 133        | 282        |
| D46         | Myelodysplastic syndromes  | M | 63                       | 85         | 85                       | 98            | 86            | 75   | 95     | 102        | 184        |
|             |  | F | 88                       | 105        | 85                       | 91            | 62            | 86   | 85     | 100        | 178        |
| D47         | Other neoplasms of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue | M | 47                       | 61         | 173                      | 56            | 90            | 76   | 112    | 122        | 129        |
|             |  | F | 59                       | 57         | 162                      | 59            | 72            | 69   | 118    | 122        | 152        |
| D48         | Neoplasm of uncertain or unknown behaviour of other and unspecified sites                        | M | 26                       | 225        | 61                       | 119           | 35            | 59   | 48     | 99         | 175        |
|             |  | F | 48                       | 208        | 38                       | 140           | 81            | 53   | 58     | 61         | 197        |
| O01         | Hydatidiform mole  | F | 325                      | 140        | 83                       | 206           | -             | -    | 96     | 63         | 142        |

Table 9 Series MB1 no. 36

To link to Excel version of the table - click on the red box surrounding the table title

**Table 9 Cancer mortality to incidence ratios:<sup>1</sup> site, sex and Government Office Region of residence, 2005** **England, Government Office Regions Registered by October 2007**

| ICD-10 code      | Site description  |   | Government Office Region |             |             |                          |               |               |             |             |             |             |
|------------------|---|---|--------------------------|-------------|-------------|--------------------------|---------------|---------------|-------------|-------------|-------------|-------------|
|                  |   |   | England                  | North East  | North West  | Yorkshire and The Humber | East Midlands | West Midlands | East        | London      | South East  | South West  |
| C00-C97          | All cancers   | M | <b>0.43</b>              | <b>0.45</b> | <b>0.43</b> | <b>0.42</b>              | <b>0.38</b>   | <b>0.43</b>   | <b>0.44</b> | <b>0.52</b> | <b>0.46</b> | <b>0.35</b> |
|                  |   | F | <b>0.41</b>              | <b>0.43</b> | <b>0.41</b> | <b>0.40</b>              | <b>0.37</b>   | <b>0.41</b>   | <b>0.43</b> | <b>0.49</b> | <b>0.43</b> | <b>0.34</b> |
| C00-C97 excl.C44 | All cancers excluding nmsc <sup>2</sup>   | M | <b>0.55</b>              | <b>0.60</b> | <b>0.55</b> | <b>0.56</b>              | <b>0.53</b>   | <b>0.56</b>   | <b>0.54</b> | <b>0.55</b> | <b>0.56</b> | <b>0.51</b> |
|                  |   | F | <b>0.51</b>              | <b>0.55</b> | <b>0.52</b> | <b>0.52</b>              | <b>0.48</b>   | <b>0.51</b>   | <b>0.50</b> | <b>0.51</b> | <b>0.51</b> | <b>0.47</b> |
| C00-C14          | Malignant neoplasm of lip, mouth and pharynx  | M | <b>0.36</b>              | 0.47        | 0.47        | 0.29                     | 0.29          | 0.32          | 0.37        | 0.33        | 0.36        | 0.31        |
|                  |   | F | <b>0.34</b>              | 0.33        | 0.38        | 0.45                     | 0.27          | 0.35          | 0.26        | 0.36        | 0.36        | 0.28        |
| C00              | Malignant neoplasm of lip   | M | <b>0.05</b>              | 0.00        | 0.14        | 0.00                     | 0.00          | 0.00          | 0.00        | 0.09        | 0.13        | 0.06        |
|                  |   | F | <b>0.07</b>              | 0.10        | 0.08        | 0.14                     | 0.10          | 0.00          | 0.00        | 0.00        | 0.15        | 0.00        |
| C01              | Malignant neoplasm of base of tongue  | M | <b>0.10</b>              | 0.25        | 0.12        | 0.00                     | 0.15          | 0.03          | 0.09        | 0.19        | 0.11        | 0.06        |
|                  |   | F | <b>0.11</b>              | 0.00        | 0.07        | 0.00                     | 0.14          | 0.10          | 0.08        | 0.13        | 0.33        | 0.07        |
| C02              | Malignant neoplasm of other and unspecified parts of tongue                           | M | <b>0.42</b>              | 0.37        | 0.37        | 0.28                     | 0.35          | 0.45          | 0.47        | 0.32        | 0.70        | 0.39        |
|                  |   | F | <b>0.42</b>              | 0.44        | 0.46        | 0.53                     | 0.41          | 0.39          | 0.28        | 0.42        | 0.43        | 0.44        |
| C03              | Malignant neoplasm of gum   | M | <b>0.27</b>              | 0.33        | 0.44        | 0.14                     | 0.20          | 0.33          | 0.73        | 0.08        | 0.11        | 0.38        |
|                  |   | F | <b>0.21</b>              | 0.00        | 0.18        | 0.71                     | 0.30          | 0.18          | 0.17        | 0.38        | 0.11        | 0.00        |
| C04              | Malignant neoplasm of floor of mouth  | M | <b>0.20</b>              | 0.19        | 0.27        | 0.04                     | 0.29          | 0.20          | 0.29        | 0.26        | 0.16        | 0.05        |
|                  |   | F | <b>0.25</b>              | 0.00        | 0.26        | 0.20                     | 0.33          | 0.45          | 0.13        | 0.26        | 0.17        | 0.33        |
| C05              | Malignant neoplasm of palate  | M | <b>0.20</b>              | 0.00        | 0.35        | 0.27                     | 0.07          | 0.13          | 0.15        | 0.09        | 0.30        | 0.40        |
|                  |   | F | <b>0.17</b>              | 0.29        | 0.32        | 0.00                     | 0.13          | 0.25          | 0.18        | 0.11        | 0.24        | 0.06        |
| C06              | Malignant neoplasm of other and unspecified parts of mouth                            | M | <b>0.58</b>              | 1.13        | 0.81        | 1.00                     | 0.20          | 0.27          | 0.92        | 0.56        | 0.32        | 0.52        |
|                  |   | F | <b>0.50</b>              | 0.88        | 0.36        | 0.87                     | 0.25          | 0.38          | 0.75        | 0.70        | 0.32        | 0.50        |
| C07              | Malignant neoplasm of parotid gland   | M | <b>0.37</b>              | 0.50        | 0.50        | 0.31                     | 0.22          | 0.37          | 0.53        | 0.42        | 0.31        | 0.27        |
|                  |   | F | <b>0.28</b>              | 0.08        | 0.40        | 0.20                     | 0.14          | 0.38          | 0.07        | 0.45        | 0.47        | 0.32        |
| C08              | Malignant neoplasm of other and unspecified major salivary glands                     | M | <b>0.34</b>              | 0.50        | 0.63        | 0.00                     | 0.50          | 0.25          | 0.25        | 0.33        | 0.33        | 0.14        |
|                  |   | F | <b>0.27</b>              | 0.00        | 0.22        | 0.67                     | 0.00          | 0.00          | 0.00        | 0.43        | 0.44        | 0.33        |
| C09              | Malignant neoplasm of tonsil  | M | <b>0.26</b>              | 0.29        | 0.48        | 0.24                     | 0.23          | 0.10          | 0.27        | 0.19        | 0.33        | 0.23        |
|                  |   | F | <b>0.27</b>              | 0.09        | 0.30        | 0.40                     | 0.11          | 0.46          | 0.44        | 0.24        | 0.16        | 0.44        |
| C10              | Malignant neoplasm of oropharynx  | M | <b>0.69</b>              | 7.00        | 0.73        | 0.80                     | 0.63          | 0.56          | 0.63        | 0.75        | 0.44        | 0.36        |
|                  |   | F | <b>0.94</b>              | 0.33        | 1.13        | 1.00                     | 1.00          | 1.00          | 1.00        | 1.20        | 1.00        | 0.33        |
| C11              | Malignant neoplasm of nasopharynx   | M | <b>0.39</b>              | 0.45        | 0.32        | 0.27                     | 0.27          | 0.73          | 0.47        | 0.52        | 0.32        | 0.25        |
|                  |   | F | <b>0.47</b>              | 0.33        | 1.00        | 1.33                     | 0.17          | 0.33          | 0.25        | 0.25        | 0.64        | 0.27        |
| C12              | Malignant neoplasm of pyriform sinus  | M | <b>0.29</b>              | 0.33        | 0.37        | 0.40                     | 0.24          | 0.26          | 0.21        | 0.16        | 0.33        | 0.31        |
|                  |   | F | <b>0.16</b>              | 1.00        | 0.33        | 0.00                     | 0.00          | 0.50          | 0.11        | 0.00        | 0.25        | 0.00        |
| C13              | Malignant neoplasm of hypopharynx   | M | <b>0.60</b>              | 0.57        | 0.81        | 0.46                     | 1.17          | 0.56          | 0.75        | 1.00        | 0.33        | 0.18        |
|                  |   | F | <b>0.65</b>              | 3.00        | 0.40        | 1.00                     | 1.00          | 0.25          | 0.38        | 0.60        | 0.40        | 0.60        |
| C14              | Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynx | M | <b>1.06</b>              | 1.36        | 1.27        | 0.53                     | 0.73          | 1.89          | 1.00        | 0.83        | 1.05        | 1.31        |
|                  |   | F | <b>0.54</b>              | 0.40        | 0.71        | 0.29                     | 0.38          | 0.80          | 0.80        | 0.30        | 0.92        | 0.13        |
| C15              | Malignant neoplasm of oesophagus  | M | <b>0.96</b>              | 1.11        | 1.00        | 0.99                     | 0.89          | 1.03          | 1.10        | 0.89        | 0.89        | 0.89        |
|                  |   | F | <b>0.91</b>              | 1.09        | 0.82        | 1.01                     | 0.88          | 1.01          | 0.84        | 0.95        | 0.99        | 0.80        |
| C16              | Malignant neoplasm of stomach   | M | <b>0.68</b>              | 0.61        | 0.65        | 0.71                     | 0.63          | 0.72          | 0.61        | 0.68        | 0.74        | 0.73        |
|                  |   | F | <b>0.76</b>              | 0.88        | 0.73        | 0.80                     | 0.74          | 0.75          | 0.69        | 0.66        | 0.83        | 0.83        |
| C17              | Malignant neoplasm of small intestine   | M | <b>0.37</b>              | 0.64        | 0.48        | 0.38                     | 0.22          | 0.32          | 0.30        | 0.34        | 0.50        | 0.29        |
|                  |   | F | <b>0.34</b>              | 0.55        | 0.38        | 0.30                     | 0.33          | 0.54          | 0.12        | 0.43        | 0.30        | 0.32        |
| C18-C20          | Malignant neoplasm of colon and rectum  | M | <b>0.43</b>              | 0.46        | 0.44        | 0.44                     | 0.39          | 0.43          | 0.40        | 0.41        | 0.45        | 0.42        |
|                  |   | F | <b>0.45</b>              | 0.43        | 0.47        | 0.44                     | 0.43          | 0.46          | 0.43        | 0.48        | 0.47        | 0.45        |

1. See section 4.3.

2. These figures exclude non-melanoma skin cancer (ICD-10 C44) - see section 4.2.

To link to Excel version of the table - click on the red box surrounding the table title

Table 9 Cancer mortality to incidence ratios - continued

| ICD-10 code | Site description   |   | Government Office Region |            |            |                          |               |               |      |        |            |            |
|-------------|--|---|--------------------------|------------|------------|--------------------------|---------------|---------------|------|--------|------------|------------|
|             |  |   | England                  | North East | North West | Yorkshire and The Humber | East Midlands | West Midlands | East | London | South East | South West |
| C18         | Malignant neoplasm of colon  | M | <b>0.44</b>              | 0.36       | 0.49       | 0.44                     | 0.40          | 0.45          | 0.40 | 0.44   | 0.47       | 0.45       |
|             |  | F | <b>0.47</b>              | 0.42       | 0.48       | 0.44                     | 0.46          | 0.46          | 0.44 | 0.48   | 0.49       | 0.47       |
| C19         | Malignant neoplasm of rectosigmoid junction  | M | <b>0.42</b>              | 0.86       | 0.27       | 0.45                     | 0.36          | 0.41          | 0.36 | 0.47   | 0.47       | 0.32       |
|             |  | F | <b>0.40</b>              | 0.63       | 0.33       | 0.27                     | 0.27          | 0.37          | 0.43 | 0.55   | 0.45       | 0.39       |
| C20         | Malignant neoplasm of rectum   | M | <b>0.40</b>              | 0.56       | 0.40       | 0.44                     | 0.36          | 0.39          | 0.40 | 0.33   | 0.41       | 0.37       |
|             |  | F | <b>0.43</b>              | 0.39       | 0.48       | 0.46                     | 0.40          | 0.47          | 0.38 | 0.45   | 0.44       | 0.40       |
| C21         | Malignant neoplasm of anus and anal canal  | M | <b>0.35</b>              | 0.19       | 0.41       | 0.37                     | 0.46          | 0.32          | 0.39 | 0.34   | 0.33       | 0.39       |
|             |  | F | <b>0.33</b>              | 0.26       | 0.32       | 0.24                     | 0.25          | 0.44          | 0.31 | 0.30   | 0.42       | 0.33       |
| C22         | Malignant neoplasm of liver and intrahepatic bile ducts  | M | <b>0.86</b>              | 0.90       | 0.71       | 0.92                     | 0.74          | 0.92          | 0.96 | 0.89   | 0.92       | 0.90       |
|             |  | F | <b>0.94</b>              | 1.02       | 0.65       | 0.95                     | 0.98          | 1.06          | 1.30 | 1.08   | 1.08       | 0.86       |
| C23         | Malignant neoplasm of gallbladder  | M | <b>0.65</b>              | 0.54       | 1.06       | 0.67                     | 0.56          | 0.82          | 0.57 | 0.59   | 0.50       | 0.62       |
|             |  | F | <b>0.72</b>              | 0.67       | 0.65       | 0.81                     | 0.67          | 0.84          | 0.54 | 0.76   | 0.74       | 0.75       |
| C24         | Malignant neoplasm of other and unspecified parts of biliary tract                                   | M | <b>0.21</b>              | 0.75       | 0.23       | 0.23                     | 0.14          | 0.20          | 0.18 | 0.06   | 0.27       | 0.21       |
|             |  | F | <b>0.30</b>              | 0.29       | 0.29       | 0.43                     | 0.31          | 0.30          | 0.29 | 0.17   | 0.34       | 0.37       |
| C25         | Malignant neoplasm of pancreas   | M | <b>0.93</b>              | 0.88       | 0.95       | 0.96                     | 0.87          | 0.98          | 0.90 | 0.86   | 0.92       | 0.99       |
|             |  | F | <b>0.97</b>              | 1.04       | 1.00       | 1.04                     | 0.88          | 0.95          | 1.03 | 0.90   | 0.97       | 0.96       |
| C26         | Malignant neoplasm of other and ill-defined digestive organs   | M | <b>3.98</b>              | 94.00      | 3.86       | 11.30                    | 3.41          | 5.40          | 3.24 | 2.78   | 3.83       | 1.96       |
|             |  | F | <b>3.58</b>              | 26.00      | 3.72       | 9.46                     | 3.35          | 3.38          | 4.25 | 2.64   | 2.90       | 2.29       |
| C30         | Malignant neoplasm of nasal cavity and middle ear  | M | <b>0.14</b>              | 0.08       | 0.09       | 0.38                     | 0.00          | 0.00          | 0.00 | 0.20   | 0.31       | 0.14       |
|             |  | F | <b>0.16</b>              | 0.00       | 0.31       | 0.22                     | 0.00          | 0.50          | 0.33 | 0.10   | 0.06       | 0.13       |
| C31         | Malignant neoplasm of accessory sinuses  | M | <b>0.60</b>              | 0.33       | 0.33       | 0.57                     | 3.00          | 0.44          | 0.33 | 0.56   | 1.63       | 0.08       |
|             |  | F | <b>0.67</b>              | 0.00       | 0.67       | 0.80                     | 0.60          | 0.67          | 1.50 | 0.40   | 2.00       | 0.40       |
| C32         | Malignant neoplasm of larynx   | M | <b>0.34</b>              | 0.33       | 0.38       | 0.27                     | 0.21          | 0.56          | 0.37 | 0.34   | 0.29       | 0.28       |
|             |  | F | <b>0.42</b>              | 0.38       | 0.30       | 0.52                     | 0.36          | 0.67          | 0.65 | 0.32   | 0.41       | 0.45       |
| C33-C34     | Malignant neoplasm of trachea, bronchus and lung   | M | <b>0.87</b>              | 0.88       | 0.87       | 0.87                     | 0.84          | 0.90          | 0.88 | 0.86   | 0.89       | 0.86       |
|             |  | F | <b>0.86</b>              | 0.90       | 0.83       | 0.88                     | 0.79          | 0.84          | 0.86 | 0.87   | 0.90       | 0.86       |
| C33         | Malignant neoplasm of trachea  | M | <b>0.65</b>              | 1.00       | 0.60       | 0.00                     | 0.00          | 0.67          | 1.00 | 1.00   | 1.00       | 0.00       |
|             |  | F | <b>0.61</b>              | 1.00       | 0.29       | 1.33                     | 1.00          | 0.67          | 1.00 | 0.00   | 0.50       | 0.50       |
| C34         | Malignant neoplasm of bronchus and lung  | M | <b>0.87</b>              | 0.88       | 0.87       | 0.87                     | 0.84          | 0.90          | 0.88 | 0.86   | 0.89       | 0.86       |
|             |  | F | <b>0.86</b>              | 0.90       | 0.84       | 0.88                     | 0.79          | 0.84          | 0.86 | 0.87   | 0.90       | 0.86       |
| C37         | Malignant neoplasm of thymus   | M | <b>0.42</b>              | 0.00       | 0.23       | 0.33                     | 0.00          | 1.00          | 2.33 | 0.29   | 0.57       | 0.25       |
|             |  | F | <b>0.31</b>              | 0.00       | 0.25       | 0.00                     | 0.50          | 0.50          | 1.00 | 0.17   | 0.40       | 0.25       |
| C38         | Malignant neoplasm of heart, mediastinum and pleura  | M | <b>0.46</b>              | 0.71       | 0.29       | 0.42                     | 0.28          | 0.80          | 0.90 | 0.63   | 0.27       | 0.44       |
|             |  | F | <b>0.35</b>              | 0.67       | 0.23       | 0.40                     | 1.33          | 0.33          | 2.00 | 0.14   | 0.27       | 0.18       |
| C39         | Malignant neoplasm of other and ill-defined sites in the respiratory system and intrathoracic organs | M | <b>3.25</b>              | 0.00       | 0.00       | 0.00                     | 0.00          | 0.00          | 0.00 | 0.00   | 0.00       | 0.33       |
|             |  | F | <b>3.50</b>              | 0.00       | 0.00       | 0.00                     | 0.00          | 0.00          | 0.00 | 0.00   | 0.00       | 0.00       |
| C40         | Malignant neoplasm of bone and articular cartilage of limbs  | M | <b>0.16</b>              | 0.14       | 0.13       | 0.10                     | 0.14          | 0.14          | 0.23 | 0.13   | 0.14       | 0.27       |
|             |  | F | <b>0.17</b>              | 1.50       | 0.27       | 0.13                     | 0.00          | 0.17          | 0.38 | 0.22   | 0.06       | 0.00       |
| C41         | Malignant neoplasm of bone and articular cartilage of other and unspecified sites                    | M | <b>0.86</b>              | 1.00       | 0.47       | 0.47                     | 1.56          | 3.00          | 0.53 | 1.47   | 0.74       | 0.89       |
|             |  | F | <b>1.16</b>              | 2.00       | 0.63       | 1.13                     | 2.50          | 2.00          | 1.50 | 1.63   | 1.08       | 0.89       |
| C43         | Malignant melanoma of skin   | M | <b>0.22</b>              | 0.27       | 0.18       | 0.18                     | 0.22          | 0.23          | 0.25 | 0.39   | 0.19       | 0.20       |
|             |  | F | <b>0.17</b>              | 0.10       | 0.16       | 0.15                     | 0.16          | 0.17          | 0.18 | 0.20   | 0.18       | 0.16       |
| C44         | Other malignant neoplasms of skin  | M | <b>0.01</b>              | 0.00       | 0.01       | 0.00                     | 0.01          | 0.01          | 0.01 | 0.04   | 0.01       | 0.00       |
|             |  | F | <b>0.01</b>              | 0.00       | 0.01       | 0.00                     | 0.00          | 0.01          | 0.01 | 0.03   | 0.01       | 0.01       |

Table 9 Series MB1 no. 36

To link to Excel version of the table - click on the red box surrounding the table title

Table 9 Cancer mortality to incidence ratios - continued

| ICD-10 code | Site description  |   | England     | Government Office Region |            |                          |               |               |      |        |            |            |
|-------------|---|---|-------------|--------------------------|------------|--------------------------|---------------|---------------|------|--------|------------|------------|
|             |   |   |             | North East               | North West | Yorkshire and The Humber | East Midlands | West Midlands | East | London | South East | South West |
| C45         | Mesothelioma  | M | <b>0.90</b> | 1.15                     | 0.79       | 0.76                     | 0.80          | 0.82          | 0.96 | 1.00   | 0.94       | 0.94       |
|             |   | F | <b>0.82</b> | 0.73                     | 0.80       | 0.70                     | 1.16          | 0.74          | 0.71 | 0.79   | 0.84       | 0.97       |
| C46         | Kaposi's sarcoma  | M | <b>0.05</b> | 0.00                     | 0.08       | 0.00                     | 0.00          | 0.00          | 0.13 | 0.06   | 0.00       | 0.00       |
|             |   | F | <b>0.24</b> | 0.50                     | 0.00       | 0.00                     | 0.50          | 0.00          | 0.00 | 0.00   | 0.00       | 1.00       |
| C47         | Malignant neoplasm of peripheral nerves and autonomic nervous system    | M | <b>0.40</b> | 0.00                     | 0.33       | 0.40                     | 0.75          | 0.50          | 0.00 | 0.80   | 0.60       | 0.33       |
|             |   | F | <b>0.31</b> | 0.00                     | 0.25       | 1.00                     | 0.50          | 0.20          | 1.00 | 0.00   | 0.25       | 0.20       |
| C48         | Malignant neoplasm of retroperitoneum and peritoneum                    | M | <b>0.32</b> | 1.00                     | 0.22       | 0.18                     | 0.20          | 1.00          | 0.33 | 0.11   | 0.29       | 0.44       |
|             |   | F | <b>0.52</b> | 0.41                     | 0.40       | 0.61                     | 0.52          | 0.67          | 0.47 | 0.48   | 0.51       | 0.71       |
| C49         | Malignant neoplasm of other connective and soft tissue                  | M | <b>0.50</b> | 0.54                     | 0.36       | 0.40                     | 0.47          | 0.58          | 0.92 | 0.69   | 0.57       | 0.29       |
|             |   | F | <b>0.55</b> | 0.48                     | 0.34       | 0.49                     | 0.52          | 0.57          | 0.85 | 0.84   | 0.62       | 0.39       |
| C50         | Malignant neoplasm of breast  | M | <b>0.31</b> | 0.18                     | 0.17       | 0.25                     | 0.56          | 0.52          | 0.38 | 0.27   | 0.40       | 0.17       |
|             |   | F | <b>0.27</b> | 0.28                     | 0.26       | 0.25                     | 0.28          | 0.26          | 0.28 | 0.29   | 0.28       | 0.26       |
| C51         | Malignant neoplasm of vulva   | F | <b>0.32</b> | 0.23                     | 0.34       | 0.25                     | 0.31          | 0.33          | 0.30 | 0.42   | 0.40       | 0.23       |
| C52         | Malignant neoplasm of vagina  | F | <b>0.39</b> | 0.36                     | 0.60       | 0.41                     | 0.13          | 0.52          | 0.43 | 0.18   | 0.50       | 0.50       |
| C53         | Malignant neoplasm of cervix uteri                                      | F | <b>0.37</b> | 0.42                     | 0.41       | 0.34                     | 0.28          | 0.38          | 0.39 | 0.38   | 0.40       | 0.33       |
| C54         | Malignant neoplasm of corpus uteri                                      | F | <b>0.18</b> | 0.21                     | 0.17       | 0.17                     | 0.18          | 0.19          | 0.16 | 0.20   | 0.20       | 0.13       |
| C55         | Malignant neoplasm of uterus, part unspecified                          | F | <b>1.42</b> | 1.00                     | 1.21       | 1.59                     | 1.19          | 1.05          | 1.08 | 2.43   | 1.55       | 2.81       |
| C56-C57     | Malignant neoplasm of ovary and other unspecified female genital organs | F | <b>0.66</b> | 0.61                     | 0.65       | 0.70                     | 0.57          | 0.72          | 0.71 | 0.64   | 0.72       | 0.59       |
| C56         | Malignant neoplasm of ovary   | F | <b>0.66</b> | 0.60                     | 0.65       | 0.69                     | 0.59          | 0.71          | 0.70 | 0.64   | 0.72       | 0.60       |
| C57         | Malignant neoplasm of other and unspecified female genital organs       | F | <b>0.62</b> | 1.00                     | 0.62       | 1.50                     | 0.21          | 0.94          | 0.91 | 0.62   | 0.64       | 0.20       |
| C58         | Malignant neoplasm of placenta  | F | <b>0.33</b> | 0.00                     | 0.00       | 0.00                     | 0.00          | 0.00          | 0.00 | 1.00   | 0.00       | 1.00       |
| C60         | Malignant neoplasm of penis   | M | <b>0.22</b> | 0.29                     | 0.30       | 0.15                     | 0.11          | 0.13          | 0.31 | 0.28   | 0.19       | 0.20       |
| C61         | Malignant neoplasm of prostate  | M | <b>0.29</b> | 0.28                     | 0.26       | 0.29                     | 0.29          | 0.27          | 0.30 | 0.33   | 0.33       | 0.31       |
| C62         | Malignant neoplasm of testis  | M | <b>0.04</b> | 0.04                     | 0.06       | 0.06                     | 0.01          | 0.03          | 0.03 | 0.02   | 0.03       | 0.03       |
| C63         | Malignant neoplasm of other and unspecified male genital organs         | M | <b>0.20</b> | 0.00                     | 0.10       | 0.13                     | 0.00          | 0.00          | 0.33 | 0.40   | 0.00       | 0.60       |
|             |   | F | <b>0.53</b> | 0.52                     | 0.57       | 0.56                     | 0.50          | 0.62          | 0.51 | 0.46   | 0.63       | 0.42       |
| C64         | Malignant neoplasm of kidney, except renal pelvis                       | M | <b>0.53</b> | 0.52                     | 0.57       | 0.56                     | 0.50          | 0.62          | 0.51 | 0.46   | 0.63       | 0.42       |
|             |   | F | <b>0.52</b> | 0.48                     | 0.55       | 0.54                     | 0.55          | 0.57          | 0.53 | 0.46   | 0.56       | 0.44       |
| C65         | Malignant neoplasm of renal pelvis                                      | M | <b>0.06</b> | 0.00                     | 0.10       | 0.09                     | 0.05          | 0.00          | 0.07 | 0.06   | 0.06       | 0.00       |
|             |   | F | <b>0.11</b> | 0.00                     | 0.00       | 0.05                     | 0.00          | 0.22          | 0.13 | 0.30   | 0.24       | 0.06       |
| C66         | Malignant neoplasm of ureter  | M | <b>0.29</b> | 0.12                     | 0.41       | 0.36                     | 0.25          | 0.81          | 0.27 | 0.17   | 0.40       | 0.06       |
|             |   | F | <b>0.30</b> | 0.67                     | 0.25       | 0.47                     | 0.33          | 0.44          | 0.19 | 0.00   | 0.32       | 0.18       |
| C67         | Malignant neoplasm of bladder   | M | <b>0.42</b> | 0.47                     | 0.37       | 0.42                     | 0.48          | 0.47          | 0.45 | 0.44   | 0.39       | 0.41       |
|             |   | F | <b>0.55</b> | 0.47                     | 0.54       | 0.54                     | 0.60          | 0.61          | 0.58 | 0.49   | 0.54       | 0.59       |
| C68         | Malignant neoplasm of other and unspecified urinary organs              | M | <b>0.34</b> | 0.50                     | 0.56       | 0.44                     | 0.33          | 0.08          | 0.45 | 0.56   | 0.77       | 0.11       |
|             |   | F | <b>0.67</b> | 1.00                     | 1.40       | 1.67                     | 0.57          | 0.43          | 0.00 | 0.80   | 1.00       | 0.13       |

To link to Excel version of the table - click on the red box surrounding the table title

Table 9 Cancer mortality to incidence ratios - *continued*

| ICD-10 code | Site description  |   | England     | Government Office Region |            |                          |               |               |      |        |            |            |
|-------------|---|---|-------------|--------------------------|------------|--------------------------|---------------|---------------|------|--------|------------|------------|
|             |   |   |             | North East               | North West | Yorkshire and The Humber | East Midlands | West Midlands | East | London | South East | South West |
| C69         | Malignant neoplasm of eye and adnexa  | M | <b>0.18</b> | 0.22                     | 0.24       | 0.06                     | 0.11          | 0.44          | 0.18 | 0.13   | 0.13       | 0.22       |
|             |   | F | <b>0.25</b> | 0.33                     | 0.14       | 0.46                     | 0.13          | 0.33          | 0.50 | 0.24   | 0.14       | 0.26       |
| C70         | Malignant neoplasm of meninges  | M | <b>0.44</b> | 0.00                     | 0.00       | 0.00                     | 0.00          | 0.50          | 0.50 | 1.00   | 1.00       | 0.00       |
|             |   | F | <b>0.41</b> | 0.00                     | 0.50       | 0.00                     | 0.00          | 2.00          | 0.00 | 0.25   | 0.00       | 0.25       |
| C71         | Malignant neoplasm of brain   | M | <b>0.76</b> | 0.65                     | 0.68       | 0.84                     | 0.77          | 0.83          | 0.73 | 0.77   | 0.79       | 0.75       |
|             |   | F | <b>0.74</b> | 0.71                     | 0.69       | 0.68                     | 0.72          | 0.68          | 0.75 | 0.73   | 0.84       | 0.81       |
| C72         | Malignant neoplasm of spinal cord, cranial nerves and other parts of central nervous system | M | <b>0.07</b> | 0.00                     | 0.00       | 0.33                     | 0.00          | 0.00          | 0.11 | 0.11   | 0.09       | 0.00       |
|             |   | F | <b>0.16</b> | 0.00                     | 0.00       | 0.00                     | 0.33          | 0.50          | 0.00 | 0.11   | 0.40       | 0.17       |
| C73         | Malignant neoplasm of thyroid gland   | M | <b>0.24</b> | 0.27                     | 0.24       | 0.24                     | 0.26          | 0.21          | 0.24 | 0.16   | 0.31       | 0.28       |
|             |   | F | <b>0.18</b> | 0.19                     | 0.15       | 0.18                     | 0.22          | 0.13          | 0.21 | 0.18   | 0.19       | 0.14       |
| C74         | Malignant neoplasm of adrenal gland   | M | <b>0.64</b> | 1.33                     | 0.57       | 0.55                     | 1.20          | 0.38          | 0.38 | 0.46   | 0.90       | 0.83       |
|             |   | F | <b>0.49</b> | 1.00                     | 0.47       | 0.67                     | 0.18          | 0.75          | 0.50 | 2.00   | 0.50       | 0.33       |
| C75         | Malignant neoplasm of other endocrine glands and related structures                         | M | <b>0.40</b> | 0.00                     | 0.73       | 0.11                     | 1.50          | 0.44          | 0.38 | 0.25   | 0.38       | 0.25       |
|             |   | F | <b>0.76</b> | 1.00                     | 1.13       | 2.00                     | 1.00          | 1.00          | 2.00 | 0.25   | 0.25       | 1.00       |
| C76         | Malignant neoplasm of other and ill-defined sites   | M | <b>0.79</b> | 1.33                     | 1.47       | 1.40                     | 1.08          | 2.88          | 0.55 | 0.22   | 0.63       | 0.96       |
|             |   | F | <b>0.99</b> | 1.18                     | 2.10       | 1.19                     | 1.71          | 1.39          | 0.76 | 0.45   | 0.72       | 0.95       |
| C77         | Secondary and unspecified malignant neoplasm of lymph nodes                                 | M | <b>0.02</b> | 0.00                     | 0.02       | 0.02                     | 0.03          | 0.00          | 0.03 | 0.00   | 0.02       | 0.00       |
|             |   | F | <b>0.01</b> | 0.00                     | 0.00       | 0.00                     | 0.00          | 0.00          | 0.03 | 0.00   | 0.02       | 0.00       |
| C78         | Secondary malignant neoplasm of respiratory and digestive organs                            | M | <b>0.15</b> | 0.19                     | 0.28       | 0.15                     | 0.09          | 0.21          | 0.09 | 0.18   | 0.12       | 0.09       |
|             |   | F | <b>0.14</b> | 0.17                     | 0.32       | 0.12                     | 0.06          | 0.17          | 0.16 | 0.16   | 0.14       | 0.09       |
| C79         | Secondary malignant neoplasm of other sites   | M | <b>0.17</b> | 0.20                     | 0.27       | 0.13                     | 0.18          | 0.10          | 0.17 | 0.19   | 0.13       | 0.21       |
|             |   | F | <b>0.15</b> | 0.21                     | 0.32       | 0.21                     | 0.09          | 0.11          | 0.20 | 0.14   | 0.11       | 0.10       |
| C80         | Malignant neoplasm without specification of site  | M | <b>2.30</b> | 1.98                     | 1.82       | 2.64                     | 3.60          | 1.74          | 2.09 | 1.95   | 2.95       | 3.05       |
|             |   | F | <b>2.21</b> | 2.06                     | 1.89       | 2.38                     | 3.38          | 1.80          | 2.04 | 2.04   | 2.36       | 2.80       |
| C81         | Hodgkin's disease   | M | <b>0.18</b> | 0.22                     | 0.18       | 0.26                     | 0.14          | 0.13          | 0.27 | 0.14   | 0.17       | 0.13       |
|             |   | F | <b>0.17</b> | 0.13                     | 0.20       | 0.17                     | 0.16          | 0.24          | 0.06 | 0.16   | 0.19       | 0.25       |
| C82-C85     | Non-Hodgkin's lymphoma  | M | <b>0.43</b> | 0.51                     | 0.45       | 0.48                     | 0.38          | 0.45          | 0.43 | 0.44   | 0.43       | 0.39       |
|             |   | F | <b>0.45</b> | 0.54                     | 0.50       | 0.50                     | 0.32          | 0.49          | 0.46 | 0.47   | 0.44       | 0.39       |
| C82         | Follicular [nodular] non-Hodgkin's lymphoma   | M | <b>0.09</b> | 0.08                     | 0.16       | 0.13                     | 0.13          | 0.04          | 0.08 | 0.09   | 0.04       | 0.10       |
|             |   | F | <b>0.07</b> | 0.03                     | 0.10       | 0.06                     | 0.05          | 0.08          | 0.06 | 0.11   | 0.04       | 0.07       |
| C83         | Diffuse non-Hodgkin's lymphoma  | M | <b>0.12</b> | 0.11                     | 0.11       | 0.12                     | 0.12          | 0.11          | 0.11 | 0.24   | 0.11       | 0.11       |
|             |   | F | <b>0.08</b> | 0.10                     | 0.06       | 0.10                     | 0.05          | 0.05          | 0.07 | 0.20   | 0.08       | 0.05       |
| C84         | Peripheral and cutaneous T-cell lymphomas   | M | <b>0.41</b> | 0.15                     | 0.36       | 0.35                     | 0.38          | 0.38          | 0.58 | 0.75   | 0.44       | 0.24       |
|             |   | F | <b>0.33</b> | 0.38                     | 0.85       | 0.35                     | 0.19          | 0.19          | 0.35 | 0.50   | 0.36       | 0.22       |
| C85         | Other and unspecified types of non-Hodgkin's lymphoma                                       | M | <b>1.07</b> | 1.52                     | 0.95       | 1.64                     | 1.15          | 1.58          | 0.98 | 0.65   | 1.17       | 1.08       |
|             |   | F | <b>1.24</b> | 1.60                     | 1.21       | 2.05                     | 1.10          | 1.99          | 1.25 | 0.76   | 1.26       | 1.11       |
| C88         | Malignant immunoproliferative diseases  | M | <b>0.50</b> | 4.00                     | 0.30       | 0.40                     | 1.17          | 0.37          | 0.78 | 0.57   | 0.35       | 0.40       |
|             |   | F | <b>0.38</b> | 3.00                     | 0.20       | 1.00                     | 0.33          | 0.36          | 0.43 | 0.20   | 0.13       | 0.62       |
| C90         | Multiple myeloma and malignant plasma cell neoplasms  | M | <b>0.61</b> | 0.78                     | 0.66       | 0.55                     | 0.59          | 0.64          | 0.67 | 0.56   | 0.66       | 0.52       |
|             |   | F | <b>0.67</b> | 0.65                     | 0.60       | 0.79                     | 0.71          | 0.84          | 0.69 | 0.69   | 0.69       | 0.50       |
| C91-C95     | All leukaemias  | M | <b>0.59</b> | 0.88                     | 0.61       | 0.49                     | 0.57          | 0.59          | 0.68 | 0.56   | 0.58       | 0.56       |
|             |   | F | <b>0.62</b> | 0.86                     | 0.64       | 0.58                     | 0.64          | 0.77          | 0.72 | 0.56   | 0.55       | 0.55       |
| C91         | Lymphoid leukaemia  | M | <b>0.41</b> | 0.82                     | 0.50       | 0.29                     | 0.38          | 0.39          | 0.52 | 0.44   | 0.36       | 0.33       |
|             |   | F | <b>0.42</b> | 0.86                     | 0.55       | 0.39                     | 0.50          | 0.44          | 0.63 | 0.32   | 0.31       | 0.33       |

Table 9 Series MB1 no. 36

To link to Excel version of the table - click on the red box surrounding the table title

Table 9 Cancer mortality to incidence ratios - *continued*

| ICD-10 code | Site description   |   | England       | Government Office Region |            |                          |               |               |      |        |            |            |
|-------------|--|---|---------------|--------------------------|------------|--------------------------|---------------|---------------|------|--------|------------|------------|
|             |  |   |               | North East               | North West | Yorkshire and The Humber | East Midlands | West Midlands | East | London | South East | South West |
| C92         | Myeloid leukaemia  | M | <b>0.77</b>   | 0.83                     | 0.74       | 0.72                     | 0.76          | 0.79          | 0.80 | 0.70   | 0.83       | 0.81       |
|             |  | F | <b>0.77</b>   | 0.75                     | 0.68       | 0.76                     | 0.70          | 1.13          | 0.72 | 0.75   | 0.75       | 0.79       |
| C93         | Monocytic leukaemia  | M | <b>0.41</b>   | 0.00                     | 1.50       | 0.00                     | 0.50          | 0.50          | 0.00 | 0.00   | 0.30       | 0.33       |
|             |  | F | <b>0.24</b>   | 0.00                     | 1.00       | 0.00                     | 0.00          | 0.18          | 0.00 | 0.00   | 0.36       | 0.00       |
| C94         | Other leukaemias of specified cell type  | M | <b>0.45</b>   | 0.00                     | 0.33       | 0.00                     | 0.50          | 0.40          | 0.00 | 0.20   | 0.43       | 0.00       |
|             |  | F | <b>0.50</b>   | 0.00                     | 0.00       | 0.00                     | 3.00          | 0.00          | 1.00 | 0.33   | 0.50       | 0.00       |
| C95         | Leukaemia of unspecified cell type   | M | <b>0.99</b>   | 4.50                     | 0.55       | 1.00                     | 1.00          | 1.38          | 1.19 | 0.57   | 1.25       | 1.00       |
|             |  | F | <b>1.08</b>   | 2.25                     | 0.90       | 1.33                     | 1.25          | 1.18          | 2.40 | 0.71   | 1.23       | 0.69       |
| C96         | Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue | M | <b>0.33</b>   | 0.00                     | 0.00       | 0.00                     | 1.00          | 1.00          | 0.50 | 0.00   | 0.50       | 0.33       |
|             |  | F | <b>0.44</b>   | 0.00                     | 0.00       | 1.00                     | 0.00          | 0.00          | 0.00 | 0.00   | 0.00       | 0.00       |
| C97         | Malignant neoplasms of independent (primary) multiple sites                              | M | <b>476.00</b> | 0.00                     | 0.00       | 0.00                     | 0.00          | 0.00          | 0.00 | 0.00   | 0.00       | 39.00      |
|             |  | F | <b>0.00</b>   | 0.00                     | 0.00       | 0.00                     | 0.00          | 0.00          | 0.00 | 0.00   | 0.00       | 0.00       |

To link to Excel version of the table - click on the red box surrounding the table title

**Table 10 Directly age-standardised<sup>1</sup> registration rates per 100,000 population: site and sex, 1996 to 2005**

|                              |   |          |              |              |              |              |              |              |              |              | England      |              |
|------------------------------|---|----------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|
| ICD-10 code                  | Site description  |          | 1996         | 1997         | 1998         | 1999         | 2000         | 2001         | 2002         | 2003         | 2004         | 2005         |
| <b>C00-C97, D00-D48, O01</b> | <b>All registrations</b>  | <b>M</b> | <b>504.9</b> | <b>523.1</b> | <b>528.9</b> | <b>543.4</b> | <b>553.8</b> | <b>559.3</b> | <b>553.5</b> | <b>553.8</b> | <b>572.3</b> | <b>574.1</b> |
|                              |   | <b>F</b> | <b>502.2</b> | <b>522.9</b> | <b>535.4</b> | <b>553.1</b> | <b>546.9</b> | <b>548.2</b> | <b>541.8</b> | <b>553.2</b> | <b>556.7</b> | <b>564.9</b> |
| <b>C00-C97</b>               | <b>All cancers</b>  | <b>M</b> | <b>473.6</b> | <b>488.8</b> | <b>494.9</b> | <b>502.8</b> | <b>507.4</b> | <b>513.0</b> | <b>505.6</b> | <b>505.7</b> | <b>519.9</b> | <b>516.8</b> |
|                              |   | <b>F</b> | <b>380.7</b> | <b>398.9</b> | <b>402.5</b> | <b>415.0</b> | <b>410.8</b> | <b>414.0</b> | <b>407.7</b> | <b>417.8</b> | <b>422.5</b> | <b>425.0</b> |
| <b>C00-C97 excl.C44</b>      | <b>All cancers excluding nmsc<sup>2</sup></b>   | <b>M</b> | <b>401.1</b> | <b>407.2</b> | <b>403.0</b> | <b>410.6</b> | <b>411.1</b> | <b>413.7</b> | <b>405.1</b> | <b>401.1</b> | <b>410.2</b> | <b>402.8</b> |
|                              |   | <b>F</b> | <b>332.0</b> | <b>344.3</b> | <b>342.3</b> | <b>353.0</b> | <b>345.7</b> | <b>346.8</b> | <b>339.5</b> | <b>348.4</b> | <b>348.3</b> | <b>349.6</b> |
| C00-C14                      | Malignant neoplasm of lip, mouth and pharynx  | M        | 8.9          | 9.2          | 9.4          | 10.3         | 10.3         | 10.4         | 9.9          | 10.9         | 10.6         | 10.8         |
|                              |   | F        | 4.0          | 4.5          | 4.4          | 4.7          | 4.7          | 4.8          | 4.4          | 4.8          | 4.8          | 5.0          |
| C00                          | Malignant neoplasm of lip   | M        | 0.7          | 0.6          | 0.5          | 0.6          | 0.6          | 0.6          | 0.6          | 0.6          | 0.4          | 0.5          |
|                              |   | F        | 0.2          | 0.2          | 0.2          | 0.2          | 0.3          | 0.2          | 0.2          | 0.2          | 0.2          | 0.2          |
| C01                          | Malignant neoplasm of base of tongue  | M        | 0.4          | 0.4          | 0.5          | 0.6          | 0.6          | 0.8          | 0.8          | 0.8          | 0.8          | 0.9          |
|                              |   | F        | 0.1          | 0.1          | 0.2          | 0.2          | 0.2          | 0.2          | 0.3          | 0.2          | 0.3          | 0.3          |
| C02                          | Malignant neoplasm of other and unspecified parts of tongue                           | M        | 1.5          | 1.7          | 1.6          | 1.7          | 1.8          | 1.7          | 1.7          | 1.9          | 1.8          | 1.8          |
|                              |   | F        | 0.8          | 1.0          | 0.9          | 1.0          | 0.9          | 1.0          | 0.9          | 1.0          | 1.1          | 1.0          |
| C03                          | Malignant neoplasm of gum   | M        | 0.3          | 0.3          | 0.2          | 0.3          | 0.5          | 0.4          | 0.4          | 0.4          | 0.5          | 0.4          |
|                              |   | F        | 0.2          | 0.2          | 0.2          | 0.3          | 0.3          | 0.3          | 0.2          | 0.2          | 0.3          | 0.3          |
| C04                          | Malignant neoplasm of floor of mouth  | M        | 0.9          | 0.9          | 0.9          | 1.0          | 1.0          | 1.0          | 0.8          | 0.9          | 0.9          | 0.9          |
|                              |   | F        | 0.3          | 0.3          | 0.3          | 0.3          | 0.3          | 0.3          | 0.3          | 0.4          | 0.4          | 0.3          |
| C05                          | Malignant neoplasm of palate  | M        | 0.4          | 0.5          | 0.5          | 0.5          | 0.5          | 0.5          | 0.4          | 0.5          | 0.5          | 0.5          |
|                              |   | F        | 0.2          | 0.3          | 0.3          | 0.3          | 0.3          | 0.3          | 0.3          | 0.3          | 0.3          | 0.4          |
| C06                          | Malignant neoplasm of other and unspecified parts of mouth                            | M        | 0.7          | 0.7          | 0.7          | 0.8          | 0.7          | 0.7          | 0.7          | 0.7          | 0.7          | 0.7          |
|                              |   | F        | 0.4          | 0.5          | 0.5          | 0.5          | 0.5          | 0.4          | 0.4          | 0.5          | 0.4          | 0.5          |
| C07                          | Malignant neoplasm of parotid gland   | M        | 0.6          | 0.6          | 0.7          | 0.7          | 0.6          | 0.7          | 0.6          | 0.7          | 0.7          | 0.7          |
|                              |   | F        | 0.4          | 0.5          | 0.5          | 0.5          | 0.4          | 0.5          | 0.4          | 0.4          | 0.4          | 0.4          |
| C08                          | Malignant neoplasm of other and unspecified major salivary glands                     | M        | 0.2          | 0.2          | 0.3          | 0.2          | 0.2          | 0.2          | 0.2          | 0.2          | 0.2          | 0.2          |
|                              |   | F        | 0.2          | 0.2          | 0.2          | 0.2          | 0.2          | 0.2          | 0.1          | 0.2          | 0.2          | 0.2          |
| C09                          | Malignant neoplasm of tonsil  | M        | 1.0          | 1.1          | 1.2          | 1.3          | 1.4          | 1.4          | 1.4          | 1.7          | 1.7          | 1.8          |
|                              |   | F        | 0.3          | 0.4          | 0.4          | 0.4          | 0.5          | 0.4          | 0.5          | 0.5          | 0.5          | 0.5          |
| C10                          | Malignant neoplasm of oropharynx  | M        | 0.4          | 0.3          | 0.3          | 0.4          | 0.4          | 0.4          | 0.3          | 0.3          | 0.4          | 0.5          |
|                              |   | F        | 0.1          | 0.1          | 0.1          | 0.1          | 0.1          | 0.1          | 0.1          | 0.1          | 0.1          | 0.1          |
| C11                          | Malignant neoplasm of nasopharynx   | M        | 0.6          | 0.6          | 0.5          | 0.6          | 0.5          | 0.5          | 0.5          | 0.5          | 0.5          | 0.6          |
|                              |   | F        | 0.3          | 0.2          | 0.2          | 0.2          | 0.3          | 0.2          | 0.2          | 0.2          | 0.2          | 0.2          |
| C12                          | Malignant neoplasm of pyriform sinus  | M        | 0.6          | 0.6          | 0.7          | 0.8          | 0.8          | 0.7          | 0.7          | 0.7          | 0.7          | 0.6          |
|                              |   | F        | 0.1          | 0.1          | 0.1          | 0.1          | 0.1          | 0.1          | 0.2          | 0.1          | 0.1          | 0.1          |
| C13                          | Malignant neoplasm of hypopharynx   | M        | 0.2          | 0.3          | 0.3          | 0.3          | 0.3          | 0.3          | 0.3          | 0.3          | 0.3          | 0.3          |
|                              |   | F        | 0.2          | 0.2          | 0.2          | 0.2          | 0.1          | 0.2          | 0.1          | 0.2          | 0.1          | 0.1          |
| C14                          | Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynx | M        | 0.5          | 0.4          | 0.5          | 0.5          | 0.5          | 0.4          | 0.6          | 0.5          | 0.5          | 0.5          |
|                              |   | F        | 0.2          | 0.2          | 0.2          | 0.2          | 0.2          | 0.2          | 0.2          | 0.2          | 0.2          | 0.2          |
| C15                          | Malignant neoplasm of oesophagus  | M        | 12.5         | 13.1         | 12.7         | 13.1         | 13.4         | 13.8         | 13.8         | 13.8         | 13.8         | 14.0         |
|                              |   | F        | 5.4          | 5.6          | 5.6          | 6.0          | 5.7          | 5.7          | 5.5          | 5.6          | 5.3          | 5.6          |
| C16                          | Malignant neoplasm of stomach   | M        | 19.5         | 19.8         | 19.0         | 18.7         | 17.8         | 16.6         | 16.4         | 14.5         | 14.1         | 13.8         |
|                              |   | F        | 7.5          | 7.8          | 7.2          | 6.9          | 6.9          | 6.6          | 6.1          | 6.1          | 5.9          | 5.3          |
| C17                          | Malignant neoplasm of small intestine   | M        | 1.0          | 1.0          | 1.2          | 1.3          | 1.3          | 1.2          | 1.1          | 1.2          | 1.3          | 1.3          |
|                              |   | F        | 0.7          | 0.8          | 0.7          | 0.9          | 0.8          | 0.8          | 0.8          | 0.8          | 0.9          | 0.9          |
| C18-C20                      | Malignant neoplasm of colon and rectum  | M        | 54.6         | 55.2         | 55.5         | 55.8         | 55.7         | 53.4         | 52.8         | 53.1         | 54.1         | 53.9         |
|                              |   | F        | 35.7         | 35.1         | 36.3         | 36.1         | 35.2         | 34.2         | 33.4         | 33.2         | 34.1         | 34.0         |
| C18-C21                      | Malignant neoplasm of colon, rectum and anus  | M        | 55.5         | 56.2         | 56.5         | 56.8         | 56.7         | 54.4         | 53.8         | 54.2         | 55.1         | 54.9         |
|                              |   | F        | 36.7         | 36.4         | 37.4         | 37.4         | 36.4         | 35.4         | 34.6         | 34.5         | 35.3         | 35.3         |

1. Directly age-standardised using the European Standard Population - see section 5.7.

2. These figures exclude non-melanoma skin cancer (ICD-10 C44) - see section 4.2.

Table 10 Series MBI no. 36

To link to Excel version of the table - click on the red box surrounding the table title

Table 10 Directly age-standardised rates - *continued*

England

| ICD-10 code | Site description   |   | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002  | 2003  | 2004  | 2005  |
|-------------|--|---|------|------|------|------|------|------|-------|-------|-------|-------|
| C18         | Malignant neoplasm of colon  | M | 32.3 | 32.7 | 31.9 | 32.5 | 32.4 | 31.4 | 30.4  | 30.8  | 31.3  | 31.5  |
|             |  | F | 24.3 | 23.8 | 24.3 | 24.0 | 23.8 | 23.1 | 22.4  | 22.2  | 22.9  | 22.6  |
| C19         | Malignant neoplasm of rectosigmoid junction  | M | 4.2  | 4.4  | 4.6  | 4.8  | 4.5  | 4.4  | 4.8   | 4.6   | 4.9   | 4.9   |
|             |  | F | 2.5  | 2.5  | 2.6  | 2.7  | 2.6  | 2.4  | 2.3   | 2.6   | 2.8   | 2.8   |
| C20         | Malignant neoplasm of rectum   | M | 18.0 | 18.0 | 18.9 | 18.6 | 18.7 | 17.5 | 17.6  | 17.7  | 17.8  | 17.5  |
|             |  | F | 8.9  | 8.8  | 9.4  | 9.4  | 8.8  | 8.7  | 8.7   | 8.4   | 8.5   | 8.6   |
| C21         | Malignant neoplasm of anus and anal canal  | M | 0.9  | 1.0  | 1.0  | 1.0  | 1.0  | 1.0  | 1.0   | 1.1   | 1.0   | 0.9   |
|             |  | F | 1.0  | 1.2  | 1.2  | 1.2  | 1.2  | 1.2  | 1.2   | 1.2   | 1.3   | 1.2   |
| C22         | Malignant neoplasm of liver and intrahepatic bile ducts  | M | 4.0  | 4.2  | 4.3  | 4.4  | 4.9  | 4.7  | 5.0   | 5.0   | 5.0   | 5.4   |
|             |  | F | 2.0  | 2.1  | 2.1  | 2.1  | 2.3  | 2.4  | 2.4   | 2.2   | 2.5   | 2.5   |
| C23         | Malignant neoplasm of gallbladder  | M | 0.4  | 0.4  | 0.4  | 0.4  | 0.4  | 0.4  | 0.4   | 0.4   | 0.5   | 0.5   |
|             |  | F | 0.8  | 0.8  | 0.8  | 0.8  | 0.8  | 0.8  | 0.8   | 0.8   | 0.9   | 0.9   |
| C24         | Malignant neoplasm of other and unspecified parts of biliary tract                                   | M | 1.3  | 1.2  | 1.1  | 1.2  | 1.1  | 1.1  | 1.1   | 1.0   | 1.0   | 1.1   |
|             |  | F | 0.9  | 0.8  | 0.9  | 0.9  | 0.8  | 0.8  | 0.7   | 0.7   | 0.7   | 0.8   |
| C25         | Malignant neoplasm of pancreas   | M | 10.4 | 10.5 | 10.3 | 10.5 | 10.6 | 10.3 | 10.3  | 10.3  | 10.5  | 10.4  |
|             |  | F | 7.6  | 7.6  | 7.3  | 8.2  | 7.9  | 7.7  | 7.7   | 7.9   | 8.2   | 8.2   |
| C26         | Malignant neoplasm of other and ill-defined digestive organs   | M | 0.9  | 1.2  | 1.1  | 1.0  | 0.9  | 0.8  | 0.8   | 0.8   | 0.8   | 0.9   |
|             |  | F | 0.6  | 0.9  | 0.7  | 0.8  | 0.6  | 0.7  | 0.7   | 0.7   | 0.7   | 0.6   |
| C30         | Malignant neoplasm of nasal cavity and middle ear  | M | 0.4  | 0.5  | 0.4  | 0.4  | 0.5  | 0.4  | 0.4   | 0.4   | 0.5   | 0.3   |
|             |  | F | 0.2  | 0.2  | 0.2  | 0.3  | 0.3  | 0.3  | 0.2   | 0.3   | 0.3   | 0.3   |
| C31         | Malignant neoplasm of accessory sinuses  | M | 0.4  | 0.3  | 0.3  | 0.4  | 0.3  | 0.4  | 0.3   | 0.3   | 0.3   | 0.2   |
|             |  | F | 0.2  | 0.2  | 0.2  | 0.2  | 0.2  | 0.2  | 0.2   | 0.2   | 0.1   | 0.1   |
| C32         | Malignant neoplasm of larynx   | M | 5.9  | 5.9  | 5.7  | 5.7  | 6.0  | 5.6  | 5.1   | 5.1   | 5.1   | 5.0   |
|             |  | F | 1.0  | 1.1  | 1.0  | 1.0  | 1.0  | 1.0  | 0.9   | 1.0   | 0.8   | 0.9   |
| C33-C34     | Malignant neoplasm of trachea, bronchus and lung   | M | 75.0 | 74.6 | 71.4 | 70.2 | 68.3 | 66.2 | 63.0  | 60.8  | 61.6  | 59.2  |
|             |  | F | 33.2 | 33.6 | 33.9 | 34.4 | 34.5 | 34.2 | 33.5  | 34.2  | 34.3  | 35.0  |
| C33         | Malignant neoplasm of trachea  | M | 0.1  | 0.2  | 0.1  | 0.1  | 0.1  | 0.1  | 0.1   | 0.1   | 0.1   | 0.1   |
|             |  | F | 0.1  | 0.1  | 0.1  | 0.1  | 0.1  | 0.1  | 0.1   | 0.1   | 0.1   | 0.1   |
| C34         | Malignant neoplasm of bronchus and lung  | M | 74.9 | 74.5 | 71.3 | 70.1 | 68.2 | 66.1 | 62.9  | 60.8  | 61.4  | 59.2  |
|             |  | F | 33.1 | 33.5 | 33.9 | 34.3 | 34.4 | 34.1 | 33.5  | 34.1  | 34.3  | 35.0  |
| C37         | Malignant neoplasm of thymus   | M | 0.1  | 0.1  | 0.1  | 0.1  | 0.1  | 0.1  | 0.2   | 0.1   | 0.2   | 0.2   |
|             |  | F | 0.1  | 0.1  | 0.1  | 0.1  | 0.1  | 0.1  | 0.1   | 0.1   | 0.1   | 0.1   |
| C38         | Malignant neoplasm of heart, mediastinum and pleura  | M | 0.7  | 0.7  | 0.6  | 0.7  | 0.7  | 0.5  | 0.5   | 0.5   | 0.5   | 0.4   |
|             |  | F | 0.3  | 0.4  | 0.3  | 0.3  | 0.3  | 0.3  | 0.2   | 0.3   | 0.3   | 0.2   |
| C39         | Malignant neoplasm of other and ill-defined sites in the respiratory system and intrathoracic organs | M | 0.0  | 0.1  | 0.0  | 0.0  | 0.0  | 0.0  | 0.0   | 0.0   | 0.0   | 0.0   |
|             |  | F | 0.0  | 0.0  | 0.0  | 0.0  | 0.0  | 0.0  | 0.0   | 0.0   | 0.0   | 0.0   |
| C40         | Malignant neoplasm of bone and articular cartilage of limbs  | M | 0.5  | 0.5  | 0.5  | 0.5  | 0.6  | 0.5  | 0.5   | 0.4   | 0.4   | 0.4   |
|             |  | F | 0.4  | 0.3  | 0.4  | 0.4  | 0.4  | 0.4  | 0.4   | 0.4   | 0.3   | 0.3   |
| C41         | Malignant neoplasm of bone and articular cartilage of other and unspecified sites                    | M | 0.5  | 0.5  | 0.4  | 0.6  | 0.4  | 0.5  | 0.5   | 0.4   | 0.5   | 0.6   |
|             |  | F | 0.4  | 0.3  | 0.3  | 0.4  | 0.4  | 0.4  | 0.3   | 0.3   | 0.3   | 0.3   |
| C43         | Malignant melanoma of skin   | M | 7.9  | 8.6  | 8.8  | 8.9  | 10.0 | 10.6 | 11.0  | 11.3  | 12.5  | 13.2  |
|             |  | F | 9.8  | 10.1 | 10.1 | 10.5 | 11.5 | 12.4 | 12.5  | 12.8  | 13.9  | 14.5  |
| C44         | Other malignant neoplasms of skin  | M | 72.5 | 81.6 | 92.0 | 92.2 | 96.3 | 99.3 | 100.5 | 104.6 | 109.7 | 114.0 |
|             |  | F | 48.7 | 54.5 | 60.2 | 62.0 | 65.0 | 67.1 | 68.2  | 69.4  | 74.2  | 75.4  |
| C45         | Mesothelioma   | M | 3.8  | 4.2  | 4.7  | 4.9  | 5.0  | 5.2  | 5.2   | 5.3   | 5.3   | 5.2   |
|             |  | F | 0.5  | 0.6  | 0.6  | 0.7  | 0.7  | 1.0  | 0.9   | 0.8   | 0.8   | 0.8   |

To link to Excel version of the table - click on the red box surrounding the table title

Table 10 Directly age-standardised rates - continued

England

| ICD-10 code | Site description  |   | 1996  | 1997  | 1998  | 1999  | 2000  | 2001  | 2002  | 2003  | 2004  | 2005  |
|-------------|---|---|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| C46         | Kaposi's sarcoma  | M | 0.4   | 0.4   | 0.3   | 0.2   | 0.2   | 0.3   | 0.2   | 0.3   | 0.3   | 0.4   |
|             |   | F | 0.0   | 0.0   | 0.0   | 0.0   | 0.0   | 0.1   | 0.1   | 0.1   | 0.1   | 0.1   |
| C47         | Malignant neoplasm of peripheral nerves and autonomic nervous system    | M | 0.2   | 0.2   | 0.2   | 0.2   | 0.2   | 0.2   | 0.2   | 0.2   | 0.2   | 0.2   |
|             |   | F | 0.2   | 0.2   | 0.2   | 0.2   | 0.2   | 0.2   | 0.1   | 0.2   | 0.2   | 0.1   |
| C48         | Malignant neoplasm of retroperitoneum and peritoneum                    | M | 0.4   | 0.4   | 0.4   | 0.4   | 0.5   | 0.3   | 0.3   | 0.3   | 0.3   | 0.4   |
|             |   | F | 0.5   | 0.5   | 0.6   | 0.6   | 0.6   | 0.6   | 0.7   | 0.8   | 0.9   | 1.1   |
| C49         | Malignant neoplasm of other connective and soft tissue                  | M | 2.2   | 2.1   | 2.4   | 2.2   | 2.3   | 2.2   | 2.1   | 2.1   | 2.3   | 2.2   |
|             |   | F | 1.5   | 1.5   | 1.4   | 1.7   | 1.5   | 1.6   | 1.5   | 1.5   | 1.5   | 1.6   |
| C50         | Malignant neoplasm of breast  | M | 0.7   | 0.9   | 1.0   | 0.9   | 0.8   | 0.8   | 0.9   | 1.0   | 0.9   | 0.9   |
|             |   | F | 108.3 | 114.7 | 115.3 | 120.2 | 116.8 | 117.8 | 116.9 | 122.9 | 122.9 | 123.2 |
| C51         | Malignant neoplasm of vulva   | F | 2.1   | 2.2   | 2.3   | 2.3   | 2.2   | 2.4   | 2.3   | 2.4   | 2.2   | 2.3   |
| C52         | Malignant neoplasm of vagina  | F | 0.5   | 0.5   | 0.5   | 0.6   | 0.5   | 0.5   | 0.5   | 0.5   | 0.6   | 0.6   |
| C53         | Malignant neoplasm of cervix uteri                                      | F | 10.0  | 9.8   | 9.3   | 9.6   | 8.7   | 8.8   | 8.2   | 8.2   | 7.9   | 8.0   |
| C54         | Malignant neoplasm of corpus uteri                                      | F | 13.1  | 13.8  | 13.5  | 14.4  | 15.6  | 15.3  | 14.9  | 16.3  | 16.1  | 17.0  |
| C55         | Malignant neoplasm of uterus, part unspecified                          | F | 0.8   | 0.9   | 1.0   | 1.0   | 0.8   | 0.8   | 0.9   | 0.9   | 0.8   | 0.8   |
| C56-C57     | Malignant neoplasm of ovary and other unspecified female genital organs | F | 18.7  | 19.6  | 19.5  | 19.1  | 18.7  | 19.3  | 18.4  | 18.5  | 17.4  | 17.1  |
| C56         | Malignant neoplasm of ovary   | F | 18.3  | 19.0  | 19.0  | 18.6  | 18.3  | 19.0  | 18.1  | 18.1  | 17.1  | 16.7  |
| C57         | Malignant neoplasm of other and unspecified female genital organs       | F | 0.4   | 0.6   | 0.5   | 0.5   | 0.4   | 0.4   | 0.3   | 0.4   | 0.3   | 0.4   |
| C58         | Malignant neoplasm of placenta  | F | 0.0   | 0.0   | 0.0   | 0.0   | 0.1   | 0.0   | 0.0   | 0.0   | 0.0   | 0.0   |
| C60         | Malignant neoplasm of penis   | M | 1.2   | 1.2   | 1.2   | 1.1   | 1.5   | 1.2   | 1.2   | 1.2   | 1.2   | 1.4   |
| C61         | Malignant neoplasm of prostate  | M | 71.2  | 70.7  | 71.6  | 77.8  | 84.6  | 95.4  | 94.8  | 94.7  | 101.3 | 95.6  |
| C62         | Malignant neoplasm of testis  | M | 5.9   | 6.1   | 6.4   | 7.1   | 6.9   | 6.9   | 6.2   | 6.2   | 6.6   | 6.8   |
| C63         | Malignant neoplasm of other and unspecified male genital organs         | M | 0.2   | 0.4   | 0.2   | 0.2   | 0.2   | 0.2   | 0.2   | 0.2   | 0.2   | 0.2   |
| C64         | Malignant neoplasm of kidney, except renal pelvis                       | M | 9.7   | 10.1  | 10.4  | 10.1  | 10.6  | 10.6  | 11.1  | 10.7  | 11.3  | 11.3  |
|             |   | F | 4.9   | 5.0   | 4.9   | 5.3   | 5.2   | 5.3   | 5.4   | 5.7   | 5.7   | 5.7   |
| C65         | Malignant neoplasm of renal pelvis                                      | M | 0.7   | 0.8   | 0.8   | 0.7   | 0.8   | 0.8   | 0.8   | 0.8   | 0.7   | 0.8   |
|             |   | F | 0.4   | 0.5   | 0.4   | 0.4   | 0.4   | 0.4   | 0.4   | 0.4   | 0.4   | 0.4   |
| C66         | Malignant neoplasm of ureter  | M | 0.5   | 0.5   | 0.5   | 0.5   | 0.6   | 0.6   | 0.6   | 0.7   | 0.6   | 0.7   |
|             |   | F | 0.2   | 0.2   | 0.3   | 0.2   | 0.3   | 0.3   | 0.2   | 0.2   | 0.3   | 0.3   |
| C67         | Malignant neoplasm of bladder   | M | 28.5  | 27.7  | 27.6  | 27.6  | 22.2  | 22.3  | 20.6  | 20.2  | 19.1  | 19.6  |
|             |   | F | 7.8   | 8.0   | 7.7   | 8.0   | 6.3   | 6.3   | 5.8   | 5.9   | 5.5   | 5.7   |
| C68         | Malignant neoplasm of other and unspecified urinary organs              | M | 0.3   | 1.0   | 0.3   | 0.2   | 0.3   | 0.3   | 0.3   | 0.3   | 0.4   | 0.4   |
|             |   | F | 0.1   | 0.2   | 0.1   | 0.1   | 0.1   | 0.1   | 0.1   | 0.1   | 0.1   | 0.1   |
| C69         | Malignant neoplasm of eye and adnexa                                    | M | 0.8   | 1.0   | 0.9   | 0.8   | 1.0   | 0.8   | 0.8   | 0.8   | 0.7   | 0.7   |
|             |   | F | 0.8   | 0.8   | 0.6   | 0.7   | 0.7   | 0.6   | 0.6   | 0.6   | 0.7   | 0.6   |

Table 10 Series MBI no. 36

To link to Excel version of the table - click on the red box surrounding the table title

Table 10 Directly-age standardised rates - continued

England

| ICD-10 code | Site description  |   | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 |
|-------------|---|---|------|------|------|------|------|------|------|------|------|------|
| C70         | Malignant neoplasm of meninges  | M | 0.1  | 0.1  | 0.1  | 0.1  | 0.1  | 0.1  | 0.1  | 0.1  | 0.1  | 0.1  |
|             |   | F | 0.1  | 0.1  | 0.1  | 0.1  | 0.1  | 0.2  | 0.1  | 0.2  | 0.2  | 0.1  |
| C71         | Malignant neoplasm of brain   | M | 7.8  | 8.5  | 7.9  | 8.2  | 8.4  | 8.1  | 8.0  | 7.8  | 7.8  | 8.1  |
|             |   | F | 5.3  | 5.4  | 5.4  | 5.1  | 5.5  | 5.2  | 5.4  | 4.9  | 4.8  | 4.9  |
| C72         | Malignant neoplasm of spinal cord, cranial nerves and other parts of central nervous system | M | 0.3  | 0.3  | 0.2  | 0.2  | 0.2  | 0.2  | 0.2  | 0.2  | 0.3  | 0.2  |
|             |   | F | 0.2  | 0.3  | 0.2  | 0.2  | 0.3  | 0.2  | 0.1  | 0.2  | 0.2  | 0.2  |
| C73         | Malignant neoplasm of thyroid gland   | M | 1.2  | 1.2  | 1.3  | 1.2  | 1.2  | 1.3  | 1.2  | 1.3  | 1.4  | 1.4  |
|             |   | F | 2.4  | 2.5  | 2.8  | 2.7  | 3.0  | 3.2  | 3.4  | 3.5  | 3.7  | 3.9  |
| C74         | Malignant neoplasm of adrenal gland   | M | 0.3  | 0.4  | 0.3  | 0.3  | 0.4  | 0.3  | 0.3  | 0.4  | 0.3  | 0.3  |
|             |   | F | 0.3  | 0.3  | 0.3  | 0.3  | 0.3  | 0.4  | 0.3  | 0.3  | 0.3  | 0.3  |
| C75         | Malignant neoplasm of other endocrine glands and related structures                         | M | 0.2  | 0.1  | 0.2  | 0.2  | 0.2  | 0.2  | 0.2  | 0.2  | 0.2  | 0.3  |
|             |   | F | 0.1  | 0.1  | 0.1  | 0.1  | 0.1  | 0.1  | 0.1  | 0.1  | 0.1  | 0.1  |
| C76         | Malignant neoplasm of other and ill-defined sites   | M | 0.6  | 0.7  | 0.6  | 0.8  | 0.9  | 0.7  | 0.9  | 0.8  | 0.9  | 0.7  |
|             |   | F | 0.7  | 0.7  | 0.7  | 0.8  | 0.9  | 0.8  | 1.0  | 1.0  | 0.8  | 0.7  |
| C77         | Secondary and unspecified malignant neoplasm of lymph nodes                                 | M | 1.5  | 1.7  | 1.1  | 1.2  | 1.2  | 1.2  | 1.1  | 1.2  | 1.2  | 1.1  |
|             |   | F | 1.0  | 1.1  | 0.6  | 0.7  | 0.8  | 0.7  | 0.8  | 0.7  | 0.9  | 0.9  |
| C78         | Secondary malignant neoplasm of respiratory and digestive organs                            | M | 6.7  | 6.8  | 6.8  | 6.8  | 6.6  | 6.5  | 5.7  | 5.7  | 5.3  | 5.3  |
|             |   | F | 5.3  | 5.3  | 5.1  | 5.1  | 4.8  | 5.2  | 5.1  | 4.8  | 4.6  | 4.6  |
| C79         | Secondary malignant neoplasm of other sites   | M | 3.3  | 3.1  | 2.9  | 2.8  | 2.7  | 2.8  | 2.4  | 2.2  | 2.2  | 2.3  |
|             |   | F | 2.4  | 2.4  | 2.2  | 2.1  | 2.2  | 2.3  | 1.9  | 1.8  | 1.8  | 1.7  |
| C80         | Malignant neoplasm without specification of site  | M | 11.5 | 11.6 | 11.0 | 10.0 | 8.6  | 7.8  | 8.2  | 7.2  | 7.1  | 6.5  |
|             |   | F | 8.5  | 9.1  | 8.1  | 8.1  | 7.3  | 7.2  | 6.7  | 6.3  | 6.1  | 5.5  |
| C81         | Hodgkin's disease   | M | 2.6  | 2.7  | 2.8  | 2.8  | 3.1  | 2.8  | 3.1  | 2.5  | 2.8  | 2.9  |
|             |   | F | 1.9  | 1.9  | 2.0  | 2.0  | 2.0  | 2.0  | 1.8  | 1.9  | 2.2  | 2.1  |
| C82-C85     | Non-Hodgkin's lymphoma  | M | 14.5 | 15.3 | 15.2 | 15.9 | 15.7 | 16.0 | 15.4 | 15.7 | 16.0 | 16.1 |
|             |   | F | 9.9  | 10.5 | 10.8 | 11.6 | 11.3 | 11.4 | 11.0 | 11.4 | 11.6 | 11.3 |
| C88         | Malignant immunoproliferative diseases  | M | 0.4  | 0.5  | 0.5  | 0.6  | 0.5  | 0.5  | 0.5  | 0.5  | 0.4  | 0.3  |
|             |   | F | 0.2  | 0.2  | 0.2  | 0.3  | 0.3  | 0.2  | 0.2  | 0.2  | 0.2  | 0.2  |
| C90         | Multiple myeloma and malignant plasma cell neoplasms  | M | 5.5  | 5.6  | 6.1  | 6.1  | 6.0  | 5.8  | 5.7  | 6.1  | 6.0  | 5.8  |
|             |   | F | 3.8  | 3.8  | 4.0  | 4.2  | 4.3  | 3.8  | 3.8  | 3.9  | 3.9  | 3.9  |
| C91-C95     | All leukaemias  | M | 12.0 | 12.4 | 12.3 | 13.0 | 13.1 | 12.7 | 12.2 | 12.6 | 12.3 | 12.0 |
|             |   | F | 7.3  | 7.8  | 7.7  | 8.2  | 7.5  | 7.6  | 7.5  | 7.5  | 7.3  | 7.2  |
| C91         | Lymphoid leukaemia  | M | 6.7  | 6.4  | 6.5  | 7.1  | 7.1  | 6.8  | 6.6  | 6.5  | 6.5  | 6.2  |
|             |   | F | 3.6  | 3.5  | 3.5  | 3.9  | 3.7  | 3.7  | 3.6  | 3.5  | 3.4  | 3.3  |
| C92         | Myeloid leukaemia   | M | 4.8  | 5.4  | 5.2  | 5.2  | 5.4  | 5.3  | 5.0  | 5.6  | 5.2  | 5.2  |
|             |   | F | 3.4  | 3.9  | 3.7  | 3.9  | 3.5  | 3.5  | 3.6  | 3.7  | 3.5  | 3.5  |
| C93         | Monocytic leukaemia   | M | 0.1  | 0.1  | 0.1  | 0.2  | 0.1  | 0.2  | 0.2  | 0.1  | 0.1  | 0.1  |
|             |   | F | 0.1  | 0.1  | 0.1  | 0.1  | 0.1  | 0.1  | 0.1  | 0.1  | 0.1  | 0.1  |
| C94         | Other leukaemias of specified cell type   | M | 0.1  | 0.1  | 0.1  | 0.1  | 0.1  | 0.1  | 0.1  | 0.1  | 0.1  | 0.1  |
|             |   | F | 0.1  | 0.1  | 0.0  | 0.1  | 0.0  | 0.0  | 0.0  | 0.0  | 0.1  | 0.0  |
| C95         | Leukaemia of unspecified cell type  | M | 0.4  | 0.4  | 0.4  | 0.4  | 0.4  | 0.3  | 0.3  | 0.3  | 0.4  | 0.4  |
|             |   | F | 0.2  | 0.3  | 0.3  | 0.3  | 0.2  | 0.2  | 0.2  | 0.2  | 0.2  | 0.2  |
| C96         | Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue    | M | 0.2  | 0.4  | 0.1  | 0.1  | 0.1  | 0.1  | 0.1  | 0.1  | 0.1  | 0.1  |
|             |   | F | 0.2  | 0.2  | 0.0  | 0.1  | 0.1  | 0.0  | 0.0  | 0.0  | 0.1  | 0.0  |
| D05         | Carcinoma in situ of breast   | M | 0.1  | 0.0  | 0.1  | 0.1  | 0.0  | 0.1  | 0.1  | 0.0  | 0.0  | 0.1  |
|             |   | F | 7.8  | 9.2  | 9.9  | 10.9 | 11.5 | 11.7 | 12.3 | 13.2 | 14.0 | 15.3 |
| D06         | Carcinoma in situ of cervix uteri   | F | 82.8 | 81.4 | 89.4 | 90.3 | 85.9 | 83.1 | 83.1 | 83.2 | 78.9 | 80.9 |